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ABSTRACT
The resurgence of pertussis in several highly vaccinated countries has stimulated this study 
of the genotypic diversity and epidemiological typing of Bordetella pertussis. The genotypic 
variation of B. pertussis investigated in 318 UK clinical isolates from 1920-2002, using
pertactin iprnA) and pertussis toxin SI subunit iptxA) gene typing. Isolates before 1979 
were all (97/97) prnA{V), and identical to the three UK Wellcome whole-ceU vacchie 
(WCV) strains. Since 1982, the novel typesprnA(7) andprnAip) were recovered, so that 
from 1998-2002, 81/133 (61%) isolates were non-prnA(p) (P—0.0006). Tw optxA  variants, 
ptxA ip) andptxAilZ), were found and these botli occur in the UK Wellcome WCV. The 
temporal expansion o fp txA il) in UK isolates is also significant (P<0.0001), from 40/73 
(55%) isolates between 1920-1956, to 133/133 (100%) p tx A il)  isolates between 1998-2002. 
These p txA  UK data argue against the theory of vaccine-driven evolution, proposed after a 
study in The Netherlands reported a shift in circulating B. pertussis strains towards non­
vaccine types. To challenge tlris theory furtlier, 149 isolates were randomly-picked from 
1940-1999 to calculate the genotypic diversity (GD) in each decade using IS/002-based 
restriction fragment length polymorphism (RFLP) analysis. O f the 24 different RFLP types 
identified, RFLP-1 was present in aU decades in 64/149 (43%) isolates. The three types 
RFLP-1, RFLP-2, and RFLP-3, which are present in the Wellcome WCV, constituted a 
major proportion of isolates in the 1990s at 32/36 (89%). The calculated GD values 
revealed a drop after the introduction of the pertussis WCV in 1957 from the 1940s (0.81) 
to the 1950s (0.64), (P=0.092), and a significant decrease from the 1980s to the 1990s (0.84 
compared to 0.57, P<0.01). An association was seen between die UK pertussis notification 
figures and tlie GD values of each decade, hence, when pertussis notifications were high, 
the GD hicreased, which could be due to the clonal expansion of B. pertussis. Comparisons 
witii otiier countries c o n c e r n i n g a n d p txA  gene types, RFLP types and genotypic 
diversity are discussed.
Ninety UK isolates, from September 1998 to Aprü 1999, were investigated, along with 
corresponding chnical and epidemiological information, for any associations with the 
laboratory typing data. The most significant findings were tliat the under two month age 
group is mostly at risk of pertussis infection, and that cases admitted to hospital are more 
hkely to be infected witli a serotype 1,2 (P=0.017) and/or ÇiprnA(V) (P—0.025) strain. 
Incidentally, tliere was a very significant association between serotype 1,2 withprnA{\), and 
serotype 1,3 withpruA^l) (P<0.001). These associations may be viewed as indicators of 
severe pertussis disease.
xvin
Isolates (n=44) from Missouri, USA were also characterised, after an increase in pertussis 
in the summer months o f 1999. Epidemiological typing confirmed that RFLP-1 and RFLP- 
2 are successful global Hneages of B. pertussis, and that the number of RFLP types dropped 
from 10 types in the 1980s to 4 types in the 1990s. A novel pertactin gene type,p/y&4(9), 
was found in two of the isolates and differs fromprnA(7) by an extra GGFGP repeat. Ten 
isolates from Kansas City were ah serotype \,2 ,prnA (p),ptxA {i), and RFLP-1, but were 
divided into two PFGE types, PFGE-2 and PFGE-3, which emphasises the difficulty of 
choosing an optimum typing method for epidemiological investigations.
To date, the evaluation of typing methods used for B. pertussis has not been performed 
extensively. Therefore, in this thesis, the recognised methods, namely serotyping, pulsed- 
field gel electrophoresis (PFGE) using X hA , and IS/002-RFLP analysis, were evaluated 
according to guidelines recommended by Struelens, M. J. and the Members of the 
European Study Group on Epidemiological Markers 1996, Clin Microbiol Infect, vol. 2, no. 1, 
pp. 2-11. It was found that, PFGE typing gave a good discrirnination index value, but gave 
a low score for reproducibility, and further work is required to optimise this method. 
Furthermore, if prnA  andp/xH gene typing were included in the evaluation, combined with 
serotyping, this combination would equal the discrimination of PFGE.
Other typing methods attempted for B. pertussis included ditect sequencing of adenylate 
Idnase [adk) and filamentous haemagglutinin genes (fbaB), and single-enzyme amplified 
fragment length polymorphism (AFLP) analysis with a selection of enzymes and selective 
primers. The type strain and a clinical strain, generated one and six single nucleotide 
polymorphisms (SNPs) in adk and fbaB, respectively. The discriminatory ability of the 
single-enzyme AFLP analysis was not satisfactory, as only a few different profiles were seen 
in the nine isolates tested. However, at least four AFLP profiles were generated using Pstl 
enzyme, and the selective primer Pst-C.
The direct detection and epidemiological typing of B. pertussis in 20 previously untypable 
clinical samples was attempted usingpraAl andp txA  as targets. Six clinical extracts 
generated prnA  andp/xH (5/6) sequence data, therefore confirming that these typing 
procedures on B. pertussis PCR-positive clinical specimens is worthwhile in order to 
generate the prnA  and p txA  distributions from babies or adults presenting atypical 
symptoms. This strategy should also be encouraged in other countries that have studied 
prnA  andpbod allele distributions, in order to update the representation of the genetic 
diversity of B. pertussis.
XIX
1 INTRODUCTION
1.1 B ordetella  species
At the time of writing this thesis, eight Bordetella species had been described (Table 1.1, 
page 5). A chronological account of how these species became members of the Bordetella 
genus is given below.
1.1.1 Historical account of the Bordetella genus
An epidemic of whooping cough was first described in 1578, by the French physician de 
Baülou (Holmes, 1940.). In 1906, Joules Bordet and Octave Gengou isolated the causative 
agent from a patient in the acute stage of the disease (Table 1.1, page 5) (Bordet and 
Gengou, 1906). This organism, originally known as Haemophilus pertussis (LesHe and 
Gardner, 1931), is now the type species of the Bordetella genus (Pittman, 1984). The host 
range of B. pertussis is limited to humans and it is the only species in the genus to produce 
pertussis toxin, which may contribute to the prolonged paroxysmal coughing that is most 
severe witli B. pertussis mî&ctson. Bordetella hronchiseptica, described hi 1912, causes respiratory 
disease in a broad range of hosts. These diseases include kennel cough in dogs, atrophic 
rhinitis in pigs, and other illnesses in many other domestic and wild anhnals, including 
horses and rabbits (Ferry, 1912). However, it is an infrequent opportunist in humans 
(Pittman, 1984). Bordetella parapertussis, first described in 1938, generally causes a milder 
form of whooping cough hi humans, and was originally differentiated from B. pertussis by 
its more rapid growth, and its ability to produce a brown pigment on tyrosine agar 
(Eldering and Kendrick, 1938). Bordetella parapertussis hsis also been isolated from sheep 
(CuUhiane et aL, 1987). However, human and sheep isolates oiB. parape/iussishscse. distinct 
characteristics (van der Zee et aL, 1996a).
Until recently, classification of the genus Bordetella has been based prhuarhy on the three 
‘classical’ species described above, B. pertussis, B. parapertussis and B. bronchiseptica (Gerlach et 
aL, 2001). However, in 1984 Kersters and colleagues proposed the species Bordetella avium 
(originally identified as Alcaligenes faecalis (Simmons et aL, 1980)) to include organisms 
isolated from the respiratory tract of turkeys and other bhds presenting turkey coryza or 
rhhiotracheitis (see Table 1.1, page 5) (Kersters et aL, 1984). At this thue. Volume I of 
Bergey’s Manual of Systematic Bacteriology, described B. avium as a "'"Bordetella bromhiseptica- 
hlce bacterium”, and defined the Bordetella genus as:
“Minute coccobachlus, 0.2-0.5 |Ltm in diameter and 0.5-2.0 pm in length, often 
bipolar stained, and arranged singly or in pahs, more rarely in chains. Gram-
negative. Nonmotüe, two species; motile, one species, by peiitrichous flagella. 
Strictly aerobic. Optimmn température, 35-37'’C. Colonies on Bordet-Gengou 
medium are smooth, convex, pearly, glistening, nearly transparent and surrounded 
by a zone of hemolysis without definite periphery. Metabolism respiratory, never 
fermentative. Chemoorganotrophic, require nicotinamide, organic sulfur (e.g., 
cysteine) and organic nitrogen (amino acids). Utilize oxidatively glutamic acid, 
proline, alanine, aspartic acid and serine with production of ammonia and COg. 
Litmus milk is made aUcaline. Mammalian parasite and pathogen. Localize and 
multiply among the epithelial cilia of the respiratory tract. The mol% G+C of the 
DNA is 66-70 (TJ.”
(Pittman, 1984)
After prior assignments to Æcaligenes, brucella and H.aemophihts (Pittman, 1984), de Ley and 
colleagues (1986), proposed that the four ^ordetella species should be included in a new 
 ^Æcaligenaceae  ^ together A.chromohacter “m A Alcaligenes based on DNA-
rRNA hybridisation and phenotypic analyses.
A group of isolates wliich were Gram-negative, non-oxidising, soluble, brown pigment- 
producing rods were initially classified in the Centers for Disease Control and Prevention 
(CDC), Atlanta, United States of America (USA) as CDC non-oxidiser group 2 (NO-2) 
(Weyant et aL, 1995). These isolates were found mostly in the blood of young adults, and 
therefore were not initially considered as members of the Bordetella genus, possibly due to 
the lack of association with respiratory disease (Weyant et a l, 1995). However, after genetic 
and chemotaxonomic analyses, these isolates were described as Bordetella holmesii (Table 1.1, 
page 5) (Weyant et al^ 1995). Subsequently, they have been isolated from nasopharyngeal 
specimens (Mazengia et al, 2000; Yih et aL, 1999). Isolation of B. holmesd h^s been described 
in patients with certain underlying conditions such as sickle-ceU anaemia (Njamkepo et aL,
2000) and those undergoing haemodialysis (Greig et aL, 2001). Anotlier Bordetella species, 
Bordetella was also described in 1995, and is similar to Bordetella avium in that they have 
botli been isolated from birds (Vandamme et aL, 1995). Bordetella hin^i has also been 
isolated from immuno-compromised patients, such as those with acquired immune 
deficiency syndrome (AIDS) (Cookson et al, 1994) and cystic fibrosis (Funke et aL, 1996). 
Bordetella trematum was described in 1996 (Vandamme et ai, 1996) and has to date, not been 
isolated from the respiratory tract, but from wounds and ear infections of humans. 
Genotypic and phenotypic comparisons of these three Bordetella species have placed them 
in the Bordetella genus.
Prior to 2001, all members of the Bordetella genus were obligatory parasites of either 
humans, other mammals or birds, and mostly isolated from the epithelial cüia of the 
respiratory tract (Table 1.1, page 5). Bordetella pertussis, B. parapertussis and B. bronchiseptica are 
capable of intracellular survival in host cells (Forde et al, 1998; Friedman et ai, 1992; Lee et 
al, 1990). Furthermore, B. bronchiseptica and B. parapertussis have been shown to grow and 
survive in natural waters and other low-nutrient conditions, suggesting that they might have 
an environmental reseivoit (Porter et aL, 1991; Porter and Wardlaw, 1993). This suggestion 
was fardier supported by die description in 2001 of Bordetellapetrii, which was isolated from 
river sediment and enriched in an anaerobic, dechlorinating bioreactor (von Wintzingerode 
et al, 2001). This new species, through phylogenetic and chemotaxonomic comparisons, 
was found to be most closely related to the Bordetella species (von Wintzingerode et al,
2001). Although B. petrii an environmental isolate and a facultative anaerobe, this 
designation has been accepted, but its pathogenicity and animal hosts, if any, are unknown.
1.1.2 Amended definition of the Bordetella genus
The description of B. petrii has caused the definition of the Bordetella genus to be modified 
to:
“Gram-negative, catalase-positive, asaccharolytic coccobaciUi with an DNA [mole 
percent of guanine and cytosine content] G+C content of 60-69 mol%. Growth 
occurs stricdy aerobically, facultatively anaerobically and non-fermentatively. One 
species [J5. petrii\ is able to grow anaerobically under conditions favouring 
respiratory nitrate and selenate reduction. Species assimilate citrate under aerobic
conditions, one species [B. petrii\ asshnhates D-gluconate...................Strains were
isolated from humans and warm-blooded animals, one strain [B. petrii] was isolated 
from the environment. Based on comparative 16S rRNA gene sequence analysis, 
the species forms a distinct cluster separated from members of the genera
A.chromobacter and Alcaligenes within die fd-Proteobacteria. The type species of the genus 
is B. pertussisP
(von Wintzingerode et al, 2001) 
Thus, the Bordetella genus has expanded to include recently described species.
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1.1.3 Differentiation of species within the Bordetella genus
Bordetella species can be differentiated by a number of phenotypic tests including motility, 
presence of flagella, and die time taken for appearance of visible colonies on agar plates 
(Table 1.1, page 5). Other useful tests include the lack of growth on MacConkey agar for B. 
pertussis and some B. holmesii strains, and that only B, parapertussis and B. holmesii are able to 
produce a brown pigment when grown on agar containing tyrosine. Biochemical tests such 
as urease and oxidase production are also useful for differentiating the Bordetella species 
(Roberts and Parton, 2001; von Wintzingerode et al, 2001 and 2002).
1.2 B ordetella  virulence factors and pathogenesis
Consistent with their close genetic relationship, the three “classical’^  Bordetella species, B. 
pertussis, B. parapertussis and B. bronchiseptica, have many virulence factors in common (Table 
1.2, page 7). These can be divided into two classes dependent on their function: toxins 
including pertussis toxin (PTX) and adenylate cyclase toxin (ACT), and adhesins such as 
filamentous haemagglutinin (FHA) and fimbriae (FIM). Most of the important virulence 
factors have been characterised for B. pertussis, and those central to this diesis are described 
further.
1.2.1 Regulation of virulence factor expression
The regulation of the expression of Bordetella virulence factors has been studied for many 
years. Infrequent changes in virulence properties of fresh isolates were first described by 
Leslie and Gardner (1931) as "phase variation’. Lacey, in 1960, introduced the term 
"antigenic modulation’, where B. pertussis isolates, when grown under submodulating 
conditions, can reversibly convert from an X mode (virulent), to the C mode (avirulent) via 
an intermediate mode (I) (Lacey, 1960). In 1984, Weiss and Fa&ow (1984) brought 
together the infrequent action of phase variation and the freely reversible antigenic 
modulation by suggesting a common regulatory mechanism was involved, identified as the 
virulence regulatory locus, vir, and later re-named the bordetella virulence gene {bv^.
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The bvg locus is present in B. pertussis, B. parapertussis, B. bronchiseptica and B. amim (Aiico et 
al, 1991; Gentry-Weeks et al, 1991), and codes for two proteins, BvgA and BvgS, as part of 
a two-component system (Figure 1.1, page 9). The bvglocu.^ is activated (Bvg^ phase) when 
the temperature is above 30"C and no nicotinic acid or magnesium sulphate (MgSO^) is 
present. Transcription of many virulence-activated genes (vags) seems to be activated at 
different times after transfer to the non-modulating conditions (Uhl and Miller, 1994; Uhl 
and Miller, 1995). "Early activated’ promoters include those genes encoding adhesins FIM 
and FFIA, whilst the "late activated’ vag genes encoding PTX and ACT, are expressed two 
hours later (Scaiiato et al, 1991). The gene encoding pertactin (PRN), an adhesin, is 
intermediately transcribed (Kinnear et al, 1999). At low temperatures, or in tire presence of 
nicotinic acid or MgSO.^, the genes are silent, and anotlrer set of genes, the virulence- 
repressed genes {vr^ are expressed (Bvg“phase). These genes, studied more extensively in
B. bronchiseptica, are involved in motihty, iron-scavenging, urease and phosphatase activity 
(Akeiiey et al, 1992; Giardina et al, 1995; McMillan et al, 1996; Chhatwal et al, 1997). An 
intermediate bvg phase (Bvg phase) has been reported recently, and is characterised by the 
expression of BipA, a bordetella Bvg-inteimediate phase protein (Stockbauer et al, 2001).
A second two-component regulatory system (regulator of intracellular response, the ris 
locus) has been described recently in B. hnmhiseptica and Bpertussis, although its proposed 
role in bacterial resistance to oxidative stress, the production of acid phosphatase and in vivo 
persistence has been observed only in B. bronchiseptica (Jungnitz et al, 1998).
1.2.2 Toxins
1.2.2.1 Pertussis toxin
Pertussis toxin is produced only by B. pertussis, and although B. bronchiseptica and B. 
parapertussis both possess the genes for this complex protein, they are silent and tlierefore 
the protein is not transcribed. The protein PTX is a 117 KDa A-B exotoxin, similar to 
those produced by Cotynebactermm diphtheriae and Vibrio chokrae. It is made up of five 
different polypeptides (SI to 85) in a 1:1;1:2:1 ratio, with the 81 subunit comprising the A 
protomer, and tlie B cell-binding subunit involving the otlier polypeptides 82 to 85 
(Roberts and Parton, 2001).
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The B oligomer forms a triangular structure for the SI subunit for correct insertion into the 
cytoplasm of mammalian cells (Stein et ai, 1994). The S2 and S3 subunits constitute die 
receptor-binding domain, preferentially binding to glycoproteins. After receptor binding, 
the SI subunit dissociates from the B oligomer and is translocated through the 
endoplasmic reticulum membrane, probably via the retrograde transport system (el Baya et 
ai, 1997). A set of nine pertussis toxin liberation genes (pt!) are involved in the 
transportation of the pertussis toxin through the inner and outer membranes of B. pertussis 
(Farizo et ai, 2002). Transportation of PTX through the outer membrane could be due to 
the formation of a püus-Hke structure of the p tl products, where extra PTL proteins are 
added on to the structure to push out the pertussis toxin (see Figure 1,1, page 9). The ptxA  
and j)//loci are present in B. parapertussis and B. bronchiseptica, but due to mutations in die 
p txA  promoter gene, diey are not transcribed and therefore, there is no expression (Locht 
and Antoine, 1999).
The SI subunit (the A protomer) possesses an enzymatic activity, specifically causing the 
adenosine diphosphate (ADP)-ribosylation o f a host-cell G protein, Gj, that normally 
inhibits mammalian adenylate cyclase (AC) activity. This results in continuous activation of 
AC by another stimulatory G protein, Gg. The SI subunit has various pathophysiological 
and immunomodulating activities, such as histamine and serotonin sensitisation, activation 
of insulin secretion, stimulation of haemagglutination and inhibition of neutrophil oxidative 
burst (Mills, 2001). The immunomodulating activities make PTX a good candidate for 
inclusion in aceUular vaccines (ACVs) (Munoz, 1985; MiUs, 2001). Formaldehyde-toxoided 
PTX (PTXd) gives protection in mice against both intra-cerebral (i.e.) and aerosol 
challenges with B. pertussis (Sato and Sato, 1984). Genetically-inactivated pertussis toxin 
developed by Peppoloni and colleagues (1995) for inclusion in ACVs, contains three T cell 
antigenic sites in the SI subunit: 1 to 42, 181 to 211, and 212 to 235 arrdno acids. These 
sites in the SI subunit have been shown by Mooi et al (1998) to exhibit polymorphisms at 
the genetic level, and this will be described later (1.6.4, page 46).
1.2.2.2 Adenylate cyclase toxin
Adenylate cyclase toxin (ACT) is a bifunctional 177 KDa protein belonging to the RTX 
(repeat in toxin) family, and is produced by B. pertussis, B. parapertussis and B, bronchiseptica 
(Roberts and Parton, 2001). It possesses weak haemolytic activity and, because of its 
cahuoduHn-dependent adenylate cyclase activitiy, is capable, after gaining entry, of 
intoxicating a wide range of eucaryotic cells, including neutrophils, monocytes, 
macrophages and natural Idller cells (NKCs) (Hewlett and Gordon, 1988). Antibodies
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against adenylate cyclase are produced during pertussis infection and in humans vaccinated 
with pertussis whole-cell vaccines (WCVs) (Farfel et al, 1990). Adenylate cyclase toxin is 
protective in mice against respiratory tract challenge with B. pertussis (Guiso et ai, 1991; 
Hormozi et ai, 1999), and there have been suggestions to include a detoxified form of ACT 
in ACVs.
1.2.2.3 Dermonecfotic toxin
Dermonecrotic toxin (DNT), becomes completely inactive when heated at 56°C for 10 
minutes, hence the alternative name, heat-labile toxin (Nakase and Endoh, 1988). The toxin 
was later renamed dermonecrotic toxin, because it can cause necrotic lesions when injected 
subcutaneously into rabbits, mice or guinea pigs (Locht and Antoine, 1999).
Dermonecrotic toxin is highly lethal when injected intravenously in mice (LDgg^b.O ng), 
and the mouse toxicity test for WCV safety was introduced by Pittman and Cox (1965), 
chiefly to ensure DNT was destroyed during vaccine production. This 160 KDa toxin is 
produced in B. pertussis, B. parapertussis and B. bronchiseptica, and was one of the first 
bordetella toxins to be described. Bordetella avium also produces DNT, but at a slightly lower 
mass of 140 KDa (Gentry-Weeks et ai, 1988). Dermonecrotic toxin is not secreted 
extracellularly and is locahsed in the cytoplasm. This, and also the very low expression level 
of DNT, has made it problematic to purify the protein (Smitli et al., 2001).
1.2.2.4 Tracheal cytotoxin
Tracheal cytotoxin (TCT) was discovered by Goldman and colleagues (1982), due to its 
ability to cause ciliostasis and ciliated cell extrusion in hamster tracheal organ cultures, and 
inhibition of DNA synthesis in hamster tracheal epithelial cells. A similar action is seen in 
the primary cytopathology of pertussis in humans and in turkey coryza (Goldman, 1988). A 
non-protein toxin, TCT is a low mass (921 Da) disaccharide-tetrapeptide, derived from the 
peptidoglycan of the bacterial cell envelope and is released extracellularly (Goldman, 1988). 
Inteiieuldn-l production is induced by TCT, which then activates host cell nitric oxide 
(NO) production, which is the actual cytotoxic factor (Fleiss et aL, 1994). Cytoldne- 
inducible N O  synthase is, however, detected only when TCT and B. pertussis 
lipopolysaccharide (described below) are both present (Flak and Goldman, 1999). Tracheal 
cytotoxin also inhibits neutrophil chemotaxis and oxidative metabolism, which may 
contribute to B. pertussis survival (Mhls, 2001). Tracheal cytotoxin production, unHlte otlier 
virulence factors of Bordetella, is not controlled by the BvgA/S regulatory system (1,2.1, 
page 6) (Locht, 1999).
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1.2.2.5 Lipopolysaccharide
In common with other Gram-negative bacteria, Bordetella species produce 
lipopolysaccharide (LPS) or endotoxin (Roberts and Parton, 2001). Known as 
HpooHgosaccharide in B. pertussis due to the absence of the polysaccharide O antigen 
moiety, it is a major component o f tlie outer membrane and comprises of a hpid and a core 
oligosaccharide. The hpid domain possesses the potent endotoxin activity, has adjuvant 
properties and can induce resistance to virus infection (Kerr and Matthews, 2000). The 
core oHgosaccharide induces pyrogenicity, and mitogenicity is seen in spleen cell cultures 
(Locht and Antoine, 1999). Bordetella pertussis has two different forms of LPS, (LPS-A and 
LPS-B) and these differ in the structure of the core oHgosaccharide moiety (Chaby and 
Caroff, 1988). The ratio of LPS-A to LPS-B can also differ between strains of B. pertussis 
(Locht and Antoine, 1999). LipooHgosaccharide from B. pertussis together witli TCT have 
been shown to induce inflammation in the respiratory mucosa and cause damage to ciliated 
epithehal cells (Flak and Goldman, 1999). The stimulation of secretion of both pro- 
inflammatory and anti-inflammatory cytokines, makes Hpopolysaccharide a major factor in 
the systemic and neurological responses to infection (Mills, 2001).
1.2.3 Adhesins
1.2.3.1 Filamentous haemagglutinin
The most studied and major adhesiti of B. pertussis, filamentous haemagglutmin (FFIA), is 
also produced by B. parapertussis and B. bronchiseptica, and an unrelated haemagglutinin is 
present in J3. avium (Parton, 1998). Filamentous haemagglutinin is produced as a 370 KDa 
precursor in B. pertussis and is proteolyticahy processed at both tlie arnino (N-) and carboxyl 
(C-) terminals, resulting in the mature 220 KDa form. The predicted structure of FHA 
based on electron microscopy, circular dichroism spectroscopy and computational analysis, 
is a filamentous monomeric molecule of approximately 2-4 nm in diameter and 40-50 nm 
long (Figure 1.1, page 9) (Makhov et al., 1994). The protein contains two large repeat 
regions: one from 344-1065 amino acids consisting of 38 copies of a 19-residue sequence, 
and the other between 1440-1688 amino acids of 13 copies of a different 19-residue 
sequence. These two regions are thought to form short /5-strands connected by two ^-turns, 
which may form a hairpin-Hke structure, with the head composed o f the two terminal 
regions, the shaft consisting of the ^-sheets, and the tah containing the important arginine- 
glycine-aspartic acid (RGD) motif.
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Filamentous haemagglutinin is encoded by the 10.1 Kb gene fhaB, and consists of an N- 
pi'oximal haemolysin-homologue region, tlie two large repeats, an irnmunodorninant 
domain and the C-terminal region (Delisse-Gathoye et aL, 1990). The secretion and post- 
translational maturation requires another g&n&,jhaC. These two genes are separated by 
genes encoding proteins involved in fimbtial synthesis, and are Imown as the fim!flea gene 
cluster. This indicates a close relationship between the expression of tliese adhesins. The 
protein FhaC interacts with the 115-residue haemolysin-homologue region and forms a /5- 
barrel, outer-membrane pore for FFIA to translocate through the outer membrane (Smith 
et aL, 2001). The 150 KDa C-terminal domain of FHA is then cleaved and the mature FHA 
protein can form the hairpin structure.
The N-terminus of FFA  exhibits heparin-binding to epithelial cells such as W D r (a human 
colon carcinoma cell line) and Cliinese hamster ovary (CFIO) cells (Brennan et ai, 1991; 
Menozzi et al., 1994). The RGD binding site of FHA promotes adhesion to the 
macrophage integrin CR3, which may lead to phagocytosis witliout triggering an oxidative 
burst. The irnmuno-doiuinant domain of FHA via carbohydrate-binding mediates the 
attachment of FHA to cüia, and has been demonstrated in human cüiated ceUs in vitro and 
ciliated cells in annuals (Weiss, 1997). Füamentous haemagglutinin inltibits the classical 
pathway of complement activation by binding to C4b-binding protein (Berggard et ai,
1997). Secretion of IL-10 by macrophages, which is mediated by FHA, inhibits lL-12 
production, and may explain the suppressed T-ceU response in the lungs of mice during B. 
pertussis iniection (Müls, 2001). A strong immunogen, purified FFIA protects mice against 
aerosol challenge with B. pertussis. Füamentous haemagglutinin has therefore been included 
in many second-generation ACVs due to its adhesin and protective properties.
1.2.3.2 Fimbriae
Bordetella pertussis, B. parapetiussis, B. bronchiseptica, and B. avium aU produce fimbriae, also 
Imown as püi (Parton, 1998). In B. pertussis, tliey are composed of major and minor 
subunits, the major subunits forming a pentameric repeat unit, each 13 nm long and about 
5 nm in diameter (Steven et al., 1986). The major subunits, Fim2 and Fim3 are 22.5 KDa 
and 22.0 KDa, and are identical to serotype 2 and serotype 3 agglutinogens respectively. 
The minor subunit FituD, is 40.0 KDa, and is the adhesin located at the tip of the Fhu2 
and/or Fim3 stacked structures.
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Bh&JïmB a n d jfe i genes lie independently in the genome, as does the silent pseudogene 
fimX. Accessory proteins essential for fimbrial biogenesis include a periplasmic chaperone 
(FimB), an outer membrane transport/anchor protein (FimC), and the minor fimbrial 
subunit FimD, described above (Willems et al, 1992).
Agglutination properties of B. pertussis are now known to be attributed, at least in part, to 
the fimbriae, after evidence that anti-fimbrial antibodies in the sera of infected or 
vaccinated children agglutinated the bacteria (Locht, 1999). This property has been 
developed as a serotyping scheme to follow epidemiological trends in B. pertussis 
populations (Eldering et al, 1957). These schemes initially used more than three 
agglutinogens, but presendy, France, The Netherlands and die UK detect three 
agglutinogens by sHde agglutination using either antisera from rabbits or monoclonal 
antibodies (Preston, 1963; Mooi, 1994; Guiso et al, 2001b). The serotypes of Bordetella 
pertussis are controlled by the expression of Fim2 and Fim3; eidier Fim2 or Fim3 determine 
serotypes 1,2 or 1,3, respectively; expression of bodi Fim2 and Fim3 simultaneously, results 
in a serotype 1,2,3 strain; and when expression of bodi Fim2 and Fim3 is absent, serotype 1 
strains are recorded (Parton, 1998). This is dependent on the level of transcription, and the 
switching between die activation of the fim2 and Jtm3 promoters, in a process called 
serotype variation. The fimbrial promoters each possess a long run of cytosine residues, 
which can vary in nuiuber due to insertions or deletions of extra cytosine residues, caused 
by shpped-strand mispaicing during chromosome replication (Mooi, 1994). The crucial 
aspect is thought to be an optimum distance between the putative —10 box and die 
activator (BvgA) binding site for transcription to occur, which results in the expression of 
fimbriae (Smith et al, 2001).
The minor fimbrial subunit FimD, binds to VLA-5 receptors and promotes attachment of 
fiiubriae to monocytes (Hazenbos et al, 1993), and the authors have proposed diat this 
interaction could be critical for B. perti{Ssis 'm\i2iceBxAM: survival. Two regions of Jim2, HI 
and H2, can also bind heparin, a sulphated sugar which is ubiquitous in the respitatory tract 
(Geuijeii et al, 1998). Recent studies using epithelial cell lines derived from the human tract 
indicate that fimbriae from B. pertussis play a role in the infection of die laryngeal mucosa 
(Locht et al, 2001).
A correlation was also observed between the presence of anti-fimbrial antibodies and 
subsequent protection in infected or vaccinated children (Locht, 1999), and purified 
fimbriae protect mice against respiratory infection with B. pertussis (Ashwordi et al, 1988).
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Due to their protective and antigenic properties, both Fitn2 and Fim3 have been included 
in some ACVs (Parton, 1998).
1.2.3.3 Pertactin
Only produced by B. pertussis, B. parapertussis, and B. bronchiseptica, the surface-associated 
adhesin pertactin (PRN) was initially designated P69 or OMP69 in B. pertussis due to its 
apparent relative molecular mass of 69 KDa, following sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (Charles et aL, 1989). The PRN proteins 
of B. parapertussis and B. bronchiseptica are 70 KDa and 68 KDa respectively and aU are 
transcribed as larger precursor proteins. The PRN precursor in B. pertussis is 93,5 KDa, and 
is processed at both the N-terminus, to cleave the 3 KDa signal peptide responsible for 
translocation of the protein across the inner membrane, and at the C-terminus, which 
forms a channel through tlie outer membrane for the mature pertactin protein to reach the 
cell surface (Charles et at., 1994). Homologues of this C-terminal domain are also seen in 
other Gram-negative proteins that are collectively known as autotransporters (Henderson et 
aL, 1998), since they do not require accessory proteins for biogenesis, unhke PTX and FHA 
(Weiss et al., 1993; Smith et al, 2001).
The crystal structure of the mature pertactin protein has been elucidated as a monomer 
composed of 16 parallel strands that form a /5-heHx, which is V-shaped in cross-section 
(Figure 1.1, page 9). Loops protrude from the jd-helix core and they have been associated 
with the biological activities of pertactin (Emsley et al., 1996). These include an RGD motif, 
also found in FHA (1.2.3.1, page 12), and mediates binding of pertactin to CHO cells and 
possibly integrins on mammalian cell surfaces (ICerr and Matthews, 2000). Two other loops 
contain proHne-rich repeat regions: the first repeat, region 1, is located close to the RGD 
motif and has the sequence Gly-Gly-x-x-Pro (GGxxP), and the second repeat, region 2, is 
located close to the C-terminus and bears the sequence Pro-GIn-Pio (PQP) (Figure 1.2, 
page 16) (Emsley et al., 1996). Both regions are immunodominant B-ceU epitopes, as 
revealed by mapping these regions with pertactin-specific monoclonal antibodies (Charles et 
ai, 1991). These two proUne-rich, hmuunodominant regions have recently been found to 
be polymorphic within strains of Bordetella, differing in either the number of repeats or the 
amino acids present in the repeat. Most polymorphisms are located at region 1 in B. pertussis 
(Mooi et al., 1998), and at region 2 in B. bronchiseptica (Boursaux-Eude and Guiso, 2000), and 
their significance will be discussed later (1.6.4, page 46).
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Peitactin-deleted mutants of B, pertussis found to be capable of colonising and 
multiplying in the respkatoty ti'act of mice, implymg that PRN is not essential for bacterial 
persistence (Roberts et ai, 1991). Other research using site-directed mutagenesis to change 
a PRN-derived RGD motif (Arg-Gly-Asp) to a RGB motif (Arg-Gly-Glu), also showed no 
difference in tliek ability to promote adhesion to Hep-2 or CHO cells (Everest et al, 1996). 
There has been some evidence that PRN and FHA functionally interact for efficient cell 
binding (Arico et al, 1993), but the exact role and mechanism of pertactin in adherence has 
yet to be elucidated.
Pertactki was initially discovered during the development o f a veterinary vaccine against B. 
bronchiseptica and found to be a good protective knmunogen (Locht, 1999). Pertactin from 
B. pertussis has also been demonstrated to protect mice against aerosol challenge with B. 
pertussis and, together widi FHA, also protects mice agakist i.e. challenge (Roberts et al, 
1991). This knmunogenicity has made pertactin become one of the main constituents in 
the preparation of ACVs,
1.2.3.4 Bordetella resistance to killing protein
The second autotransporter to be described, bordetella resistance to killing protein (BrltA), 
has 29% overall skmlarity to the nucleotide sequence of pertactin and shares 55% amkio 
acid sknilarity in tlie C-termkial autotransporter domaki (Fernandez and Weiss, 1994), The 
brkA. gene, also translated by B. parapertussis and some strains of R. bronchiseptica, contains 
two RGD motifs and two potential bmding sites for sulphated glycoconjugates, suggestmg 
its role in adherence to host cells. BordetellapertussisBùih mutants are approxknately ten­
fold more susceptible to classical-pathway complement-dependent killing by human sera. It 
was also shown that B. pertussis strains carrying an extra copy of the brk locus secreted 
kicreased levels of BrlcA (Fernandez and Weiss, 1998). The brk locus contakis two genes 
that are transcribed m opposite dkections, brkA and brkB (Fernandez and Weiss, 1994), 
and are essential for serum resistance and tlie secretion of the BrlcA protein. The 
immunogeikc properties of BrlcA have so far not been studied, and this protein has 
therefore not been considered as an ACV component.
1.2.3.5 Tracheal colonisation factor
The thkd auto transporter to be identified was the tracheal coloiksation factor (TCP) (Finn 
and Stevens, 1995). While it is only expressed in B. pertussis, the gene codmg for TCF is also 
present in B. parapertussis and B. bronchiseptica. A B. pertussis mutant laclckig TCF was found
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to have a reduced ability to colonise the trachea, but not the lungs of mice (Finn and 
Stevens, 1995), The C-terminal domain shows 50% amino acid similarity to die pertactin 
equivalent (1.2.3.3, page 15) and thus is predicted to translocate the mature 64 KDa TCF 
protein through the outer membrane. The protein also contains an RGD motif and is 
proline-rich, similar to PRN and BrlcA (Finn and Stevens, 1995). Pertactin, BrlcA, and TCF 
are all surface-associated proteins. However, TCF has also been detected in culture 
supernates as a slightiy smaller 60 KDa secreted form (Finn and Stevens, 1995). There is a 
significant reduction of B. pertussis tracheal colonisation in mice when immunised widi 
attenuated V, chokrae expressing TCF (Chen et al, 1998), aldiough the protective potential 
of TCF has yet to be fully determined,
1.2.3.6 Virulence-activated gene 8
Through screening for ^g^-controlled genes tiiat were positively regulated, the virulence- 
activated gene 8 ipagS) was identified (Knapp and Mekalanos, 1988). The gene is expressed 
in B. pertussis and B. bronchiseptica as a 95 KDa protein. A vagS gene homologue is also 
present in B. parapertussis, but is not transcribed. Classed as an auto transporter, VagS 
possesses similar characteristics to PRN, BrkA, and TCF, aldiough it is not Imown whetlier 
the C-terminal domain in Vag8 is cleaved, as the predicted size corresponds to die size 
determined by SDS-PAGE (Finn and Amsbaugh, 1998). Conflicting results have been 
reported concerning die pathogenesis of Vag8 using a mouse aerosol model (Finn and 
Amsbaugh, 1998). A mutant Vag8 B. pertussis strain was defective in colonisation in both 
the lungs and the trachea, but strains with an internal deletion in the vag8 strucmral gene 
could colonise as well as die wild-type. The authors suggest diat tiiis loss in function of 
mg8 may be compensated for by odier virulence factors (Finn and Amsbaugh, 1998). In B. 
bronchiseptica, it has recentiy been reported that VagS is required for type III secretion 
(Foremaii-Wykert ct al, 2002), but type III secretion is not expressed in B. pertussis (Yuk et 
al, 1998), and hence die role of Vag8 in B. pertussis, if any, is unknown.
1.2.4 Other virulence factors
Widi the aid of a new suicide vector, pFUS2 (Antoine et al, 2000), microarray analysis (Hot 
et al, 2003), and the recent availability of the three Bordetella genomes, B. pertussis, B. 
pat'apertussis, and B, bronchiseptica (Parkhill et al, 2003), novel genes have been discovered 
recentiy with similarities to well-characterised virulence factors. These include the 
bordetella autotransporter protein C {bapC, originally described as bap5), a 79.5 KDa 
predicted protein possessing an RGD motif (Blackburn, 2000). Recent work has also
18
demonstrated that a bapC deficient strain of B. p e r t u s s i s less able to colonise tlie 
respiratory tract in mice than die wild-type and that the mutant also had reduced 
complement-mediated Idlling (Bokhari, 2002). A positively regulated BvgAS, iron-mediated 
outer membrane protein, Vir90, has also been described, and Passerini de Rossi et al (2003) 
predict one function of this newly characterised protein as a receptor for ferrichrome or a 
siderophore. Fifteen other virulence factor genes have been submitted to GeiiBank, 
including one coding for a cold-shock protein (Phg) (Antoine et al., 2000).
1.3 Clinical aspects and diagnosis of pertussis
1.3.1 Clinical symptoms, complications, and treatment of pertussis infection
Transmission of B. pertussis from an infected to a susceptible person is via droplet spread 
from the respiratory tract, followed by an incubation period of seven to 14 days. Classical 
pertussis can be split into three stages: catarrhal, paroxysmal, and convalescent (Roberts 
and Parton, 2001). The catarrhal stage may last from three days to two weeks, and 
resembles a “common” viral cold, widi the infected individual showing symptoms such as a 
mild cough, profuse mucoid rhinorrhoea, and sometimes a mild fever. These symptoms 
can be easily confused with those caused by odier respiratory pathogens but, with prior 
Imowledge of contact history of the patient, treatiuent can be given to reduce or stop the 
organism’s spread from person to person. Prophylaxis (e.g., erytiiromycin) is best given at 
this time to help shorten or even abort the pertussis illness (Linnemann et ai, 1975; Dodhia 
et al., 2002).
Without medical treatment, the mild cough develops into a paroxysmal cough, which can 
last from one to six weeks. A paroxysmal episode consists of six to ten forceful expiratory 
coughs, followed by the characteristic “whoop” sound of the inhalation, caused by the air 
rushing in the partially closed glottis (WaUcer, 1988). Up to 20 or more of diese paroxysmal 
spasms can occur in 24 hours, where they are more common at night, and diey are 
frequendy interrupted by vomiting. The World Healdi Organisation (WHO) case definition 
of pertussis is a niinimuiii o f paroxysmal cougliing for 21 days with laboratory 
confirmation or epidemiological linkage (World Health Organisation, 1991). This severe 
stage is both detrimental and tiring for the patient, and most complications occur during 
this stage. Apnoea, subconjunctival haemorrhage, hernia, and rectal prolapse are some of 
the complications which develop due to the pressure effects of the paroxysms. Other 
complications can result in pneumonia and otitis media, and very rarely, central nervous
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system complications such as seizures and encephalopathy, can also occur (Roberts and 
Parton, 2001).
Many cases of pertussis infection require hospitalisation, especially in infants under six 
months old, and up to 50% can be hospitalised (Health Protection Agency, 2003c). 
Convalescence follows the paroxysmal stage and can last between a few weeks to many 
months, depending on the severity of disease and the complications encountered. Death 
due to complications can occur, widi the majority of cases being under six months old 
(Edwards et al., 1999). A recent study using data from the UK arrived at an estimate of 28 
deaths due to pertussis between 1995 and 1997 (van Buynder et al, 1999).
Clinical symptoms of pertussis are lessened in vaccinated children, adolescents and adults.
In adults, a persistent cough with a mean duration of 36 to 48 days is typical, and sleep can 
be affected. Whooping, vomiting and sweating attacks can also occur, with complications 
such as rib fracture, incontinence, back pain and secondary infection being reported (von 
Konig et al, 2002).
1.3.2 Laboratory diagnosis of Bordetella pertussis infection
Culture and isolation of B. pertussis from suitable respiratory samples is considered to be the 
gold standard for the laboratory diagnosis of B. pertussis infection (Roberts and Parton, 
2001). The medium first used for isolation contained blood, potato extract, and glycerol 
and was named after the developers, Bordet and Gengou (BG) (Bordet and Gengou, 1906). 
Bordet-Gengou medium is stUl used today, as well as Regan-Lowe medium, a charcoal agar 
supplemented with 10% horse blood. Liquid media include Stainer-Scholte broth 
containing (2,6-0-dimethyl)-/5'-cyclodextrin (Roberts and Parton, 2001). The antibiotic 
cephalexin can also be added to the media to inhibit normal nasopharyngeal flora growth. 
The sensitivity of culture can differ widely, and isolation rates are higher; (i) before the 
paroxysmal stage; (ii) from an aspirate rather than a swab specimen; (üi) after a shorter 
transport time; and (iv) from younger, unvaccinated patients than from older, vaccinated 
ones (Roberts and Parton, 2001). Antibiotic therapy, if given, will also reduce the rate of B. 
pertussis hohitLon (Birkebaek, 2001). Consequently, sensitivity of culture can be as low as 20- 
40% (Heininger, 2001) and can take three to four days for colonies to appear (Parton, 
1998). Thus, faster, more sensitive methods of diagnosis would help in the administration 
of correct treatment, and hence reduce transmission.
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Serological assays have been evaluated for laboratory diagnosis of B. pertussis for over 30 
years, originally using complement fixation and agglutination assays (Anon, 1970). These 
have been replaced roughly 20 years ago witlr antigen-specific assays, namely, enzyme- 
Hnked immunosorbent assays (ELISAs) (Viljanen et al, 1982). These assays have been 
valuable in vaccine efficacy and epidemiology studies due to their sensitivity (57-100%)
(von Konig et al., 2002). For diagnosis, ELISAs have been used to detect IgG antibodies 
specific to PT, FHA, PRN, or FIM. Only PT is specific for B. pertussis, as other bordeteUae 
can produce tlie other named factors tliat can induce an immune response, such as 
antibodies to FFIA, which can be detected after an infection with B. parapertussis (Michaels, 
1998). Paired sera are desirable to show a recent infection, the first serum sample ideally 
taken two weeks after tlie onset of cough, and the second about two to three weeks later 
(I-Cerr and Matthews, 2000). For diagnosis however, a single serum sample can be used, but 
this requires prior knowledge of background values from healtliy control individuals and 
defined cut-off values (de Melker et al, 2000b; Nardone et al, 2004). Due to these 
difficulties, and that ELISAs require highly skilled personnel to generate and analyse the 
data, inter-laboratory comparisons can be problematic. Serology is useful in showing recent 
infections of B. pertussis, but does not affect tlie treatment of the individual, and therefore a 
more rapid method is required to affect the transmission of B. pertussis.
The development of diagnostic polymerase chain reaction (PGR) assays over recent years 
has allowed health care professionals to rapidly detect a wide range of bacteria and viruses 
causing disease in man (Louie et al, 2000; Elnifro et al, 2000). This rapid and sensitive 
method has been applied to tlie fastidious, slow-growing B. pertussis, targeting genes such as 
die pertussis toxin promoter (Houard et al, 1989), and the repeated insertion sequence, 
IS^<?/ (Glare et al, 1990). Using the same respiratory sample as for culture isolation, B. 
pertussis DNA can be extracted, amplified and detected in less than a day. Consensus 
recommendations have been published to niinimise that no false positives are detected 
(Meade and BoUen, 1994), partly by including internal and external controls. Other 
advantages of PCR-based assays include the detection of B. pertussis in clinically atypical, 
vaccinated or antibiotic-treated patients. Sensitivity rates can reach three-fold higher for 
PGR detection compared to culture isolation (Fry et al, 2004; Heininger, 2001). Major 
technological advances in recent years have yielded machinery capable of sinaultaneously 
amphfying and detecting B. pertussis witiiin four hours (Reischl et al, 2001; Kosters et
al, 2001).
Problems with PCR techniques include DNA extraction efficiency, where there are 
relatively low amounts of B. pertussis DNA compared to host (i.e., human) DNA, technical 
difficulties with the assay, PCR inhibitors and false positives. This latter problem has been 
found recently in a real-time PCR targeting for 1S481 (Reischl et ai, 2001). The B. pertussis 
Tohama-I genome contains 238 copies of the IS481 element (Parldhll et al, 2003), and this 
element has also been detected in the newly discovered Bordetella species, B, holmesii. Only 
eight to ten copies of 1845/ were found in B. holmesii strains, but this is sufficient to 
produce a positive result in tlie sensitive real-time PCR assay targeting the 1845/ element. 
The authors therefore recommend cautious use of this 1845/ assay, and suggest tlie 
concurrent use of another target (Reischl et al, 2001). The 1845/ element was also found in 
two B. bronchiseptica strains isolated from humans, although the insertion element has not 
been found in other B. bronchiseptica strains (Gladbach et al, 2002). Despite this, PCR is a 
powerful tool in detecting B. pertussis within a sufficient time frame to affect transmission 
and treatment (Birkebaek, 2001). However, it has been recommended that culture isolation 
should continue, as strain variation, antibiotic resistance and other characteristics may not 
be studied by PCR-based systems alone (Hewlett, 2000).
1.4 Epidem iology and prevention
Before mass vaccination against pertussis was introduced, B. pertussis was responsible for 
childhood morbidity and mortality worldwide (Roberts and Parton, 2001). An endemic 
disease, pertussis epidemics were seen every three to four years, occurring in approximately 
20% of infants younger than one year, and up to 60% in children between one to four 
years, pealdng at three years old (Edwards et al, 1999). Pertussis was an early childhood 
infectious disease and mortality rates were liighest in neonates. Due to this severe and 
highly transmissible disease, vaccines against pertussis were formulated soon after the 
isolation of the causative organism in 1906, and tlie first whole-cell pertussis vaccine 
(WCV) was licensed in the USA in 1914 as a suspension of Idhed B. pertussis organisms 
(Edwards et al, 1999).
1.4.1 Pertussis vaccination in the United Kingdom
The WCV was gradually introduced in the UK from 1937 and immunisation against 
pertussis became national policy in 1957 (Grant and Cherry, 2002). Initially the Burroughs 
Wellcome WCV was comprised of two B, pertussis strains, CN4132 and CN2992, exliibiting 
serotypes 1,2 or 1,2,3, respectively. One study showed that circulating strains before 1958 
were serotypes 1,2 and 1,2,3, and, by 1963 to 1964, strains had shifted to mostly serotype
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1,3, and it was suggested that a vaccine containing serotype 1,2 could not protect against a 
pertussis infection by a serotype 1,3 strain (Preston, 1965). Furthermore, a study by the 
Public Health Laboratory Service (PHLS) Whooping-cough Committee and Working Party 
reported that serotype 1,2,3 was isolated more frequently from unvaccinated than from 
vaccinated children (Abbott et ai, 1973). Therefore, a third strain, CN5476 (serotype 1,3), 
was added in 1966 to include aU three serotypes and the potency of pertussis vaccine was 
increased according to the British Bbarmocopoeia requirements. In 1979, the WHO 
recommended that aU pertussis vaccine preparations should contain serotype antigens 1,2, 
and 3 (World Health Organisation, 1979). The pertussis WCV is adrninistered as part of a 
combined vaccine with diphtheria and tetanus toxoids (DTP). In the UK, since 1990, the 
previous schedule at tliree, five, and ten months has been replaced by the accelerated 
immunisation schedule at two, three, and four months of age.
Following the introduction of WCV in the UK, cases of pertussis dropped significantly 
(Figure 1.3, page 25), although the three-yearly cyclic peaks are still present. This indicates 
tliat, whilst the number of pertussis cases have been reduced, transmission of the organism 
is still occurring, albeit at a reduced rate (Rohani et al, 2000). The vaccine uptake was over 
80% between 1969 to 1973, and pertussis notifications fell from 85,000 in 1957, to 2400 in 
1974, thus lowering the incidence of pertussis in aU age groups (Immunisation Division, 
CDSC, I-IPA, 2004a).
Despite the success of the WCV, adverse effects, such as redness, swelling and pain at the 
site of injection in half of the children in receipt of the vaccine, have been reported 
(Edwards et al, 1999). Other common reactions are fever, irritability, drowsiness and 
excessive crying. Convulsions and seizures have also been associated with the WCV, but 
are rare (Edwards et al, 1999). In 1974 and 1977, two reports linked tlie pertussis 
component of the DTP vaccine widi acute neurological disorders in children in the UK 
(Department of Health and Social Security, 1977). This was widely publicised in the media, 
and public confidence towards pertussis vaccination fell. Vaccine uptake then dropped 
dramatically to 30% in 1978. This low vaccine coverage led to two pertussis epidemics, 
peaking in 1978 and 1982 (Figure 1.3, page 25) (Immunisation Division, CDSC, HP A, 
2004a).
Further studies by a number of groups, including the American Academy of Neurology, 
the British Paediatric Association, the National Advisory Committee on Immunization 
(Canada) and the Advisory Committee on Immunization Practices (USA), concluded that
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these data did not link encephalopathy with the pertussis vaccine (Edwards et al, 1999). 
Gradually, public confidence was regained and vaccine uptake slowly recovered to current 
levels of 93% (Immunisation Division, CDSC, HPA, 2004a). The reported incidence of 
pertussis in the UK is now historically low, and only 409 cases in England and Wales were 
reported in 2003 (Figure 1.3, page 25). This drop in incidence may however be due to 
under-reporting of pertussis cases, which is described later (1.4.4, page 28) (Crowcroft and 
Britto, 2002).
1.4.2 AceUular vaccines
Concerns about the safety and adverse reactogenicity of the WCV (1.4.1, page 22) led to 
the development of aceUular vaccines (ACVs). First introduced in 1981 in Japan, six 
licensed ACVs initiaUy consisted of formaldehyde-toxoided PT (PTXd) and FHA, with 
some also containing PRN and FIM as contaminants. Due to the exclusion of LPS, these 
vaccines were less reactogenic (Edwards et al., 1999). Results from these first ACVs 
convinced other countries and companies to develop second-generation vaccines using 
other detoxification methods, including gluteraldehyde, hydrogen peroxide, and genetic 
engineering (Edwards et al, 1999). Large-scale trials in Sweden, Germany, Italy and Senegal, 
tested the efficacy and reactogenicity of various ACVs. These ACVs differed in amount 
and number of components, the purification method and adjuvant used. The trials were 
also different in design and the vaccine regimen tested, so comparing results directly is 
difficult. In general, the efficacy of ACVs ranged from 59% to 93%, vaccines containing 
three to five antigens were better than those comprising only one or two, and ACVs were 
less reactogenic than WCVs (Edwards et al, 1999).
With the success of these trials, pertussis ACVs combined with vaccines against diphtheria 
and tetanus toxoids (DTaP) have been licensed and used in many countries, including the 
USA, Japan and most European countries (Edwards et al, 1999). These have been 
successful in reducing pertussis notifications and, due to their low reactogenicity, ACVs can 
be used as boosters (Edwards et al, 1999). Pertussis boosters have been introduced in other 
European countries such as France, Germany, and The Netherlands (Therre and Baron,
2000). In addition to DTaP, multi-combination vaccines have been developed. Several 
countries, including Denmark, Austria and Italy are using tetravalent or pentavalent 
vaccines with Haemophilus influencée b and/or inactivated pohovirus (DTaPHib, DTaPIPV 
or DTaPHiblPV) (Therre and Baron, 2000).
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The enhanced surveillance system was introduced in 1994 to monitor whooping cough in 
England and Wales, the vaccine efficacy, and to assess the need for infant pertussis booster 
vaccination (Miller et aL^  1994). This surveillance entails the collaboration between the 
Communicable Diseases Surveillance Centre (CDSC) and Manchester University to follow 
up all culture-confttmed cases of pertussis for information on vaccination liistory, severity, 
antibiotic prophylaxis/treatment and history of exposure. Early analysis showed tliat 
mortality and morbidity was still prevalent in the very young and suggested booster 
vaccination could reduce this (van Buynder et aL, 1999). Further studies supported this 
proposal through unimmunised infant case reports (Ranganathan et ai, 1999; Crowcroft et 
ai, 2003), surveillance data (Beard and Finn, 2000), and potential health gain and cost 
consequence estimates (Edmunds et al., 2002; Stevenson et aL, 2002). In November 2001, 
die Department of Health introduced a pre-school aceUular vaccine (ACV) booster (around 
four to five years old) in England and Wales, with a recommendation to introduce the 
booster to Scotland and Northern Ireland (Healtii Protection Agency, 2003c). This 
intervention has yet to be evaluated for its impact on pertussis notifications and 
improvement in vaccine efficacy.
1.4.3 Pertussis in other countries
Currendy, 80% of the world’s children are vaccinated against pertussis, mosdy with WCV. 
Despite this, there are still 20 to 40 million cases and 200,000 to 400,000 deaths due to 
pertussis each year (Anon, 1999a). Over 90% of these cases are from developiig countries 
and die WHO Expanded Programme of Immunisation (EPI) is slowly reducing this, but 
their goal of lowering the incidence of pertussis to below one in 100,000 by 2010 may not 
be achieved.
In contrast, many developed countries with good immunisation programmes have 
managed to reduce pertussis incidence to low levels (Anon, 1999a). However, pertussis 
vaccination programmes have been dramaticaUy affected by the media and anti-vaccine 
movements, such as in the UK (1.4.1, page 22), Japan and Sweden. In Japan, nearly 80% 
vaccine coverage was achieved in 1974, but because of the resulting low incidence, and 
reports of neurological reactions resulting after DTP vaccination, one province switched to 
a vaccine containing just diphtheria and tetanus toxoids (D l) (Gangarosa et aL, 1998). The 
diphtheria and tetanus vaccine was then quicldy introduced throughout the whole country 
after two infants died within 24 hours of receiving DTP. With no pertussis vaccine, an 
epidemic occurred in 1979 culminating in 13,000 cases and 41 deaths. Japan later
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introduced ACVs, and pertussis incidence fell sharply to levels seen before the interruption. 
Sweden’s vaccine was also suspended in 1979 after suggestions that the WCV had poor 
efficacy and hnks to neurological events. Pertussis incidence increased four-fold, major 
outbreaks occurred and incidents of serious complications approached global rates. After 
several major clinical studies of various ACVs in Sweden, the country introduced 
widespread immunisation with an ACV in 1996, and notification figures are now faUing 
(Anon, 1999b). Ireland and Australia were also indirectly affected after the adverse media 
coverage in the UK. Expressed as “passive anti-vaccine movements”, this resulted in low 
vaccine coverage, a raised incidence and major outbreaks in Ireland and Australia 
(Gangarosa et al, 1998). Events in tiiese countries illustrate how important it is to sustain 
high vaccination rates to help reduce the possibility of pertussis epidemics from occurring.
In some countries with high, sustained vaccination coverage, there have been reports of 
outbreaks and rising pertussis incidence (Cherry, 1996), including Canada (De Serres et ai,
1995) and the USA (Guris et ai, 1999b). In Quebec, and other parts of Canada, outbreaks 
occurred yearly from 1988 to 1994, but there was no explanation for their cause (De Serres 
et al, 1995). With the replacement o f ACV in 1997, the resurgence of pertussis in Canada 
subsided, but a large outbreak in British Columbia in 2000 has re-established concern. 
Recent data indicate that there is an increase of pertussis in ten to 19 year olds, and a 
decrease amongst infants and pre-school children (Skowronsld et al, 2002). These authors 
now believe that the introduction of the ACV, a waning immunity and changes in 
laboratory metliods may account for this apparent resurgence of pertussis (Skowronski et 
al, 2002). Lilce Canada, the USA has also seen an increase of pertussis in older children (ten 
to 14 years) from 1980 to 2000, and consequendy, pertussis is regarded as a re-emerging 
infection (Roberts and Parton, 2001). An increase of pertussis has also been seen in infants 
under four months of age since 1991 (Guris et al, 1999b). A change from WCV to ACV 
has not affected this increase, so improved diagnosis and reporting in these two age groups 
are thought to be contributing to dûs apparent resurgence (Guris et al, 1999b).
Australia has reported pertussis epidemics since 1993, despite vaccination coverage 
approaching 90%. Due to an observed increased rate in children aged five to 14 years, a 
fifth WCV dose was introduced in 1995 for children aged four to five years, and dûs 
appears to have lessened die burden in younger clûldren (Andrews et al, 1997). The 
introduction of improved diagnostic methods such as serology in the 1980s and PCR later, 
may have also contributed to the apparent increased incidence in pertussis (World Healdi 
Orgarûsation, 2001). The Netherlands experienced a pertussis epidemic in 1996, with 2,771
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cases compared to just 319 in 1995, Vaccine coverage after three doses of WCV was at 
96% when the epidemic happened, but tiie cause was unknown (de MeUrer et al.^  1997).
AU of these countries with apparently high pertussis vaccine coverage have reported an 
increased incidence in pertussis. Many factors have been suggested for this resurgence, 
including; (i) waning vaccine-induced immunity; (ii) a decrease in vaccine quality; (hi) 
improved surveUlance and laboratory diagnosis; (iv) a recent change in case definition of 
pertussis, amended in 1991 by WHO; and (v) the expansion of strains which are 
antigenicaUy distinct from the vaccine strains (Mooi et al^ 1998). The last tlieory, proposed 
by Mooi and his coUeagues in The Netherlands (1.6.4, page 46) (1998), was tested during 
the course of this thesis and the results and conclusions are described later.
1.4.4 Recent changes in the dynamics of pertussis disease
Mortahty and morbidity due to pertussis have decreased due to immunisation, with a shift 
in tlie age distribution of those affected, from mostly infants and young children, to 
younger unvaccinated neonates, adolescents and adults (Crowcroft and Britto, 2002). In the 
USA, 28% of reported cases occurred in subjects ten years or older in 1992 to 1994, 
compared to just 3% in over 15 year olds before vaccination was introduced (Edwards et 
ai, 1999). This increase in adolescents and adults has also been seen in Austraha, Canada, 
the UK and other countries in Europe, to 10 to 12% of all cases reported in over fifteen 
year olds (Anon, 1999a). Better laboratory diagnosis using serology and PCR-based assays 
may account for this reported increase in adolescents and adults, where culture isolation 
alone may have caused under-reporting. However, the adult population, initially assumed to 
be immunised, is now thought to represent those with waning immunity and can be 
susceptible to subsequent pertussis infections (von Konig et al.^  2002). Furtliermore, when 
infected, these patients’ symptoms may be atypical and the disease can go undetected. 
Through studies of households, hospitals, and outbreaks, it is now drought that these 
adolescents and adults transmit pertussis to vuhierable unimmunised young infants or 
those that are not yet fuHy immunised (Rosenthal et ai^ 1995; von Konig et al.^  2002;
Christie et al.^  2001; Crowcroft et at., 2003). Together with the high mortahty rate in these 
young infants, the possible prolonged iUness, and loss of work hours, various proposals to 
introduce boosters for adolescents have been put forward (Edwards, 2001; Heiniiiger,
2001; von Konig et al.^  2002). In 1998, France introduced an ACV booster for 11 to 13 year 
olds (Fletcher et al., 2001) and, very recendy, Germany and Canada have also recommended 
adolescent boosters (Anon, 2003a and 2003b). Administering pertussis vaccine to health-
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care workers has also helped in containing outbreak situations. In Germany, paediatric 
workers are required by law to receive boosters (von Konig et ai, 2002).
Although die reported incidence of pertussis in England and Wales is low, a B. pertussis 
surveillance study, compiling data from various sources in England and Wales between 
1995 to 1997, analysed the composite data-set for any significant associations between 
clinical, epidemiological and laboratory data (van Buynder et al., 1999). Death due to 
pertussis occurred only in infants less than six months old and was thought to be under­
estimated. This has been exempHfied widi a recent report concluding that national 
mortahty statistics under-estimate deaths from pertussis in England, and that the enhanced 
laboratory surveillance identifies most of these deaths (Crowcroft et al, 2002).
Unvaccinated subjects were more hkely to be liospitaHsed than vaccinated subjects, and 
severity of pertussis disease was reduced when appropriate antibiotics were given to case 
contacts before onset (van Buynder et al, 1999). An association between serotype 1,2 and 
severe disease was also found, together with an increase of serotype 1,2 in strains isolated. 
Tills prevalence of serotype 1,2 has also been found in The Netherlands with an increase of 
disease (de MeUrer et al, 2000a; Mooi, 1994).
Pertussis epidemiology appears to be dynamic, dependent on vaccination status, diagnostic 
methods and surveillance programmes. In Europe, new projects such as the European 
seroepidemiology network (ESEN) and the European network for vaccine preventable 
diseases (EUVAC-NET) whl aid standardisation of diagnosis, vaccine coverage and 
surveillance across several countries (World Health Organisation, 2001; Schmidt et al,
2001). In developing countries, however, pertussis causes high morbidity and mortahty, 
although reports in South-East Asian and African regions of vaccine coverage are sparse 
(World Health Organisation, 2001). The Introduction of AC Vs has increased pubhc 
confidence towards pertussis vaccination due to its efficacy and low reactogenicity. 
However, the high cost of AC Vs compared to WCVs may be unaffordable to developing 
countries. Whilst there is dependence on private pharmaceutical companies to produce 
both, an assurance that WCVs wiU be available to poorer countries is needed. When 
vaccination was introduced, tlie eradication of B. pertussis was envisaged, but because of 
resurgence m developed countries and poor vaccine distribution in developing countries, 
tliis seems to be unhlcely. Basic laboratory survehlance and control measures need to be 
focused in countries with high mortahty to reduce pertussis globahy (Crowcroft and Britto,
2002).
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1.5 Genotypic typing of bacteria
1,5.1 Caveats to typing bacteria
Microbiologists and epidemiologists use various methods to characterise bacteria from 
infection in a single host to global bacterial populations, and these can involve either short­
term or long-term investigations (Struelens eî al, 1996). Fields such as bacterial population 
genetics, pathogenesis of infection, epidemiological surveillance and outbreak 
investigations can employ genotypic typing to discriminate between genomes. The study of 
population genetics on a large data-set of isolates from various backgrounds can generate 
information on the clonaHty of an organism. This can then form a basis for the study of 
pathogenesis, as it can highlight differences between groups of bacteria and their virulence 
properties. Epidemiological surveillance entaüs combining clinical and laboratory data over 
time as an ongoing process, which then enables tlie identification of trends such as disease 
frequency, epidemic clones, drug resistance and risk factors in a target population 
(Struelens et al, 1996; Struelens, 1998). An outbreak can be defined as;
‘"an increased incidence of an infectious disease in a specific place during a given 
period that is above the basehne rate for that place and time frame” .
(Tenover et al, 1995)
In an outbreak investigation, the use of genotypic methods can allow the tracking of 
important clones (a group of isolates within the same type) and the identification of 
reservoirs of infection and vehicles of transmission. If performed within a rapid time 
frame, it allows health-care personnel the potential to control infection by containing or 
interrupting the spread of the organism (Struelens et al, 1996).
Several recommendations or criteria have been proposed to evaluate bacterial typing 
systems for microbial epidemiology (Maslow et al, 1993) including typability, 
reproducibility, discrirrtinatoiy power, stability and epidemiological concordance. The 
typabüity is the proportion of isolates that can be assigned a type, within tlie test 
population. Reproducibility is the ability of the typing system to correctly assign a strain to 
the same type repeatedly. This criterion is thought to be the most difficult to ascertain for 
many typing techniques and, as the reproducibility affects the discriminatory power, it is 
also one of the most important (Struelens et al, 1996). The discriminatory power is tlie 
average probabihty of two unrelated strains being assigned different types, as shown by 
Simpson’s index of diversity (Hunter, 1990). The stability of markers can be affected by 
recombination events on the bacterial genome, and variations can occur after prolonged 
storage or in large-scale epidemics (Struelens et al, 1996). This variation may be acceptable
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if the typing system can still show the clonal lelatedness of epidemiologically-linked strains. 
The epidemiological concordance is the probabihty that presumed single-clone outbreaks 
result in epidemiologicaUy-related strains that can be assigned to the same type or clone 
(Struelens «/., 1996).
Most of the above criteria: typabihty, reproducibihty, discriminatory power, stabüity and 
epidemiological concordance can be calculated definitively with a formula, and their values 
vary from zero to one (Table 1.3, page 32) (Struelens et al., 1996). Other criteria that are 
useful in selecting an appropriate typing system include rapidity, availability, cost, ease of 
performance and interpretation.
The typing methods used to differentiate bacterial strains and their clones can be sorted 
into two groups, phenotypic and genotypic (Maslow et al, 1993). Phenotypic methods rely 
on the abihty of an organism to express the characteristic chosen to be typed, and are 
dependent on the genes controlling these characteristics. This can produce low typabüity, 
reproducibihty or discriminatory values and therefore, genotypic methods have been 
developed for typing bacteria, as they test tlie genome or genes directly (Maslow et al,
1993). For the purpose of this thesis, only the genotypic methods and some suggested 
apphcations are described.
1.5.2 Genotypic methods
Genotypic methods can involve cleavage by restriction endonucleases, amphfication via the 
polymerase chain reaction (PCR), and direct amphfication and sequencing of the bacterial 
genes on chromosomal or plasmid DNA. Many of them are detailed below.
1.5.2.1 Plasmid typing
Plasmid typing was one of the first genotypic methods to be used for epidemiological 
typing and entails the isolation of plasmids from the strain and determimng the number 
and sizes via agarose gel electrophoresis (Maslow et al, 1993). Although the technique is 
easy to perform and is moderately priced (Table 1.3, page 32), plasmid typing can vary in 
typabihty and discrhuinatory power, according to the presence and number of plasmids and 
the bacteria studied (Maslow and Mulligan, 1996). Reproducibihty can also be poor, as 
supercoüed and open circular forms of the same plasmid can migrate differently during 
electrophoresis (Maslow and MuUigan, 1996), and due to their extrachromosomal nature, 
they can be lost or acquired spontaneously (Maslow et al, 1993).
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1.5.2.2 Restriction endonuclease analysis
Restriction endonuclease analysis (REA), a restriction fragment length polymorphism 
(RFLP) method, uses enzymes tliat will cleave the chromosomal and/or the plasmid DNA 
(if present) at specific sites, and potentially this can generate several hundred small 
fragments, which are then separated by conventional gel electrophoresis (Struelens et <?/., 
1996). Different strains of the same species can have different REA profiles due to the 
variations in their genomes and the subsequent changes in restriction sites (Maslow et ai^ 
1993). This simple technique can be used for any bacterial species and, after standardising 
conditions, such as enzyme selection, separation conditions and band size range, REA can 
be very reproducible and discriminatory (Struelens et al.^  1996). Streptococcus pyogenes^  
Clostridium difficile and Ijegionellapneumophila have been typed successfully using REA (Cleary 
et al.^  1988; Clabots et al, 1992; Fry et al^ 1999), however, the interpretation of the complex 
profiles is difficult. Also, any plasmid DNA present may affect the pattern generated, so 
that differences may be influenced by tlie plasmid and not due to any genomic variation 
(Maslow et aL^  1993).
1.5.2.3 Insertion sequence- restriction fragment length polymorphism analysis and 
ribotyping
Another RFLP approach is to transfer the REA profiles from tlie gel to a membrane, 
otherwise Imown as Southern blotting (Soutliern, 1975). Nucleic acid probes designed to 
target genes, insertion sequence (IS) elements or rRNA genes can then be hybridised to 
specific fragments which contain a homologous sequence to the probe (Maslow et al.,
1993). Insertion sequences and transposons can be found in various bacterial 
chromosomes and may be used as probes. Generally, aU IS elements are under 2.5 Kb and 
can insert multiple copies in a bacterial genome affecting the expression of neighbouring 
genes, but are sufficiently stable to be applied to RFLP studies (Malihlon and Chandler,
1998). One such established metliod is the 1S61 /fi-based DNA fingerprinting for 
Mycobacterium tuberculosis, and recommendations for standardisation are published (van 
Embden et al., 1993). A number of tuberculosis investigations, including confirmation of an 
outbreak in institutional settings, and tracking geograpliical spread of M. tubercrdosis clones 
have used ISti'/ /0-RFLP (Foxman and Riley, 2001). Ribotyping uses the ribosomal gene, rrn 
as the probe and, as ah bacteria contain this gene, the typability is high (Table 1.3, page 32) 
(Maslow et al, 1993). These Soutliern blot approaches are however, relatively laborious and 
time-consuming (Struelens et al, 1996).
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1.5.2.4 Pulsed-fîeid gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) is similar to REA, but generally uses rare-cutting 
restriction enzymes to produce less than 30 large genomic fragments, which are between 10 
Kb to 800 Kb in size (Maslow et al, 1993). The conditions for separating these fragments 
differ from conventional electrophoresis, in that the orientation of the electric field is 
pulsed periodically (Maslow and Mulligan, 1996). Field inversion gel electrophoresis 
(FIGE), is a simple form of PFGE, and uses forward and reverse current at 180°, although 
another form, named counter-clamped homogenous electric field (CHEF), has electrodes 
in a hexagonal array winch are capable of generating an unlimited variety of field strengths 
and angles to further separate similarly-sized fragments (Sambrook and Russell, 2001). This 
method is technically demanding, but can be used on all bacteria, and can be liighly 
discriminatory and reproducible (Table 1.3, page 32) (Struelens et al, 1996). Lilre the 
Southern blot methods, PFGE is also a lengthy process, typically talcing two to sis days to 
obtain results, and the initial outlay of equipment is expensive (Maslow and MuUigan,
1996). There lias also been a lack of inter-laboratory standardisation of PFGE, wliich 
makes comparing data difficult between laboratories (Struelens et al, 1996). Despite these 
drawbacks however, many bacterial patliogens, including Hscherichia coli. Staphylococcus aureus, 
and Mycohacterlium avium have been epidemiologicaUy-typed successfuUy using PFGE (Arbeit 
et al, 1990; Prévost et al, 1992; Arbeit et al, 1993).
1.5.2.5 PCR amplification methods
A further genotypic approach exploits DNA amplification with PCR, using either; (i) 
arbitrary primers and/or conditions of low stringency, loiown as arbitrarily primed-PCR 
(AP-PCR) (Welsh and McCleUand, 1990) or randomly amplified polymorpliic DNA 
(RAPD) (WiUiams et al, 1990); or (ii) primers directed outward from repetitive elements to 
amplify short spacer sequences, namely Inter-repeat element PCR (rep-PCR) (Versalovic et 
al, 1991). By separating the resulting different-sized ampUcons using gel electrophoresis, a 
DNA fingerprint can be visualised and, due to the speed of PCR, a result can be generated 
within a day (Struelens et al, 1996). The methods AP-PCR and RAPD can be used for a 
variety of bacteria, although identifying suitable primers and conditions that give good 
discrimination for a particular organism may prove difficult (Maslow et al, 1993). Inter­
laboratory reproducibihty has also been demonstrated to be problematic (Table 1.3, page 
32), and is documented by van Belkum and coUeagues (1995) for Staphylococcus aureus. In 
theit study, seven laboratories typing 59 isolates by AP-PCR generated 16 to 30 different 
genetic types (van BeUcum et al, 1995). The thitd approach, rep-PCR, uses various
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repetitive elements, but these are mostly organism-specific, and therefore this technique 
may not be universally applicable to aU bacteria. These elements include repetitive 
extragenic palindromes (REP), found in E. coli and Salmonella tjphimurium (Gilson et al,
1984); enterobacterial repetitive intergenic consensus (ERIC) sequences, present in many 
enterobacteria (Hulton et al, 1991); and the BOX elements found in Streptococcus pneumoniae 
(Martin et al., 1992).
1.5.2.6 Amplified fragment length polymorphism analysis
The PCR methods described above can be processed further using restriction enzymes, 
which may increase the dis crimination of the technique (Maslow and Mulligan, 1996). One 
method, amplified fragment length polymorphism (AFLP) analysis, is essentially a three 
step procedure; an initial enzyme digest-Hgation of genomic DNA, tlien the selective 
amplification of the restriction fragments using specific primers, and finally the gel analysis 
of the amplified fragments (Vos et al, 1995). The AFLP technique thus combines the 
reliability of the RFLP technique with the power of PCR to produce a reproducible, 
discritninatory, rigorous, and quick method (Table 1.3, page 32) (Vos et al, 1995). For most 
bacteria, a double enzyme digest is performed for AFLP (Janssen et al., 1996). However, 
single-enzyme AFLP has been applied to some bacteria, including L. pneumophila, and 
AFLP has been chosen by the European Working Group on Legionella Infections 
(EWGLI) to standardise and use as an epidemiological typing scheme across 11 European 
countries (Fry et al., 2000). The AFLP metliod has been furtlier developed by amplifying 
restriction fragments using fluorescently-labeUed primers, (fluorescent-AFLP) and utilises 
automated DNA sequencers to determine the size of tlie labelled amplified fragments. 
Fluorescent-AFLP also permits the inclusion of internal size standards and has been shown 
to be accurate, discriininatoiy, reproducible and may be capable o f standardisation for E. 
coli (Arnold et al, 1999). There are however some drawbacks in this and other PCR typing 
methods, which include: optimisation and choice of reagents/ protocols; inter-run and 
inter-lab oratory reproducibility; and interpretation of results, malting these methods 
difficult to standardise (Struelens et al., 1996).
1.5.2.7 DNA sequencing
Another genotypic approach to type bacteria is through gene variation, detected by 
sequencing the gene investigated. Sequencing of 168 rDNA is well established for 
phylogenetic classification, but tlie relative stability of the 168 rRNA gene makes it 
unsuitable for typing below the species level, so other, more variable loci are used. Multi­
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locus sequence typing (MLST) was developed from tlie phenotypic technique, multi-locus 
enzyme electrophoresis (MLEE) (Maiden et ai, 1998). Briefly, MLEE involves the 
preparation of between 15 to 25 enzyme extracts, and their subsequent electrophoresis 
using horizontal starch gels. The relative mobility of each enzyme locus varies in different 
strains of a particular species, and can be given a specific allele number, which correlates 
with amino acid substitutions (Maslow et al, 1993). When these multiple loci are combined 
as an electrophoretic type (ET), a potentially large number of different ETs can be 
generated for a particular organism. Due to its moderate discriminatory value, and its slow 
and technically demanding nature, MLEE is used more for population genetics than 
epidemiological typing (Maslow et al, 1993), and has also been used to estimate genetic 
diversity in several bacteria (Selander et al., 1986). The MLST scheme requires the DNA 
sequencing of some o f tlie genes encoding the enzymes used in MLEE, where each variant 
o f the corresponding genes are given an allele number, and when combined, wtU produce 
an allelic profile or sequence type (ST) for each strain tested. Schemes for Neisseria 
meningitidis, Streptococcus pneumoniae, and Staphylococcus aureus have been published to study 
global epidemiology, and have reported on the population structure, serotype correlation, 
and important MRSA clones (Maiden etal, 1998; Enright and Spratt, 1998; Enright et al.,
2000), respectively. Multi-locus sequence typing, combining optimal typabihty, excellent 
discrimination, and a simple, portable way of comparing data between laboratories, 
however can be labour intensive, and the initial expenditure and further costs are very high 
(Table 1.3, page 32) (Maiden et al., 1998). Nevertheless, MLST has been successful in typing 
meningococci directly from chnical specimens where the isolate has not been recovered, 
therefore generating a typing result for enhancing surveillance (Diggle et al., 2003). 
Virulence genes can also be targeted for typing, such as porA and porB in N. meningitidis, 
which encode the serotyping antigen (Leavers et al., 1999). Tliis single locus approach can 
enable the study of virulence factors under environmental pressure, but these genes can be 
highly variable and may obscure true relationships between species (Gurtler and Mayall,
2001). Nevertheless, this approach may be necessary for species with limited genetic 
diversity, such as B. pertussis, which is described later (1.6, page 39).
1.5.3 Genetic events in bacteria visualised using genotypic methods
When using genotypic methods, the variations observed are caused by essentially four 
evolutionary genetic mechanisms; mutation, hypermutation, genetic recombination and 
natural selection (van Belkum et al., 2001). Mutations are thought to be random events and 
are heritable via vertical transmission. They are caused either by DNA replication errors
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such as base pair substitutions, insertions and deletions, or by the movement of 
transposons and IS elements within the genome. Hypermutation is probably caused by a 
lack of DNA mismatch repait, which can enhance the “mutabiUty” of a cell and the 
resulting organisms are called “mutators” (van Belkum et aL, 2001). Rapid mutation and a 
high rate of DNA exchange are thought to be advantageous for mutators to adapt to a new 
environment. SHpped-strand mispairing can occur when these hypermutable genes contain 
short sequence repeats, such as those present in IS elements. Thus, the IS elements can 
control cassette switching and affect the expression of genes, wliich can then be identified 
as a different phenotypic trait (van Belkum et al., 2001).
Genetic recombination and horizontal gene transfer can include the acquisition of genes 
into genomes and make the estimates of clonal evolution difficult to calculate (van BeUrum 
et al., 2001). The rate of recombination influences the clonahty of the organism, where 
bacteria witli low recombination are highly clonal and stable (e.g.. Salmonella enterica) and 
those with high recombination are non-clonal and panmictic (where gene exchange occurs 
randomly and at a high rate in a population) (e.g., N. meningitidis) (Maynard Smith et al., 
1993). Researchers have tlius found difficulties when deciphering an ancestral lineage for 
panmictic species such as Helicobacter pylori, due to their high genetic variability.
Natural selection has an overall role of filtering out any new genotypes produced by 
mutations or recombination tliat have detrimental fitness effects. Two variables affect 
natural selection: the fitness of the new genotype (whether it is neutral, detrimental or 
beneficial), and die population size. Understandably, variant genotypes are more Hlrely to 
be present in larger populations, due to the mutation and efficient selection of the 
organism in question.
These genetic events, detailed above, have been interpreted for PFGE as changes in band 
patterns (Tenover et al, 1995). As PFGE patterns rely on the presence of specific sites at 
which a restriction endonuclease wiU cleave the genome, mutations and recombinations 
affecting these sites can be visualised as changes. This interpretation for PFGE is based on 
die number of fragment differences between the profiles, to which the authors have 
defined particular genetic events (Tenover et al, 1995). As typing methods are used for 
comparing relatedness, in an outbreak setting tiiese PFGE interpretations can help in 
characterising strains. Tenover et al (1995) state that if there are two to three fragment 
differences between the outbreak pattern and that produced from the test isolate, tliis 
corresponds to either a point mutation or an insertion or deletion, and is therefore closely
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related and probably part of tlie outbreak. Two genetic events in an isolate generating four 
to six fragment differences are interpreted as possibly part of the outbreak. Unrelated 
isolates that are not part of the outbreak are indicated by seven or more fragment 
differences, where there have been three or more genetic events. This is based on 
observations of isolates collected over a six-month period or from large, extended 
outbreaks (Tenover et al., 1995).
Tenover et al. (1995) do not recommend their criteria for studies of large populations or 
organisms that have been collected over periods of one year or longer, as they are too 
stringent, yet these recommendations have been applied universally for a number of 
bacteria. When evaluating a particular metliod therefore, its appropriateness, the genetic 
variation it reveals, and its interpretation are major factors to consider, as well as the 
clonahty of the organism investigated.
1.5.4 The “ideal” bacterial typing system
By applying the recommended criteria to a particular typing system (1.5.1, page 30), the 
appropriateness of a metliod can be evaluated for each species smdied. An ideal typing 
system should possess;
“ ... optimal typabihty, a high degree of reproducibihty, adequate stabihty, and 
unprecedented resolving power . . .”.
(van Belltum et al., 2001) 
The system chosen must also fit the purpose of the study, whether for genetic diversity, 
population dynamics or epidemiological typing. Standardisation of bacterial typing has been 
attempted for E. coli 0157:H7, M. tuberculosis, and E. pneumophila, using PFGE, 184/10- 
RFLP and AFLP, respectively, and has enabled worlong groups in separate laboratories to 
compare results (Swamhiathaii et al., 2001; van Embden et al., 1993; Fry et al., 2000).
Many typing methods have been apphed to B. pertussis for studies of genotypic diversity, 
population dynamics and epidemiological typing, and have revealed seemingly 
contradictory evidence concerning the stability of the B. pertussis g&nomc. However, to date, 
standardisation of these methods has not been estabhshed.
38
1.6 Genetic diversity and epidem iological typing o f B ordetella  
p ertu ssis
1.6.1 Genome plasticity of Bordetellâpertussis
In order to study evolution, diversity and epidemiology of B. pertussis, deterrnining the 
stability or plasticity of the genome helps in the choice of typing method and interpretation 
of tlie data. Genome plasticity is the accumulation of changes in a genome, based on 
molecular processes such as transposition (transposable elements, insertion sequences, or 
transposons, wliich can translocate to another site of the chromosome), transformation 
(the transfer of DNA by a bacterium from the surrounding environment), or mutation (van 
Bellcum et al, 2001).
Stibitz and Yang (1999) characterised 14 B. pertussis stX2ms> representative o f 14 different 
PFGE patterns obtained from 70 strains isolated from a whooping cough outbreak in 
Alberta, Canada from December 1989 to May 1991. Using a 'chromosomal surveying’ 
approach, they measured die distances between 19 B. pertussis genes within each genome, 
using vectors, the intron-encoded restriction enzyme I-Jfgl, and PFGE (using 'KbaS) to size 
the fragments. Ten chromosome maps were deduced from the 14 strains and these 
revealed large chromosomal inversions. The molecular mechanism for these inversions is 
unlmown, but Stibitz and Yang suggested that insertion elements could catalyse such an 
inversion in the B. pertussis chromosome (Stibitz and Yang, 1999). They also proposed diat 
changes in PFGE patterns could be affected by these large chromosomal rearrangements, 
and not solely by the loss or gain of restriction sites as described by Tenover et al (1995). 
This implies a dynamic B. pertussis population structure and genetic diversity studies are 
detailed below.
1.6.2 Genotypic diversity of Bordetellâ pertussis
Musser et al (1986) studied genetic diversity in Bordetella species using MLEE, and included 
23 strains of B. pertussis. They deduced that the genetic diversity of B. pertussis is lower than 
that of other bacteria tested, such as FJ. influettî^ ae, E. pneumophila and E. coli (Musser et al, 
1986), with only 3 ETs identified using 15 enzymes. This could be due to; pertussis 
vaccination, which has reduced the population size; the niche specialisation of B. pertussis, 
whose host is exclusively human; or a recent evolutionary origin, as the earliest recorded 
description of whooping cough was in 1578 (Musser et al, 1986). They also reported that 
tire type strain of B. pertussis, 18323^ (NCTC 10739^), used in mouse potency tests for
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WCVs, was more genetically similar to B. hronchiseptica and B, parapertussis than B. pertussis, 
supporting the view that the type strain is an unusual strain of B. pertussis (Musser et aL,
1986).
This work was extended later in an analysis of 18 B. peHussis strains (188 Bordetella strains in 
total) by MLEE, and tlie presence of any of the three IS elements, H)481, IS/Oti/, and 
l'S1002 (Table 1.4, page 41) (van der Zee et al., 1997). This study revealed only four- 
different ETs, resulting from only four of die 15 enzymes, were polymorphic for the B. 
pertussis i^o\20&e>. These authors deduced that B. pertussis strains cluster separately from B. 
parapertussis and B. hronchiseptica due to their ETs and the presence oilS481  and IS1002.
Khattak et al. (1992) tested 105 B. pertussis \s,d\2 .X&% from the UK and Germany, including 
circulating strains, vaccine strains and control isolates, by PFGE. They found 17 PFGE 
types in total, with one type accounting for 25 of the 105 isolates tested. The authors 
concluded that B. pertussis E a highly genetically variable organism, but no statistical 
calculations were presented. The work of Stibitz and Yang (1999), showing genomic 
plasticity in B. pertussis, supported tliis conclusion, but conflicted with the results of the 
MLEE studies of Musser et al. (1986) and van der Zee et al. (1997).
IS / ddZ-restriction fragment length polymorpliism (IS /002-RFLP) analysis, a method 
developed for B. pertussis by van der Zee et al (1996b), demonstrates a sufficiently liigh 
degree of variation in the profiles to allow typing of B. pertussis. Van der Zee et al (1996b) 
studied 106 B. pertussis from The Netherlands, Germany, Canada, the USA, China,
Japan and the UK. The resulting profiles were sorted into 36 different RFLP types, which 
could be clustered into five clades (A to E) of related profiles. Results indicated a partial 
geographic isolation for some of the RFLP types. In particular, nine of the ten isolates 
from Japan were clustered into one clade (clade E) that contained only two other isolates, 
both from Canada (van der Zee et al, 1996b). Also, 15 isolates from Canada which were 
previously resolved as 15 different PFGE types (de Moissac et al, 1994), were differentiated 
into 12 IS/dd2-RFLP types, and the authors suggested that the discrimination of 18/0(92- 
RFLP, if a little lower, is comparable to PFGE for B. perfmsis (van der Zee et al, 1996b). 
One particular RFLP type, named D l, was present in five of the six countries analysed, 
indicating that diis is a successful clone (group of isolates sharing the same RFLP type) that 
has spread globally.
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Table 1.4. Insertion elements present in B ordetella
Insertion
element
Present i 
B. pertussis 
Tohama-I
number of copies 
B. parapertussis 
12822
in genome sequt 
B. hronchiseptica 
RB50
;nced^)
B. holmesii
IB481
IS1001
IB1002
IS1663*
Yes (238) 
No
Yes (6) 
Yes (17)
No
Yes (22) 
Yes (9) 
No
Yes" (0) 
Yes" (0) 
Yes" p) 
No
Yes^
NK
NIC
NIC
^Numbers in parentheses indicate tlie number of copies of the particular insertion sequences in the 
genomes sequenced (not B. holmesH) at tlie Sanger Institute (PaiidiiU et aL, 2003). ^The B. 
hronchiseptica strain chosen to be sequenced by the Sanger Institute contained no copies of the stated 
insertion elements, however, other reports suggest there are copies present in other strains (van der 
Zee et al, 1996a; Gladbach et al,, 2002). BB481 has been detected in B. holmesii using PCR-based 
methods (Reischl et al, 2001; Sloan etal, 2002). previously unlmown insertion element in B. 
pertussis, discovered after genomic sequencing of the Tohama-I strain at the Sanger Institute 
(Parldiill et al, 2003).
NK=not Imown.
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The authors also suggested that, after analysing isolates from The Netlierlands, 1S1002- 
RFLP analysis could be used in an epidemiological setting, as two clusters containing 3 and 
4 strains revealed two RFLP patterns, type D l and C2, respectively (van der Zee et al., 
1996b). Strains from an epidemic in 1994 revealed tliat 15/21 (71%) of them belonged to 
two RFLP types, B3 or C5, and suggested that clonal expansion cause pertussis epidemics. 
The RFLP type D l, found in several countries, was also present in ah four periods between 
1954 and 1994, indicating this RFLP type is persistent through time as weU as space (van 
der Zee et al., 1996b).
The two strains in the Dutch WCV exhibited RFLP types A l and D2. These RFLP types 
were only found a few times between 1950 and 1954 and not in later periods. The authors 
hypothesise that;
“ ... over 40 years of vaccination has resulted in the expansion of strains which are 
less affected by vaccine-induced immunity due to antigenic differences witli the 
vaccine strains . . .” .
(van der Zee etal, 1996b) 
Another explanation is that the differences reflect the normal dynamics of B. pertussis 
populations.
Further work from The Netherlands using IS / 002-RFLP analysis also supported the 
hypothesis of B. pertussis adaptation due to vaccine-induced immunity (van Loo et al., 1999). 
A total of 213 Dutch isolates from 1949 to 1996 were collected and grouped into five tiiue 
periods, and 45 RFLP types were observed. Prior to vaccination (1949 to 1954), there were 
12 RFLP types present in the B . p o p u l a t i o n ,  including the two vaccine strains. 
Between 1965 and 1972, the two vaccine RFLP types disappeared, and only five RFLP 
types were observed. From 1965 onwards, three RFLP types dominated the B.pertMssis 
population (DNA types dt-12, dt-29, and dt-35). Furthermore, one o f these types, dt-12, 
was found in all five time periods from 1949 to 1996. A smaller study in Italy, analysed 76 
B. pertussis strains from an Italian vaccine field trial which started in 1993, and found similar 
results in that dt-12, dt-29, and dt-35 dominated in 75% of tlie strains tested (Mastrailtonio 
et al., 1999).
Genotypic diversity (GD) values were also calculated for each time period of these Dutch 
data (van Loo et al, 1999), based on DNA polymorphisms detected by restriction 
endonuclease analysis and assuming that evolution mainly occurs by mutation and genetic 
drift (Nei and Tajima, 1981). These values are therefore dependent on the bacterial
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population size and frequency of each RFLP type, widi values approacliing one being of a 
high genotypic diversity, and values approaching zero having a low genotypic diversity. The 
highest GD of 0.89 was observed in 1949 to 1954, and the lowest at 0.60 was seen in the 
next time period studied, 1965 to 1972 (van Loo etal., 1999). This significant drop in 
genotypic diversity is thought by the authors to have been caused by a decrease in the 
bacterial population size and/or by clonal expansion of “more fit” strains after vaccination 
was introduced (van Loo et al, 1999). This clonal expansion theory was further supported 
by the appearance of dt-29 in 11/18 (61%) of the isolates from 1965 to 1972 and the 
persistence of tliis RFLP type in subsequent years. The genotypic diversity then increased, 
suggesting a gradual expansion of other RFLP types. Most o f tlie strains 120/213 (56%) 
were collected between 1991 and 1996 possibly skewing the results. Flowever, the authors 
suggest tliat;
“ ... vaccination has selected for strains that are adapted to a liighly vaccinated
population ... ”,
(van Loo et al., 1999) 
and that this may be the cause of pertussis re-emergence in otlier countries.
Pulsed-field gel electrophoresis and IS / 002-RFLP analysis are more preferable methods of 
studying genotypic diversity tlian the phenotypic technique, MLEE. Data from MLEE 
analysis show B. pertussis as a clonal species within a highly-related genus (Musser et al., 
1986). Flowever, results from PFGE and IS / 002-RFLP analysis suggest a more dynamic 
species (Khattak et al., 1992; van Loo et al, 1999). These observation using PFGE and 
IS/002-RFLP analysis are supported by the demonstraion of the genomic plasticity of B. 
pertussis (1,6.1, page 39) (Stibitz and Yang, 1999).
1.6.3 Epidemiological typing of Bordetella pertussis
Serotyping of B. pertussis using the fimbriae/agglutinogens has been used for many decades 
for epidemiological investigations of pertussis (Eldering et al, 1957). In Sweden, clinical 
isolates collected between 1970 and 1995 were investigated by serotyping, and it was found 
that serotype 1,2,3 isolates predominated from 1970 to 1978, with serotype 1,3 bemg 
related to outbreaks of pertussis (Piru et al, 1997). However, following the cessation of 
general pertussis vaccination in 1979 (Therre and Baron, 2000), serotype distribution 
changed, so that in 1995, serotype 1,2 was present in over 80% of isolates (Piru et al, 1997). 
In the UK, during the two large pertussis epidemics of 1977 to 1979 and 1981 to 1983, 
serotyping data and vaccination status were collected for 855 cases (Preston and Carter,
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1992). This study reported that serotype 1,3, as in Sweden, predominated in both 
epidemics, and serotypes 1,2 and 1,2,3 were found in 243/769 (32%) of unvaccmated 
children compared to only 9/86 (10%) in vaccinated subjects, which was statistically 
significant. These authors also stated that WCVs had a higher efficacy against serotypes 1,2 
and 1,2,3 than against serotype 1,3 (Preston and Carter, 1992). Therefore, it was advised 
that AC Vs should contain agglutinogens for each serotype to ensure adequate efficacy and 
protection against pertussis disease (Preston and Carter, 1992).
Due to the low discrimination of serotyping, it is not suitable for short-term outbreak 
investigations and PFGE has been used for more recent epidemiology studies. An outbreak 
in Alberta, Canada, from December 1989 to May 1991, initiated a study to determine 
whether the movement o f virulent B. pertussis strains within and/or between towns and 
communities caused the outbreak (de Moissac et al, 1994). A total of 70 strains were typed 
by PFGE using Xhal, and various epidemiological grouping analyses were performed. 
Fourteen isolates from the city of Edmonton and one from each of 14 northern Alberta 
towns (n=28) generated 13 PFGE profiles. A highly heterogeneous population was initially 
observed in Edmonton, thus reveahng that PFGE could discriminate amongst known 
epidemiologically-linked isolates, which could further complicate the analysis of prevalence 
and spread of the isolates tested. A further sk  pairs of intrafamUial isolates (n=12) were 
tested. Each isolate from each pair shared identical PFGE types, suggesting direct 
transmission within families was occurring in the outbreak. Isolates from Fort Smith 
(n=18), a town north of Edmonton, all exliibited an identical PFGE type, type a, indicating 
the outbreak in Fort Smith was due to one strain. Another town shared anotirer PFGE 
type, type b, in 11 out of 12 isolates, and both types a and b accounted for 44 of the 70 
isolates. The authors concluded that a single, highly infectious strain of B. pertussis did not 
cause the whooping cough outbreak and by studyiug the vaccination status of the 
population, they suggested that vaccination was less protective in periods of peak pertussis 
activity (de Moissac et al, 1994).
Another rise in whooping cough cases occurred in 1993 in the UK and was investigated by 
PFGE and serotyping of isolates received by the Pertussis Reference Laboratory in 
Manchester (Syedabubakar et al, 1995). O f the 4000 notifications of pertussis in tlris peak 
year, 280 B. pertussis isolates were received at theit laboratory, of which 180 were typed and 
29 different PFGE types produced. DNA type 1 predominated in 72/180 (40%) of the 
isolates tested, and DNA type 3 encompassed 42/180 (23%). There were 11 unique DNA 
types containing one isolate each. Studying the temporal distribution, 17 DNA types
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appeared in the upswing phase of tlie epidemic compared to just 8 DNA types in the 
downswing phase, suggesting greater genetic plasticity in the upswing phase (Syedabubakar 
et al, 1995),
In a separate study, no significant correlation was found between PFGE type and serotype. 
DNA type 1 occurred in strains from nine fuUy vaccinated children, seven of which were 
serotype 1,2. DNA type 2 accounted for 10/67 (15%) of isolates from September 1990 to 
March 1991 (Khattak etal, 1992), but was markedly absent a couple of years later in 1993. 
Comparison of the data from Khattak et al (1992), with that o f Syedabubakar et al (1995), 
revealed that only eight of the 15 DNA types were seen in both 1990 to 1991 and 1993, 
and 21 new types were identified from the 1993 isolates. Syedabubakar and colleagues 
(1995) proposed that the 1993 pertussis epidemic was caused, in part, by the emergence of 
genetic variants after the “failure” or mis-match of the WCV, though they did not report 
the DNA types of the vaccine strains. Neverdieless, this theory has been supported by 
studies in The Netherlands (van der Zee et al, 1996b; Mooi et al, 1998; van Loo et al,
1999).
The studies in Canada and the UK mentioned above, reported that pertussis epidemics 
may not be caused by a single, highly virulent strain (de Moissac et al, 1994; Syedabubakar 
et al, 1995). In contrast, Beall et al (1995) analysed 78 isolates from the USA and Senegal, 
and reported indistinguishable PFGE profiles from epidemic strains. The authors used 
three different enzymes QibeA, Spel, and Dral), and 16 PFGE profiles were generated. All 
of the 54 isolates from an outbreak in Delaware in 1986 were of one PFGE type. Only one 
of die 25 sporadic isolates matched the epidemic PFGE type, but clinical data revealed that 
this isolate was cultured from a laboratory worker who had been worldng on die epidemic 
strains. The audiors therefore concluded that these data;
. justified an association between a single PFGE type and epidemic pertussis
(Beall et al, 1995)
They also explained that although die 1989 to 1991 epidemic in Canada was province-wide 
and lasted 18 months, the diree month outbreak which occurred in Fort Smidi generated 
only one PFGE type (de Moissac etal, 1994), which is more comparable to the smaller, 
three month situation in Delaware. BeaU and colleagues concluded that PFGE of B, pertussis 
could enable the;
“ ... characterisation of endemic and epidemic patterns, secondary attack rates,
vaccine efficacy, and the role of atypical illness in transmission
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(Beall et ai, 1995)
In order to correctly identify virulent strains or clones that cause severe disease or 
outbreaks, the collection of clinical and epidemiological data are important and, combined 
with the equivalent typing data, associations can be tested. Clinical data, such as isolation 
date, age of subject, vaccination status, and geographical origin are essential in deducing 
whether particular isolates are indeed from the same strain. Unfortunately, the 
standardisation of both the methodology and nomenclature of PFGE for B, pertussis has 
not been established and is necessary if direct comparison is required. It would be useful to 
Imow whetlier there are any prevalent strains causing most of the pertussis cases, or more 
severe disease on a global scale, such as the successful IS/002-RFLP type D l (van der Zee 
et al., 1996b).
1.6.4 Gene sequence variation of Bordetella pertussis
Following the pertussis epidemic in The Netherlands in 1996, and the B. pertussis 
population study using IS / 002-RFLP analysis by van der Zee et al. (1996b), Mooi et al. 
(1998) investigated whether this resurgence was due to the emergence of different B. 
pertussis geiiedc variants to that of tlie WCV strains. Mooi et al. (1998) chose two B. pertussis 
virulence factors, the adhesm pertactin (1.2.3.3, page 15) and pertussis toxin (1.2.2.1, page 
8), and sequenced the genes for these factors from isolates obtained before and after 
vaccination was introduced, to investigate whether any antigenic variation may have 
occurred in the Dutch B. pertussis population. After sequencing approximately 90% of the 
pertactin {prnAp gene of six J3. pertussis isolates, two repeat regions encoding the amino 
acids GGxxP and PQP in regions 1 and 2, respectively, were found. Polymorphism was 
found in region 1, which differed in the number of repeats present, and/or the amino acid 
composition. ThreeprnA  types were revealed in the isolates from 1949 to 1996, namely 
prnA(V),pruA(l2l), andpi'nA(?>) (Figure 1.2, page 16) (Mooi et al., 1998). When sorted by year 
of isolation, 35 isolates between 1949 and 1980 were aUprnA{\), which was also found in 
the two strains used to produce the Dutch WCV. However, since 1981, types prnApT) and 
prnAi?)) have appeared and percentages of both tliese types has gradually risen temporally.
2 As the genetic nomenclature for pertactin and pertussis toxin used by Mooi and coUeagues has varied from 
publication to publication, and is nonstandard according to the Nomenclature Committee o f the American 
Society for Microbiology (ASM) Publications Board, tlie foUowing wiU be used throughout the thesis; 
V.69A=prn1, P.69B=y)/7?2, V.(i9C=prn3, etc, wiU becom epritA(3),pt'nA(^,priiA(p), etc, and S\A =ptxS 1, 
S\B =ptxS2, S \D =ptxS 4, etc, wUl becom ep tx A {\) ,p tx A i7 ),p tx A (p ), etc.
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Since 1993 these two novel types have comprised approximately 90% (123/133 isolates) of 
the Dutch B. pertussis population.
The pertactin sequence data from isolates between 1989 and 1996, were also analysed using 
the age groups of tlie pertussis cases, to determine whether tlie vaccination stams of an 
individual was associated with a particular pertactin type. Mooi and colleagues (1998) thus 
assumed that at 0 to 3, 4 to 11, 12 to 48, and over 48 months, children had no, partial, 
optimal, and waning immunity, respectively. The authors found that the percentage of the 
vaccine type prnA{\) revealed a downward trend in the no, partial and optimal immunity 
groups (from 22% to 8%) (Mooi et aL, 1998). This showed that infection by tlie non- 
vaccine types, jùr/ïM(2) andprnAip), was more likely in vaccinated subjects, and the authors 
stated that;
“ ... vaccine-induced immunity againstp7'nA(l) strains is stronger tlian those against
prnAiiP) andprnApS) . . . ” .
(Mooi et al., 1998)
No information regarding the vaccination status of the individuals were available, so 
confidence in tlie immunity levels cannot be determined, although from 1993 to 1996, 85% 
of pertussis patients older tiian 12 months were vaccinated (de MeUrer et al, 1997).
Polymorphism was also found in the gene encoding the SI subunit of pertussis toxin 
(ptxA) for 49 B. pertussisEohte.^ (Mooi et al., 1998), as single nucleotide polymorphisms 
(SNPs) in two regions that were previously identified as T  cell epitopes (Peppoloni et al., 
1995). Threep txA  types were <do%çxrrç.à,ptxA{S),ptxAip!l), andptxAdpi), (Figure 1.4, page 
48). When grouped into tliree time periods, isolates from the pre-vaccination era, 1949 to 
1954, either containedy>/xM(2) orptxAilS), which were found in the two strains of the 
Dutch WCV. In 1978 to 1985, a novelp txA  type., ptxA{\) appeared and was present in 
12/15 (80%) of the isolates. This predominantp txA  type increased further, to 15/17 (88%) 
of isolates, between 1990 and 1996.
Mooi et al. (1998) concluded that these new pertactin and pertussis toxin types not found in 
the Dutch WCV appeared in the B. pertussis population through time due to vaccine-driven 
evolution. They also suggested that this antigenic shift may be contributing to the 
resurgence of pertussis in other countries with high WCV coverage (1.4.3, page 26), and 
that further work was needed to study the population structure of B. pertussis in other 
countries (Mooi et al., 1998).
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Following the studies in The Netherlands, Mooi collaborated with workers in Finland and 
Italy to determine the polymorphism of the genes coding for pertactin and pertussis toxin 
in isolates from these countries (Mooi et al, 1999; Mastrantonio etal, 1999). In Finland, a 
genetic shift was seen in B. isolates from 1953 to 1996. The Finnish WCV also
contains strains possessing/»?7zM(l),F/>t/l(2) andptxAilll). Five isolates tested from 1953 to 
1964 wereprnApy) andptxA(y!), but sk  isolates from 1982 demonstrated a sliift toprnAilE) 
andptxA(V). The 43 most recent Finnish isolates from 1990 to 1996 were allptxA{\.), but 
revealed four pertactin types, uncovering a new type,y>r/zM(4), with only 3 (7%) of the 
isolates containingy?r/zM(l), whilstprnA(7) predominated in 31 (72%) of the isolates. The 
numbers of isolates in this study in Finland are low however and, although antigenic shifts 
may be occurring, there have not been any major outbreaks or resurgence of pertussis in 
Finland compared to The Netherlands. The authors suggested that this lack of resurgence 
may be due to differing levels of protection by the WCV when challenged with pertactin 
variants. Furthermore, they stated that the frequency ofprnA{?)) m The Netherlands was 
higher than in Finland; 51%, compared to 5/43 (12%), and that the frequency of prtA.(?>) 
may have caused the 1996 epidemic in The Netherlands. Experiments using mouse 
challenge models may elucidate this matter (Mooi et al, 1999).
The study in Italy focused on B. pertussis Isolates from vaccinated and unvaccinated children 
to investigate any association between pertactin and pertussis toxin variants and vaccination 
status (Mastrantonio et al, 1999). These isolates were collected during an Italian pertussis 
vaccine trial between 1993 and 1995 and, therefore, a temporal analysis over a larger time 
scale cannot be made due to the unavailability of isolates. In 129 isolates, four pertactin 
variants were found,y?r/LT(l), (2), (3) andp>'uA(S), another novel type. The vaccines tested 
all containedpruAiV), and this type was present in only 8/129 (6%) of the isolates tested. 
The prevalentprnA  types in Italy were of similar frequencies to those of the recent isolates 
from The Netlierlands: prnA{2), 53/129 (41%) andpruA{5), 65/129 (51%) in Italy, 
compared to 36% and 51%, respectively. Interestingly, there was no significant association 
between the distribution of pertactin variants among the vaccinated and unvaccinated 
group. However, tlie authors stated that;
“ ... isolates withprnA{\) are more affected by vaccine-induced immunity than 
isolates withpniAigll) o rprnAilS) . . .” .
(Mastrantonio et al, 1999) 
Only 30 Italian isolates were investigated for pertussis toxin gene polymorphism. AU 
isolates tested were of typeptxA{ï), reflecting similar recent distributions of B. peiiussis srs. 
The Netlierlands and Finland, and the vaccines used in the Italian trials also contained
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eitherp t x A ^  and /o rptxAOpi). The authors concluded that, although vaccine coverage was 
lower in Italy than in The Netherlands, the population structure of B. pertussis was similar 
(Mastrantonio et aL, 1999). Their findings did not support the theory of vaccine-driven 
evolution, but suggested that either the population structure may have been influenced by 
neighbouring countries witli high vaccine coverage, or that even a relatively low vaccine 
coverage may have had a significant effect on the B. pertussis population (Mastrantonio et al., 
1999).
1.7 Aims of thesis
Bordetella pertussis research has had a recent revival after the resurgence of pertussis in many 
countries with high vaccine coverage. The Netherlands produced data suggesting a tlieory 
that circulating strains had emerged wliich were different to the vaccine strains and was 
thus causing a pertussis resurgence (Mooi et al., 1998). Although there has been no 
apparent resurgence in the UK, determining the genotypic diversity and establishing 
epidemiological typing of B. pertussis'\s,ohX&s in tlie UK would be invaluable. Thus, an 
evaluation of tlie current B. pertussis situation will be made, together with the impact of 
vaccination policy and the resulting pertussis incidence. Direct comparisons with other 
countries such as The Netherlands and the USA wiU also be performed (Mooi et al., 1998; 
van Loo et al, 1999). Therefore the aims of this diesis are described below.
1.7.1 To characterise the range and distribution of sequence variation in 
pertactin and pertussis toxin genes of Bordetella pertussis  isolates 
from the United Kingdom
Bordetella pertussis isolates wiH be obtained from archive collections from various sources in 
the UK, and recent isolates selected from those submitted to the Pertussis Reference 
Laboratory at Manchester University. These isolates wiU be investigated for pertactin and 
pertussis toxin SI gene variation, and analysed for any temporal trends that have occurred 
since widespread vaccination against pertussis was introduced in the UK in 1957 (Chapter 
3).
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1.7.2 To investigate the genotypic diversity of a representative sample of 
historical, through to current, UK Bordetella pertussis  isolates
The genotypic diversity of UK isolates will be calculated by selecting isolates from the 
initial data-set collected for aim 1.7.1 (see above) at random, and applying the IS/002-RFLP 
typing metliod of van Loo et al. (1999). Genotypic diversity values wdl then be directly 
compared with those from The Netherlands, and to elucidate whether;
“ ... vaccination has selected for strains that are adapted to a highly vaccinated 
population . . .” .
(van Loo et al., 1999)
This investigation is covered in Chapter 3.
1.7.3 To examine current Bordetella pertussis isoX&Xes for any association 
between clinical, epidemiological, and laboratory data
For isolates obtained from the Pertussis Reference Laboratory, Manchester, there are 
extensive epidemiological data stored at the Immunisation Division, CD SC, London. These 
include age, sex, vaccination history, severity and outcome of iUness of the patients. 
Laboratory data such as serotyping, pertactin and pertussis toxin sequence types, and 
IS/002-RFLP types, wTl be merged with the epidemiological data and interrogated to 
identify any association between strain characteristics and disease patterns (Chapter 3).
1.7.4 To characterise Bordetella pertussis  strains collected by the Missouri 
State Public Health Laboratory from Missouri, USA
A small number of B. pertussis strains from Kansas City, Missouri were collected when there 
was an increase in pertussis incidence, and these were tested alongside some earlier and 
contemporary strains for their relatedness. Phenotypic and genotypic methods to be used 
included; s e r o t y p i n g , a n d p txA  gene sequencing, PFGE and IS / 002-RFLP analysis. 
These data wdl then be discussed and compared to the UK data in Chapter 4.
1.7.5 To evaluate molecular typing techniques for their indices of 
discrimination by using a panel of Bordetella perm ssis isolates
From the main set of B. pertussis isohx&s collected for tliis study, a smaller panel of isolates 
wdl be carefuUy selected accorddig to their isolation date, serotype (if Imown), and 
ptxA. type, patient vaccdiation status, date of birth and severity of disease. These wdl then
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be randomised into a final panel, including epidemiologicaUy-related strains and replicates 
of strains, and then blinded so as not to bias experiments. This panel wdl be analysed using 
various methods including PFGE and IS / 002-RFLP analysis, so that direct comparisons 
can be made between methods (Chapter 5).
1.7.6 To expand work on a DNA sequence-based approach to the genotypic 
characterisation of Bordetella pertussis
An MLST scheme based on the MLEE technique used on B. pertussis (Musser et al, 1986), 
wdl be devised to deduce whether tliis approach gives enough discrimination for genotypic 
characterisation. Virulence genes wdl be tested for tlieir variability, and inclusion of tlie 
aforementioned targets pertactin and pertussis toxin SI subunit genes wdl also be 
considered in a sequence-based typing scheme^. Sequence-based typing wdl enable dkect 
comparisons between laboratories for any B. pertussis strain. This work is featured in 
Chapter 6.
1.7.7 To identify novel molecular methods to type Bordetella pertussis 
isolates
Molecular methods such as PFGE and IS/002-RFLP analysis have been used with some 
success in discrduinating B. pertussis isolates (BeaU et al., 1995; van Loo et al., 1999). Another 
study comparing RAPD, ERIC-PCR and PFGE, concluded that RAPD and ERIC-PCR 
are simple and rapid methods, yet the poor discrimination level in both these techniques 
makes them unsuitable for studying the epidemiology of B. pertussis (Moissenet et al., 1996). 
Single-enzyme AFLP analysis has been applied to several bacteria as a flexible, sdnple, 
quick and relatively inexpensive technique, but there has been no evidence of any prior 
investigations using AFLP for B. pertussis epidemiology. A selection of enzymes and primers 
wdl therefore be tested for theit abdity to type Bordetella pertussis isolates. Results are 
described in Chapter 7.
"^ During the course of this thesis, Van Loo et al. (2002) reported an M L ST  scheme based on surface protein germ, which has 
shoum some further discrimination and this has affected the approach of this aim.
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1.7.8 To investigate a number of epidemiologically-significant markers by 
using clinical material obtained from Bordetella perfu55is-positive 
patients
Although primary culture/isolation of B. pertussis h  the ‘‘gold standard” for pertussis 
diagnosis, it is relatively insensitive and can take up to four days for colonies to appear. The 
detection of pertussis infection has been successful using other methods such as serology 
and PCR. However, subsequent typing techniques such as PFGE and IS/002-RFLP 
analysis require a large amount o f bacterial DNA to obtain adequate results. Direct 
sequence typing will therefore be attempted on nasopharyngeal aspirates (NPAs) and 
pernasal swabs (PNSs) received by RSÏL that were previously culture and/or PCR-positive 
for B. pertussis. Targets such as pertactin and the pertussis toxin SI subunit genes wdl be 
amplified by PCR directly on clinical samples and, if successful, tlie ampHcons sequenced 
(Chapter 8).
Before this project began, the sequencing of the B. pertussis geftome was still at the contigimis sequences 
(contig) assembly stage at the Wellcome Trust Sanger Institute in Cambridge. When the genome project was 
at the final annotation stage, the principal investigator, Dr Julian Tarkhill gave me specialpermission to 
access the unpublished genome. The annotated genome was eventually published in September 2005 
(Parkhili et al., 2003).
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2 MATERIALS AND METHODS
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All methods and procedures used at the Respiratory and Systemic Infection Laboratory 
(RSIL), Central Public Health Laboratory (CPHL), London, were performed using Good 
Laboratory Practice and witli due regard to safety. In addition. Control of Substances 
Hazardous to Health (COSHH) regulations, appropriate Risk Assessments (RAs) and 
Pubhc Health Laboratory Service (PHLS) Standard Operating Procedures (SOPs) were 
consulted. Patient data were handled according to Caldicott guidelines and the Data 
Protection Act of 1998.
The addresses of supphers of equipment and chemicals referred to in this tlresis are listed 
in Appendix 2. Plastic consumables were obtained from the Stores department at CPHL, 
unless otherwise stated.
2.1 BordeteJla isolates
AU 495 Bordetella strains available for this thesis are Usted in Appendix 3 and summarised in 
Table 2.1 (page 56).
2.1.1 Historical Bordetella joerrwssis isolates
Prior to 2002, no systematic coUection of Bordetellapertussis isolates from the United 
Kingdom was available for examination. Therefore, stored isolates were
identified and obtained from various sites in the UK, including the Wellcome Bacterial 
CoUection, held by the National CoUection of Type Cultures (NCTC); NCTC’s own 
reference coUection, PHLS CPHL, London; the University of Glasgow, Glasgow, Scotland; 
Pertussis Reference Laboratory (PRL), Manchester University, Manchester; and tlie Centre 
for Applied Microbiology and Research (CAMR), Salisbury. Isolates are detaUed in 
Appendix 3, Part A (page 297). Date of isolation, or where this was not known, the year 
deposited, was used for aU analyses. Information concerning the depositor and source was 
known mostly for the isolates from the Wellcome Bacterial CoUection. A total of 294 
isolates were coUected from 1920 to 1986, although not aU were used in this thesis (see 
“Reasons for exclusion” in Appendix 3, Part A, page 297).
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Table 2.1. Summary of bacterial isolates available for this thesis
S o u r c e  o f  i s o l a t e s  ( A p p e n d i x  3 ,  
p a r t )
O r g a n i s m E n c o m p a s s i n g
p e r i o d
N u m b e r  o f  
i s o l a t e s
Wellcome Bacterial Collection (Part A) B. pertussis 1941-1985 116
National Collection of Type Cultures 
(Part A)
B. pertussis 1920-1967 14
University of Glasgow (Part A) B. pertussis 1977 11
Manchester University (Parts A and B) B. pertussis 1978-1979;
1998-1999
5;
103
Centre for Applied Microbiology and 
Research (Part A)
B. pertussis 1981-1985 148
Respiratory and Systemic Infection 
Laboratory (Part B)
B. pertussis 1999-2002 35
Wellcome Bacterial Collection, 
National Institute for Biological 
Standards and Control, Aventis 
Pasteur, National Collection of Type 
Cultures, National Institute of Public 
Health and the Environment in The 
Netherlands, and Institut Pasteur (Part
C)
B. pertussis n/a 16
Missouri PHL, USA (Part D) B. pertussis 1984-2001 45
National Collection of Type Cultures 
and National Institute of Public Health 
and the Environment in The 
Netherlands, (Part E)
B. parapertussis n/a 2
Total available 1920-2002 495
n /a= no t applicable, these strains were either used for reference, or were vaccine strains.
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2.1.2 Contempofafy UK Bordetella pertussis isolates
Bordetelia pertussis were collected between September 1998 and April 1999 from
Manchester University (Appendix 3, Part B, page 307). This sub-set of isolates represents 
every B. pertussis isolate in England and Wales in this time period referred to Manchester 
University for serotyping. A selection of isolates which were submitted directly to RSIL, 
PHLS CPHL, London were either from the Paediatric Intensive Care Unit (PICU) study, 
wliich ran from November 1998 to November 2000 (Crowcroft et al, 2003) or from the 
enhanced laboratory diagnosis of pertussis for England & Wales, formally established on 
the first of April 2002 (Anon, 2002). This latter scheme was introduced to confirm 
pertussis cases using PCR (for infants under six months of age with suspected pertussis) 
and ELISA serology (for adults with a cough persisting for over 21 days and children with 
a cough persisting for over 14 days), where botli tests are available through RSIL. The use 
of die additional tests, PCR and serology has increased the diagnostic yield over culture 
(Fry et a/, 2004). Clinical and epidemiological data were available for the isolates from 
Manchester University, and were obtained from the enhanced surveillance database, held at 
die Communicable Diseases Surveillance Centre (CDSC), London, see Appendix 3, Part B 
(page 307). A total of 138 recent UK isolates were available for diis thesis.
2.1.3 Bordetella pertussis yo.ccine and reference strains
Enquiries made to various vaccine manufacturers and the National Institute for Biological 
Standards and Control (NIBSC) identified three strains used in the UK whole-cell vaccine 
(WCV) made by Burroughs Wellcome (referred to in text as Wellcome) from 1957 to 1996. 
The strains CN2992B and CN3099, which are identical to CN2992 and CN4132, 
respectively, were obtained from die Wellcome Bacterial Collection, and strain CN5476, 
was obtained from NIBSC, Potters Bar (Appendix 3, Part C, page 315). From 1996, a 
WCV manufactured by Aventis Pasteur has been used in the UK, although unfortunately, 
die two strains IM1414 and IM1416, were not obtained for further evaluation. Information 
of their serotype, pertactin and pertussis toxin SI genotype are, however, known 
(Njamkepo et ai, 2002). The strains used for two pertussis acellular vaccines (ACVs) used 
in the UK since 1999, the Tohama-I strain and strain 10536 (“Kendrick” strain), were 
obtained from NIBSC and Aventis Pasteur, Maidenhead, respectively.
The B. pertussis type strain 18323^ (NCTC 10739^) was obtained from NCTC, CPHL 
(Appendix 3, Part C, page 315). Reference strains for two typing mediods IS/062-based 
restriction fragment lengdi polymorphism (IS / 662-RFLP) analysis, and pulsed-field gel
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electrophoresis (PFGE), were Idndly donated by Han van der Heide from die National 
Institute of Public Healdi and the Environment in The Nedierlands (RIVM) or Elisabeth 
Njamkepo from the Institut Pasteur in Paris.
2.1.4 Bordetella pertussis  isolates from Missouri, USA
Forty-five clinical isolates of B. pertussis from Missouri PHL were sent to RSIL, for analysis, 
one of which was later identified as B. parapertussis and dierefore excluded from further 
analysis (Appendix 3, Part D, page 316). Ten isolates were from Kansas City, which were 
geographically and temporally clustered within seven weeks between June and July 1999. 
The other isolates were epidemiologically-unrelated, with 15 collected between 1984 and 
1989 and 19 between 1996 and 2001. CUnical data were limited to isolates from May 1989 
to January 2001 and are detailed in Appendix 3, Part D (page 316).
2.1.5 Bordetella parapertussis
A  strain of Bordetella parapertussis, NCTC 10853, was obtained from die NCTC and listed in 
Appendix 3, Part E  (page 318). The B. parapertussis strain B24, used to produce the probe 
for the IS/6(92-RFLP analyses, was obtained from Han van der Heide of the RIVM, The 
Netherlands.
2.2 Revival, growth and preservation of B ordetella  species
2.2.1 Revival of Bordetella from freeze-dtied ampoules
Strains from the Wellcome Bacterial Collection, NCTC, CAMR, and the University of 
Glasgow, were received as freeze-dried cultures in ampoules. These were recovered as 
recommended by the NCTC and PFILS (CPHL and PFILS, 2000a). Ampoules were etched 
with a diamond cutter and a heated glass pipette applied for one to two seconds to produce 
an audible and encircling crack. The ampoule was left for approximately five minutes in a 
rack to allow the pressure inside the ampoule to equilibrate with tliat outside.
The following was performed in a Class 1 Safety cabinet. Approximately 0.5 ml of nutrient 
broth (Media Services, CPHL) was added to tlie ampoule and then incubated at room 
temperature for five to ten minutes. Two to three drops of mixed bacterial suspension were 
inoculated onto a pre-warmed charcoal blood agar (CHAR) plate, containing 10% volume 
to volume ratio (v/v) horse blood (Media Services), and left to dry for three to five
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minutes. The inoculum was then streaked around the entire plate using a sterile loop. Plates 
were incubated at 37”C and checked for growth after three days, and incubated for at least 
seven days. To ensure that strains were pure, a single colony was picked and subcultured 
onto a fresh CHAR plate for a further two to four days.
The remaining bacterial suspension was transferred to a labelled sterile 1.5 ml 
microcentrifuge tube. This was centrifuged at 16,000 for five minutes (14,000 rpm on a 
model 5415D, Eppendorf UK Limited). The supernate was aspkated uskig a fresh pipette 
tip and the pellet stored at -80"C. These samples were used for further revival or DNA 
extraction attempts.
2.2.2 Culture conditions
All Bordetella pertussis strains were grown on CHAR plates. An addition of 40 mg/1 of 
cephalexki was used to inhibit growth of other bacteria (CHC), where necessary.
Inoculated plates were incubated at 37‘’C in a humid envkonment for three to seven days. 
Small, silver colonies were accepted as the morpholoigcal identification of B. pertussis. 
Bordetella parapertussis isolates were also grown on CHAR plates (Media Services). These 
were incubated uskig the same conditions as for B. pertussis, but for a shorter time interval 
of two to four days.
2.2.3 Preservation of Bordetella pertussis isolates
A Standard Operating Procedure (SOP) produced by the CPHL was followed for 
preservation (CPHL and PHLS, 2000b). Sterile beads (2 mm embroidery beads, Creative 
Beadcraft Ltd) were prepared for use by placing approximately 0.5 ml of the beads into 2 
ml Sarstedt tubes, which were then autoclaved. Uskig aseptic techniques, bacterial culture 
was emulsified ki approximately 1-2 ml of sterke nutrient broth with 5% (v/v) glycerol 
(Media Services) in a bijou, to make a heavy suspension. The suspension was mixed using a 
pipette, and then spHt into two labelled, sterke Sarstedt tubes containing beads. The tubes 
were capped then agitated to release any ak bubbles around the beads, and then left for 5- 
10 minutes. The excess suspension was removed using a fresh pipette, and transferred into 
two to four labeUed sterke 1.5 ml microcentrifuge tubes to a volume of approxknately 0.5 
ml per tube. The tubes were then centrifuged at 16,000 x^ (14,000 rpm) for five mkiutes. 
The supernate was aspkated using a fresh pipette and both die ceU peUets and die beads 
were stored at —80°C, splitting die aliquots between freezers. DNA extraction was 
performed using the ceU peUets (2.4.1, page 60),
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2.3 Serotyping of B ordetella p ertu ssis
Serotyping was performed at RSIL or at Manchester University (one isolate from 1964, 
three from 1978, two from 1979, 37 from 1998, and 61 from 1999). The method below 
was used at RSIL.
Polyclonal rabbit antisera to agglutinogens 1, 2, and 3 (B. anti-agglutinogen 1 [no.
89/596], B. pertussis anti-agglutinogen 2 [no. 89/598], and B. pertussis anti-agglutinogen 3 
[no. 89/600], NIBSC) were used in a sUde-aggluttnation assay. Briefly, a loopful of B. 
pertussis previously grown on CHAR plates was suspended in approximately 200 pi of 
phosphate buffered saline (PBS) (Media services). A glass microscope sHde was wiped with 
70% ethanol and 5 pi each of cell suspension, and anti-agglutinogen 1, 2, or 3 were mixed 
and then rotated for approximately four minutes, to test for agglutination. A positive or 
negative reaction was recorded for each agglutinogen tested, and a negative control (PBS) 
was performed for each isolate on the slide. Controls NCTC 10908 (serotype 1,3) and 
NCTC 10907 (serotype 1,2) were tested for agglutinogens 1, 2, and 3, each time serotyping 
was performed.
At Manchester University, they follow a similar slide-agglutination assay, although they 
produce rabbit antisera in-house, which would require further standardisation and testing.
2.4 D N A  extraction
2.4.1 D NA purification from pure culture
To ensure recovery o f high molecular weight DNA, the Nucleon blood and cell culture 
(BACC) 2 Kit was used (Amersham Biosciences UK Ltd). The BACCl protocol for small 
volumes were followed from the manufacturer’s instructions (revision date 1997), with 
some minor adjustments:
Cell preparation, cell lysis and deproteinisation were performed on the bench. A B. pertussis 
pellet was re-suspended in 700 pi of Reagent B (400 mM Tris-HCl (pH 8.0), 60 mM 
EDTA, 150 mM NaCl, 1% w /v  SDS) (350 pi if the pellet was small) by gentle mixing using 
a pipette, and spht into two 1.5 ml microcentrifuge tubes, to approximately 350 pi per tube. 
One of the two ahquots was then stored at —80'’C for archive. To each working aliquot, 2.5
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pi of a 50 pg/m l RNaseA solution (R-4875, Sigma) were added and incubated at 37”C for 
30 minutes. Deproteinisation was acbeived by adding 100 pi of the 5M sodium perchlorate 
solution. Tubes were gently inverted several times for 10 to 20 seconds to ensure thorough 
mixing.
The stages where chloroform was handled were carried out in a fmne cupboard. The DNA 
was extracted by adding 600 pi of chloroform to the suspension, and then inverting several 
times for 10 to 20 seconds to produce a müky-white emulsion. To produce a physical layer 
between the aqueous and tire organic phase, 150 pi of the Nucleon silica suspension was 
added and inverted as before. Tubes were centrifuged at 350 x^ for 1 minute to separate tlie 
aqueous and organic phase. Without disturbing tlie middle skica layer, the upper aqueous 
phase containing DNA in solution, was transferred to a fresh 1.5 ml microcentrifuge mbe 
(approximately 450 pi).
The DNA precipitation and washing was performed on tlie bench. Approximately two 
volumes of cold absolute ethanol were added to the aqueous phase (900 pi). Tubes were 
tlien inverted a few tknes to precipitate the DNA, which appears as tiny white strands. To 
peket tlie DNA, die mbes were centrifuged at 4,500 xg (7000 rpm) for 5 minutes. The 
supernate was pipetted or poured carefuUy into a suitable waste ethanol container, taldng 
care not to disrupt the DNA peket One ml of 70% cold ethanol was added to tlie peket 
and the mbe inverted several times to wash tlie DNA. The mbes were re-centrifuged as 
before, and the supernate discarded.
The DNA peket was air-dried for 15 to 30 minutes with the mbe caps open and mbes 
inverted to remove any remaining ethanol. DNA was re-suspended in 50 pi of 1 x TE 
buffer (10 mM Tris (T-6066, Sigma), 1 mM EDTA (E-5134, Sigma), pH 8.00 ± 0.05) to 
initiaky dissolve the peket. The DNA suspension was either placed on a rotary shaker 
(Mikroshaker 20 E, Camlab Limited) for two hours or stored overnight at 4°C to fuky 
dissolve the DNA. The DNA extracts were then eitiier quantified as below (2.4.2, page 61) 
or stored at -40°C until use.
2.4.2 Quantification of DNA
The concentration of extracted DNA was calculated using tlie GeneQuant 
spectrophotometer (Amersham). The DNA was measured ki tripkcate at with the
concentration automaticaky calculated, based on the assumption that double-stranded
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DNA has a concentration of 50 pg/m l in a 10 mm pathlength cell at an optical density 
(OD) of 1 (± 1% of the reading). Mean concentration values were calculated and recorded. 
Measurements by tins method were reproducible and reliable.
2.4.3 DNA purification from clinical samples
Bacterial DNA from frozen nasopharyngeal aspirates (NPAs) and pernasal swabs (PNSs) 
was isolated using the Qiagen Blood & CeU. Culture DNA Mini Kit (Qiagen). This Itit was 
chosen because of its success in purifying high molecular weight DNA from various types 
o f samples. The ‘Blood and Body Fluid Spin Protocol’ (revision date January 1999) was 
followed and all reagents were provided in the Idt, unless stated otiierwise.
The NPAs/PNSs samples were taken from —70°C and allowed to thaw at room 
temperature. Into each labelled 1.5 ml microcentrifuge mbe, 40 pi of QIAGEN Proteinase 
K  was added. To this, 400 pi each of the sample and Buffer AT was pipetted into the mbe 
and pulse-vortexed immediately for 15 seconds. (NOTE: If the N PA /PN S was less than 
400 pi, tiien the other reagents were adjusted accordingly, e.g., a 200 pi sample requires 20 
pi QIAGEN Protease and 200 pi Buffer AL.). Tubes were then incubated for 10 minutes 
at 56°C for the cells to lyse.
After a brief centrifuge, 400 pi (or appropriate volume) of 100% ethanol was added to the 
mbes to precipitate die DNA. This was briefly vortexed, then centrifuged again, before the 
mixmre was transferred to a labelled QIAamp spin column (within a 2 ml collection mbe). 
The columns were centrifuged at 6,000 x^ for 1 minute to collect the DNA in the filter and 
remove die lysate. The collection mbe was discarded and replaced with a clean mbe. Buffer 
AWl (500 pi) was added to the column and centrifuged at 6,000 x^ for 1 minute to wash 
tlie DNA. The collection mbe was discarded and replaced as before. A final wash with 500 
pi of Buffer AW2 was performed and centrifuged at 20,000 x^ for 3 minutes. To prevent 
possible Buffer AW2 carryover, the spin column was placed in a clean collection mbe and 
centrifuged for a further minute at 20,000 xg. The spin column was then transferred to a 
sterile, labelled 1.5 ml microcentrifuge mbe and 200 pi of Buffer AE, which was pre-heated 
to 56°C, was added. Tubes were incubated for 1 minute at room temperamre to increase 
DNA yield and then centrifuged at 6,000 xg for 1 minute.
The eluate was tiien divided into two ahquots and stored at -80°C until required.
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2.5 D N A  sequencing
All the genes studied in this thesis ate hsted in Table 2.2 (page 65). Targets were sequenced 
either to screen for variation as possible epidemiological markers, or to determine tlieir 
genetic stability as molecular probes (for example, the 1S1002 probe).
2.5.1 Design of oligonucleotide primers for PCR amplification and DNA  
sequencing
Primers were designed for the following genes: pertactin (prfiA), adenylate Idnase (ad/i), and 
filamentous haemagglutinin (fhaB). Appropriate B. pertussis sequences were downloaded 
from GenBank, National Centre for Biotechnology Information (NCBI), Bethesda, MD. 
(http://www.ncbi.nhn.nih.gov). For pertactin, aU the variants o f this gene were ahgned in 
GeneBase (Apphed Maths) (Table 2.2, page 65). Prhner design was based on the complete 
pertactin gene sequence available (GenBank accession number, J04560), and the 
constructed ahgnment was used to check for suitable primer sites. Primers for adk and ftooB 
were designed using the sequences Z29715 and X53405, respectively (GenBank).
Suitable primers were chosen using GeneBase with the foUowing considerations: (i) due to 
the high G+C content of the B. pertussis (67.72%), short ohgonucleotides (17-20
nt) were chosen to keep the predicted temperature of dissociation (T^ under 65°C; (ii) to 
ehminate hairpin loops and primer dimer formation, the “maxhnum internal 
complementary units” function in GeneBase was set to 8 to stop structures of more than 4 
complementary bases within tlie prhner(s) from occurring; (hi) the internal stabihty of 
prhners was checked, such that primers that had GC-rich 5'-ends were chosen in 
preference to those primers with GC-rich 3'-ends; and (iv) when designing primers for 
PCR reactions, the prhners should not complement each other, but should have similar Tj 
values, + /-  5°C. Candidate primers were then synthesised by MWG Biotech, purified using 
theh High-Purity Salt-Free (HPSF®) method, see Table 2.3. (Page 66).
2.5.2 General methodology for PCR
Each gene target is described separately in 2.5.4, 2.6.1, 6.2 and 8.2 (pages 68, 81, 218, and 
250), with all PCR parameters tested. All PCR reactions were prepared in a clean 
envkonment, by using a PCR cabinet decontaminated with ultra-violet hght, and dedicated 
pipettes and tips. Latex or nitrile gloves were worn throughout the PCR preparation and all
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plastic disposables were certified DNase-free. To validate aU PCRs, positive and negative 
controls were prepared for each PCR assay, adding genomic DNA from B. pertussis NCTC 
10739^ and nuclease-free water (Promega), respectively. Reactions were all at a final volume 
of 50 pi, with the Taq DNA polymerase, the 10 x PCR buffer and 50 mM MgCl^ obtained 
from Invitrogen, the dNTPs from Roche, the primers synthesised by MWG Biotech and 
nuclease-free water from Promega. Further details of the primers are given in Table 2.3, 
page 66. The amplifications were performed using the PTC-200 DNA Engine, or the PTC- 
225 DNA Engine Tetrad (MJ Research) in 0,2 ml PCR tubes, or the Hybaid TouchdowiE"^ 
Thermal Cycler (Hybaid Ltd) using 0,5 ml PCR tubes.
Some optimisation or adaption of a published metliod was required. Tins involved either:
(i) the addition o f dimethyl sulphoxide (DMSO), to facilitate DNA strand separation and 
prevent secondary strucmres, (ii) the adjustment of MgCl^ concentration and/or the 
annealing temperature to maximise the specificity of the PCR reaction, and (hi) the 
adjustment of DNA template concentration.
2.5.3 Separation and visualisation of PCR products
PCR products (5 pi) were loaded on a 1.25-2% (weight to volume ratio, w/v) agarose gel 
(Invitrogen), with 3 pi of 6 x gel-loading buffer type II, 0.25 % (w/v) bromophenol blue, 
0.25 % (w/v) xylene cyanol FF, 15 % (w/v) FicoU in water (Sambrook and Russell, 2001). 
Standard ladders of either 100 bp or 1 Kb (Invitrogen) were also loaded at least twice on 
each gel row, to allow accurate size estimation of the amplicons produced. Fragments were 
analysed on a horizontal gel electrophoresis apparatus in 1 x TBE (89 mM Tris, 89 mM 
boric acid, 2 mM EDTA, pH 8.3, Sigma) at eitlier 5.3 V /cm  for 45-60 minutes in a GNA- 
100 tank or at 4.1 V /cm  for 1-2 hours in a GNA-200 tank, (Amersham). Gels were then 
transferred to 1 Utre of distilled water containing 1 pg/m l ethidium bromide (Sigma), and 
left to stain for approximately 30 minutes. Gels were then photographed using the Polaroid 
MP-4 system with black and white 667 fkm (Polaroid), under UV light at 305 nm.
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2.5.4 PCR amplification of the pertactin and the pertussis toxin SI subunit 
genes
2.5.4.1 Pertactin gene
This PCR protocol was adapted from Mooi et al. (1998). To encompass the two 
polymorphic regions (see 1.6.4, page 46), primers AF and BR were used to produce an 
amplicon of approximately 1428 bp (Figure 2.1, page 69). When the entire pertactin gene 
was sequenced, two further ampHcons were required, a 626 bp ampHcon at the 5'-end 
generated with primers PR8F and PRN707R, and a 973 bp 3'-end fragment using 
PRN1976F and PR5R. Optimisation reactions (50 pi) contained 10% v /v  DMSO, 1,5-3.5 
mM MgClj, 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP, 10 pmol each of 
forward and reverse primers, 2.5 U Taq DNA polymerase, and 10-100 ng template DNA.
Cycling conditions were as follows, initial dénaturation at 95°C for 3-5 minutes, then 30 or 
40 cycles consisting of dénaturation at 95°C for either 10,15, 20 or 30 seconds, annealing at 
47-71°C for 10, 15, 20 or 30 seconds, and extension at 72°C for 45 seconds or 1 minute, 
followed by a final extension of 7 minutes at 72°C, with a final 4°C hold.
Figure 2.2 (page 70) illustrates the optimisation experhnents using the primer pair AF and 
BR, adjusting the DNA template concentration and annealing temperature. AmpHfication 
of the 5'-ampHcon (Figure 2.3, page 71) did not require optimisation, but ampHfication of 
the 3'-ampHcon using PRN1976F and PR5R was optimised by adjusting the annealing 
temperature (Figure 2.4, page 72).
Optimised conditions
For ampHfication of the pertactin gene using any of the forward and reverse prhner 
combinations above, the reaction mixture contained 10% v /v  DMSO, 2.5 mM MgClg, 10 
mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP, 10 pmol each o f primers, 2.5 U Taq 
DNA polymerase, and 100 ng template DNA from pure culture extraction.
The cycHng conditions used with prhners AF and BR comprised an initial denamration at 
95”C for 5 minutes, then 30 cycles consisting of dénaturation at 95°C for 15 seconds, 
anneaHng at 57°C for 15 seconds, and extension at 72°C for 45 seconds, foUowed by a fhial 
extension of 7 minutes at 72°C, witli a final 4°C hold.
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Amplification of the 5'-end of the pertactin gene needed no optimisation, and used primers 
PR8F and PRN7Û7R. The cycling conditions were as follows: initial dénaturation at 95°C 
for 5 minutes, then 30 cycles consisting of dénaturation at 95“C for 30 seconds, annealing 
at 55°C for 30 seconds, and extension at 72"C for 45 seconds, followed by a final extension 
of 10 minutes at 72°C, with a final 4°C hold (Figure 2.3, page 71).
To amplify die 3'-end o f the pertactin gene, primers PRN1976F and PR-5R were used. The 
cycHng conditions were as follows: initial dénaturation at 95°C for 5 minutes, then 30 cycles 
consisting of dénaturation at 95°C for 30 seconds, annealing at 58.4°C for 30 seconds, and 
extension at 72°C for 45 seconds, followed by a final extension of 10 minutes at 72”C, witii 
a final 4°C hold (Figure 2.4, page 72).
2.5.4.2 Pertussis toxin SI subunit gene
The PCR to amplify theptxA  gene was also adapted from Mooi et ai. (1998). The same 
primers (SF and SR) were used to generate a product of approximately 876 bp (Figure 2.5, 
page 74). Reactions of 50 pi were optimised witii or without 5% v /v  DMSO, and 
contained 1.5-3.0 mM MgCl^, 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP, 10 
pmol each of forward and reverse primers, 2.5 U Taq DNA polymerase, and 10 or 100 ng 
template DNA.
Amplification parameters for optimisation consisted of initial dénaturation at 95"C for 3 or 
5 minutes, then 30 cycles of 95°C for 15 seconds, annealing between 48-68°C for 15 
seconds, and 72”C for 45 seconds or 1 minute, with a final extension of 72°C for 7 or 10 
minutes, and a final 4°C hold.
Figure 2.6 (page 75) illustrates the optimisation experiment used with die primer pair SF 
and SR, and adjusting the MgCl^ concentration in tlie presence or absence of DMSO.
Optimised conditions
Reaction mixtures for the amplification of the pertussis toxin gene using the primer 
combination SF and SR contained 1.5 mM MgClj, 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 
200 pM dNTP, 10 pmol each of primers, 2.5 U Taq DNA polymerase and 100 ng of 
template DNA.
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The cycling conditions used with primers SF and SR comprised an initial dénaturation at 
95”C for 3 minutes, then 30 cycles consisting of dénaturation at 95”C for 15 seconds, 
annealing at 59“C for 15 seconds, and extension at 72°C for 1 minute, foUowed by a final 
extension of 10 minutes at 72°C, with a final 4°C hold.
2.5.5 PCR product purification
Excess dNTPs, primers and Taq DNA polymerase were removed from tlie PCR amplicon 
with the Wizard® PCR Preps DNA Purification System Kit (Promega). This kit was 
chosen for its ease of use, speed and abkity to recover large amplicons (>1.5 Kb) at a high 
yield. Manufacturer’s instructions were foUowed (revision date 5/01), with some alterations 
detaked below.
One hundred microHtres of the Wizard® PCR Preps DNA Purification Buffer were added 
to labeUed sterke 1.5 ml microcentrifuge tubes, the number of tubes dependent on the 
number of amplicons purified. Triplicate PCR reactions were usuaUy pooled to give a 
better yield, thus, approximately 135 pi PCR reaction was transferred to the respective 
labelled tube for purification. These were agitated and tlien 1 ml of Wizard® PCR Preps 
DNA Purification Resin was added. Tubes were vortexed for 3 x 5  second bursts over a 1 
minute period.
If seven or more samples were processed at the same time, then the Vac-Man® Laboratory 
vacuum manifold (Promega) was used (maximum of 20 samples), fokowing section V.A, of 
the manufacmrer’s kistructions (2.5.5.1, page 76). Section V.B. was fokowed, a metliod 
using 2 ml syringes, when six or fewer samples were processed (2.5.5.2, page 77).
2.5.5.1 Vacuum manifold method for PCR product purification
The manifold was set up with a vacuum pump (BDH) and moisture trap. Labeked 
Wizard® Minicolumns were placed on to the required number of inlets, and a syringe 
barrel (3 ml, provided in kit) screwed into the Luer-Lok® extension of each minicolumn. 
The resin-DNA mixture was then transferred into the syringe barrel and vacuum was 
applied to draw the mixture into the iitinicoluinn. This captures the resin, to which tlie 
DNA is attached.
The vacuum was stopped and 2 ml of 80% isopropanol added to the syringe barrel to wash 
the DNA. The vacuum was tlien re-appked to draw the isopropanol through the column.
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When the miiiicolumn was clear o f hqnid, the vacuum was stopped and the column was 
transferred to a fresh, labelled 1.5 ml microcentrifuge tube. Tubes were then centrifuged at 
10,000 for 2 minutes to remove residual liquid. The minicolumn was transferred to a 
fresh, labelled 1.5 ml microcentrifuge tube and 50 pi of nuclease-free water was added to 
die column to elute the DNA. Tubes were centrifuged again at 10,000 xg for 30 seconds to 
recover die DNA. The rninicolumn was removed and discarded, the waste from the 
manifold was discarded and the purified PCR product was stored at 4°C awaiting DNA 
quantification (2.4.2, page 61),
2.5.5.2 Syringe method for PCR product purification
Fresh microcentrifuge mbes were labelled, and a minicolumii placed onto each mbe. 
Disposable, sterile 2 ml syringes were dismantied, with the barrel being placed firmly onto 
the minicolumn, and the plunger set aside. The resin-DNA mixmre was then transferred 
into the syringe barrel and, over a waste jar, die plunger was inserted back into the barrel. 
The plunger was then gendy pushed to force the slurry through the minicolumn and into 
the waste jar.
The plunger was removed from the barrel and 2 ml of 80% isopropanol added to the resin. 
As before, die plunger was inserted into the barrel and gendy pushed to wash the DNA 
and to clear the barrel o f liquid. The syringe was then discarded and the mbe with the 
minicolumn was centrifuged as detailed above in 2.5.5.1 (page 76).
Purified PCR products were stored at 4”C, until DNA quantification (2.4.2, page 61) was 
performed, and then stored at —30'’C until required.
2.5.6 Sequencing reaction and precipitation protocols
Two systems were used to generate sequence data, both based on the dideoxynucleotide 
method (Sanger et al, 1977) either; (i) using an ABI Prism® 377 DNA Sequencer (Apphed 
Biosystems) at the University of Durham; or (h) the CEQ™ 2000 (Beckman Coulter) at 
RSIL from Aprk 2000, which was upgraded to a CEQ'^^ 2000XL in Aprk 2001, then to a 
CEQ^'^ 8000 in September 2002. Manufacturer’s instructions were followed, using 75-150 
ng of purified PCR product as template.
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AU sequence reaction mixtures were prepared in a PCR cabinet (described in 2.5.2, page 
63), and all plastic consumables and other reagents not included in tlie kits were previously 
sterUised or certified DNase-free. There were differences between the two systems in the 
preparation of the sequence reactions and the precipitation, and these are described below.
2.5.6.1 ABI Prism® BigDye^^ Terminator Cycle Sequencing Ready Reaction Kit
This kit was used primarily for sequencing the pertactin and pertussis toxin SI ampUcons 
of most UK and Missouri B. pertussis (see Chapters 3 and 4). The revised version C
(1998) protocol was foUowed, using the “Cycle Sequencing on the DNA Thermal Cycler 
(TCI) or DNA Thermal Cycler 480” section for the cycling conditions. Reactions were 
performed in 0.5 ml thin-waUed PCR tubes on the Hybaid Touchdown^^ Thermal Cycler 
(Hybaid Ltd).
The following were added to a 0.5 ml thin-waUed PCR tube; 8 pi Terminator Ready 
Reaction Mix (ABI), 3.2 pmol of sequencing primer, 90 ng of PCR product template and 
nuclease-free water to a final volume of 20 pi. A drop of mineral oU overlaid the sequence 
reaction to reduce evaporation during the PCR cycling. The cycling conditions were as 
foUows; initial dénaturation at 95°C for 1 minute, then 25 cycles of dénaturation at 96°C for 
30 seconds, annealing 50°C for 15 seconds and extension at 60°C for 4 ininutes, foUowed 
by a 20°C hold.
To separate the sequence reaction mixture from the mineral oil, the entire mixture 
(approximately 50 pi) was transferred onto a lengtli of Parafilm ‘M’ (15 cm x 5 cm). The 
Parafdm was then gently rocked lengthways to move and separate the mineral oil from the 
aqueous phase, as the oil adheres to the Parafdm. The clean sequence reaction mixture 
(approximately 20 pi) was then transferred to a sterile 1.5 ml Sarstedt tube and the 
isopropanol precipitation method was followed.
To each reaction, 80 pi of 75% isopropanol was added. The tubes were vortexed briefly to 
mix the isopropanol and reaction, and then left at room temperature for 15 minutes to 
precipitate the extension products. To separate the product from the supernate, the tubes 
were centrifuged at 14,000 xg for 20 minutes. The supernate was aspirated and discarded, 
taking care not to dislodge or touch the pellet, where the tubes were marked to identify the 
location of the pellet. The pellet was then washed witli 250 pi o f 75% isopropanol, to 
remove any residual salts, and tlien centrifuged for 5 minutes at 14,000 x .^ The supernate
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was again aspirated carefully and discarded. A small piece of Parafilm was stretched over 
the mouth of each tube and a hole was made using a pipette tip. These were then vacuum 
dried using a vacuum chamber for approximately 30 minutes, re-capped, packaged and sent 
to University of Durham for further processing on an ABI Prism® 377 DNA Sequencer.
2.S.6.2 CEQT^ 2000 Dye Terminator Cycle Sequencing with Quick Start Kit
The manufacturer’s protocol, version B C IP /N  608118:AA (2000) was used with the 
Beckman Coulter platform. A pUC18 control template (provided in Idt) was included each 
time a batch of sequencing reactions was performed. The PTC DNA Engines Models 200 
or 225 (MJ Research) were used with 0.2 ml thin-waUed PCR tubes.
Sequence reactions were set up as in 2.5.6.1 (page 78), but in labelled 0.2 ml tubes; 8 pi 
DTCS Quick Start Master Mix (Beckman Coulter), 3.2 picomoles of sequencing primer, 
75-150 ng of PCR product template and nuclease-free water to a final volume of 20 pi. The 
cycling conditions were as follows; 30 cycles of dénaturation at 96”C for 20 seconds, 
annealing at 50"C for 20 seconds and extension at 60°C for 4 minutes, followed by a 4° C 
hold.
For precipitating the dye terminators, a Stop Solution was prepared by mixing 3 M NaOAc 
(Sigma), 100 mM EDTA (Sigma) and 20 m g/m l glycerol (provided in Idt) at a 2:2:1 ratio. 
This Stop Solution was prepared fresh on the day, corresponding to the number of 
reactions processed (e.g., for 8 reactions, 16 pi EDTA, 16 pi NaOAc and 8 pi glycerol is 
required).
The 20 pi reaction mixture was transferred into a labelled, sterile 1.5 ml microcentrifuge 
tube. Five microlitres of Stop Solution was added to each tube and gently agitated. Ice-cold 
ethanol (95%, 60 pi) was added and mixed thoroughly. The tubes were tlien centrifuged at 
4°C for 15 iTunutes at 19,000 x^ (14,000 rpm). The supernate was gently aspirated (approx. 
90-95 pi), leaving a small wliite pellet at the bottom of the tube. The pellet was then rinsed 
twice with 200 pi 70% ice cold etlranol, with each rinse requiring a centrifuge at 4°C for 2 
minutes at 19,000 x^ (14,000 rpm). After the second rinse, tire tube lids were closed and a 
hole was made in each Kd to allow the pellet to dry. The tubes were tlien placed in the 
vacuum chamber for about 20 minutes, or until the pellets were dry.
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The pellets were then prepared to run on the CEQ'^^ 2000 analyser by dissolving them in 
30 pi of Sample Loading Solution (SLS, containing formamide). Care was taken to locate 
the pellet before opening the tube, as the pellet may be statically charged and can be lost or 
not properly dissolved in the SLS. The SLS was initially mixed up and down using a filter- 
free tip (formamide in the SLS can react witli die filter polymer to produce aerosols that 
can degrade the deoxy terrninators) until dissolved and left on die bench for 5 minutes.
The sample was then transferred to the 96-well sequencing plate and overlaid widi a drop 
of mineral oil to stop the sample from degrading and the formamide from oxidising. The 
sample plate coidd then be loaded straight onto the CEQ^i^ 2000 analyser to determine the 
sequence, or sealed witii a Seal & Sample Aluminum Foil Lid (Beckman Coulter) and 
stored at —40°C.
2.5.7 Sequence analysis
The sequence data were analysed using both the chromatogram file, a hard copy of the 
chromatogram and the nucleotide sequence. All sequences from either die ABI Prism®
377 DNA Sequencer or the CEQ^^ 2000 analyser, were checked manually by studying the 
chromatogram. The pUC18 control sequence was compared with the reference sequence 
for quality control purposes. The contigs were constructed by aligning die novel sequences 
with Imown sequences from GenBank. The software packages used were either GeneBase 
or Kodon (Applied Maths).
Alignment of sequence data was performed using GeneBase version 1.0 with a reference 
sequence. The hard copy chromatogram and the unknown sequence were edited manually 
and simultaneously. The edited sequence file was dien saved in an appropriate folder and 
given a unique name according to its strain designation and the primer used. This sequence 
was clustered with other Imown variants of the appropriate gene and then identified to a 
known type, e.g.,pr/^M(l), or given a new designation, if novel.
GeneBase was updated in February 2002 by Applied Matlis, who introduced Kodon as a 
sequence and whole genome analysis software package. The chromatogram and the 
unknown sequence were edited semi-automaticaUy, with both the chromatogram and 
sequence saved in a Kodon database. The contig was then aligned witli a cluster of Imown 
variants and designated as above.
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Where a sequence was of poor quality (e.g., too many ambiguities, low signal, insertion or 
deletion of bases due to mis-caUing) the sequence reaction was repeated (2.5.6, page 77) 
and, in some circumstances, the target gene was re-amplified (2.5.4, page 68) and re­
sequenced.
2.6 ISi^ft^Restriction Fragment Length Polymorphism analysis
This method was adapted from van Loo et al (1999). One major change to this protocol 
was in the labelling and detection, from peroxidase and X-ray film with the Enhanced 
Cheinilurninescence Gene Detection System (Amersham), to the digoxigenin ^ IG )  system 
(Roche), using colorimetric detection. Key steps in optimising this technique were; (i) the 
PCR amplification of the DIG-labeUed 1^1002 probe (2.6.1, page 81), (ii) the concentration 
of probe (2.6.5, page 85), (iii) the temperature required for hybridisation (2.6.5, page 85), 
and (iv) the subsequent washing conditions (2.6.6, page 86).
2.6.1 Digoxigetiin-labelling of the I S p r o b e  via PCR amplification
The 293 bp \?>1002 probe was produced by PCR using the PCR D IG  Labelling Mix from 
Roche. This Idt was chosen, as the DIG-dUTP is incorporated into the amplicon where 
there is a thymine base, and thus tlie probe becomes highly labelled and very sensitive. 
Bordetellaparaperttmis DNA from strain B24 was used for the amplification of the probe. 
Tliis particular strain of B. parapertussis is used to minimise cross-hybridisation witlr the 
similar insertion elements IS4<?/ and IS>1001, as strain B24 does not contain these other 
elements compared to otlier B. parapertussis (pers comm, Han van der Heide).
Optimisation
Optimisation of tliis PCR reaction was performed with the following parameters; reaction 
mixtures (100 pi) were prepared in a PCR cabinet and transferred into 0.2 ml thin-walled 
tubes with or without 10% v /v  DMSO containing, 2.5 mM MgCl^, 10 mM Tris-HCl (pH 
8.3), 2.5 mM KCl, 200 pM dNTP (containing 70 pM DIG-dUTP), 10 pmol each of Hgl 
and Hg2 primers (Table 2.3, page 66), 2.5 U Taq DNA polymerase, and 10 ng of template 
DNA.
Tubes containing mixtures were transferred to a tliermal cycler and amplified as follows; 
initial dénaturation of 95°C for 5 minutes, tlien 30 or 35 cycles of dénaturation 95°C for 45 
seconds, annealing 40-64°C for 45 seconds and elongation 72°C for 1 minute, with a final
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extension of 72°C for 7 minutes, and a 4°C hold. Figure 2.7 (page 83) shows the 
optimisation when 10% v /v  DMSO is included and 35 amplification cycles are performed.
Optimised conditions
The 1^1002 element was amplified successfully when the reaction contained 10% v /v  
DMSO, 2.5 mM MgCl^, 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP 
(containing 70 pM DIG-dUTP), 10 pmol each of primers, 2.5 U Taq DNA polymerase and 
10 ng of template DNA. The optimum cycling conditions had an initial dénaturation of 
95”C for 5 minutes, then 35 cycles consisting of dénaturation at 95°C for 45 seconds, 
annealing at 50°C for 45 seconds, and extension at 72°C for 1 minute, followed by a final 
extension of 7 minutes at 72°C, witli a final 4”C hold (Figure 2.7, page 83).
PCR products were then visualised as in Section 2.5.3 (page 64), with a 100 bp ladder 
(Invitrogen) to identify fragments of 293 bp. If tlie 1^1002 fragment was present, 3x100  
pi mixes were pooled and purified using the Wizard® PCR Preps DNA Purification 
System Kit (2.5.5, page 76). Purified l ‘b1002 fragments were then quantified (2.4.2, page 61) 
and stored at -30°C until use (2.6.5, page 85).
2.6.2 Restriction endonuclease digestion with Smai
Five pg of extracted genomic DNA (see 2.4.1, page 60) were digested for 4 hours at 37°C 
with 10 U of the restriction endonuclease Smal (recognition sequence CCCIGGG, Roche) 
in 1 X Buffer A (provided with SmdB) in a final volume of 50 pi. Reactions were stopped by 
die addition of 15 pi of 6 x gel-loading buffer type II (Sambrook and Russell, 2001), mixed 
thoroughly, and products stored at —30°C.
2.6.3 Separation of D N A  fragments by Field Inversion Gel Electrophoresis
The same CHEF-Mapper XA System (Bio-Rad) apparatus was used for every gel to 
increase reproducibility and to allow comparison of the reference strain across different 
blots. Electrophoresis was performed overnight for 20 hours.
82
en
aIUl
a
CJw
c
s
cngO
■g>
ÏCD
C
a
<u
C0
■5(UcnC
1II
o
GO
■gV«!
u&
(S
&
E
%%%
.0 u
Ioc
§
83
A 1% agarose gel was prepared using 200 ml of 0.5 x TBE and 2 g of pulsed field certified 
agarose (Bio-Rad). A gel tray of 25 cm x 16 cm was wiped with 70% ethanol and a 25-tooth 
comb was placed near the top of the tray. The CHEF-Mapper tank was filled with 1800 ml 
of 0.5 X TBE, the pump switched on at speed 7 and the chiller system set to 20”C. After 
cooling and casting, the gel was placed in die tank and secured well with pipette tips. The 
gel was left to equilibrate hi die TBE buffer for at least 15 minutes.
The digests were prepared as described hi Section 2.6.2. (page 82) and the molecular-weight 
ladders were taken from -30°C and allowed to thaw at room temperature. Two of the three 
ladders were applied as a mixture by initially pre-heating 1.5 pi of a 100 ng /p i dilution of 
CFIEF DNA 8-48 Kb ladder (Bio-Rad) at 65°C for 5 minutes. After equilibrating to room 
temperature, 1.5 pi of a 100 ng /p l dilution of a 1 Kb ladder (Invitrogen) was added, and 
made up to 15 pi with 12 pi of 6 x gel-loading buffer type II. The DIG-labeUed DNA 
molecular weight marker II (Roche) was prepared by adding 5 pi of 6 x gel-loading buffer 
type II to every 10 pi of marker. Twelve Smal DNA digests were run on each gel along 
with the B, pertussis strain (NCTC 10739^), to determine die intra-gel and inter-gel 
reproducibility. The pump was switched off before loading the samples. The combhied 
CFIEF/1 Kb ladder mix was loaded hi the first and last wells, die D IG  marker in every 
fourth well, and the reference strahi NCTC 10739^ next to the outer two D IG  markers, 
and hi the middle well (well numbers 4, 13, and 22), using a total of 23 wells. Each gel was 
run for 20 hours at 180 V (equivalent to 5.5 V/cm , forward voltage), and reverse voltage of 
120 V (~ 3.6 V/cm), widi forward and reverse switch times of 0.1 seconds, and a linear 
ramp. To ensure that the DNA had run into die gel, the pump was left off for 5 minutes 
after starting electrophoresis, then switched back on to re-chculate the TBE buffer and 
prevent the tank from over-heating. On completion of die run, the gel was stained hi 1 
pg/m l ethidium bromide for 30 minutes to visualise the restricted DNA, and a photograph 
was taken. The gel was then processed immediately to transfer the DNA to a nylon 
membrane.
2.6.4 Vacuum transfer of D NA to a nylon membrane
The gel was prepared before transfer of DNA to Flybond N^ nylon membranes 
(Amersham), as follows; the gel was denatured for 2x15 mhiutes in 200 ml denaturing 
solution, 1.5 M NaCl, 0.5 M NaOH (Sigma), and then rinsed in sterüe distilled water 
briefly. The gel was then neutralised in 200 ml neutralising solution, 1.5 M NaCl, 0.5 M 
Tris-HCl, pH 7.6 (Sigma) for 2x15 minutes, then rinsed again in sterile distilled water. A
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piece of nylon membrane was prepared by cutting a size that encompasses the bands from 
the gel, with at least a 5 mm overlap, and labelled in the upper right-hand corner with the 
date transferred. The membrane was tlien equilibrated for at least 5 minutes in 100 ml of 2 
X SSC solution, (0.3 M NaCl, 30 mM sodium citrate) (Invitrogen), and the solution was 
kept for use later.
The VacuGene XL vacuum blotting system (Amersham) was prepared following the 
manufacturer’s instructions. A vacuum of approximately 50 cm^ was applied and 50 
ml of transfer buffer (10 x SSC buffer) were poured on to the surface o f the gel. Transfer 
buffer was topped up when tlie gel surface was dry and approximately 100 ml was used in 
total. The vacuum was applied for over an hour to ensure adequate transfer of DNA 
fragments to the nylon membrane.
To prevent the DNA smearing on the membrane, the gel was first removed, and then the 
pump was switched off. The membrane was rinsed for two minutes in the 2 x SSC solution 
retained from earlier and then dried at 37°C for approximately 20 minutes between two 
pieces of clean filter paper. The gel was re-stained in 1 pg/m l ethidium bromide for 30 
minutes and re-examined under UV iUumination to ensure that DNA transfer was 
successful. The DNA was fixed to the nylon membrane by UV cross-linking. Each 
membrane was placed DNA side down on the UV transilluminator, and then exposed to 
UV at 305 nm for 1-2 minutes. The membrane was then either stored in a dark, dry place 
at room temperature indefinitely, or immediately processed following the section below.
2.6.5 Pre-hybridisation and hybridisation of membranes
The membrane was transferred to a hybridisation bag (Invitrogen) and 20 ml of D IG  Easy 
Hyb buffer (Roche) added. Air bubbles were expelled before the bag was heat-sealed, and 
then incubated in a water-bath at 47°C for 4 hours. The corner of the bag was cut and the 
DIG Easy Hyb buffer removed.
Optimisation
An experiment to establish die optimal amount of probe, and the temperature of 
hybridisation was performed with eight replicate membrane strips (approximately 30 mm x 
155 mm). The initial gel was run and blotted as in 2.6.3 and 2.6.4, respectively, where each 
strip had the D IG  ladder and a B. pertussis stuTin from Missouri (MO-234, MO-83, MO-73, 
or MO-9). Membrane strips were labelled 1 through to 8, and treated in separate
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hybridisation bags (Table 2.4.a, page 88). Concentrations of IS/002 probe used were 3.3,
1.3, 0.7, and 0.3 pmol probe/cm^ membrane, and two water baths were set at 42“C and 
52°C. In smaller, separate bags with the individual strips, the probe was added to 0.5 ml 
D IG  Easy Hyb buffer, the air bubbles were removed, the bag was re-sealed, and then 
incubated in the relevant water-bath overnight. Subsequent washing and blocldng of the 
strips were performed together. Detection of bands were carried out in separate bags, and 
the volume of Buffer 3, 5-bromo-4-chloro-3-iiidolylphosphate p-toluidine salt (BCIP) and 
nitroblue tetrazohum chloride (NBT) (Invitrogen) was adjusted accordingly (see 2.6.6, 
below). Figure 2.8 (page 89) shows the developed strips, numbered 1 to 8.
Optimised conditions
A hybridisation temperature of 47“C and a IS/002 probe concentration of 3.3 pmol/cm 
in 1 ml of DIG Easy Hyb buffer was used for all subsequent experiments. The next step 
(2.6.6, page 86) followed immediately.
2.6.6 Washing and detection of digoxigenin-labelled bands
All washes and incubations were performed on a shaking platform in plastic boxes, to give 
even, tliorough results for each membrane treated. The corner of the hybridisation bag was 
cut and die hybridisation buffer was collected using a 1 ml Gilson pipette. The 
hybridisation buffer was frozen at -30°C in a sterile plastic bijou, for one further use on an 
unhybridised membrane. The membrane was rinsed in a few mis of Wash solution A (2 x 
SSC, 0.1% w /v  SDS), pre-warmed to 37°C, to remove any excess hybridisation buffer. A 
further two washes, each for 5 minutes with 200 ml V^ash solution A, were carried out on 
the shaking platform. The membrane was then washed for 2 x 5  minutes witli 200 ml Wash 
solution B (0.1 X SSC, 0.1% w /v  SDS) at 37 C.
Optimisation
An optimisation experiment was used to test die stringency of the washing conditions by 
varying the concentration of SSC and the temperature of the second wash, in Wash 
solution B. Six replicate membrane strips (approximately 30 mm x 155 mm) were produced 
as above (2.6.5, page 85), and each included the D IG  ladder, a B. pertussis strain (CN 2055) 
and a B. parcpertussis strain (UK 38 or NCTC 10853). Membrane strips were labeUed 1 
through to 6, and were washed in separate plastic boxes (see Table 2.4.b, page 88).
Volumes of Wash solution A were adjusted according to membrane size and the 
concentrations of SSC in V/ash solution B were tested at 0.1 x and 0.01 x. Aliquots of
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Wash solution B were incubated either at room temperature on a shaking platform, or in 
two water baths at 52°C and 68°C with gentle rocking. Washing times were the same as 
above, and subsequent washing and blocking of the strips and the detection of bands were 
performed together (see below). Figure 2,9 (page 90) shows the developed strips, 
numbered 1 to 6.
To prevent non-specific binding o f the probe, die membrane was incubated for 30 to 45 
minutes with 100 ml Buffer 2, 1% w /v  blocking reagent (Roche), 0.1 M Tris-HCl, 0.15 M 
NaCl, pH 7.6. The anti-DIG-AP Fab fragments (Roche) were centrifuged at 13,000 xg  for 
5 minutes prior to initial use, and 1 minute before each use thereafter. This was to remove 
any small antibody aggregates diat could lead to background noise (spots) at the detection 
stage. The antibody was diluted 1:4000 in Buffer 1 (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.6) 
(20 pi antibody, 80 ml Buffer 1). The membrane was incubated in the antibody solution for 
30 minutes, and the reaction stopped by wasliing the membrane twice for 5 minutes in 200 
ml Buffer 1.
The membrane was equilibrated in 100 ml of Buffer 3 (0.1 M Tris-HCl, 0.1 M NaCl, 50 
mM MgClg, pH 9.5) for 5 minutes. The membrane was then drained and transferred in to a 
plastic bag (24 cm x 18 cm). To detect the DIG-labeUed bands, 25 ml of substrate solution 
(0.1 M Tris-HCl, 0.1 M NaCl, 50 mM MgCl^, 175 pg/m l BCIP, 337 pg/m l NBT) was 
pipetted into the bag, the aie bubbles carefuUy expeUed, and the bag heat-sealed. The 
developing membrane was then incubated in the dark at room temperature. The labeUed 
bands usuaUy appeared after an hour but the membranes were typicaUy incubated for 6-16 
hours, depending on the background level. To stop the reaction the membrane was 
removed from the bag and washed in distilled sterUe water. The membrane was then dried 
between two sheets of clean filter paper. Membranes were stored in a dark, cool 
environment, until the next step (2.6.7, see below).
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Table 2.4. Optimisation o f ISJ?^â2-RFLP with membrane strips
a. Membrane strips used to optimise the hybridisation temperature and concentration 
of IS1002 probe.
Strip
number
Bordetella 
pertussis strain
Hybridisation
temperature
lS1002ptohe: concentration 
(pmol/cm^)
1 MO-234 42°C 0.3
2 MO-83 42°C 0.7
3 MO-73 42°C 1.3
4 MO-9 42°C 3.3
5 MO-234 52°C 0.3
6 MO-83 52°C 0.7
7 MO-73 52T 1.3
8 MO-9 52°C 3.3
b. Membrane strips used to optimise the stringency of the washing conditions, using 
Wash solution B.
Strip
number
Bordetella
pertussis
strain
Bordetella
parapertussis
strain
SSC buffer 
concentration
Washing
temperature
1 CN 2055 UK 38 0.1 X  SSC Room temperature
2 CN 2055 UK 38 0.1 X  SSC 52"C
3 CN 2055 UK 38 0.1 X  SSC 68"C
4 CN 2055 UK 38 0.01 X  SSC Room temperature
5 CN 2055 NCTC 10853 0.01 X  SSC 52°C
6 CN 2055 NCTC 10853 0.01 X  SSC 68”C
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2.6.7 Analysis of IS#A2-Restriction Fragment Length Polymorphism 
profiles
Developed membranes were scanned at 200 dpi (HP ScanJet ADF; Hewlett Packard), 
encompassing approximately the same area for each membrane, to ininimise variation in 
analysis. The tagged information file format (TIFF) files were tiien imported into the 
BioNumerics software (version 2.5; Applied Maths), for the normalisation and band 
assignment of the IS/d02-RFLP profiles. This was done in four steps according to the 
BioNumerics manual; i) the 21 lanes were defined using a thiclmess setting of 31 points 
with diree nodes, and the background subtraction and spot removal was set at 20 points 
and 6 points, respectively; ii) the densitometric curves (taken from the intensity of the 
hybridisation on the membrane) were defined using lanes with a thickness of 19 points and 
two nodes. For each membrane, a spectral analysis was performed, and values from this 
were used for the background subtraction and the arithmetic average filtering; iii) die DIG- 
labeUed DNA marker contained six visible bands after detection (23130 bp, 9416 bp, 6557 
bp, 4361 bp, 2322 bp, and 2027 bp), and these bands were selected to normaUse the 
profUes across the membrane. The reference system used to estimate the band sizes is 
dependent on the six bands in die DIG-labeUed DNA marker, and the BioNumerics 
manual recommends using a logarithmic-dependent cubic spUne fit; and iv) the initial band 
assignment used the foUowing band search filter settings; minimum profiling, 5.0%; “gray 
zone”, 5.0% (relative to the maximum value); minimum area, 0.00%; and shoulder 
sensitivity, 5.
After this automatic selection, the assignment of bands were checked as a quaUty exercise, 
according to the relative intensities of hybridised bands and the curve intensities. These 
varying intensities were due to: the amount o f restricted DNA loaded on the gel; die 
efficiency of the vacuum transfer of DNA to the nylon membrane; the hybridisation of 
probe and; the wasliing and detection times. However, weakly hybridised bands were not 
assigned at the author’s discretion.
Optimisation for identification of IS/002-RFLP types
To identify IS/0ti2-RFLP types, normaUsed IS/£?d2-RFLP profUes were compared with the 
Dice coefficient of similarity, and clustered using die unweighted pair group method widi 
aridimetic averages (UPGMA). Odier simUarity coefficients (Pearson, Jaccard) and 
dendrogram types (Ward) were used to analyse the data, but these were sub-optimal when
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analysed visually, and did not compare reliably with previous studies (van der Zee et ai, 
1996b; van Loo et aL, 1999).
A range of band position tolerances (from 0.0 to 1.2%) and optimisation settings (from 0.0 
to 1.0%) were used. A range of percentage similarity values (from 90 to 100%) was also 
assessed to determine the optimal settings for type allocation. In order to define optimal 
conditions, the data were examined visually to ensure tliat the percentage similarity 
threshold (at or above which tlie patterns were considered to belong to the same type) were 
consistent with their intra- and inter-gel appearance (Fry et ai, 1999). The type strain of B. 
pertussis (NCTC 10739^) was also used as a reference strain to determine intra- and inter-gel 
variation. To optimise the definition of an 1S/902-RFLP type effectively, aU 291 isolates 
that were typed by this method were included in this optimisation stage.
Optimum conditions for identification of IS /9<72-RFLP types 
The reproducibility (as measured by variation in the molecular sizes calculated with 
reference to the type strain) ranged from 92.1% to 100.0% (average 99.5%) for intra-gel 
and 91.8% for inter-gel variation. Optimal conditions for type allocation were with 0.6% 
optimisation and 1.0% tolerance, and using 91.8% similarity settings within the 
dendrogram produced. Using these criteria, a total of 45 different RFLP types were 
observed (Figure 2.10, page 93). The number of bands per RFLP type varied between 3 
and 9, with DNA band sizes of between approximately 2096 bp to 23.3 Kb.
Initially, the type RFLP-5 was identified as a separate type to RFLP-1, because of the 
apparent size difference of the highest band hybridised (approximately 16.4 Kb in RFLP-5 
compared to 15.4 Kb in RFLP-1). Upon further investigation, however, when clustered 
using the optimised conditions, RFLP-5 isolates clustered with over 91.8% similarity with 
RFLP-1, and therefore, isolates exhibiting RFLP-5 were re-classified as RFLP-1. This re­
classification also occurred for RFLP-37 isolates to become RFLP-25 isolates, as they 
clustered at 93.3% similarity, which is over the 91.8% similarity cut-off.
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2.7 Pulsed-Field Gel Electrophoresis
Tills method, using Xbal (recognition sequence TJCTAGA), was adapted from a paper 
which recommended the procedure after a consensus meeting of pertussis epidemiologists 
from 10 countries (Mooi et aL, 2000). One main adaption was the removal of 
phenylmethylsulfonyl fluoride (PMSF), which is liighly toxic and also requires dissolving in 
a volatile organic solvent. As PMSF stops the action of proteinase IC, the omission of 
PMSF necessitated multiple washes to remove proteinase K  activity (2.7.1, see below). The 
concentration of B. pertussis cells to be embedded in agarose, as measured by then 
absorbance at 650 nm, was also optimised.
2.7.1 Preparation of genomic D NA
Bordetella pertussis isolates were cultured on CHAR plates and incubated at 37"C for 48 
hours. Plug moulds were prepared, witli six moulds being used per isolate (each 1 x 0.6 x 
0.1 cm). Approximately half a plate of B. pertussis colonies was suspended in 1 ml of 1 x TE 
(10 mM Tris-HCl pH 8.0,1 mM EDTA) and the absorbance was measured at Ag^ onm 
(Helios Epsilon Spectrometer, Unicam Ltd). Measurements of B, pertussis cells at Ac5o„,„ 
values of approximately 0.6, 1.0 and 1.3 were tested, and it was found that an absorbance 
o f 1.3 at Agso provided the best result. A 3% solution of low melting-point agarose 
(SeaPlaque, BMA) was prepared in 0.5 x TBE (0.3 g in 10 ml) and cooled to 40°C. Equal 
volumes of tlie B, pertussis suspension and agarose (approximately 700 pi each) were then 
mixed carefully and pipetted in to the plug moulds. The plugs were left for 30 minutes at 
room temperature to harden, tlien transferred into 5 ml of proteolysis buffer, 0.5 M EDTA 
pH 8.0,1% w /v  sarkosyl (BDH), 0.5 m g/m l proteinase K  (Sigma), in 25 ml glass universal 
tubes. Tubes were incubated overnight in a waterbath at 55°C.
The plugs were then washed five times in 5 ml of 1 x TE (pH 8.0) on a rocker for 30 
minutes each at 37"C. They were stored in 10 ml of 1 x TE at 4°C, changing the TE at 
monthly intervals. To reduce the smearing of the PFGE profiles, the plugs were left in the 
fridge for at least two hours before starting the restriction step (2.7.2, see below).
2.7.2 Restriction endonuclease digestion with X6al
A thicd of a plug (0.3 x 0.6 x 0.1 cm) was initially equilibrated at room temperature in 200 
pi of 1 X buffer solution H (provided with restriction endonuclease X h a \ Roche) for 30 
minutes. This was then replaced with 200 pi of fresh 1 x buffer solution H and 40 U of
94
Xbal (Roche), and incubated overnight at 37°C. The reaction was stopped by the addition 
of 500 pi of 0.5 M EDTA (pH 8.0), and stored at 4°C for several weeks, or until separation 
by electrophoresis.
2.7.3 Separation and detection of D N A  fragments
A 1% agarose gel was prepared (SeaKem Gold, BMA), with 225 ml of 0.5 x TBE for a gel 
tray of 20 x 25 cm. The buffer of each restricted shce was changed to 200 pi of 0.5 x TBE 
and equilibrated at room temperature for 30 minutes. The melted agarose was poured in to 
the gel tray, retaining a few mis to seal die wells, and allowed to set for 30 minutes. Two 
litres of 0.5 x TBE was poured in to the electrophoresis tank of a CHEF DR II system 
(Bio-Rad), and the pump switched on with the chiller set to 16°C. The gel comb was 
carefully removed and the plugs loaded. At die first and every fourth well a lambda ladder 
PFG marker (~ 0.75 pg, New England BioLabs) was loaded, which comprises multiple 
concatemers of 48.5 Kb, increasing to 1018.5 Kb. The restricted DNA slices are also 
loaded in the appropriate wells, using a total of 22 wells. The wells were then sealed with 
the remaining agarose and left to set for 10 minutes. The gel was transferred to the tank, 
fixed firmly in place, and left to equilibrate for 30 minutes.
Two running programs were attempted to evaluate which method was better for separating 
the large restricted fragments. The first had a running time of 26 hours; ramping 4 to 30 
seconds, 6 V /cm , 18 hours and ramping 30 to 50 seconds, 6 V/cm , 8 hours. However, this 
did not give adequate separation and, therefore, a 40 hour programme was used for aU 
strains analysed; ramping 5 to 6 seconds, 5.5 V /cm , 16 hours and ramping 8 to 35 seconds, 
5.5 V/cm , 24 hours.
Gels were transferred to 1 litre of distilled water containing 1 pg/m l ethidium bromide 
(Sigma), and left to stain for approxhnately 30 minutes and tlien photographed using the 
Polaroid MP-4 system with black and white 667 film (Polaroid), under UV light at 305 nm.
2.7.4 Analysis of Pulsed-Field Gel Electrophoresis profiles
The PFGE profiles were analysed by the same metliod as for the IS/002-RFLP 
membranes (2.6.7, page 91), using tlie same software package (BioNumerics). The inverted 
densiometric value was selected for the PFGE experiment type to automatically invert tlie 
image from white bands on a black background to black on white. The settings used in the
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four steps when processing the membrane in BioNumerics, are as follows; i) 21 lanes were 
defined, each of a thickness of 23 points with five nodes, and the background subtraction 
and spot removal was set at 20 points and 4 points, respectively; h) the densitometric 
curves were defined using lanes with a thickness of 13 points and two nodes. For each 
PFGE gel, a spectral analysis was performed, and values from this were used for the 
background subtraction and the arithmetic average filtering; id) the lambda marker 
consisted of concatemers of 48.5 Kb fragments, seen visually as 10 separate fragments 
from 48.5 Kb to 485 Kb, with an additional high band assigned as 1018.5 Kb. These bands 
were selected to normalise the profiles across the gel and were used as the reference system 
using a logarithmic-dependent cubic spline fit; and iv) when the bands were assigned for 
each profile, partially-restricted fragments, seen as weak-intensity high-mass bands, 
(compared to their strong-intensity counterparts) were not assigned.
Optimisation for identification of PFGE types
AU PFGE profiles were defined in the same way as the IS /002-RFLP data but using only 
113 isolates (2.6.7, page 91). Normalised PFGE profiles were compared with the Dice 
coefficient of similarity, and clustered using the unweighted pair group method with 
arithmetic averages (UPGMA). As for the IS/002-RFLP data, other similarity coefficients 
(Pearson, Jaccard) and dendrogram types (Ward) were used to analyse the data. However, 
when the profiles were checked manuaUy after clustering, it was found that visually similar 
profiles were not being grouped accordingly, so these other coefficients were considered 
sub-optimal.
The same ranges of band position tolerances and optimisation settings used for the IS /002- 
RFLP optimisation, were attempted on the PFGE analyses (2.6.7, page 91). The type strain 
of B. pertussis, (NCTC 10739^) was also used as a reference strain to determine intra- and 
inter-gel variation.
Optimum conditions for identification of PFGE types
The reproducibility (as measured by variation in the molecular sizes calculated with 
reference to the type strain) ranged from 93.4% to 100% (average 98.4%) for intra-gel and 
91.5% for inter-gel variation. Optimal conditions for type allocation were with 0.65% 
optimisation and 1.0% tolerance, and using 94.0% similarity settings within the 
dendrogram produced. With these criteria, a total of 33 different PFGE types were 
observed (Figure 2.11, page 97). The DNA band sizes ranged between approximately 27.91 
Kb and 895.27 Kb.
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2.8 Data analysis
2.8.1 Calculation of genotypic diversity values
Genotypic diversity (GD) values were calculated using 1S1002-KFLV data from tlie UK, 
using the following formula (Nei and Tajima, 1981):
G D = ( l-S x /)x n /n - l ,
i=l
where Xj is the frequency of strains in each RPLP type and n —number of RFLP types per 
sub-set. Genotypic diversity values that are closer to 1 indicate a liigh diversity with many 
RFLP types, and a value approaching zero indicate few types and a low diversity.
Genotypic diversity values were compared using the Pearson’s Chi-squared (x ) test, and P 
values were based on 1000 computer simulations, by randomly shuffling tlie different 
RFLP types over the different sub-sets, without changing the number of RFLP types 
observed or the number of RFLP types found in each sub-set. The number of times the 
simulated squared GD exceeded die observed was counted, and dien divided by 1000 to 
produce an estimate of the P value. This method has been described by van Loo et ûL
(1999). Confidence intervals of 95% were calculated by performing 1000 simulations from 
a multinomial distribution. These analyses were calculated using GLIM software 
(Numerical Algorithms Group Ltd) and Excel (Microsoft).
2.8.2 Identification of associations between clinical and laboratory data
The clinical and laboratory data were collected for the B. pertussis isolates from England and 
Wales, isolated between September 1998 and April 1999 (Appendix 3, Part B and C, pages 
307 and 315). Relevant fields were chosen from tlie enhanced pertussis surveillance 
database, held at the PFILS Communicable Disease Surveillance Centre (CDSC), which 
included age, sex, geographical location, vaccination status, any detailed complications and 
outcome of disease. Unique identifiers (date of isolation, isolate number, name of patient 
and their date of birth, referral laboratory) were used to combine the clinical data with the 
laboratory results in Excel 2000 (Microsoft). Any discrepancies were rectified by referring 
to the original paperwork (see Appendix 4, page 319).
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The data were then imported into STATA v 7.0 or 8.2 (Stata Corporation, Texas, USA) 
and analysed for any apparent significant associations. Laboratory data were compared 
against epidemiological data sequentially using test. Any association with a P value under
0.200 (borderline significance) was interrogated further using multiple logistic regression 
analysis. Odds ratios values were then generated for each variable where possible, to 
compare theit relative distributions and significance, with 95% confidence limits and thek 
related P value. Linear trend analysis was also performed using STATA on the time-related 
aspects, age cohorts and tlie interval of isolation collection (temporal trend).
2.8.3 Evaluation of typing methods
The following formulae are taken from (Struelens et aL, 1996).
The typabihty (T) of a particular method can be expressed as a number between zero to 
one, where one represents a method that can type every isolate tested. The formula is:
T = N /N
where N, is the number of isolates assigned a type and N  the number of isolates tested. 
Reproducibility (R) values were calculated using the formula:
K = N JN
where IV,. is the number of isolates assigned the same type on repeat testing and N  the 
number of isolates tested.
Indices of discrknination (D) were calculated, using Sknpson’s index of diversity:
3
D = L  1/N(N-1) X E  nj (/^-l)
where N  is the total number of strains in the sample population, T is the total number of 
types described, and pis the number o f strains belonging to theyth type (Hunter, 1990).
Values of epidemiological concordance (E) were calculated using tlie formula:
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E=^NJN
where N ,is the number of strains assigned to epidemic clones and N  die number of strains 
tested from well-defined outbreaks.
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3 Population dynamics of Bordetella pertussis isolates
in the UK
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The national introduction of the pertussis WCV in the UK in 1957 helped reduce cases of 
pertussis to drop from 85,017 in 1957 to just 409 in 2003 (Immunisation Division, CDSC, 
HPA, 2004a). The UK vaccine coverage rate, at the time of writing, is 93%, although other 
countries witlr a high vaccine coverage have experienced a resurgence in pertussis. This 
study was designed therefore to evaluate the current situation of the B. pertussis population 
in the UK, both before and after widespread vaccination was introduced, as there has been 
no apparent resurgence. Recent epidemiological data was also used to identify any 
associations with the laboratory data generated, and whether there are any important clones 
o f B. pertussis causing particular clinical outcomes. Dhect comparisons with other countries 
such as The Netherlands and the USA were also performed and discussed.
3.1 Strategy
3.1.1 DNA sequencing of the pertactin and pertussis toxin genes
Bordetella pertussis isolates were obtained from archive collections from various sources in 
the UK, and recent isolates submitted to either Manchester University or the RSIL, CPHL, 
London (2.1, page 55). These isolates were investigated for pertactin and pertussis toxin 
gene variation (methods described in 2.5.4, page 68), and analysed for any temporal trends 
that have occurred since widespread vaccination against pertussis was introduced in 1957.
The pertactin gene types are based primarily on the variation in regions 1 and 2 (Figure 1.2, 
page 16), as designated by Mooi et al (1998). To ensure that there were no nucleotide 
differences outside the two polymorphic regions 1 and 2 (Mooi et al, 1998), over 90% of 
the pertactin gene was sequenced (3000 bp according to GenBank accession number 
J 04560) for six B. pertussis UK clinical isolates and the three strains from the UK Wellcome 
WCV. This included the entire coding region, and required tlie three overlapping PCR 
amplicons described in 2.5.4.1 (page 68).
3.1.2 Genotypic diversity of UK Bordetella pertussis strains between 1940 
and 1999
The genotypic diversity was calculated by following the typing method IS/902-RFLP 
analysis in section 2.6 (page 81) and using the formula detailed in section 2.8.1 (page 98). 
The B. pertussis insertion element 1^1002 is targeted, and its variation in copy number and 
position in the genome between different strains of B. pertussis makes it a suitable marker
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foi- population studies. Genotypic diversity values could then be directly compared with 
those from The Netlierknds, and used to elucidate whether;
, vaccination has selected for strains that are adapted to a highly vaccinated 
population
(van Loo et ûL, 1999)
3.1.3 Identifîcatioti of associations between clinical and laboratory data
To establish whether any associations or significant findings in a previous UK study 
between 1995 and 1997 (van Buynder et aL, 1999) were apparent in the current UK B.
population, isolates from 1998 to 1999 from the UK were used. For diese strains 
there are extensive epidemiological data stored at the Communicable Diseases Surveillance 
Centre (CDSC), London, including age, sex, vaccination history, severity and outcome of 
illness of the patients. Laboratory data such as serotyping, pertactin and pertussis toxin 
sequence types, and IS/002-RFLP types, were merged with the epidemiological data and 
interrogated to identify any association between strain characteristics and disease patterns.
3.2 M ethods
The following techniques used in this chapter are described in Chapter 2; serotyping, 
pertactin and pertussis toxin SI subunit gene typing (PCR amplification using primer pairs 
AF and BR, and SF and SR, respectively) and IS/002-RFLP analysis. The formula for 
calculating the genotypic diversity values is expressed in section 2.8.1 (page 98) and details 
of the association analysis are described in section 2.8.2 (page 98).
3.2.1 DNA sequencing of the pertactin and pertussis toxin genes
Before April 2000, tire products of the pertactin and pertussis toxin sequencing reactions 
were sent to tire University of Durham, and only sequencing using one sequencing primer 
(eitlrer forward or reverse) was done on an ABI Prism® 377 DNA Sequencer, to reduce 
processing costs. The sequence data received were of good quahty in the regions of 
interest, although most contained a few unclassified nucleotides (ambiguous calls) at the 
beginning and the end of die generated sequence. After die Beckman 2000
analyser was installed in RSIL, sequencing of both forward and reverse strands for each 
target gene was performed. In general, the results from the pUC controls were of good 
quality, and therefore inadequate results were probably due to the individual sequence 
reaction. If a sequence reaction failed or a low signal was seen, then an increased amount of
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\TMpurified PCR template was used in a new sequence reaction and re-run on the CEQ’
2000 analyser. If the generated sequence contained mosdy ambiguous calls, tlie initial 
amplification of the PCR template was repeated, the product purified, and new sequence 
reactions were prepared (see 2.5, page 63).
3.2.2 Random selection of UK Bordetella pertussis strains between 1940 and 
1999 for ISy<?A^Restriction Fragment Length Polymorphism analysis
In order for tlie data to be within complete and successive decades, 291 B. pertussis iso\a.tes 
from 1940 to 1999, of previously determined pertactin and pertussis toxin gene types, were 
available for random sampling. The data were sorted initially into decades from the 1940s 
to 1990s, and then numbered sequentially from 1 to % within each decade. The 
“randbetween” function was used in Excel to select the isolates randomly. The selection 
was performed in three stages, with the first stage to deduce whether there was a relative 
change in RFLP types between tire decades. The nine available isolates from the 1970s 
were tested and a further 12 isolates from each other decade were chosen. The second 
selection stage was performed to increase the number of isolates tested and, tlierefore, all 
19,13 and 9 isolates from the 1950s, 1960s and 1970s were tested, respectively, and 12 
further isolates were chosen at random from each of the 1940s, 1980s and 1990s. At die 
third selection stage, a third set of 12 isolates were randomly selected from the 1940s,
1980s and 1990s. Therefore the following 149 isolates were investigated by 1S1002-KFLV: 
1940s, 36; 1950s, 19; 1960s, 13; 1970s, 9; 1980s, 36; and 1990s, 36. Although there were 
more isolates available from the 1940s, 1980s and 1990s, they were not chosen or tested to 
reduce the chance of skewing the data.
3.2.3 Identification of clinical and laboratory associations of pertussis cases 
from the UK between 1998 and 1999
Epidemiological data from the CDSC/Manchester University database were collected 
between September 1998 and Aprd 1999 (n=194) and matched with die 99 B. pert/rssis 
isolates obtained from the PRL as in 2.8.2 (page 98). After merging the two data-sets, 90 of 
die 99 cases were available for further analyses. The information fields available for each 
case are Hsted in Table 3.1 (page 107). For age-related data, only the age group was used 
rather than age in weeks/mondis or years, for easier analysis and handling of data. The age 
groups chosen are also used in the CDSC and are designed to fit the incidence of a 
chddhoood illness. The geographical regions were used radier than the laboratory or
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GP/hospital address, due to the large number of different laboratories and GPs/hospitals, 
and these are shown in Figure 3.1, page 108.
Statistical analysis of the data was performed in two stages. Firstly, associations between all 
epidemiological variables were assessed by cross tabulating them and calculating Pearson s 
probability to test for independence. This analysis helps identify variables that are highly 
related. Linear trend analysis using the score test for trends in odds was also performed to 
identify any trends by age or vaccine doses. Any associations which gave a probability value 
o f <0.20 were used in the multiple logistic regression analyses to determine the 
independent effect of these factors.
The second stage entaüed the analysis of associations between the epidemiological data and 
the laboratory typing data. This analysis was performed as above, using Pearson’s 
probability, linear trend analysis and multiple logistic regression analysis.
3.3 Results
3.3.1 Polymorphism in the pertactin gene
The pertactin sequence data of the six B. pertussis UK clinical isolates and tlie tiiree strains 
from tlie UK Wellcome WCV were assembled into contigs (over 90% of Ûs^prnA gene, 
between 2768 and 2810 base pairs), and each sequence was deposited in GenBank via the 
Bankit submission entry (http://www.ncbi.nkn.nih.gov/BankIt/index.html), under unique 
accession numbers (Table 3.2, page 109). All nine complete sequences were identical to one 
o f tlie pertactin prnA{p\ pruAP^ or ^ r/Ld(3) described previously by Mooi et ai 
(1998).
Region 1 (containing the polymorphic GGxxP repeat motif) of the pertactin gene was 
sequenced in 318 UK B. pertussis isolates. To differentiateprnA(l) îtomprnA{\), as 
previously described by Mooi et al. (1998), wherepruA(l) has a point mutation 
approximately 150 nucleotides upstream of region 2 (containing the PQP repeat motif), 
this was sequenced in 68 randomly-selected isolates of typepr/^M(l), four of rfp^pniA{2), 
and one of type A^ /zAl(3). All isolates were identical in this region when compared to their 
respective pertactin types including the 68pruA(Ÿ) isolates, and aU 73 isolates contained 
five PQP repeat units in region 2 (see Figure 1.2, page 16). There is, therefore, 99%
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confidence tliat <7.5% of the population described here asprnA(\), could actually have the 
single point mutation resulting in the designationprnAPJ) proposed by Mooi et al. (1998).
Figure 3.2 (page 110) shows the temporal analysis of pertactin types of the 318 circulating 
UK B. pertussis isolates in the years 1920 to 2002. O f the isolates obtained between 1920 
and 1979 all 97 (100%) (95% confidence intervals (Cl): 96-100%) were of typepruA(l), 
wliich is the same pertactin type as the three strains used in tlie UK Wellcome WCV 
vaccine. In 1982, the novel pertactin types described by Mooi et ai (1998),/»r/zAl(2) and 
prnAl?)), were seen. From 1982 to 1986, 32/88 (36%) (95% Cl: 26-47%) were non-prnA{\),
i.e., different from theprnAiV) type present in the UK Wellcome WCV. No clinical isolates 
from the UK were available for examination from 1987 to 1997. O f the available isolates 
analysed from recent years (1998 to 2002), 81/133 (61%) (95% Cl: 52-69%) were non- 
prnA{\). The five results from 2000 were generated directly from previously J3. pertussis 
PCR-positive cHnical specimen extracts, and not from culture positive isolates (see Chapter 
6). The decrease in die proportion ofprnA(\) isolates collected between 1982 and 1986 
compared to those isolated in 1998 to 2002, is statistically significant (%^=11.8, P=0.0006). 
Since 1996, the Aventis Pasteur WCV has also been used in the UK, where the pertactin 
types of the strains are alsoprnA{\) (Njamkepo et al.y 2002).
3.3.2 Polymorphism of the pertussis toxin SI subunit gene
Only two variants, A^xd(l) andp tx A l^ ,  were found in die 318 UK B. pertussis isolates 
analysed, and these two types also occur in the UK Wellcome WCV; ptxA{l), CN3099 and 
CN5476; andptxA{2)y CN2992 (CN2992B tested). Figure 3.3 (page 111) shows the 
temporal analysis of die p txA  types of the circulating UK B. pertussis isolates from 1920 to 
2002. The frequency o fptxA{\) in isolates before vaccination was introduced, from 1920 to 
1956, was 55% (40/73, 95% Cl: 43-66%), compared to 100% (133/133, 95% Cl: 97-100%) 
in isolates from 1998 to 2002. A linear trend analysis of the change in proportion of 
ptxA{\) out of die total number of isolates available was performed and found to be 
significant =104.225, P<0.0001). The pertussis toxin SI subunit types of the Aventis 
Pasteur WCV, used since 1996, arep tx A i^  andptxA(h) (Njamkepo et al.., 2002).
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Table 3.1. Epidem iological information available for 90 cases from 
whom  Bordetella pertussis  isolates were recovered between September
1998 and April 1999
Factor Parameter type Datacomplete?
Included in 
analysis
Gender Binary (male/female) 100% Yes
Date of birth Date 100% No
Age (in years) Number 100% No
Age (in months) Number 100% No
Age (in weeks) Number 62% No
Age group (five groups) <2 months 2-5 months 
6-11 months 
1-4 years 
5+ years
100% Yes
Laboratory Variable 100% No
General Practitioner/hospital Variable 99% No
Geographical region (nine 
regions)
Anglia and Oxford 
North Thames 
Nordi West
Northern and Yorkshire 
South Thames 
South and West 
Trent 
Wales
West Midlands
100% Yes
Date of specimen Date 100% Yes
Clinically typical symptoms 
seen
Binary (yes/no) 92% Yes
Complications Binary (yes/no) 90% Yes
Conjunctivitis Binary (yes/no) 90% Yes
Pneumonia Binary (yes/no) 90% Yes
Apnoea Binary (yes/no) 90% Yes
Convulsions Binary (yes/no) 90% Yes
Hosptdal admission Binary (yes/no) 89% Yes
Vaccination status Binary (yes/no) 94% Yes
Number of vaccine doses 0 to 4 doses 94% Yes
Mortality Binary (yes/no) 3%* Yes
Otlier comments Variable 21% No
*The incomplete data concerning the deatli of patients were due to inadequate responses from the 
enhanced questionnaires (Appendix 3, Part B), where most were unknown.
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Figure 3.1. N ational Health Service regional boundaries of England and
Wales before T* April 1999
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o
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Table 3.2. UK Bordetella pertu ssis  investigated for nucleotide
polymorphisms outside regions 1 and 2^
Isolate Year
deposited/
isolated
Origin Pertactin
type
GenBank
Accession
number
CN351 1942 Clinical isolate prnA{\) AF348480
DCH53 1982 Clinical isolate prnA{\) AF348481
DCH132 1983 Clinical isolate prnA{T) AF348482
98K300 1998 Clinical isolate prnA{\) AF348483
98K320 1998 Clinical isolate pmA{X) AF348484
99K45 ^ 1999 Clinical isolate pmA{b) AF348485
CN2992B" 1949 UKWeUcome WCV prnA{\) AF348486
CN3099 1950 UK Wellcome WCV prnA{V) AF348487
CN5476 1963 UK Wellcome WCV pmA{\) AF348488
This was accomplished by DNA sequencing 90% of the pertactin gene. 
^CN2992B is equivalent to CN2992, a Wellcome WCV strain.
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3.3.3 Combined pertactin and pertussis toxin types
Data from 318 isolates were analysed by combining their pertactin and pertussis toxin SI 
subunit types. As threeprnA  types and twop txA  types were seen in the UK, six tlieoretical 
combinations were possible. However, only fourprnA /ptxA  combinations were observed 
in die UK. Two of the UK Wellcome WCV strains, CN3099 and CN5476 are 
prnAiy) IptxA(p), whdst the third vaccine strain, CN2992B is prnA{\)/ptxA(2). The two 
strains in die Aventis Pasteur WCV arep7'nA{\)!p tx A {^  andprnA(V)!ptxAi^) (Njamkepo 
et al., 2002). TypeprnA{\)!p txA (\)  was present in isolates from 1941 to 2002 (Figure 3.4, 
page 115). TypeprnA(\)!p tx A (^  was present in 34/78 isolates (44%) from 1920 to 1963 
and one isolate from 1985, but from 1982 to 2Q^2,prnAlpi)IptxA{\) types appeared in 
97/221 of isolates (44%), and to a lesser extent7>r/zM(3)//>/xA[(l) (6/221, 3%). This shift 
was very significant (Fisher’s test, P<0.001, n=318). AU fourprnA{ptxA  types seen in the 
UK were present m die 1980s.
3.3.4 Genotypic diversity of UK Bordetella pertussis  between 1940 and 1999
Genetic diversity was determined by IS/dd2-RFLP analysis. The 149 UK isolates, chosen at 
random, generated 24 different RFLP types according to the presence and relative motility 
of bands containing the element 1^1002 when hybridised to the DIGdabeUed probe (see 
2.6.7, page 91 and Figure 3.5, page 116). The number of bands per RFLP type varied from 
four to six. Isolates with five bands represented 125/149 (84%) of die B. pertussis 
population tested and were present in all the decades (Figure 3.6, page 117). Restriction 
fragment length polymorphism types containing six bands were observed in aU decades 
except die 1990s and, conversely, types with only four bands were present from the 1960s 
onwards, after mass vaccination was introduced. This shift from more bands in earlier 
decades to less bands in later decades, was significant (Fisher’s test, P=0.029, n=149).
Data were sorted by decade and plotted on a bar chart to show the distribution of RFLP 
types (Figure 3.7, page 118). O f the 24 different RFLP types, 11 were seen in the 1940s, six 
in the 1950s, 1960s and 1970s, 11 in the 1980s, and six in die 1990s. The most abundant 
type (designated RFLP-1), occurred in 64/149 (43%) isolates, and was present in aU 
decades. Nine other RFLP types were also present in more dian one decade, including 
RFLP-2, which accounted for a furdier 25/149 (17%) of the B. pertussis tested.
The three WeUcome WCV strains exhibited one of each of the types RFLP-1, RFLP-2, and 
RFLP-3, and these types, when combined, were seen as a major proportion in isolates in 
the 1940s, 1980s, and 1990s at 24/36 (67%), 25/36 (69%), and 32/36 (89%), respectively.
1 1 2
Information regarding the RFLP types of the Aventis Pasteur WCV strains was not 
available.
When comparing the distribution of RFLP types between each decade, RFLP-3 through to 
RFLP-34 had to be grouped together because of the low numbers found in these types, in 
order to perform a valid chi-square test. Thus, RFLP-1, RFLP-2 and "other-RFLP" were 
compared for any significance between the decades. The 1940s isolates comprised 8/36 
(22%) o f type RFLP-1, and this distribution changed significantly to 10/17 (59%) RFLP-1 
isolates in the 1950s (P=0.031). The proportion of RFLP-1 isolates then decreased from 
tlie 1950s to the 1980s (P=0.12). However, by the 1990s, RFLP-1 was the most common 
type and seen in 23 of the 36 (64%) isolates, with a significant change in tlie distribution 
from the 1980s to the 1990s (P=0.032).
Genotypic diversity (GD) values were calculated for each decade depending on the 
frequency and proportion of each RFLP type, and then plotted with 95% confidence 
intervals (Figure 3.7, page 118). Genotypic diversity values that are closer to 1 indicate a 
high diversity with many RFLP types, and a GD value approaching zero indicates few types 
and a low diversity. After the introduction of the pertussis WCV in 1957, the GD dropped 
from the 1940s (0.81) to the 1950s (0.64), (P=0.092). The GD of the UK B. pertussis 
population then increased gradually from the 1950s (0.64) to the 1980s (0.84), (P=0.06). 
However, in the 1990s the genotypic diversity significantly decreased from the level seen in 
the 1980s (0.84 compared to (cf.) 0.57, P<0.01).
Genotypic diversity values of RFLP types were also calculated with respect to pertactin 
types, pertussis toxin types, and combinedprnA lptxA  types (Table 3.3, page 119). Isolates 
withprnA{\) (n=118) had a significantly higher GD value thanprnA{7) isolates (0.85, cf. 
0.39, respectively, P<0.001). Confidence of the prnAÇ>) genotypic diversity (GD=0.00) 
could not be made because only one isolate was present. Isolates displaying pertussis toxin 
type,p/xT(l) had a higher GD value thanptxAÇ ) (0.72 and 0.59, respectively), but was not 
significant (P=0.108). When the pertactin and pertussis toxin data were combined, because 
of the high GD values o fprnAiV) andptxA(V), theprnA{\)!ptxA(V) isolates exliibited a 
high GD (0.80), with respect to the RFLP type distribution. The three otherprnAjptxA  
types had lower GDs, at ^,S9,prnA(\)fptxA(l^, 0.39,A/%T(2)/pA>cT(l), and 0.00, 
prnAQ)/p txA (l) (latter type based on one strain only). AH comparisons between the GD 
values of the combined types were significant; P=0.003 betweenpm A {ï)!ptxAi^) and
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prnA{\)!ptxAil^', P<0.001 betweenprnA(\)lptxA{\) andp rn A ^Ip txA {\)', and P-0.005 
betweenprnA(\)!ptxAÇ^ andprnA(^lptxA(pL).
Restriction fragment length polymorphism types containing more than six isolates were 
included when investigating associations between RFLP types, pertactin, and pertussis 
toxin types. Therefore, only isolates from types RFLP-1, RFLP-2, RFLP-3 and RFLP-4 
were investigated, and thepmA{?>) isolate was also omitted (n= 114/149). Types RFLP-2 
and RFLP-4 showed a strong association withprnK(V) (Fisher’s test, P=0.002), and RFLP- 
1 and RFLP-3 were exclusively associated withy?/xA(l) (P<0.001). Pertussis toxin type, 
ptxA{7) is significantly associated with RFLP-2 (P<0.001), and also withprnAipC)
(P=0.003).
3.3.5 Epidemiological associations and trends of pertussis cases from the 
UK between 1998 and 1999
Associations within the epidemiological data were investigated, as any significant findings 
could skew and alter the interpretation of any further analyses. Table 3.4 (page 120) details 
the major aspects of tire 90 cases and the proportion of cases in each category. The sub-set 
consisted of 43.3% males, and ages varied from three weeks to 45 years, and when sorted 
into five cohorts; 25.6% were under two montirs, 32.2% were between two and five 
months, 4.4% were between six and 11 months; 12.2% were between one to four years; 
and 25.6% were five years and over. Pertussis cases were seen in all nine geograpliical 
regions, varying between 1.1-28.9% (Table 3.4, page 120). Details of vaccination status 
include the number of doses the individual received (Table 3.4, page 120), and 52.2% 
received no vaccination against pertussis. The majority of cases showed clinically typical 
pertussis symptoms (75.6%) and 25.5% cases encountered other complications such as 
apnoea, conjunctivitis and pneumonia. Although data were available for cases with 
convulsions, none of the 90 cases in this sub-set presented witii this complication. Sixty 
percent were hospitalised and three individuals of the 90 died due to pertussis in this eight- 
month period.
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Figure 3.5. Norm alised IS767A3-RFLP types of UK Bordetella pertussis
isolates from 1940 to 1999
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Table 3.3. Diversity of Bordetella pertussis 1S1002-RFLP types, 
according to the pertactin and pertussis toxin SI gene types, and 
combined p ru A /p tx A  types
1S1002- 
R F L P  t y p e s
P e r t a c t i n  g e n e  t y p e
ùr/tAÇl) pr/iA(2) pr/tA{3)
P e r t u s s i s  t o x i n  
S I  g e n e  t y p e
btxA(l) ptxA(2)
C o m b i n e d  prnA /ptxA  t y p e
brtiA{\)f pntA{\)! pniAt^)! pniA(y)l 
btxA{\) ptxA{2) ptxA{\) ptxA{\)
1 4 1  2 3 5 4 4 1  2 3
2 2 4  1 7 1 8 5  1 8  1
3 1 1  6 1 7 1 1  6
4 8 6  2 6  2
6 5 5 5
7 5 2  3 2  3
8 2 2 2
9 2 2 2
1 0 2 2 2
1 1 2 2 2
1 2 2 2 2
1 3 1 1 2 1 1
1 4 1
1 5 1 1
1 6 1
1 7 1 1
1 8 1
1 9 1
2 0 1
2 1 1 1
2 2 1
2 3 1 1
2 4 1 1 1 1
3 4 1
N u m b e r  o f
i s o l a t e s 1 1 8  3 0  1 1 2 1  2 8 9 0  2 8  3 0  1
N u m b e r  o f
t y p e s 2 4  3  1 2 0  8 2 0  8  3  1
G D 0 . 8 5 4  0 . 3 8 7  0 0 .7 2 1  0 . 5 8 8 0 . 7 9 5  0 . 5 8 8  0 . 3 8 7  0
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Table 3.4. Distribution o f major epidem iological factors in the 90 UK  
pertussis cases analysed from September 1998 to April 1999
Factors Category
Number of 
cases
Percentage of 
cases
Gender Male 39 43.3
Female 51 56.7
Age group <2 months 23 25.6
(from 3 wks to 45 yrs) 2-5 montlis 29 32.2
6-11 months 4 4.4
1-4 years 11 12.2
5+ years 23 25.6
Geographical region Anglia and Oxford (1)' 6 6.7
North Thames (1) 1 1.1
Nortli West (2) 14 15.6
Northern and Yorkshire (2) 11 12.2
South Thames (1) 8 8.9
South and West (3) 26 28.9
Trent (4) 10 11.1
Wales (5) 12 13.3
West Midlands (4) 2 2.2
Vaccination status No doses 47 52.2
1 dose 14 15.6
2 doses 3 3.3
3 doses 19 21.1
4 doses 1 1.1
N ot known^ 6 6.7
CHnically typical symptoms Yes 68 75.6
No 15 16.6
N ot known 7 7.8
Complications Yes 23 25.6
-Conjunctivitis 1 1.1
-Pneumonia 4 4.4
-Apnoea 11 12.2
-Pneumonia and apnoea 5 5.6
-Not Imown 2 2.2
No 58 64.4
N ot Imown 9 10.0
Hospitahsation Yes 54 60.0
No 26 28.9
N ot known 10 11.1
Mortality Yes 3 3.3
N ot known 87 96.7
’Numbers in parantheses indicate the group in which the region appeared when performing 
multivariable logistic regression analysis.
2Qne of the six cases was vaccinated, but the number of doses was not entered. Therefore, it has 
been adjusted to an unknown case.
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Associations between all epidemiological variables were initially assessed by cross tabulating 
them and calculating Pearson’s probability to test for independence. These results are 
shown in Table 3.5 (page 122), as P values. Most of the significant values (P<0.05) were 
expected (18/66 analyses), where three were associations due to explanatory variables. 
Explanatory variables are those that exist before the event, i.e., a pertussis infection occurs, 
and include age group, sex, region, vaccinated and number of vaccine doses. The outcome 
variables include typical clinical symptoms, complications (conjunctivitis, pnuemonia and 
apnoea), hospital admission and death. The geographical regions were further grouped into 
five larger areas for multivariable logistic regression analysis, due to the small number of 
cases seen (Table 3.4, page 120).
The vaccination status of tlie age cohorts was significant, as was the association between 
the number of vaccine doses received and the age cohorts (P<0.001). Tliis is due to the 
shift in proportion of those unvaccinated from 100% (23/23) of under two months old, to 
40% (8/20) o f over five year olds, and is directiy related to the UK vaccination schedule. 
The other association involving explanatory variables only, is that between sex and 
geographical region (P=0.005). When tabulated, it is apparent tliat the data are sparse and 
with no clear pattern (Table 3.6, page 123). Moreover, when this is re-examined with the 
geographical regions grouped into the five larger sets (T^ble 3.4, page 120), the association 
is not significant (P=0.17).
Due to die small number of cases that died (n=3), multivariable logistic regression analyses 
could not be meaningfully undertaken. Furthermore, aU four significant P values were 
associated with another outcome variable (clinical symptoms, comphcations, pneumonia 
and apnoea, see Table 3.5, page 122). All three deatiis were related to a complication 
(P=0.005), developed apnoea (P<0.001) and were admitted to hospital (P=0.221). Two of 
die diree cases who died also exhibited no typically clinical symptoms (P=0.030) and 
developed pneumonia (P=0.02).
121
IIcT
ON
0-1 U
1IO
Iu
II
NO so o  O o  o  o  o
C) T-I 00 (N s f  CO T-4 CN 
CO x t-  s o  O O O O
LD Csl 
O  eO: : 1 I I
O  GO T—I T 4  T—4 LOro so CO o  csjO  C s  LO O  s o  CS]o  o  o  o  c5 Ô
I-~ I >  t o  s o  s o  s o  CvlM  O  T—I LO T j- CO T f
s o  O  t-h c s  CÎS rO  0 0O O Ô O o  o  o
1-H t> o l  O S t-h COt-h O s o  OO s o  Td- ,t-h O LO cO o  Io  o  o  o  o  o  o
rOOOsOCst^Csl '^O'^L O L O L O T H s o r - c s ' ^ T - HOOT-HOOsOpOt^CA
O O O O O O O C Î O
Th o  LO m^  c s  c s  s o  oso so r -  ,00 cs CO M so  ^ ^S O O C S - r i - C s l p p p p Oo o o o o o o o oI ICO S  th r-- so ^  r;'C O  .  o  00 osO O O O lO O C ^ O OV  o  o  o  o  o  V  V CO O  CO GO CO CO o
Q f f i < P L ^ U U U : z ; > p 4
.9■x)<uII
>t1I
01 ?
.9
ba
X )4J
%f
I
<ua
1
Q
122
sot
uI0
1
V43
s(/)C^Suen'53eni
a
%
§
■§Ien
'•B
3C / D
\ oCOI
Iil
I
II
IJ
I
t l1
gCD
t-h Osm CD
csl
e s ]  OO uo
L O L O
C s |,  O '
cs so
(O
o  soCsl
es 00
OO T—I
e s  CSj
C s  T—les, r-
o
CO O '00 T-4
11
cs
cs
00
IH sI+lO
I
O'
OO
LO
C s
'S- cs
ii oot-h
so
%
V
o --ci-
P '
ocs socs
COT—^
Th
oH
I
ti
•si
o<43
es1a
%
co
‘S
'ü0en
<
o6rn1H
IH
I+lOi
Iu
C s00
oC s
C s
OO
C
O '
Csl
O
1%
î
V
o
oo
CO
soc
CO
so
?
s -cs
COcs
o
H
CL,
1
CL,
I
123
There was only one significant association involving those cases presenting with typical 
clinical symptoms of pertussis. This was with pneumonia (P=0.001), where 5/9 (56%) 
pneumonia cases did not present with typical clinical symptoms, compared to 10/72 (14%) 
with no pneumonia or clinical symptoms. Further investigations to determine whether 
clinical symptoms and pneumonia were dependent on age were performed (Table 3.7 and 
3.8, page 123). Pneumonia cases and clinical symptoms were approximately inversely 
proportional in each age group, and therefore the association was found not to be 
dependent on age. The only borderline association involving typical climcal symptoms was 
with geograpliical regions (P=0.094), and a multivariable logistic regression analysis was 
therefore not necessary.
There was a significant association between those encountering a complication and being 
admitted to hospital (P=0.032), with 18/23 (78%) encountering complications being 
admitted compared to only 3/23 (13%) encountering complications not being admitted. 
Encountering a complication was also significant with age (P—0.005), where most of those 
complications were represented in the under two month age group (13/23, 57%). The 
significant explanatory variable, age, and the borderline variables region and vaccination 
status, as well as the variable sex, were included in a multivariable logistic regression 
analysis for encountering complications (Table 3.9, page 127). The sex and vaccination 
status variables showed no evidence of an association, but age and region did (P=0.052 and 
0.008, respectively). When sex and vaccination status were dropped from a further 
multivariable analysis, age and region were both significant (P=0.003 and 0.014, 
respectively). Those under two montlis old are 5,88 more likely to encounter a 
complication following or during a pertussis infection (P=0.003). The regional data are 
harder to interpret, as there seems to be no pattern (north to south, or east to west) in the 
odds ratio values. Region 5, which contains Wales, is highly associated with no pertussis 
cases encountering a complication (10/10 in Wales, 100%).
The complication conjunctivitis, was seen in only one case in this sub-set of 90, and, 
consequently, there were no significant or borderline associations with any other factors 
(Table 3.5, page 122).
Pnuemonia was significantly associated with region (P=0.019), climcal symptoms (P= 
0.001, discussed earher), and with another complication, apnoea (P=0.004). As for the 
more general outcome of encountering a complication, the regional association witli 
pneumonia is hard to interpret, and the low P value could be due to the sparseness of
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cases. In this sub-set, 5/16 (31%) of apnoea cases also had pneumonia, compared to 11/16 
(69%) apnoea cases not having pneumonia. Multivariable logisitic regression analysis was 
not performed using pneumonia as an outcome variable, as there were insufficient 
significant associations with the explanatory variables.
Analysis of apnoea cases revealed many significant associations, including being admitted 
to hospital, where 14/16 (88%) of apnoea cases were admitted (P=0.015). Significant 
associations of apnoea are also seen with age (P=0.001), vaccination status (P=0.007), and 
pneumonia (P=0.004, see above). The significant explanatory variables, age group and 
vaccination status, together with the borderline variables, sex, regions and number of 
vaccine doses, were used in multivariable logisitic regression analyses with apnoea. An 
analysis using apnoea, sex, age, region and vaccination status did not generate significant P 
values (Table 3.10, page 127). The under two month old group and the unvaccinated were 
more hkely to encounter apnoea, and both gave similar P values and odds ratios (P=0.128 
for age group and P=0.174 for vaccination status). When the variable vaccination status 
was replaced into the analysis with the related number of vaccine doses, the P values 
changed for each of the variables. The number of vaccine doses generated a higher P value 
of 0.285. After the variables witli high P values (sex and vaccination status/number of 
vaccine doses) were dropped from the analysis, tlie age group P value dropped significantly 
to P=0.001. This also affected the odds ratio, so, where the under two month old group 
has a baseline of 1.00, there is only 0.12 (0.03 to 0.45 95% Cl) odds that the over two 
months wiU encounter apnoea. The region data produced the lowest P value (0.073) in 
relation to apnoea, but, as for the more general outcome, complication, there was no 
pattern in the odds ratios produced for each region.
There were five significant associations with the outcome hospital admissions, although 
two of these were linked to the other outcome variables, complications and apnoea 
(P=0.032 and P=0.015, respectively) (Table 3.5, page 122), A linear trend analysis shows 
that the likelihood of hospital admission decreases as the uptake of vaccine, in terms of 
number of doses, increases (%^ for trend=8.54, degrees of freedom (DF)=1, P =0.004, 
Table 3.11, page 128), although this has not been adjusted for age. All of the explanatory 
variables were used in a multivariable logistic regression analysis to calculate odds ratios 
influencing cases being admitted hospital (Table 3.12, page 128). There is an unusual 
association between gender and hospital admission, and, though the P value is not 
significant in the regression analysis, females were nearly twice as Hkely to be admitted than 
males, with an odds ratio of 1.85 (95% Cl: 0.74 to 23.14). The under two month old group
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L-e significantly (P<0.001) more likely to be admitted to hospital than any other age group, 
calculated by the very high odds ratio, and that 21/23 (91.3%) were admitted. As for the 
past analyses, the region data gave varied odds ratio values for cases admitted to hospital, 
but there is no pattern evident. Wlulst the vaccination status was not significantly 
associated with hospital admission (P=0.453), those vaccinated are roughly half as likely to 
be admitted (odds ratio of 0.51, 95% Cl: 0.09 to 3.00) than those unvaccinated (Table 3.12, 
page 128). However, when the more descriptive variable number of vaccme doses was 
switched for vaccination status, the P value increased to 0.802.
3.3,6 Laboratory typing results of the 90 UK cases from 1998 to 1999
Typing information generated in the laboratory include serotype, pertactin and pertussis 
toxin gene sequence type, and IS/902-RFLP type. O f the 90 cases, 49 (54.4%) were 
serotype 1,2; 47 (52.2%) wereprnA{V); 41 (45.6%) werepriiA(^)\ and 2 (2.2%) werepr/z/l(3) 
(Table 3.13, page 129). Isolates from all cases wereptxA{\). Figure 3.8 (page 130) shows 18 
different IS1002-KPLV typing patterns from the 90 cases from 1998 to 1999. There were 
between four and six 18^002 bands present per RFLP type. The distribution of RFLP 
types, shown in Table 3.13 (page 129), shows that tlie majority of isolates were RFLP-1 
(n=49, 54%), with the second most frequent type, RFLP-3, appearing in 14 isolates 
(15.7%). The remaining 16 RFLP types had low frequencies, of between 1 (1.1%) and 4
(4.5%) isolates.
A combined typing system was devised by the author using tlie two serotypes 1,2 and 1,3, 
the tlii-ee pettactin types, pr«A{\-S), and the 18 diffeietit RFLP types. As all 90 cases were 
of ptxA{\), this factor was not used to produce the combined types. The 24 combined 
types generated, labelled A to X. are listed in Table 3,14 (page 131), The three predominant 
combined types A (serotype l,2 ,pm A (l), RFLP-1), C (serotype l,2,p,-«A(i). RFLP-3), and 
P (serotype l,3,pr/tA(2), RFLP-1), represented 16/90 (18%), 13/90 (14%), and 33/90 
(37%) of the isolates, and the other 21 combined types contained fewer isolates, between 1
(1%) and 3 (3%).
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Table 3.9. Factors influencing likelihood o f encountering a 
complication with a pertussis infection
Factor Level Odds Ratio (95% Cl) P value
Sex Male 1.00 (baseline) 0.580
Female 1.41 (0.41 to 4.89)
Age groups <2 months 4.42 (0.94 to 20.83) 0.052
>2 months 1.00 (baseline)
Region^ Region 1 1.00 (baseline) 0.008
Region 2 0.27 (0.05 to 1.59)
Region 3 0.77 (0.16 to 3.67)
Region 4 1.86 (0.29 to 11.81)
Region 5 0
Vaccination status Not vaccinated 1.00 (baseline) 0.690
Vaccinated 0.73 (0.16 to 3.34)
Table 3.10. Factors influencing likelihood o f encountering apnoea with
a pertussis infection
Factor Level Odds Ratio (95% Cl) P value
Sex Male 1.00 (baseline) 0.920
Female 1.08 (0.25 to 4.61)
Age groups <2 months 1.00 (baseline) 0.128
>2 months 0.29 (0.06 to 1.49)
Region^ Region 1 1.00 (baseline) 0.073
Region 2 0.73 (0.08 to 6.90)
Region 3 2.54 (0.38 to 17.16)
Region 4 3.12 (0.34 to 28.38)
Region 5 0
Vaccination status Not vaccinated 1.00 (baseline) 0.174
Vaccinated 0.26 (0.04 to 1.87)
The age groups have been sorted into two larger sub-sets, as a previous analysis using the five 
separate age groups show similar P values, and, the above analysis has not shown any bias when 
comparing the log likelihood of the multivariable logistic regression analysis.
^Details of die regional groups are shown in Table 3.4 (page 120).
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Table 3.11. Association of hospital admissions with number of pertussis
v a c c in e  d o se s
N um ber of vaccine doses
H ospital
adm ission
N one 1 2 3 4 Total
N o 11 (25) 1(7) 1(33) 10 (63) 1 (100) 24 (3 1 )_
Yes 33 (75) ^ 13 (93) 2(&0 6CW) 0(0) 54 (69)
Total 44 14 3 16 1 78
U nivariable analysis o f  score test fo r trend  o f  odds: % ^ (p F - l) -8 .5 4 ,  P--0.004. 
Figures in parentheses are percentages.
Table 3.12. Factors influencing likelihood of adm ission to hospital with
a pertussis infection
Factor L,evel Odds Ratio (95% Cl) P value
Sex Male 1.00 (baseline) 0.088
Female 1.85 (0.74 to 23.14)
Age group <2 months 00* <0.001
2-5 months 1.00 (baseline)
6-11 montlis 0.02(0.01 to 0.71)
1-4 years 0.02 (0.01 to 0.24)
5+ years 0.03 (0.01 to 0.22)
Region^ Region 1 1.00 (baseline) 0.241
Region 2 2.72 (0.24 to 30.39)
Region 3 5.14 (0.38 to 69.67)
Region 4 00^
Region 5 9.39 (0.66 to 133.61)
Vaccination status Not vaccinated 1.00 (baseline) 0.453
Vaccinated 0.51 (0.09 to 3.00)
lAn infinity odds ratio was generated, as all under two months old (21/21) were admitted to 
hospital.
^Details of the regional groups are shown in Table 3.4 (page 120).
’An infmity odds ratio was generated, as 8/10 cases from Region 4 were admitted to hospital.
128
Table 3.13. The distribution of typing information of the 90 UK 
pertussis cases analysed from September 1998 to April 1999
N um ber of Percentage of
cases cases
Serotype 1,2 49 54.4
1,3 41 45.6
Pertactm gene type 1 47 52.2
2 41 45.6
3 2 2.2
Pertussis toxin 81 gene type 1 90 100.0
IS/002-RFLP type 1 49 54.5
2 3 3.3
3 14 15.7
4 3 3.3
7 4 4.5
13 1 1.1
20 1 1.1
22 2 2.2
34 1 1.1
35 1 1.1
36 1 1.1
39 3 3.3
40 1 1.1
42 2 2.2
43 1 1.1
44 1 1.1
45 1 1.1
46 1 1.1
129
I
00
§5
.2
gI•SII(4-,0CA
E
1aiÏc/5l-H
00rn
&£
lO'4-
?
m'T
CNTT
O
o\m
vOm
LO
m
' Tm
<N
(N
o
(N
m
I I
I
m
(N
2.
I
('
I I I
I I I I I I
om
p o p
O  1-0 CM 04  —  —
o P « - 0  p  LT) O  LO O  LO 
G \ o d M  r ^ \ 6 \ 6  LO LO ^
Ip LOro
-5
•S1
I
Ieu
o
130
Table 3.14. Combined types o f Bordeteîla pertussis  from 1998 to 1999 in 
the UK, and their corresponding serotype, pertactin gene type, and
IS1002-RVU? type
Com bined
type
Serotype Pertactin gene 
type
ISit?6!2-RFLP
type
N um ber of isolates 
(%)
A 1,2 1 1 16 (18)
B 1,2 1 2 2(2)
C 1,2 1 3 13 (14)
D 1,2 3 1(1)
E 1,2 1 4 2(2)
F 1,2 1 7 3(3)
G 1,2 1 13 1(1)
H 1,2 1 20 1(1)
I 1,2 1 22 2(2)
J 1,2 35 1(1)K 1,2 1 39 2(2)
L 1,2 1 42 2(2)
M 1,2 1 43 1(1)
N 1,2 1 44 1(1)O 1,2 1 46 1(1)
P 1,3 2 1 33 (37)
Q 1,3 2 2 1(1)
R 1,3 2 4 1(1)
S 1,3 2 7 1(1)
T 1,3 2 34 1(1)
U 1,3 2 36 1(1)V 1,3 3 39 1(1)
w 1,3 3 40 1(1)X 1,3 2 45 1(1)
24
N um ber of types
2 3 18
T otal isolates 
90
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Analyses of associations between laboratory typing data and epidemiological data were 
performed using Pearson’s probability to test for independence, where the laboratory 
data were treated as an explanatory variable. Initial analyses were performed looking at the 
association between all explanatory variables: typing data, sex, age, geographical 
distribution, time period and vaccination status. The associations between the outcome 
variables (typical clinical symptoms, complications, conjunctivitis, pnuemonia and apnoea, 
hospital admission and death) and the typing data were then examined. Any significant 
associations found were then subjected to multivariable logistic regression analyses, wliich 
aims to determine the independent effect. Trends by age and time were examined in the 
laboratory typing data using the score test for tlie trend in odds.
When analysing the pertactin data, cases exhibitingprnA.i^') isolates were omitted from 
calculations, as there were only two present. Simdary, when using the IS 1002-RTLP data 
and the combined types (serotype, pertactin type and IS/<9f?2-RFLP type combined), types 
containing less than four cases were grouped to ensure confidence when performing 
statistical tests. Therefore, for the RFLP data, cases were analysed using three groups, 
RFLP-1, RFLP-3 and the other RFLP types grouped as one type, “other RFLPs”. The 
combined types were analysed using four groups, the combined types A, C, and P, and the 
remaining combined types clustered as “Z ”.
3.3.6.1 Associations of Bordetellapertussis serotypes in the 90 pertussis cases
Analyses with the other explanatory variables resulted in only two borderline significant 
associations with serotype: age (P=0.091) and vaccination status (P=0.128) (Table 3.15.a, 
page 133). When analysed as two age groups, the under 2 month old group exhibited 16 
serotype 1,2 cases and seven serotype 1,3 cases. This was compared to the rest of tlie cases 
analysed (>2 months), where they were equally proportioned with 33 cases of serotype 1,2 
and 34 isolates of serotype 1,3 (P=0.091). This shows some evidence that individuals under 
two months old were more likely to be infected with B. pertussis expressing serotype 1,2. 
Eighteen out of forty-eight (47%) of serotype 1,2 isolates and 20/37 (53%) of serotype 1,3 
isolates were found in vaccinated cases compared to 30/48 (64%) of serotype 1,2 and 
17/37 (36%) serotype 1,3 in unvaccinated cases (P=0.128). Age and vaccination status are 
however hnked, where the under two month old group are not vaccinated.
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Table 3.15. Probability values between serotypes of Bordetella pertussis
isolates and associated factors
a. Single variable analysis
Factor P value
Sex 0.598
Age groups 0.091
Region 0.775
Temporal trend^ 0.851
Vaccination status 0.128
Vaccination doses 0.354
Typical pertussis symptoms 0.940
CompHcations 0.802
Conjunctivitis 0.356
Pneumonia 0.937
Apnoea 0.863
Hospital admission 0.017
b. Multivariable analysis with hospital admissions as the outcome
Factor Level Odds Ratio (95% Cl) P value
Sex Male 1.00 (baseline) 0.083
Female 4.67 (0.73 to 33.33)
Age group <2 months 00^ <0.001
2-5 montlis 1.00 (baseline)
6-11 months 0.02 (0.01 to 1.08)
1-4 years 0.01 (0.01 to 0.27)
5+ years 0.02 (0.01 to 0.24)
Region‘s Region 1 1.00 (baseline) 0.197
Region 2 2.15 (0.18 to 26.05)
Region 3 6.14 (0.40 to 93.37)
Region 4 oo^
Region 5 9.10 (0.58 to 141.84)
Vaccination status N ot vaccinated 1.00 (baseline) 0.425
Vaccinated 0.48 (0.08 to 2.97)
Serotype Serotype 1,2 3.70 (0.69 to 20.00) 0.117
Serotype 1,3 jl.OO (baseline)
iThe age groups have been sorted into two larger sub-sets, as a previous analysis using the five 
separate age groups show similar P values, and, the above analysis has not shown any bias when 
comparing tlie log UkeHhood of the multivariable logistic regression analysis.
^Isolates are between September 1998 and April 1999, and are sorted into calendar months.
3An infinity odds ratio was generated, as all under two months old (21/21) were admitted to 
hospital.
^Details of the regional groups are shown in Table 3.4 (page 120).
^An infinity odds ratio was generated, as 8/10 cases from Region 4 were admitted to hospital.
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Hospital admission was the only outcome variable that was significandy associated with the 
serotype of B, pertussis (P=0.017) (Table 3.15.a, page 133). Cases infected with isolates 
expressing serotype 1,2 were more likely to be admitted (34/54 serotype 1,2 isolates, 
compared to 20/54 serotype 1,3 isolates). Multivariable analysis was performed, with 
hospital admission as the outcome variable (Table 3.15.b, page 133). This analysis further 
revealed that females were over four times as likely to be admitted to hospital (P=0.083), 
and those infected with serotype 1,2 isolates were nearly four rimes as Hlrely to be admitted 
to hospital than those with serotype 1,3 isolates (P=0.117).
3.3.6.2 Associations of Bordetella pertussis pertactin gene types in the 90 pertussis 
cases
The single variable analysis with the pertactin types against tlie other explanatory variables 
generated only one borderline significant association with age (P=0.109) (Table 3.16.a, page 
136). When analysing the pertactin types and the proportion of isolates recovered from 
individuals under two months old, 15/47 (32%) o fprnA(\) isolates were associated, 
compared with 7/41 (17%) ofprnA(p) isolates and 1/2 (50%) ofprnAips) isolates.
As for the serotype data, the pertactin data showed a significant association with hospital 
admission (P=0.025). There are moreprnA(\) andpmA{p) isolates associated witli cases 
admitted to hospital than prnA(!p^ isolates (32/41 pruA{\) isolates (78%) and 2 /2  prnA(p>) 
isolates (100%), compared to 20/37 prnAipl) isolates (54%)). When included in a 
multivariable logistic regression analysis (Table 3.16.b, page 136), females are more than 
four times as lilrely to be admitted tlian males (P=0.083), the under two month old group 
are significantly more likely to be admitted (P<0.001), and cases are nearly four times as 
hlrey to be infected w ithprnA(\) isolates thanprnA (^  isolates (P=0.118). The twoprnA(p) 
isolates were excluded from the multivariable analysis, but they were associated with cases 
that were under three montlis old, exhibited typical symptoms of pertussis, developed the 
comphcation apnoea and were admitted to hospital.
3.3.6.3 Associations of Bordetella pertussis IS./6?A^Restriction Fragment Length 
Polymorphism types in the 90 pertussis cases
After the IS/0f?2-RFLP data were sorted into three groups (RFLP-1, RFLP-3 and “otlier 
RFLPs”), single variable analysis indicated that only one significant association with the 
geographical regions (P=0.025) and a borderline association witli tlie complication 
conjunctivitis (P=0.071) were present (Table 3.17, page 137). The significant association
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may be due to the presence o f RFLP-3 isolates in only the North West, Nortliern and 
Yorkshire, South Thames and South and West, as RFLP-1 and “other RFLPs” seem to be 
spread randomly throughout the regions (Table 3.18, page 137). There was only one 
conjunctivitis case seen in the 90 cases studied, which could make any association 
significant, as there are no null values. Nonetheless, the B. pertussis strain associated with 
this case was type RFLP-3. As there were no significant associations with any outcome 
variables, multivariable logistic regression analysis was not performed using RFLP types.
3.3.6.4 Associations of Bordetella pertussis combined types in the 90 pertussis 
cases
The combined data was analysed against other explanatory and outcome variables using the 
following four groups: combined types A, C, P and “Z” (the other 21 combined types). 
Combined type A showed a borderline association with the under two montlis old group 
(P=0.100), where there were 8/16 (50%) type A isolates associated with this age group, 
compared to 3/13 (23%) type C isolates, 6/33 (18%) type P isolates and 6/28 (21%) type 
“Z ” isolates (Table 3.19, page 138). Combined type A is comprised of serotype 1,2, 
ptmAip), RFLP-1 isolates. Single variable analysis also generated a borderline significant 
association between the combined types and geographical regions (P=0.121). When 
tabulated (Table 3.20, page 138), combined type C was seen in the four regions mentioned 
above (3.3.6.3, page 134), and this could be due to type C consisting of RFLP-3 isolates, 
which may be the cause of this borderline probability. The outcome variable, 
comphcations, showed a borderline association with the combined types (P=0.125), where 
7/13 (54%) of type A isolates were associated with complications, compared to 4/12 (33%) 
type C isolates, 7/30 (23%) type P isolates and 5/26 (19%) type “Z ” isolates. As for the 
RFLP types, the comphcation conjunctivitis was associated with the combined types 
(P=0.121), but because there is only one case, multivariable logistic regression analyses 
could not be performed (Table 3.19, page 138).
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Table 3.16. Probability values between pertactin gene types of
Bordetella pertussis isolates and associated factors
a. Single variable analysis, including all three pertactin gene types present
Factor
Sex
Age groups 
Region
Temporal trend^ 
Vaccination status 
Vaccination doses 
Typical pertussis symptoms 
Complications 
Conjunctivitis 
Pneumonia 
Apnoea
Hospital admission
P value
0.576
0.109
0.732
0.825
0.266
0.542
0.581
0.670
0.345
0,577
0.742
0.025
b. Multivariable analysis with hospital admissions as the outcome, excluding /)y%M(3)
Factor Level Odds Ratio (95% Cl) P value
Sex Male 1.00 (baseUne) 0.086
Female 4.61 (0.71 to 30.30)
Age group <2 months 00^ <0.001
2-5 months 1.00 (baseUne)
6-11 months 0.02 (0.01 to 1.08)
1-4 years 0.02 (0.01 to 0.28)
5+ years 0.02 (0.01 to 0.24)
Region‘S Region 1 1.00 (baseline) 0.200
Region 2 2.16 (0.18 to 26.08)
Region 3 6.00 (0.39 to 91.66)
Region 4 00®
Region 5 9.03 (0.58 to 140.46)
Vaccination status Not vaccinated 1.00 (baseline) 0.412
Vaccinated 0.47 (0.08 to 2.90)
Pertactin gene type pmA(V) 3.70 (0.69 to 20.00) 0.118
prnA(2) 1.00 (baseline)
Hhe age groups have been sorted into two larger sub-sets, as a previous analysis using the five 
separate age groups show similar P values, and, the above analysis has not shown any bias when 
comparing die log UkeHhood of the multivariable logistic regression analysis.
Tsolates are between September 1998 and Aprü 1999, and are sorted into calendar months.
^An infinity odds ratio was generated, as aU under two months old (21/21) were admitted to 
hospital.
'^Details of die regional groups are shown in Table 3.4 (page 120).
^An infinity odds ratio was generated, as 8/10 cases from Region 4 were admitted to hospital
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Table 3.17. Probability values between ISWOZBJBU? types of Bordetella
pertu ssis  isolates and associated factors
Factor P value
Sex 0.826
Age groups 0.605
Region 0.025
Temporal trend^ 0.920
Vaccination status 0.713
Vaccination doses 0.565
Typical pertussis symptoms 0.385
Complications 0.530
Conjunctivitis 0.071
Pneumonia 0.780
Apnoea 0.839
Hospital admission 0.355
*The age groups have been sorted into two larger sub-sets, as a previous analysis using the five 
separate age groups show similar P values, and, tlie above analysis has not shown any bias when 
comparing the log UkeHhood of the multivariable logistic regression analysis.
isolates are between September 1998 and April 1999, and are sorted into calendar months.
Table 3.18. Geographical distribution o f IS7(?(?.2-RFLP types
Region RFLP-1 RFLP-3 "other" R FLP Total
AngUa and Oxford 3(50) 0(0) 3(50) 6
North Thames 1 (100) 0(0) 0(0) 1
North West 4(29) 6(43) 4(29) 14
Northern and Yorkshire 2(18) 3(27) 6(55) 11
South Thames 3(38) 1 (12) 4(50) 8
South and West 16 (62) 4(15) 6(23) 26
Trent 9(90) 0(0) 1(10) 10
Wales 9(75) 0(0) 3(25) 12
West Midlands 2 (100) 0(0) 0(0) 2
Total 49 (54) 14 (16) 27 (30) 90
Figures in parantlieses indicate percentages according to region distribution.
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Table 3.19. Probability values between combined types of Bordetella
pertu ssis  isolates and associated factors
Factor P value
Sex 0.834
Age groups 0.100
Region 0.121
Temporal trend^ 0.867
Vaccination status 0.289
Vaccination doses 0.266
Typical pertussis symptoms 0.483
Complications 0.125
Conjunctivitis 0.121
Pneumonia 0.367
Apnoea 0.638
Hospital admission 0.221
^The age groups have been sorted into two larger sub-sets, as a previous analysis using the five 
separate age groups show similar P values, and, the above analysis has not shown any bias when 
comparing tire log likelihood of the multivariable logistic regression analysis.
^Isolates are between September 1998 and April 1999, and are sorted into calendar months.
Table 3.20. Geographical distribution o f com bined types
Region A C P “Z ” Total
Anglia and Oxford 1(17) 0 (0) 2 (33) 3(50) 6
North Thames 0 (0) 0 (0) 1 (100) 0 (0) 1
North West 0 (0) 5(36) 4 (28) 5(36) 14
Northern and Yorkshire 1 (9) 3 (27) 1 (9) 6C%) 11
South Thames 1(13) 1(13) 2 (24) 4(50) 8
South and West 4(15) 4(H% 12 (47) 6(23) 26
Trent 3 (30) 0 (0) 6 (60) 1(10) 10
Wales 5(42) 0 (0) 4 (33) 3(25) 12
West Midlands 1(50) 0 (0) 1 (50) 0 (0) 2
Total 16 (18) 13 (14) 33 (37) 28 (31) 90
Figures in parantlieses indicate percentages according to region distribution.
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3.3.6.5 Age cohorts trend analysis
The distribution of serotype and pertactin gene type in each age group was investigated and 
showed a sifnüar trend (Tables 3.21 and 3.22, page 140). There were 15/23 (65%) of babies 
under two months old infected with J3. whose isolates were serotype 1,2 and/or
prnA{\)^ and this proportion gradually decreased to 1 /4  (25%) in the six t o l l  month old 
babies. The proportion of serotype 1,2 andprnAiV) isolates then rose to 11/23 (48%) of 
the individuals in the five year old and above age group. There was, incidently, a very 
significant association between serotype 1,2 withpm A (\) (47/90 isolates, 52%), and 
serotype 1,3 withprnA(^) (39/90, 43%) (P<0.001). The significance o f a linear trend was 
borderline through the age groups for serotype (%^  for trend=3.15, P=0.076, Table 3.21, 
page 140), and for pertactin, when theprnAil>) cases were removed, (%^  for trend=2.64, 
P=0.104, Table 3.22, page 140).
3.3.6.6 Temporal trend analysis
The isolation dates were demoted into the mondi of isolation, and resulted in eight 
consecutive months, between September 1998 and Aprü 1999. The distributions of 
serotypes and pertactin types showed a shift between February 1999 and March 1999 
(Tables 3.23 and 3.24, respectively, page 141). The serotype distribution shifted from 4/8 
(50%) t o l l / 1 8  (61%) serotype 1,2 isolates from September to February, to 5/13 (38%) in 
March. The calculated odds ratios showed an increased proportion of serotype 1,3 in 
March with the only value higher than 1 (1.60), but the temporal trend o f this shift was not 
significant (%^  for trend=0.46, P-0.497, Table 3.23, page 140). In addition, only 5% of 
isolates collected after 1999, and not included in this analysis were serotype 1,2 (1 isolate of 
serotype 1,2 and 21 isolates of serotype 1,3).
The distribution of pertactin gene types has also changed temporally, from 4/8  (50%) to 
10/18 prnAiV) isolates in September to Febmary, to 5/13 (38%) pm A{\) in March, 
raising the frequency ofprnAipl) to 8/13 (62%) (Table 3.24, page 141). To perform the 
linear trend analysis, ji)mA[(3) isolates had to be omitted, andpm A (t) andpruA(i^ formatted 
as binary numbers. The shift betweenprnA{\) andprnA (^  however, was also not 
significant (%^  for trend=0.35, DF=1, P=0.554). The 23 isolates collected between 2001 
and 2002 consisted o f 21 isolates p o s s e s s i n g (2), and one of each pruA{V) andprnAi?)), 
indicating a later shift towards prnA i^  variants.
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Table 3.21 Distribution of Bordetella pertussis  serotype through age
cohorts
Age Cohort
Serotype <2
months
2-5
months
6-11
months
1-4
years
5+ years Total
1,2 16 (70) 17 (59) 1(25) _ _ 4(36) 11 (48) 49 (54)
1,3 ^ 7(30) 12 (41) 3(75) 7(64) 12 (52) 41 (46)
Total 23 29 4 11 23 90
Score test for trend of odds: 1)—3.15, P—0.076.
Table 3.22. Distribution of Bordetella pertu ssis pettActm  gene type
through age cohorts
Age Cohort
Pertactin
type
<2
months
2-5
months
6-11
months
1-4
years
5+ years Total
pm4(l) 15 (65) 16(55) L(25) _ 4(36) 11 (48) 47 (52)pmAÇL) 7(31) 12 (41) 3 0^ 5) 7(64) 12 (52) 41 (46)prnA(p) 1(4) 1(4) 0(0) 0(0) 0(0) 2 (3
Total 23 29 4 11 23 90
Score test for trend of odds; %^(DF=1)=2.64, P=0.104. This trend analysis was performed without 
prnA(p) isolates (n=2)
Figures in parentheses are percentages.
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These temporal shifts in serotype and pertactin distributions coincide, and were probably 
due to the association between serotype and pertactin type, described in 33.6.5 (page 139).
3.4 D iscussion
Following the recent resurgence of pertussis in countries such as the USA, Canada, 
Australia and The Netherlands (De Serres et al, 1995; Andrews et al, 1997; de Mellrer et al, 
1997; Guris et al, 1999b), the genotypic diversity and population dynamics of Bordetella 
pertussis in the United Kingdom was investigated. To detect any changes in the B. pertussis 
population, strains dating from 1920 to 2002 were collected from a number of sources. 
Techniques which have been published previously were initially chosen for this study so 
that direct comparisons could be attempted with studies performed in other countries. 
These methods included serotyping, sequence typing of the genes coding for pertactin and 
pertussis toxin subunit 1 and IS/002-RFLP analysis (Preston, 1963; van der Zee et al, 
1996b; Mooi et al, 1998). In the UK, only serotyping and PFGE have been used previously 
to study the population dynamics of B. pertussis. Serotyping has a limited use due to its low 
discriminatory power and the ability of the organisms to switch at a low frequency between 
serotype 1,2,1,3 and 1,2,3 (Preston, 1988; Roberts and Parton, 2001). Pulsed-field gel 
electrophoresis of jB. pertussis has had limited use in the UK and is mostly a tool for 
epidemiological investigations (Khattak et al, 1992; Syedabubakar et al, 1995). Also 
available were epidemiological data for a sub-set of isolates to elucidate any associations 
with the typing results generated.
3.4.1 Variation in the pertactin gene
The six UK clinical isolates and three Wellcome WCV strains studied for any 
polymorphisms outside of the polymorphic regions 1 and 2, showed no variation in over 
90% of the pertactin gene (3000 base pairs) for tire types that Mooi et al (1998) had 
described. Since work on this thesis began, tenprnA  types have been described, and the 
sequences can be accessed from public sequence databases, e.g., GenBank. An ahgnment is 
illustrated in Figure 1.2 (page 16). Most differences occur in region 1 of the pertactin gene, 
varying either in the composition or the number of GGxxP-encoded repeats, or a 
combination of both. However, two pertactin types, jf)mM(l) andprnAÇ), are identical at 
region 1, and differ only by a point mutation approximately 150 nucleotides upstream of 
region 2. Therefore, 68/214 (32%) of isolates identified as pmAiV) by sequencing region 1, 
were also sequenced upstream of region 2, and were aU found to be designated as prnA{\)
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isolates. To à?Lt&,pmAÇ) has been isolated only from a strain used in some vaccine 
preparations and in earlier strains from The Netherlands (van Loo and Mooi, 2002).
There were three pertactin types found in the 318 UK B. pertussis isohxes sequenced 
between 1920 and 2002. Between 1920 to 1979, all isolates wereprnAiV), which is the same 
type as in the strains used in both the Wellcome and the Aventis Pasteur WCVs. From 
1982 however, new variants prnA (^  andpruAip) emerged and their proportions gradually 
increased within the circulating population so that in 2002, 20 of the 22 isolates sequenced 
were prnA{2). Altliough the data-set was large (n=318), there was some sampling bias due 
to tlie difficulty in obtaining earlier isolates. Consequently, this study utilised 51 isolates 
from the 1940s when pertussis incidence was very high (between 53,000 to 173,000 cases 
per year), compared to 106 isolates from the 1990s when incidence was low (between 1000 
to 15,000 cases per year). Therefore tlie sampling fraction was a lot lower for earlier strains 
than later ones, and this could have possibly led to a skewed distribution of isolates tested. 
The distribution of pertactin types when compared both within and between the different 
time periods, however, remained statistically vaHd.
Since this work began in the UK, studies from Finland, Italy, the USA, Japan, France, 
Poland, Belgium, Canada and Russia, on pertactin and pertussis toxin gene variation, have 
been published (Mooi et al., 1999; Mastrantonio et al., 1999; Cassiday et al, 2000; Guiso et 
al, 2001a; Weber et al, 2001; Gzyl et al, 2002; de Schutter et al, 2003; Peppier et al, 2003; 
Kourova et al, 2003). Some of the data from tlie following countries were Hmited in scope; 
(i) Japan, as only 12 clinical isolates were investigated from 1975 to 1996 (Guiso et al, 
2001a); (il) Belgium, as this was a household contact study involving only ten families (de 
Schutter et al, 2003); (in) Canada, because the isolates analysed were from 1985 to 1994 
(Peppier et al, 2003); and (iv) Russia, as the number of strains available was Hmited (n=61) 
and not all of those had been investigated by pertactin and pertussis toxin SI gene typing 
(Kourova et al, 2003). Results from tlie other countries mentioned above, including The 
Netherlands, Finland and Italy, concur with the original hypothesis of Frits Mooi et al',
“ ... vaccination has selected for \B.pertussis\ strains which are antigenicaUy distinct 
from vaccine strains...”.
(Mooi et al, 1998)
The pertactin data presented here for 318 UK isolates also appear to be concordant with 
this theory, but lilce Finland, Italy and Japan, tlie UK has not seen a resurgence in pertussis 
cases. Mooi and colleagues further suggested in their paper describing isolates in Finland 
that;
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. pertussis vaccines protect less well against strains with particularprn[A\ alleles, 
such prn\A\(3), which predominate in some countries, such as The Netherlands, 
but are less common in Finland.
(Mooi et aL, 1999)
This statement modifies tlieir original theory of vaccine-driven evolution by stipulating that 
there is a possible threshold of certain pertactin types that could be changed by vaccinating 
against pertussis. Furthermore, if this threshold of Titter’ pertactin types is breached, then 
pertussis resurgence and ensuing epidemics could occur. Tliis hypothesis could also be 
appHcable to Australia, where a recent pertussis resurgence has been reported, along with a 
sliift in pertactin types, with prnA.(p) levels between 1989 and 1998 at 42% of the 
circulating B. pert/tssis population (Poynten et ai, 2004). However, results from the USA and 
Poland, which have also seen a resurgence of pertussis, have not encountered any pniAip) 
isolates in their studies (Cassiday et al, 2000; Gzyl etal, 2002). In contrast, in Canada, 
where tliere has been a resurgence of pertussis, 166/3334 (5%) of isolates between 1985 
and 1994 wereprnA(3) (Peppier etal, 2003). In the UK, however,j&mM(3) comprised 
4/133 (3%) of diose isolates from 1998 to 2002, and tliere has been no pertussis 
resurgence.
Pertactin results from countries such as the UK and Finland, with a low incidence of 
pertussis, and from the high incidence countries such as USA and Poland, are concordant 
with die general theory of vaccine-driven evolution, but are not consistent with the 
suggestion tiiat vaccines are less protective against certainprnA  alleles. Furdier evidence 
from intranasally-chaUenged mouse models and a convalescent antibody study does suggest 
that there may be particular pertactin types that are less immunogenic than others (King et 
al, 2001; He et al, 2003). King and colleagues (2001) found tiiat, after immunising mice 
with the Dutch WCV, which contains only prnA(\) strains, dieprnA(7) and priA(p) isolates 
were significandy more effective at colonisation thanp n A { \)  isolates. Humans previously 
infected withy?r^r4(2) isolates had significandy lower levels of convalescent antibodies to 
prnA(\) than subjects infected w ithprnAipi) isolates, and those immunised with a booster 
ACV containingy?r«M(l) (He et al, 2003). The studies above therefore indicate diat non­
vaccine types would be more likely to colonise and cause infection than the vaccine types. 
Tins appears to be die situation in The Netherlands, where an increase in pertussis 
notifications has been considered to be due to the increase in non-vaccine types (Mooi et 
al, 1998). In the UK, 77/133 (58%) oiprnAÇ) isolates were circulating between 1998 and 
2002, but there has been no increase in pertussis notifications. However, this low pertussis 
incidence in the UK can not be easily explained by a good vaccine efficacy and coverage, as
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countries like France, who have good coverage and efficacy, have seen a resurgence in 
pertussis (Therre and Baron, 2000).
3.4.2 Variation in the pertussis toxin SI gene
There have been, at the time of writing, six variants of the pertussis toxin SI subunit gene 
sequence of B.perttissis deposited in GenBank (Figure 1.4, page 48). They differ from each 
other by single nucleotide polymorphisms (SNPs) at multiple sites, which can eitlier affect 
tlie translated amino acid (non-silent) or not (silent). In the UK, two of these sixp txA  types 
were found by sequencing 318 isolates from 1920-2002. Both ptxA(V) and ptxApI) were 
present in strains used for the UK Wellcome WCV, and these were also circulating in 
strains up to 1985. In The Netherlands, whereptxA(2) andptxA(3) strains are included in 
dieir WCV, ji)/Xi4(l) was considered a new variant, and was first seen there in the 1980s 
(Mooi et aL, 1998). This was also tlie situation in Finland (Mooi et al, 1999), but, later 
studies in the USA, Poland and Australia revealed their firstptxA.{\) isolates in 1970,1960 
and 1967, respectively (Cassiday et al, 2000; Gzyl et al, 2002, Poynten et al., 2004), The first 
ptxAP\) isolates in the UK were found in 1940, clearly demonstrating that this variant was 
not a new emerging one, and may have had some geographical restriction in earlier years. 
Furthermore, j^ ?/‘xM(l) was present in the UK Wellcome WCV, and is also found in the 
Australian WCV (Poynten et ai, 2004).
Recent isolates from 1998 to 2002 in the UK showed a 100% frequency of theptxA.{V) 
type, with the disappearance o fp tx A i^  isolates. This shift to predominantlyptxA (l)  has 
been seen recently for aU countries investigated. For many of these countries, strains with 
ptxA (\)  are not present in theit vaccine preparations and, therefore, vaccine-driven 
evolution seems a logical theory to explain pertussis resurgence. However, Australia has 
seen an increase in pertussis cases despite circulating strains being o f the same p txA  type as 
the vaccine (Poynten et al., 2004). The authors suggested that the change in pertactin types 
to 24/57 (42%) o fprnAip) isolates from 1989 to 1998, and a waning vaccine-induced 
immunity in older children and adults, may be factors in the resurgence of pertussis in 
Australia (Poynten et al, 2004). In die UK, a large number of isolates (n—318) has been 
investigated for the pertussis toxin SI genotype. The type,yj/x/l(l), present in the 
Wellcome vaccine, matches the circulating isolates up to 1996, and this argues against the 
theory of vaccine-driven evolution. However, since 1996, the UK has predominantly been 
using the WCV manufactured by Aventis Pasteur, which contains two strains that are 
p tx A l^  andptxA{3), thus now showing a mis-match between the vaccine strams and the
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cii-culating, recent B. pertussis population. The UK, nevertheless, has not seen a resurgence 
in pertussis cases, as reflected in tlie low number of clinical pertussis cases notified in 2003 
(n=409).
3.4.3 Combined pertactin and pertussis toxin SI types in the UK
The combination of pertactin and pertussis toxin SI typing data for each individual isolate 
reveals a more representative picture of B. pertussis popu\&.\ioiLi dynamics and major shifts of 
important genotypes through time. Three prnA  and two p txA  types were found in 318 
isolates. This should, in theory, generate six possible combinations o fprnA jptxA  types, but 
only four were seen in the UK. Similar combined results from the USA revealed five 
prnA!ptxA  types out of a possible six (Cassiday et al, 2000). These authors also labelled 
certainprnA fp txA  alleles as either “old”, “new”, or “transitional” due to the temporal shift 
o f types (Cassiday et aL, 2000), indicating an association between particular prnA  andp txA  
types. However, when the USA data are presented in three time periods spanning 1935- 
1999, “transitional” and prnA fp txA  types are seen throughout the years. If  this
labelling was applied to the UK data, then the “transitional” type ptyiA(V){ptxA{l) (bearing 
an “old” A/%/1 and a “new” y)A<v4) was seen from 1941 to 2002. Furthermore, in Canada 
this type was seen in 572/3334 (17%) of the isolates from 1985 to 1994 (Peppier et aL, 
2003). Therefore, tliis “transitional” combination should be viewed as a
successful genotype o f B. pertussis, and up until prnAii^(ptxAipC) has been present in
the majority of isolates tested in the UK.
The UK Wellcome WCV contained the combined types prnA(\) !ptxAip) from two strains 
and prnA{p)!ptxAPT) from one other. Although the proportion of type prnA(\)!p tx A (^  
has decreased in recent circulating isolates, the persistance o f typeprnAiX)/ptxA{V) may 
have some influence on the efficacy of the UK Wellcome WCV. When studying the UK 
data by decades, aU four of thep m A jp txA  combinations were identified in the 1980s. This 
evidently coincides with the emergence of new prnA variants prnA(l2) and prnA{3) at this 
time, generating two of the four prnA jptxA  combinations. However, in the ensuing period 
o f the 1990s, the disappearance o fptxA(2) from circulating strains drops the variablility to 
three prnA fp txA  types. Altliough there was a change of WCV manufacturer since 1996 to 
the Aventis Pasteur, which contains prnA(i\)(p tx A (^  andprnA{\)!ptxA^b) types, the last 
ptxAip) circulating strain was seen in 1985 and therefore before the Aventis Pasteur WCV 
was introduced to the UK.
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3.4.4 Genotypic diversity of UK B ord e te lla  p e r tu s s is  between 1940 and 1999
The pertactin and pertussis toxin SI sequencing data, as for serotyping data, did not 
generate enough discrimination in order to deduce whether there had been any changes in 
the genotypic diversity of B. pertussis isolates in tlie UK, although the data revealed some 
clear temporal shifts in genotypes. Therefore, IS/(?t?ARFLP analysis was also used and, as 
tliis method was used previously in The Netherlands, any genotypic diversity values 
calculated from the UK RFLP data could be compared directly with these studies (van der 
Zee et al, 1996b; van Loo et al, 1999).
O f the 291 B. pertussis from 1940 to 1999 studied for pertactin and pertussis toxin
SI subunit gene polymorphism, 149 were chosen at random for IS / 002-RFLP analysis and 
24 different RFLP types were generated. The difference of 24 RFLP types in 149 isolates, 
compared to just tlireeprnA  types in 318 isolates, reveals that the variability of the B. 
pertussis genome is greater when studying whole-genome profiles compared to single gene 
variations.
Assuming that each hybridised band contains one copy of the 1S1002 element, the RFLP 
types exhibited between four and six bands and therefore four to six 15>1002 elements were 
present in each B. pertussis sXr-scm. (van der Zee et aL, 1996b). However, this assumption may 
not necessarily be true, as die probe is only 293 bp and the element in B. parapertussis is 
1040 bp (van der Zee et aL, 1996b). The band sizes generated in IS/002-RFLP vary from 
2096 bp to 23.3 Kb, where two or more copies of the \5>1002 element can be tlieoreticaUy 
present. However, the intensity of the bands is consistent throughout each profile, 
suggesting that there is only one copy of \5>1002 in each hybridised band. The in silico digest 
o f the B. pertîissisTdh'àmA genome (see 5.3.6, page 202), together with the annotated 
Tohama-I genome, indicates that there are six copies of tlie IS/0612 element, which agrees 
with experimental observations. In the UK, there was a statistically significant reduction in 
the nuiuber of IS /6102-containing bands through time. An isolate from 1920, NCTC 10901, 
which was not included in this analysis, contained nine IS /002-coiitaining bands. Tliis 
could indicate that this particular IS element neither has any benefit or detriment to the 
organism, and could therefore afford to lose the elements from its’ genome over time. In 
contrast, the 15)481 element, present in the Tohama-I genome at 238 positions, is 
considered to be the catalyst for multiple recombination events which resulted in the 
rearrangement and reduction o f the chromosome when compared to the B. bronchiseptica 
genome (ParkhiU et al., 2003). Bordetella pertussis carries at least four different IS elements
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(Table 1.4, page 41, and as demonstrated by the annotated Tohama-I genome), and the 
influence of each one on the genome could be different.
When tlie isolates were sorted by tlieit RFLP type and divided into decades, tliere were 
more RFLP types present in the 1940s and 1980s than in the other decades examined. This 
is similar to the Dutch data, where 12 RFLP types were found in 1949 to 1954 and 11 types 
between 1982 and 1990 (van Loo et aL, 1999). However, the subsequent period of 1991 to 
1996 contained 22 types, whereas in the UK only six RFLP types were seen in the 1990s. 
This difference may have been due to the number of isolates examined, as only 36 UK 
isolates were tested (0.17 types per isolate), compared to 120 isolates from The Netherlands 
(0.18 types per isolate), therefore revealing more RFLP types (van Loo et ai, 1999). This 
can be compared to data reported in 3.3.5 (page 114), where 18 RFLP types were seen in 
90 UK isolates from September 1998 to April 1999 (0.2 types per isolate).
Unfortunately the designation of IS/0612-RFLP profiles that the laboratory in The 
Netherlands use could not be applied to my data. This was because o f several reasons; (i) 
technical differences due to an amended protocol, as the Dutch separated the restricted 
fragments for 16 hours (20 hours in tlie UK) and used chemiluminescence for detecting tlie 
hybridised bands (digoxygenin in the UK), the size of the membrane used for data analysis, 
and tlie gel analysis software used (with any user-defined parameters); (ii) the reference 
strains obtained from The Netherlands enabled comparison of the Dutch DNA types with 
the results generated in this study, but was limited by a manual, subjective comparison; and 
(iii) to use the Dutch designation would require a reference strain for every RFLP profile 
observed (n>80 types). Therefore, all the profiles observed in the present study were given 
an arbitrary number, and all the isolates designated appropriately. Flowever, the major 
RFLP types elucidated in this study could be matched to the DNA types designated by 
(van Loo et al, 1999) and used for comparison (Table 3.25 and Figure 3.9, page 149).
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Table 3.25 Corresponding Bordetella pertu ssis \%1002-KV\iP profiles 
between the UK and The Netherlands
UK designation Dutch designation
R F L P - 1 d t - 2 9
R F L P - 2 d t - 1 2
R F L P - 3 d t - 3 5
R F L P - 4 d t - 2 8
R F L P - 6 d t - 5 1
R F L P - 7 d t - 1 9
Figure 3.9 Bordetella pertu ssis \S1002-KV\iP profiles from the UK and
The Netherlands
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RFLP
type
RFLP-1 UK
dt-29 Dutch
RFLP-2 UK
dt-12 Dutch
RFLP-3 UK
dt-35 Dutch
RFLP-7 UK
dt-19 Dutch
Distances between bands from corresponding profiles vary due to differences in electrophoresis 
running conditions, the area analysed, and normalisation. The thin red lines indicate bands included 
in the analysis, and the pairs of coloured squares group the corresponding UK and Dutch RFLP 
types.
The Dutch IS/002-RFLP types dt-28 and dt-51, which correspond to the UK types RFLP-4 and 
RFLP-6, could not be represented. Please refer to van Loo et aL (1999).
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The most abundant type in the UK, RFLP-1 (dt-29), was also the prevalent type in The 
Netherlands, Italy, Australia and in Missouri, USA (van Loo et aL, 1999; Mastrantonio et al, 
1999, Poynten et ai, 2004, and 4.3.3, page 174). The second most abundant type RFLP-2 
(dt-12) was also seen in the above countries, and is identical to RFLP type D l, described by 
van der Zee et ai (1996b). In their study, strains collected from Germany, China, the USA 
and Canada also revealed this RFLP type D l (RFLP-2), indicating that this RFLP type has 
a global distribution. When analysed by decades, RFLP-2 was seen in the UK from the 
1940s to the 1990s, and in The Netherlands from 1949 to 1996, also revealing the 
persistence over time of tliis succesful RFLP type.
The RFLP types of the strains used in the UK Wellcome WCV are RFLP-1, RFLP-2 and 
RFLP-3. Unfortunately, the strains from the Aventis Pasteur WCV were not available and 
therefore the RFLP types of the two strains could not be determined. However, the RFLP 
types in the UK Wellcome WCV correspond to the Dutch types dt-29, dt-12 and dt-35, 
and have been found in the circulating population of both countries. These three types 
were seen in 83/120 (69%) and 32/36 (89%) of the recent isolates tested in The 
Netherlands and the UK, respectively (van Loo et aL, 1999). They were also observed in 
56/76 (74%) of isolates from Italy collected between 1993 and 1995 (Mastrantonio et al, 
1999), indicating that RFLP-1, RFLP-2 and RFLP-3 are successful lineages of B. pertussis. 
Although the UK Wellcome WCV RFLP types match with a large proportion of the UK 
circulating population, the Dutch WCV types, dt-19 (UK RFLP-7) and dt-43 (not seen in 
the UK) have not been seen in great numbers in the Dutch pertussis population (van Loo 
et al., 1999). Partly due to this mis-match, Mooi and colleagues searched for antigenic 
variation within the B. pertussis population, by sequencing the pertactin and pertussis toxin 
SI genes (Mooi et al, 1998).
By using the UK pertussis vaccination coverage figures and notification rates from the 
1940s onward, a concurrent association can be made between these, the RFLP data, and 
the genotypic diversity values. In the 1940s, before vaccination was introduced and 
notifications were high, there were many RFLP types (n= 11/24), and a high GD o f 0.81. 
After vaccination was introduced in the 1950s, the number o f RFLP types and the GD 
dropped to six types and a GD of 0.64, respectively, and this change was calculated to be 
o f borderline significance, probably due to the decreasing number o f pertussis cases, and 
the elimination or control of less-fit strains. Interestingly, the proportion of RFLP-1 
isolates increased significantly between the 1940s and the 1950s, indicating that RFLP-1 
was a successful lineage and was still circulating after vaccination was introduced. Mass
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vaccination was implemented in 1957, and through the 1960s and 1970s cases of pertussis 
dropped markedly and vaccine coverage reached approximately 80% (Healtli Protection 
Agency, 2003c). In these two decades, although tlie number of RFLP types was still low, 
the GD value rose up to 0.81 in the 1970s. This rise in GD may have been due to the low 
number of isolates sampled from the 1960s and 1970s compared to the other decades. In 
the 1980s, vaccination coverage had dropped to 30% due to reports concerning the safety 
o f the pertussis vaccine, and two large pertussis epidemics occurred. These events were 
reflected in the increased number of RFLP types and the rise in genotypic diversity to 0.84. 
This could possibly have been due to the emergence of new variants or the re-emergence 
o f less-fit B. pertussis strains, as the herd immunity in the UK was noticeably reduced. 
However, the vaccine coverage recovered to 94% in the late 1990s, resulting in the increase 
o f herd immunity. Low numbers of pertussis cases was thus seen, and the reduced B. 
pe?ittssis pQpxdsition experienced a significant drop in genotypic diversity to 0.57 (P<0.01). 
Combined with the fall in RFLP types and a significant increase in proportion of RFLP-1 
isolates, a second reduction of less-fit strains took place, with RFLP-1 expanding as a more 
fit, predominant lineage o î B. pertussis.
Due to the fall in vaccine coverage in the UK in the late 1970s, comparisons may be 
difficult to other countries with steady coverage, such as The Netherlands. However, after 
the introduction of vaccination in the early 1950s, The Netherlands also saw a decrease in 
GD, and suggested that it may have been due to;
“ ... a decrease in the bacterial population size and/or by clonal expansion ,.
(van Loo et aL, 1999)
Thereafter, genotypic diversity gradually rose and, between 1976 and 1981, the GD was 
0.69 in The Netlierlands (van Loo et al., 1999), whereas a higher GD value of 0.81 was seen 
in the UK in the 1970s. Data from the two countries gave shnilar high GD values once 
more m the 1980s (1982 to 1990 in The Netherlands). This similarity however was not 
reflected in the pertussis notification rates, as the UK experienced epidemic levels, yet The 
Netlierlands did not. The drop in genotypic diversity in the 1990s was not as pronounced 
in The Netherlands than for the UK, and this was perhaps due to the resurgence of 
pertussis in The Netherlands, where some clonal expansion was stiU occurring, compared 
to tlie ehrnination of less-fit strains in the UK. So, altliough the UK encountered a drop in 
vaccination coverage and is currently experiencmg low numbers o f pertussis cases, both the 
major RFLP types and the temporal changes in genotypic diversity are similar to those in 
The Netherlands, and yet The Netherlands has seen a recent resurgence in pertussis.
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The genotypic diversity, according to RFLP type distribution within each pertactin type, 
was calculated to allow comparisons with the Dutch data (van Loo et aL, 1999). A marked 
difference was found in the prnA(2) andprnA(p>) values, as GD values of 0.39 and 0.00 
were seen in the UK, and GD values of 0.78 and 0.57 in The Netherlands, respectively 
(van Loo et al., 1999). This difference could partly have been due to the frequencies of 
pertactin types (UK, 118/149 isolates, 79% prnA{\), c.f. 40/134, 30%y?r/iT(l) in The 
Netherlands) and the sample period used (UK isolates from 1940 to 1999, c.f. 1981 to 1996 
in The Netherlands) (van Loo et al., 1999). Van Loo et al. (1999) also reported that the 
higher GD ofpm A (\)  isolates (GD=0.91) compared to the GD values o fpmAipt) and 
prnAip) isolates suggested that prnA{V) represents tlie oldest lineage, and thatpniAÇ)) 
isolates represents a younger lineage tlian prnA(p). If this hypothesis is correct, then 
pertactin types may not necessarily share the same RFLP type, but this does occur, and wül 
be discussed later. Also, ifpriiA{\) is the oldest Hneage, and thus a more stable genotype, 
then a lower GD value would be expected, with less RFLP types. Conversely, an emerging 
variant of pertactin would result in an expansion of strains and a higher GD value. Yet the 
GD values for pertactin types from both the UK and The Netherlands are similar in that 
prnAiV) exhibits the highest GD (van Loo et al., 1999).
Genotypic diversity values were also calculated for the different pertussis toxin SI and 
combined prnA /ptxA  types. Higher GD values in ptxA{V) isolates indicate successful 
genotypes o î B. pertussis, but these are not statistically significant. Van Loo et al (1999) did 
not present the genotypic diversity in p txA  types and this could have been due to tlie small 
number of isolates sequenced for p txA  from a previous study (n=45) (Mooi et al., 1998), 
and that the GD values calculated may not have shown a significant difference between 
ptxAiV) andptxA(/2) o rptxAi/S), and hence would not have supported tlieir theory of 
vaccine-driven evolution.
As mentioned earlier, associations between RFLP types and pertactin and pertussis toxin 
SI types were investigated. Unfortunately, no data were available from The Netherlands 
concerning any statistical analysis on particular RFLP types with prnA  or p txA  types (van 
Loo et al., 1999). Strong associations between prnA{\) and RFLP-2 or RFLP-4 were 
observed in the UK isolates (114/149), but Dutch data showed a higher frequency of 
prnAi/2) isolates that were RFLP-2 (van Loo et al, 1999). Other significant associations in 
the UK included types RFLP-1 and RFLP-3 exclusively associated with ptxA{X), and 
RFLP-2 associated with ptxA(pl). AH of these associations indicate the overall clonality of 
the B, pertussis population.
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3.4.5 UK Bordeteîla pertussis  sub-set from 1998 to 1999
There is limited value in studying the population dynamics of B. pertussis by pertactin and 
pertussis toxin SI sequence typing, and IS / 002-RFLP analysis in isolation. There is no 
clinical relevance unless the isolates have associated information regarding patient status 
and epidemiological data. Tltis was achieved using epidemiological information from the 
enhanced pertussis surveillance database from CD SC, wliich was established in 1994. 
Therefore, only data from isolates that were collected from the Pertussis Reference 
Laboratory in Manchester between September 1998 and April 1999 could be merged and 
evaluated.
Van Buynder et aL (1999) reported on B. pertussis surveillance in England and Wales 
between 1995 and 1997, using data received from the Office of National Statistics (ONS), 
the Department of Health hospital episodes statistics (HES), and the enhanced pertussis 
surveillance database. Comparing the 90 isolates analysed in this thesis with the laboratory 
reports interrogated by van Buynder and colleagues (1999), the percentages for each age 
group were ahnost identical. For example, the under two montli olds encompassed 23 of 
tlie 90 isolates in this study (25.6%, 95% Cl; 17-36%), compared to 48 of the 200 isolates 
(24%, 95% Cl: 18-31%) reported in die cited paper (van Buynder et aL, 1999). The other 
four age groups differed by no more than three to four percent. Other characteristics that 
were similar between the two data-sets included sex (39/90 males, 43.3% cf. 49.8%, for the 
isolates reported here, and the isolates from van Buynder and co-autiiors (1999), 
respectively), vaccination status (no vaccination in 47 cases, 52.2%, Cl: 41-63% cf. 424/709 
cases, 60%, Cl: 56-63%), complications encountered (22 cases, 24.4%, Cl: 16-35% cf. 
177/709, 25.0%, Cl: 22-28%), hospitalised cases (54, 60.0%, Cl: 49-70% cf. 465/698, 
66.6%, Cl: 63-70%) and mortalities (three deaths in eight months cf. 12 deaths in three 
years=2.7 deatlis in an eight month period) (van Buynder et aL, 1999). The serotype 
distribution differed sUghdy between 1995 to 1997, in that 352/780 isolates (45.1%, Cl: 42- 
49%) were serotype 1,2, 411/780 (52.7%, Cl: 49-56%) were serotype 1,3, and 17/780 
(2.2%, Cl: 1-3%) were serotype 1,2,3 (van Buynder et aL, 1999). The data collected between 
1998 and 1999 for this study did not contain serotype 1,2,3, and isolates have shifted to 
49/90 (54.4%, Cl: 44-65%) of serotype 1,2 and 41/90 (45.6%, Cl: 35-56%) serotype 1,3. 
This is reflected in other past studies, where shifts in serotype expression in B. pertussis 
populations have been reported (Preston, 1988), and recent isolates from 2002 now appear 
to be 96% serotype 1,3 (71/74 isolates serotyped) (TG Harrison, per s. comm.). Overall,
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this comparatively small data-set of 90 B. pe?fussis isohx.es is epidemiologically no different 
from the larger data-set analysed from 1995 to 1997 (van Buynder et aL, 1999).
The otlier typing data generated included the pertactin and pertussis toxin SI gene 
sequence types, and IS / 002-RFLP types. Eighteen different RFLP types were seen in the 
90 isolates compared to six RFLP types from 36 isolates used for the genotypic diversity 
study (3.3.4, page 112), which were chosen from isolates between 1998 and 1999. This 
difference in RFLP types was probably due to the respective number of isolates tested and 
can be corrected when seen as ratios (0.2 types per isolate for the 90 isolate data-set and 
0.17 types per isolate for the 36 isolate data-set). Flowever, this certainly exemplifies how 
the sample size can affect results, analysis and subsequent conclusions. The two most 
dominant RFLP types occur at similar frequencies of both the 90 isolates and tlie 36 from 
the genotypic diversity study, where RFLP-1 occurs at 49/90 (54%) and 23/36 (64%), and 
RFLP-3 in 14/90 (16%) and 7/36 (19%), respectively.
To create a more informed view of the strains currently circulating within the B. pertussis 
population, the two different serotypes, three pertactin types and 18 RFLP types were 
integrated to generate 24 different combined types seen between September 1998 and April 
1999. Similar to the combinedp n iA lp txA  genotypes discussed in 3.4.3 (page 146), four out 
of a theoretical six pruA jptxA  types were seen, compared to 24 out of a tlieoretical 108 
different combined types. This suggests that B. perttissis h  clonal in terms of these 
independent typing data, exemplified by the widespread and stable dominant RFLP types, 
RFLP-1 and RFLP-3. Therefore a mechanism of genetic restriction must be occurring to 
ensure the stabihty and fitness of the J3. population.
This clonality is more pronounced when the 90 isolates were sorted into the 24 combined 
types, as only three types contained most of tlie strains (62/90 or 69% of the isolates). 
These combined types. A, C and P were generated from the following types; serotypes 1,2 
and \,?>,pruA{\) andpr/iA{2), and RFLP-1 and RFLP-3 (see Table 3.14, page 131). It can 
be therefore assumed that these different types when combined, have produced a few 
successful lineages of B. pertussis which have expanded and caused infection and disease in 
the UK population as seen in this brief period between September 1998 to April 1999. This 
indicator of a clonal species is also supported by the many, less frequent combined types 
that have not expanded into the UK B. pertussis population, and are present only in small 
numbers. However, whether these combined types A, C, and P are persistent and stable
154
cannot be deducted from these data, and further studies on B, pertussis populations may 
resolve this.
3.4.6 Associations within the pertussis epidemiological data of the 90 UK 
cases from 1998 to 1999
A primary analysis of the epidemiological data was performed to identify any dependent 
variables and to elkninate any bias when further analysing associations between 
epidemiological and laboratory data. Associations that van Buynder et aL (1999) reported 
for data obtained between 1995 to 1997 were also seen in the data from 1998 to 1999 
presented here. These included a higher hkeHhood of admission to hospital in those under 
two months old, and in the unvaccinated, in terms of number of vaccine doses received. 
The data here also showed an association between pertussis cases encountering 
compHcations, especially apnoea, and admission to hospital. These associations can be 
rooted back to the under two month old age group, where this ‘risk’ group is evidently one 
requiring hospital treatment for the compHcations of pertussis, and yet this group is not 
eUgible for the receipt of pertussis vaccine under the current UK schedule of 2, 3, and 4 
months. This over-burdened cohort has recently been addressed (von Konig et at., 1995); 
(Groweroft and Britto, 2002) and, following a study showing pertussis transmission from 
contacts to babies in five paediatric intensive care units (PlCUs), a pertussis vaccine 
booster for 4 to 5 year olds was introduced in the UK, in November 2001 (Crowcroft et aL, 
2003). Future analysis concerning burden of pertussis of this vulnerable group needs to be 
addressed, to assess whether the booster is improving the situation, or if further measures, 
such as an additional pertussis booster is required for adolescents or women at child­
bearing age.
Geographical regions in the UK also gave two significant associations; one with the 
compHcation pneumonia, and the other with gender. Studying the breakdown of data 
however, revealed that the cases seem to be random and, due to this random nature, the 
proportions between regions can vary markedly. A significant probabHity was therefore 
generated, and if a larger data-set was analysed, these associations would possibly become 
insignificant. Borderline associations with the regions were seen with the following 
outcomes: typical cHnical symptoms, encountering any compHcation, apnoea and hospital 
admission. These data, even after a multivariable analysis, were hard to interpret, probably 
due to the low number and random distribution of cases.
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Those presenting with typical clinical symptoms of pertussis were less hlrely than those not 
presenting with typical clinical symptoms to have pneumonia. This association was 
independent of age group, and there were only nine pneumonia cases seen in the total of 
90. An association between deaths and absence of typically clinical symptoms was also 
seen; of tlie three cases that died, two were under two months and the third case was in the 
two to five month age group. Neonates generally do not present with typical symptoms of 
pertussis (von Konig et aL, 2002). The England and Wales enhanced pertussis surveillance 
database derives data from questionnaires, and more emphasis may be directed to the 
complication pneumonia or death, than to whether a case has typical clinical symptoms.
The most unusual association was between gender and hospital admission, as females were 
more Hltely to be admitted than males. However, this may have been affected by various 
facets; i) a skewed proportion of females to males (51:39 respectively); ii) a higher 
proportion of females in the younger age group (15:8, female:male) and; iii) reports of 
morbidity and mortality rates being higher in females tlian males are documented 
(Edwards et aL, 1999). So altliough van Buynder et at. (1999) reported no gender differences 
with hospital admissions, an association was seen in this small data-set of 90 isolates from 
1998 to 1999, although this was not significant in the multivariable logistic regression 
analysis (P=0.088, Table 3.12, page 128). Overall, the epidemiological data of these 90 cases 
seemed to reflect earlier findings of pertussis surveillance in England and Wales (van 
Buynder 1999).
3.4.7 Association between epidemiological data and typing results of the 90 
UK Bordetella pertussis  isolates from 1998 to 1999
In the single variable analyses, three statistically significant associations were found 
between the epidemiological data and typing results, where two of these associated the 
severity measure of hospital admission with eitlier serotype or pertactin gene type. Serotype
1.2 isolates were nearly four times more lilrely than serotype 1,3 to be associated with an 
admission to hospital. Similar results were seen in a previous study in the UK, with 
pertussis cases between 1995 and 1997, where serotype 1,2 was twice as hlcely as serotype
1.3 to be associated with hospitalised cases (van Buynder et aL, 1999). The other statistical 
association was that prnA{l) isolates were nearly four times more Hlcely to be seen in 
hospital admissions than pruAipL). These two observations with serotype 1,2 andy?mH(l) 
may not be independent, as there was a strong association between serotype and pertactin 
type, where serotype 1,2 isolates were seen witli pm A (\) isolates, and serotype 1,3 with
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prnAp2). As serotype 1,2,3 was not seen, andprfiA(p) was observed in only two isolates, 
associations for these types could not be determined. The mechanism behind the 
association between serotype and pertactin has not been deduced; genome analysis and 
expression studies concerning the regulation of tlie related genes may reveal this.
The third significant association involved tlie geographical regions with RFLP types. 
Although RFLP-3 isolates were only found in four of the nine regions, the large number of 
parameters generate many degrees of freedom and high values, resulting in small P 
values. The value is also dependent on the number of isolates analysed, so this sub-set of 
90 was not sufficient to calculate associations for the aspects mentioned above, and more 
isolates are required for a more tliorough analysis.
Generally, statistical significance is measured at the 95% confidence level (P=0.05) to 
reduce the number of false positives, or in this case, false associations. But with this strict 
confidence hmit some associations may be overlooked, particularly in a small data-set. 
Therefore, any associations with a P value of 0.20 or under were noted as borderline 
significance, and were treated as such. If more data had been available, these borderline 
associations might have been ascertained at a more confident level. Examples of these 
borderline associations include; vaccination status with serotype, geographical regions with 
combined types, those encountering any complication with combined type A isolates, and 
the conjunctivitis case with combined type C. Other borderline associations link the under 
two month age group with serotype \ ,2,prnA{\) and combined type A. An earlier study in 
the UK showed a similar association, focusing on the serotype 1,3 proportion between the 
three to 12 month age group (38%) and the 12 to 24 month age group (74%)
(Syedabubakar et aL, 1995). The more recent study by van Buynder et aL (1999) did not 
reveal any significant associations between serotype and age distribution.
Trend analysis was also performed on tlie time-related aspects, age cohorts and the interval 
of isolation collection (temporal trend). The age groups showed a downward trend in the 
distribution of serotype 1,2 andprnA(\) isolates from under two months to the six to 11 
month age group. These isolate types tlien recovered slightly in the one to four, and five 
years and above age groups. This fall and rise in prnA{\) isolates through age cohorts has 
also been seen in The Netherlands (Mooi et aL, 1998), although the actual proportions were 
different to those seen in the UK (for the under two montlis in the UK, 15/23 (65%) were 
prnApp), and the under three months group in The Netherlands, 22% were prfiA{\)) Mooi 
et aL (1998). Mooi et aL (1998) also showed that tlie age groups can be converted into the
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vaccination status of individuals as they receive the pertussis vaccine at 2, 3 and 4 months 
of age, with an additional booster at 11 months. The UK pertussis vaccine is also given at 
2, 3 and 4 months of age (the booster for 4-5 year olds was introduced after the collection 
of isolates in November 2001), and the vaccine coverage was 94% in 1999 in those up to 
24 months old. Hence, the following can be deduced; individuals under two months are 
not immune, tliose between two and five months are partially immunised, those between 
six and 11 montlis, and from one to four years are fully immunised and, from five years 
onward, individuals have a waning immunity to pertussis infection. Therefore, in the UK 
most infections in unvaccinated babies are caused by serotype 1,2 and pr>iA{l) isolates and, 
as individuals get older, their pertussis vaccination course would be complete, and hence 
their immune response against 13. pertussis should be at their highest. At this point, the 
serotype l,2/pm H (l) infections decrease in the one to four year age group (Table 3.21 and 
3.22, page 140). As the individuals grow older, tlieir immunity to pertussis wanes and 
serotype \,2fpr/tAiV) isolates cause an increased number in infections. In The Netherlands, 
this was observed and interpreted as;
“ ... the notion that vaccine-induced immunity againstpmAipC) strains is stronger 
than that againstpniA(L2) andprnA(p) strains . . .” .
(Mooi et aL, 1998)
The Aveiitis Pasteur WCV used in the UK contains two pruApp) strains and, thus, if 
agreeing with Mooi et aL (1998) observations, any individual who received the vaccine may 
have a strong vaccine-induced immunity against prnAiV) and may be more Hlcely to acquire 
a non-vaccineprnA. type of pertussis infection. Therefore tliis trend of pertactin type is not 
affected by the vaccine constituents per se, but by the Hnmune status of the individual. This 
faU and rise through the age groups can also be observed in the notification data of 
pertussis (Notifications of Infectious Diseases, 2003). However, both trends of serotype 
and pertactin type across age groups are only of borderHne significance, and thus should 
only be seen as an observation and not as evidence of a definite association.
The other trend analysis regarding the coHection period with either serotype or pertactin 
type, was also not significant (score test for trend of odds at P=0.497 and 0.554, 
respectively). The proportion of both serotype 1,2 andpruAiV) isolates dropped from 4 /8  
(50%) in September 1998, to 5/13 (38%) in March 1999. As the last isolate was coUected 
on the 2"^  ^April 1999, this one isolate could not vaHdate whether this shift was true. 
However, isolates from 2002, which were used for the pertactin and pertussis toxin data 
(3.3.1 and 3.3.2, pages 105 and 106, respectively), give a more pronounced reduction in 
serotype 1,2 andprnAiV), to just 1/22 isolates (5%), and epidemiological data from the
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enhanced laboratory surveillance shows the dramatic decHne of serotype 1,2 isolates in 
1999 to under 10% (Figure 3.10, page 161) (Immunisation Division, CDSC, FIPA, 2004b). 
Reasons for this dramatic shift in serotype and pertactin type are unloiown, altliough it may 
be due to a change in vaccination policy, such as the change of WCV in 1996 to Aventis 
Pasteur, the temporary introduction of aceUular pertussis vaccine in Autumn 1999, and the 
booster in pre-school children in November 2001, wliich aU contain prnA{\) strains 
(serotypes not Imown). Another factor that could have caused this shift in proportions is a 
decrease in vaccine quality and/or efficacy, but this is highly unhkely because the UK has 
not seen an overall increase or resurgence of pertussis, which would be indicative of 
inadequate vaccine manufacture. A further point to address concerns the shift in serotype 
distribution, wliich has been observed throughout the decades in the UK, via sHpped- 
strand mispaiting, and this probably reflects a natural shift in the B. pertussis population.
Although the two pruAip) isolates were not used in the multivariable logistic regression 
analysis, they were from cases under three months old, who had typical clinical symptoms, 
developed apnoea and were admitted to hospital. These factors, although not statistically 
significant, might point to a more virulent strain of B. pertussis, Once more, additional 
isolates are required, especially those of type prnAQ), to elucidate whether these 
associations could be significant. If so, it may be supportive of a previously described 
hypothesis (Mooi et aL, 1999; Gzyl et aL, 2002). These authors suggested that an increase of 
prnAÇ>) isolates may affect tlie epidemiology of pertussis, and this may be one reason why 
The Netherlands and Finland are seeing a resurgence, and Poland is not; approximately 
65/133 (49%) and 5/43 (12%) ofprnAQ) isolates, compared to 0/19 (0%), respectively 
(Gzyl et aL, 2002).
This unique set of isolates, incorporating epidemiological data and laboratory typing results, 
albeit small, was stkl able to identify two significant associations and other borderline 
observations. Previous studies have either focused on epidemiology and surveillance using 
cHnical data (de Melker et aL, 2000a; Guris et aL, 1999b; Skowronsld et aL, 2002), or genetic 
diversity and outbreak investigations using laboratory typing (de Moissac et aL, 1994; 
Syedabubakar et al, 1995; van Loo et aL, 1999). This is unsatisfactory for the scientific 
community, as more valuable data can be generated using an integrated approach, 
especially in countries where pertussis resurgence occurs, and this could reveal a better 
picture o£ B. pertussis dynamics. Knowledge gained from such studies could have important 
vaccine implications, whether in formulating the composition or the schedule. Wltli such 
qualitative and detailed data, overinterpretation can be a problem, and associations that are
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not significant may get too much emphasis. More significant associations may have been 
identified if there were more isolates in this data-set, as borderline associations need to be 
verified. The inclusion of more isolates may still not be useful when analysing RFLP and 
the combined types however, as these methods give higher discrimination, and an increase 
o f types can impair interpretation when used with epidemiological data. However, 1S1002- 
RFLP analysis and combined types do reveal a more dynamic population of B. pertussis than 
the individual serotype, pertactin and pertussis toxin gene types.
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4 Characterisation of Bordetella pertussis isolates
from Missouri, USA
162
The study of B. pertussis isohiX&s from the UK (Chapter 3) investigated any epidemiological 
trends and long-term shifts in the bacterial population and the influence, if any, of the 
introduction and widespread use of the pertussis vaccine. The UK has not undergone an 
apparent resurgence of pertussis, unlike many other countries with high vaccination 
coverage. This chapter focuses on a smaller set of isolates from Missouri, USA, to question 
whether any short-term shifts could be identified, using a combined typing approach.
Since the late 1980s, the reported incidence of pertussis has increased in the state of 
Missouri, USA, from 0.46 cases per 100,000 in 1984 to a peak o f 2.77 per 100,000 in 1989. 
Cases remained high with a recent incidence of 1.91 per 100,000 in 2001 (Missouri 
Department of Health and Senior Services, 2002). In 1999 there were 1.38 cases per 
100,000 in Missouri (75 cases), peaking in June to July and September to October. The rise 
in June and July coincided with an increase of isolates from Kansas City sent to the 
Missouri State Public Health Laboratory (Figure 4.1, page 164). In Missouri, culture- 
positive cases are used in conjunction with the CDC clinical criteria to report a pertussis 
case (Guris et aL, 1999a), but epidemiological typing of B. peiiussis h  not currently 
performed.
4.1 Strategy
The clinical isolates obtained from Missouri, described in Appendix 3, Part D, were 
investigated using the following methods; serotyping, sequencing of the pertactin and 
pertussis toxin SI genes, IS/992-RFLP analysis and PFGE with ^ba l. No strains used in 
the USA vaccine preparations were available for examination. However, and p txA  
data from a previous USA study describing specific vaccines and strains will be referred to 
in the discussion (Cassiday et al.^  2000). The index of discrimination and associations 
between typing methods were assessed. Data gathered here were then compared to the UK 
data from Chapter 3 and other reported countries, and geographical differences and 
vaccine regimens are discussed.
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Forty-six B. pertussis isolates were sent to RSIL for analysis, one of which was subsequently 
identified as B. parapertussis and therefore excluded from this study. One other isolate was 
excluded because it was recovered from Kansas City five weeks after the last isolate from 
Kansas City; tlierefore it could not be determined whether it was an outbreak isolate or an 
unrelated isolate. The remaining 44 isolates were grouped into three subsets; (i) ten isolates 
from Kansas City, which were geographically and temporally clustered within seven weeks 
between June and July 1999 (referred to as “Kansas City” isolates throughout this chapter); 
(ii) 19 recent isolates that were epidemiologicaUy-unrelated and were collected between 
1996 and 2001 and; (iii) 15 earlier isolates also epidemiologicaUy-unrelated, coUected 
between 1984 and 1989. Isolates from 1990-1995 were not avaUable.
Sequences comprising over 90% of tlieprnA  coding region were investigated in six of the 
isolates, and were deposited in GenBank via the Bankit submission entry 
(http://www.ncbi.nlm.nih.gov/BankIt/index.html). This was to determine the level of 
sequence variation outside the two known polymorphic regions 1 and 2 of the pertactin 
gene (Mooi et ai, 1998), and required ampUfication and subsequent sequencing of tlie three 
overlapping PCR fragments described in 2.5.4.1 (page 68). The six isolates were chosen for 
their isolation date and pruA fp txA  combination. Region 1 and region 2 (Figure 1,2, page 
16), were sequenced for the remaining 38 strains, foUowing ampUfication of a 1428 bp 
fragment with primers AF and BR.
4.2 M ethods
The foUowing techniques used hi this chapter are described in Chapter 2; serotyphig, 
pertactki and pertussis toxin SI subunit gene typing (PCR ampUfication using prhner pairs 
AF and BR, and SF and SR, respectively), ÏS/002-RFLP analysis and PFG E ushig Xbal.
The serotyping scheme used for tliis tliesis differs from the scheme used in die USA, where 
three agglutinogens are tested, compared to six (Robinson et ai,y 1989). The discriminatory 
indices were calculated using die formula expressed in section 2.8.3 (page 99).
4.3 Results
4.3.1 Serotyping results
Serotype 1,3 was predominant, occurring in 39/44 (89%) of the isolates, and two isolates 
were serotype 1,2,3 and one was serotype 1,2 (Table 4.1, page 167). Two isolates gave 
discrepant results when performing the sUde-agglutination test. Serotyping was attempted
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on these two isolates a furthei' tliree times using fresh culture each time and resulted in the 
expression of agglutinogen 1 only in MO-301, and isolate MO-404 auto-agglutinated. All 
ten of the “Kansas City” isolates were serotype 1,3.
4.3.2 Polymorphism in the pertactin and pertussis toxin SI genes
The nucleotide sequences of four of the six strains for which over 90% of the pruA  coding 
region was determined (Table 4.2, page 167), were identical to the previously designated 
pertactin types prnA(y)yprnA(^ o rprnA(6)y (GenBank accession numbers AJ011091, 
AJ011092 or A Jl32095, respectively) (Mooi et al.y 1998). The nucleotide sequences from 
two isolates with the novel pertactin type prnA(^) found in tliis study were identical (100% 
for 2817 nucleotides). This novel typeprnA.(^) contains seven GGxxP repeats (GGAVP)^, 
(GGFGP)s in region 1, and five PQP repeats in region 2, and differs from prnA (^  by the 
presence of an extra GGFGP repeat (Figure 4.2, page 168). This novel pertactin type had 
not been previously reported and sequences from both strains were deposited in GenBank 
under the following accession numbers; AF218785 (strain MO-908) and AF456356 (strain 
MO-121).
Region 1 and region 2 were sequenced for all 44 isolates. N o variation was seen in region 2 
and all isolates contained the nucleotide sequence encoding five PQP repeats. The point 
mutation at approximately 150 nucleotides upstream of region 2 that differentiates pf'uAÇ) 
fromprnA{\)y previously described by Mooi et aL (1998), was not found. Tliree previously 
described prnA  variants,/>/v?At(l),^r/L4(2), andpt'nA(6)y were recovered from the isolates 
tested. The novel variant, designated prnA(9)y was seen in two of the 44 isolates.
Thirty-four of the 44 isolates were sorted into temporal groups labelled “Early” (1984- 
1989) and “Recent” (1996-2001). All four prnA  types were found in 1984-1989, nine of the 
15 isolates wereprnA(\), three were prnAi^y one prnAip) and two were of the novel type 
p m A ^ )  (Table 4.1, page 167). The frequency ofp r n A ^  isolates increased from 3/15 
(20%) isolates in 1984-1989 to 18/19 (95%) isolates in 1996-2001, with the remaining 
isolate from 1996-2001 hemgprnA{\). This shift from predominantly prnA{V) topmAi^Z) is 
significant even in such small numbers (Fisher’s exact test P=0.001). The ten isolates from 
the suscept outbreak cluster “Kansas City” were aUprnA i^.
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Table 4.1. Distribution o f serotype, pertactin and pertussis toxin SI 
subunit variants from 44 Bordetella pertu ssis  isolates from Missouri,
USA, by isolation period
Typing m ethod 
and type
Y ear period
“Early”, 1984- 
1989,11=15
“Recent”, 1996— 
2001, n=19
“Kansas City”, 
1999, n=10'
Serotvoe
1 only 1
1,2 1
1,3 12 17 10
1,2,3 1 1
auto-agglutination 1
Pertactin gene type
pmA{\) 9 1
3 18 10
pmA{G) 1
t)rnA(9) 2
Pertussis toxin SI subunit gene type
ptxA(l) 12 18 10
ptxA(2) 3 1
Pertactin/Pertussis toxin SI subunit alleles
prnA{l)/ptxA{l) 7
prnAiX)! ptxA{2) 2 1
prnA{7)l ptxA{\) 3 18 10
prnA{(i)l p txA (^ 1
pf'nA{9)! ptxA{\) 2
Values are the number of strains. The “Kansas City” data are in grey, as the isolates were not 
included in the temporal analysis.
Table 4.2. Details o f the six Bordetella pertu ssis  isolates from Missouri, 
USA, for which over 90% of the coding region o f the pertactin gene was
determined
Isolate Year
isolated
Pertactin 
gene type
GenBank Accession number 
of pertactin gene sequence
Pertussis toxin 
SI gene type
MO-20 1984 prnA{G) AF456357 ptxA{2)
MO-814 1984 prnA{\) AF456355 ptxA{V)
MO-90B 1988 prnA{9) AF218785 ptxA{\)
MO-121 1989 prnA(p}) AF456356 1 ptyA{\)
MO-1440 1999 prnA{2) AF456358 ptxA{V)
MO-1503 1999 prnA{l) AF456359 ptxA{2)
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Figure 4.2. Nucleic acid alignment of the Bordetella pertu ssis  pertactin
gene types, pm A {2) and pm A {9)
C O N S E N S U S  : C G C G G T G C G G G C A TG G C G G G C G TC TG C TC TC C A C C T G G C A TC C A A TG A A C
N
A J 0 1 1 0 9 2  p r n A ( 2 ) :  
A F 4 5 6 3 5 6  p r n A { 9 ) : 
A F 2 1 8 7 8 5  p r n A ( 9 ) :
---------------------------------------GGGCC^CTGCTCÏCCACCTGGCATCCAATGAAC
CGCGGTGCGGGCATGGCGGGCGTCTGCTCTCCACCTGGCATCCAATGAAC
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) i 
A F 4 5 6 3 5 6  p r n A { 9 ) : 
A F 2 1 8 7 8 5  p r n A { 9 )  ;
A TG T C T C T G TC A C G C A TTG TC A A G G C G G C G C C C C TG C G C C G C A C C A C G C T
M S L S R I V K A A P L R R T T L
ATGTCTCTGTCACGCATTGTCAAGGCGGCGCCCCTGCGCCGCACCACGCT 
ATGTCTCTGTCACGCATTGTCAAGGCGGCGCCCCTGCGCCGCACCACGCT 
------------------------------------------------AAGGCGGCGCCCCTGCGCCGCACCACGCT
56
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 ) i 
A F 4 5 6 3 5 6  p r n A { 9 ) ; 
A F 2 1 8 7 8 5  p r n A { 9 )  :
G G CC A TG G CG CTG G G CG CG CTG G G CG CC G C C CC G G CG G C G C ATG C CG AC T
A M A L G A L G A A P A A H A D
GGCCATGGCGCTGGGCGCGCTGGGCGCCGCCCCGGCGGCGCATGCCGACT
GGCCATGGCGCTGGGCGCGCTGGGCGCCGCCCCGGCGGCGCATGCCGACT
GGCCATGGCGCTGGGCGCGCTGGGCGCCGCCCCGGCGGCGCATGCCGACT
106
CONSENSUS
A J 0 1 1 0 9 2  p r n A { 2 )  
A F 4 5 6 3 5 6  p r n A ( 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
G G A A C A A C C A G T C C A TC G TC A A G A C C G G TG A G C G C C A G C A T G G C A TC C A T
W N N Q S I V K T G E R Q H G I H
GGAACAACCAGTCCATCGTCAAGACCGGTGAGCGCCAGCATGGCATCCAT
GGAACAACCAGTCCATCGTCAAGACCGGTGAGCGCCAGCATGGCATCCAT
GGAACAACCAGTCCATCGTCAAGACCGGTGAGCGCCAGCATGGCATCCAT
156
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  ; 
A F 4 5 6 3 5 6  p r n A { 9 )  
A F 2 1 8 7 8 5  p r n A { 9 ) ;
A TC C A G G G C TC C G A C C C G G G C G G C G TA C G G A C C G C C A G C G G A A C C A C C A T
I Q G S D P G G V R T A S G T T I
ATCCAGGGCTCCGACCCGGGCGGCGTACGGACCGCCAGCGGAACCACCAT
ATCCAGGGCTCCGACCCGGGCGGCGTACGGACCGCCAGCGGAACCACCAT
ATCCAGGGCTCCGACCCGGGCGGCGTACGGACCGCCAGCGGAACCACCAT
2 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  ■. 
A F 4 5 6 3 5 6  p r n A ( 9 ) ;  
A F 2 1 8 7 8 5  p r n A ( 9 ) ;
C A A G G TA A G C G G C C G TC A G G C C C A G G G C A TC C TG C TA G A A A A TC C C G C G G
K V S G R Q A Q G I L L E N P A
CAAGGTAAGCGGCCGTCAGGCCCAGGGCATCCTGCTAGAAAATCCCGCGG
CAAGGTAAGCGGCCGTCAGGCCCAGGGCATCCTGCTAGAAAATCCCGCGG
CAAGGTAAGCGGCCGTCAGGCCCAGGGCATCCTGCTAGAAAATCCCGCGG
2 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) ;  
A F 4 5 6 3 5 6  p r n A ( 9 ) ; 
A F 2 1 8 7 8 5  p r n A ( 9 ) :
C C G A G C T G C A G TTC C G G A A C G G C A G TG TC A C G TC G TC G G G A C A G T TG T C C
A E L Q F R N G S V T S S G Q L S
CCGAGCTGCAGTTCCGGAACGGCAGTGTCACGTCGTCGGGACAGTTGTCC
CCGAGCTGCAGTTCCGGAACGGCAGTGTCACGTCGTCGGGACAGTTGTCC
CCGAGCTGCAGTTCCGGAACGGCAGTGTCACGTCGTCGGGACAGTTGTCC
306
CONSENSUS :
A J 0 1 1 0 9 2  p r n A { 2 )  : 
A F 4 5 6 3 5 6  p r n A { 9 )  : 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
G A C G A TG G C A TC C G G C G C TT TC T G G G C A C C G TC A C C G TC A A G G C C G G C A A
D D G I R R F L G T V T V K A G K
GACGATGGCATCCGGCGCTTTCTGGGCACCGTCACCGTCAAGGCCGGCAA
GACGATGGCATCCGGCGCTTTCTGGGCACCGTCACCGTCAAGGCCGGCAA
GACGATGGCATCCGGCGCTTTCTGGGCACCGTCACCGTCAAGGCCGGCAA
356
CONSENSUS :
A J 0 1 1 0 9 2  p r n A ( 2 )  : 
A F 4 5 6 3 5 6  p r n A ( 9 )  : 
A F 2 1 8 7 8 5  p r n A { 9 )  :
G C TG G TC G C C G A TC A C G C C A C G C TG G C C A A C G TTG G C G A C A C C TG G G A C G
L V A D H A T L A N V G D T W D
GCTGGTCGCCGATCACGCCACGCTGGCCAACGTTGGCGACACCTGGGACG
GCTGGTCGCCGATCACGCCACGCTGGCCAACGTTGGCGACACCTGGGACG
GCTGGTCGCCGATCACGCCACGCTGGCCAACGTTGGCGACACCTGGGACG
4 06
CONSENSUS:
A J 0 1 1 0 9 2  p r n A { 2 )  : 
A F 4 5 6 3 5 6  p r n A { 9 )  : 
A F 2 1 8 7 8 5  p r n A { 9 )  :
A C G A C G G C A TC G C G C TC TA TG TG G C C G G C G A A C A G G C C C A G G C C A G C A TC
D D G I A L Y V A G E Q A Q A S I
ACGACGGCATCGCGCTCTATGTGGCCGGCGAACAGGCCCAGGCCAGCATC
ACGACGGCATCGCGCTCTATGTGGCCGGCGAACAGGCCCAGGCCAGCATC
ACGACGGCATCGCGCTCTATGTGGCCGGCGAACAGGCCCAGGCCAGCATC
456
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Figure 4.2. N u cle ic  acid alignm ent o f the Bordetella pertussis pertactin gene types,
pmA(^) and /7m 4(9), continued
CONSENSUS :
A J 0 1 1 0 9 2  p r n A ( 2 ) :  
A F 4 5 6 3 5 6  p r n A ( 9 )  :
G C C G A C A G C A C C C TG C A G G G CG CTG G C G G CG TG C A G A TC G A G C G C G G C G C
A D S T L Q G A G G V Q I E R G A
GCCGACAGCACCCTGCAGGGCGCTGGCGGCGTGCAGATCGAGCGCGGCGC
GCCGACAGCACCCTGCAGGGCGCTGGCGGCGTGCAGATCGAGCGCGGCGC
A F 2 1 8 7 8 5  p r n A ( 9 ) :  GCCGACAGCACCCTGCAGGGCGCTGGCGGCGTGCAGATCGAGCGCGGCGC
506
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  . 
A F 4 5 6 3 5 6  p r n A ( 9 )  : 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
CAATGTCACGGTCCAACGCAGCGCCATCGTCGACGGGGGCTTGCATATCG
N V T V Q R S A I V D G G L H I
CAATGTCACGGTCCAACGCAGCGCCATCGTCGACGGGGGCTTGCATATCG
CAATGTCACGGTCCAACGCAGCGCCATCGTCGACGGGGGCTTGCATATCG
CAATGTCACGGTCCAACGCAGCGCCATCGTCGACGGGGGCTTGCATATCG
556
CONSENSUS
A J 0 1 1 0 9 2  p r n A ( 2 )  
A F 4 5 6 3 5 6  p r n A ( 9 )  
A F 2 1 8 7 8 5  p r n A [ 9 )
GCGCCCTGCAGTCATTGCAGCCGGAAGACCTTCCGCCCAGCCGGGTGGTG
G A L Q S L Q P E D L P P S R V V
GCGCCCTGCAGTCATTGCAGCCGGAAGACCTTCCGCCCAGCCGGGTGGTG
GCGCCCTGCAGTCATTGCAGCCGGAAGACCTTCCGCCCAGCCGGGTGGTG
GCGCCCTGCAGTCATTGCAGCCGGAAGACCTTCCGCCCAGCCGGGTGGTG
606
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 ) :  
A F 4 5 6 3 5 6  p r n A ( 9 )  : 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
CTGCGCGACACCAACGTGACCGCCGTGCCCGCCAGCGGCGCGCCCGCGGC
L R D T N V T A V P A S G A P A A
CTGCGCGACACCAACG'i'GACCGCCGTGCCCGCCAGCGGCGCGCCCGCGGC
CTGCGCGACACCAACGTGACCGCCGTGCCCGCCAGCGGCGCGCCCGCGGC
CTGCGCGACACCAACGTGACCGCCGTGCCCGCCAGCGGCGCGCCCGCGGC
656
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 )  : 
A F 4 5 6 3 5 6  p r n A ( 9 )  ;
GGTGTCTGTGTTGGGGGCCAGTGAGCTTACGCTCGACGGCGGGCACATCA
V S V L G A S E L T L D G G H I
GGTGTCTGTGTTGGGGGCCAGTGAGCTTACGCTCGACGGCGGGCACATCA
GGTGTCTGTGTTGGGGGCCAGTGAGCTTACGCTCGACGGCGGGCACATCA
A F 2 1 8 7 8 5  p r n A { 9 ) : GGTGTCTGTGTTGGGGGCCAGTGAGCTTACGCTCGACGGCGGGCACATCA
7 0 6
C O N S E N S U S  : C C G G C G G 6C G G G C A 6C 6G 6G 6T G G C G G C C A TG C A A G G G G C G G TC G T G C A T  
T G G R A A G V A A M Q G A V V H  
A JO 1 1 0 9 2  p r n A ( 2 ) :  CCGGCGGGCGGGCAGCGGGGGTGGCGGCCATGCAAGGGGCGGTCGTGCAT 
A F 4 5 6 3 5 6  p r n A { 9 ) : CCGGCGGGCGGGCAGCGGGGGTGGCGGCCATGCAAGGGGCGGTCGTGCAT 
A F 2 1 8 7 8 5  p r n A ( 9 ) : CCGGCGGGCGGGCAGCGGGGGTGGCGGCCATGCAAGGGGCGGTCGTGCAT
7 5 6
CONSENSUS : C TG C A G C G C G C G A CG ATAC G G CG CG G G G AC G C G C C TG C C  
L Q R A T I R R G D A P A  
A J 0 1 1 0 9 2  p r n A ( 2 ) : CTGCAGCGCGCGACGATACGGCGCGGGGACGCGCCTGCC 
A F 4 5 6 3 5 6  p r n A ( 9 ) : CTGCAGCGCGCGACGATACGGCGCGGGGACGCGCCTGCC 
A F 2 1 8 7 8 5  p r n A ( 9 ) : CTGCAGCGCGCGACGATACGGCGCGGGGACGCGCCTGCC
CONSENSUS
A J 0 1 1 0 9 2  p r n A { 2 )  
A F 4 5 6 3 5 6  p r n A { 9 )  
A F 2 1 8 7 8 5  p r n A { 9 )
CONSENSUS
A J 0 1 1 0 9 2  p r n A { 2 )  
A F 4 5 6 3 5 6  p r n A { 9 )  
A F 2 1 8 7 8 5  p r n A { 9 )
G G CG G TG CG G T  
G G A V
GGCGGTGCGGT
GGCGGTGCGGT
GGCGGTGCGGT
TC C C  G G C G G TG C G G TTC C C  G G C G G C TTC G G TC C C  G G C G G C TTC G G TC C C  G 
P G G A V P  G G F G P  G G F G P
TCCC GGCGGTGCGGTTCCC GGCGGCTTCGGTCCC GGCGGCTTCGGTCCC G 
TCCC GGCGGTGCGGTTCCC GGCGGCTTCGGTCCC GGCGGCTTCGGTCCC G 
TCCC GGCGGTGCGGTTCCC GGCGGCTTCGGTCCC GGCGGCTTCGGTCCC G
G C G G C TTC G G TC C C  G G C G G C TTC G G TC C C  G G C G G C TTC G G TC C C  
G G F G P  G G F G P  G G F G P
GCGGCTTCGGTCCC GGCGGCTTCGGTCCC ----------------------------------
GCGGCTTCGGTCCC GGCGGCTTCGGTCCC GGCGGCTTCGGTCCC 
GCGGCTTCGGTCCC GGCGGCTTCGGTCCC GGCGGCTTCGGTCCC
G T C C T C  
V  L
GTCCTC
GTCCTC
GTCCTC
8 0 6
8 5 6
906
CONSENSUS : GACGGCTGGTATGGCGTGGACGTATCGGGCTCCAGCGTGGAGCTCGCCCA 
D G W Y G V D V S G S S V E L A Q  
A JO 1 1 0 9 2  p r n A ( 2 ) :  GACGGCTGGTATGGCGTGGACGTATCGGGCTCCAGCGTGGAGCTCGCCCA 
A F 4 5 6 3 5 6  p r n A 19) :  GACGGCTGGTATGGCGTGGACGTATCGGGCTCCAGCGTGGAGCTCGCCCA 
A F 2 1 8 7 8 5  p r n A ( 9 ) :  GACGGCTGGTATGGCG GGACGTATCGGGCTCCAGCGTGGAGCTCGCCCA
956
169
Figure 4.2. N u cle ic  acid alignm ent o f the Bordetella pertactin gene types,
pmA(^) and pmu4(9), continued
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) ;  
A F 4 5 6 3 5 6  p r n A { 9 )  ;
G TCG ATCG TC G A G G C G C C G G A G C TG G G C G C C G C AA TC CG G G TG G G CC G C G
S I V E A P E L G A A I R V G R
GTCGATCGTCGAGGCGCCGGAGCTGGGCGCCGCAATCCGGGTGGGCCGCG
GTCGATCGTCGAGGCGCCGGAGCTGGGCGCCGCAATCCGGGTGGGCCGCG
A F 2 1 8 7 8 5  p r n A { 9 ) : GTCGATCGTCGAGGCGCCGGAGCTGGGCGCCGCAATCCGGGTGGGCCGCG
1 0 0 6
CONSENSUS :
A J 0 1 1 0 9 2  p r n A { 2 )  
A F 4 5 6 3 5 6  p r n A ( 9 )  
A F 2 1 8 7 8 5  p r n A { 9 )
G C G C C A G G G TG A C G G TG TC G G G C G G C A G C TTG TC C G C A C C G C A C G G C A A T
G A R V T V S G G S L S A P H G N
GCGCCAGGGTGACGGTGTCGGGCGGCAGCTTGTCCGCACCGCACGGCAAT
GCGCCAGGGTGACGGTGTCGGGCGGCAGCTTGTCCGCACCGCACGGCAAT
GCGCCAGGGTGACGGTGTCGGGCGGCAGCTTGTCCGCACCGCACGGCAAT
1 0 5 6
CONSENSUS :
A J 0 1 1 0 9 2  p r n A { 2 )  ; 
A F 4 5 6 3 5 6  p r n A ( 9 )  \ 
A F 2 1 8 7 8 5  p r n A ( 9 )  ;
G T C A TC G A G A C C G G C G G C G C G C G TC G C TTTG C G C C TC A A G C C G C G C C C C T
V I E T G G A R R F A P Q A A P L
GTCATCGAGACCGGCGGCGCGCGTCGCTTTGCGCCTCAAGCCGCGCCCCT
GTCATCGAGACCGGCGGCGCGCGTCGCTTTGCGCCTCAAGCCGCGCCCCT
GTCATCGAGACCGGCGGCGCGCGTCGCTTTGCGCCTCAAGCCGCGCCCCT
11 0 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 )  . 
A F 4 5 6 3 5 6  p r n A ( 9 )  : 
A F 2 1 8 7 8 5  p r n A { 9 )  :
G TC G A TC A C C TTG C A G G C C G G C G C G C A TG C C C A G G G G A A A G C G C TG C TG T  
S I T L Q A G A H A Q G K A L L
GTCGATCACCTTGCAGGCCGGCGCGCATGCCCAGGGGAAAGCGCTGCTGT
GTCGATCACCTTGCAGGCCGGCGCGCATGCCCAGGGGAAAGCGCTGCTGT
GTCGATCACCTTGCAGGCCGGCGCGCATGCCCAGGGGAAAGCGCTGCTGT
1 1 5 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 ) i 
A F 4 5 6 3 5 6  p r n A { 9 ) ; 
A F 2 1 8 7 8 5  p r n A { 9 ) ;
A C C G G G TC C TG C C G G A G C C C G TG A A G C TG A C G C TG A C C G G G G G C G C C G A T
Y R V L P E P V K L T L T G G A D
ACCGGGTCCTGCCGGAGCCCGTGAAGCTGACGCTGACCGGGGGCGCCGAT
ACCGGGTCCTGCCGGAGCCCGTGAAGCTGACGCTGACCGGGGGCGCCGAT
ACCGGGTCCTGCCGGAGCCCGTGAAGCTGACGCTGACCGGGGGCGCCGAT
1 2 0 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 ) ;  
A F 4 5 6 3 5 6  p r n A ( 9 ) : 
A F 2 1 8 7 8 5  p r n A { 9 ) :
G C G C A G G G C G A C A TC G TC G C G A C G G A G C TG C C C TC C A TTC C C G G C A C G TC
A Q G D I V A T E L P S I P G T S
GCGCAGGGCGACATCGTCGCGACGGAGCTGCCCTCCATTCCCGGCACGTC
GCGCAGGGCGACATCGTCGCGACGGAGCTGCCCTCCATTCCCGGCACGTC
GCGCAGGGCGACATCGTCGCGACGGAGCTGCCCTCCATTCCCGGCACGTC
1 2 5 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A {2} : 
A F 4 5 6 3 5 6  p r n A ( 9 ) : 
A F 2 1 8 7 8 5  p r n A { 9 ) :
GATCG G G C CG CTCG AC G TG G C G C TG G C CA G C C AG G C CC G A TG G AC G G G C G
I G P L D V A L A S Q A R W T G
GATCGGGCCGCTCGACGTGGCGCTGGCCAGCCAGGCCCGATGGACGGGCG
GATCGGGCCGCTCGACGTGGCGCTGGCCAGCCAGGCCCGATGGACGGGCG
GATCGGGCCGCTCGACGTGGCGCTGGCCAGCCAGGCCCGATGGACGGGCG
1 3 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A {2) :  
A F 4 5 6 3 5 6  p r n A { 9 ) : 
A F 2 1 8 7 8 5  p r n A ( 9 ) :
C T A C C C G C G C G G T C G A C TC G C TG TC C A TC G A C A A C G C C A C C TG G G T C A TG
A T R A V D S L S I D N A T W V M
CTACCCGCGCGGTCGACTCGCTGTCCATCGACAACGCCACCTGGGTCATG
Cr’ACCCGCGCGGTCGACTCGCTGTCCATCGACAACGCCACCTGGGTCATG
CTACCCGCGCGGTCGACTCGCTGTCCATCGACAACGCCACCTGGGTCATG
1356
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 ) : 
A F 4 5 6 3 5 6  p r n A ( 9 ) :  
A F 2 1 8 7 8 5  p r n A { 9 ) :
A C G G A C A A C TC G A A C G TC G G TG C G C TA C G G C TG G C C A G C G A C G G C A G C G T
T D N S N V G A L R L A S D G S V
ACGGACAACTCGAACGTCGGTGCGCTACGGCTGGCCAGCGACGGCAGCGT
ACGGACAACTCGAACGTCGGTGCGCTACGGCTGGCCAGCGACGGCAGCGT
ACGGACAACTCGAACGICGGTGCGCTACGGCTGGCCAGCGACGGCAGCGT
1 4 0 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A { 2 )  
A F 4 5 6 3 5 6  p r n A [ 9 )  
A F 2 1 8 7 8 5  p r n A [ 9 )
C G A TTT C C A G C A G C C G G C C G A A G C TG G G C G G TT C A A G G T C C TG A C G G TC A
D F Q Q P A E A G R F K V L T V
CGATTTCCAGCAGCCGGCCGAAGCTGGGCGGTTCAAGGTCCTGACGGTCA
CGATTTCCAGCAGCCGGCCGAAGCTGGGCGGTTCAAGGTCCTGACGGTCA
CGATTTCCAGCAGCCGGCCGAAGCTGGGCGGTTCAAGGTCCTGACGGTCA
1 4 5 6
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Figure 4.2. N u cle ic  acid alignm ent o f the Bordetella pertactin gene types,
pmA(^) and pmA{^)y continued
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) ;  
A F 4 5 6 3 5 6  p r n A { 9 )  : 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
A T A C G C T G G C G G G T T C G G G G C T G T T C C G C A T G A A T G T C T T C G C G G A C C T G
N T L A G S G L F R M N V F A D L
ATACGCTGGCGGGTTCGGGGCTGTTCCGCATGAATGTCTTCGCGGACCTG
ATACGCTGGCGGGTTCGGGGCTGTTCCGCATGAATGTCTTCGCGGACCTG
ATACGCTGGCGGGTTCGGGGCTGTTCCGCATGAATG'I’CTTCGCGGACCTG
15 0 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A { 2 )  : 
A F 4 5 6 3 5 6  p r n A { 9 )  :
G G G C TG A G C G A C A A G C TG G TC G TC A TG C A G G A C G C C A G C G G C C A G C A C A G
G L S D K L V V M Q D A S G Q H R
GGGCTGAGCGACAAGCTGGTCGrCATGCAGGACGCCAGCGGCCAGCACAG
GGGCTGAGCGACAAGCTGGTCGTCATGCAGGACGCCAGCGGCCAGCACAG
A F 2 1 8 7 8 5  p r n A  {9) : GGGCTGAGCGACAAGCTGGTCGTCA'i'GCAGGACGCCAGCGGCCAGCACAG
1 5 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  \ 
A F 4 5 6 3 5 6  p r n A { 9 )  ; 
A F 2 1 8 7 8 5  p r n A { 9 )  ;
G C TG TG G G TC C G C A A C A G C G G C A G C G A G C C G G C C A G C G C C A A C A C C C TG C
L W V R N S G S E P A S A N T L
GCTGTGGGTCCGCAACAGCGGCAGCGAGCCGGCCAGCGCCAACACCCTGC
GCTGTGGGTCCGCAACAGCGGCAGCGAGCCGGCCAGCGCCAACACCCTGC
GCl’GTGGGTCCGCAACAGCGGCAGCGAGCCGGCCAGCGCCAACACCCTGC
1 6 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 )  ; 
A F 4 5 6 3 5 6  p r n A { 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 ) ;
T G C T G G T G C A G A C G C C A C TA G G C A G C G C G G C G A C C TTTA C C C TT G C C A A C
L L V Q T P L G S A A T F T L A N
TGCTGGTGCAGACGCCACTAGGCAGCGCGGCGACCTTTACCCTTGCCAAC
TGCTGGTGCAGACGCCACTAGGCAGCGCGGCGACCTTTACCCTTGCCAAC
TGCTGGTGCAGACGCCACTAGGCAGCGCGGCGACCTTTACCCTTGCCAAC
1 6 5 6
CONSENSUS
A J 0 1 1 0 9 2  p r n A { 2 )  
A F 4 5 6 3 5 6  p r n A ( 9 ) :  
A F 2 1 8 7 8 5  p r n A { 9 )  :
A A G G A C G G C A A G G TC G A TA TC G G T A C C TA T C G C T A T C G A T TG G C C G C C A A
K D G K V D I G T Y R Y R L A A N
AAGGACGGCAAGGTCGATATCGGTACCTATCGCTATCGATTGGCCGCCAA
AAGGACGGCAAGGTCGATATCGGTACCTATCGCTATCGATTGGCCGCCAA
AAGGACGGCAAGGTCGATATCGGTACCTATCGCTATCGATTGGCCGCCAA
1 7 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  \ 
A F 4 5 6 3 5 6  p r n A ( 9 ) ;  
A F 2 1 8 7 8 5  p r n A { 9 )  ;
C G G C A A TG G G CA G TG G A G C C TG G TG G G C G C G A AG G C G C CG CC G G CG CC C A
G N G Q W S L V G A K A P P A P
CGGCAATGGGCAGTGGAGCCTGGTGGGCGCGAAGGCGCCGCCGGCGCCCA
CGGCAATGGGCAGTGGAGCCIGGTGGGCGCGAAGGCGCCGCCGGCGCCCA
CGGCAATGGGCAGTGGAGCCTGGTGGGCGCGAAGGCGCCGCCGGCGCCCA
1 7 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) :  
A F 4 5 6 3 5 6  p r n A { 9 )  ; 
A F 2 1 8 7 8 5  p r n A { 9 )  ;
A G C C C G C G C C G C AG CC G G G TC C CC A G C CG CC G C A G C CG CC G C A G C CG CA G
K P A P Q P G P Q P P Q P P Q P Q
AGCCCGCGCCGCAGCCGGGTCCCCAGCCGCCGCAGCCGCCGCAGCCGCAG
AGCCCGCGCCGCAGCCGGGTCCCCAGCCGCCGCAGCCGCCGCAGCCGCAG
AGCCCGCGCCGCAGCCGGGI'CCCCAGCCGCCGCAGCCGCCGCAGCCGCAG
1 8 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A (2) : 
A F 4 5 6 3 5 6  p r n A ( 9 )  : 
A F 2 1 8 7 8 5  p r n A [ 9 )  ;
C CG G A AG CG CC G G CG CC G C A AC C G C CG G C G G G CA G G G A G TTG TC C G C CG C
P E A P A P Q P P A G R E L S A A
CCGGAAGCGCCGGCGCCGCAACCGCCGGCGGGCAGGGAGTTGTCCGCCGC
CCGGAAGCGCCGGCGCCGCAACCGCCGGCGGGCAGGGAGTTGTCCGCCGC
CCGGAAGCGCCGGCGCCGCAACCGCCGGCGGGCAGGGAGTTGTCCGCCGC
1 8 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 )  •. 
A F 4 5 6 3 5 6  p r n A { 9 ) : 
A F 2 1 8 7 8 5  p r n A ( 9 ) :
C G C C A A C G C G G C G G TC A A C A C G G G TG G G G TG G G C C TG G C C A G C A C G C TC T
A N A A V N T G G V G L A S T L
CGCCAACGCGGCGGTCAACACGGGTGGGGTGGGCCTGGCCAGCACGCTCT
CGCCAACGCGGCGGTCAACACGGGTGGGGTGGGCCTGGCCAGCACGCTCT
CGCCAACGCGGCGGTCAACACGGGTGGGGTGGGCCTGGCCAGCACGCTCT
1 9 0 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A ( 2 )  : 
A F 4 5 6 3 5 6  p r n A ( 9 )  : 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
G G TA C G C C G A A A G C A A TG C G T TG TC C A A G C G C C TG G G C G A G TT G C G C C T G  
W Y A E S N A L S K R L G E L R L  
GGTACGCCGAAAGCAATGCGTTGTCCAAGCGCCTGGGCGAGTTGCGCCTG 
GG1 ACGCCGAAAGCAA'-'GCGTTGTCCAAGCGCCTGGGCGAGTTGCGCCTG 
GGTACGCCGAAAGCAATGCGTTGTCf:AAGCGCCTGGGCGAGTTGCGCCTG
1 9 5 6
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Figure 4.2. N u cle ic  acid alignm ent o f the Bordetella /jerfuss/s pertactin gene types,
pmA(^) and /7m 4(9), continued
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) ;  
A F 4 5 6 3 5 6  p r n A { 9 )  ; 
A F 2 1 8 7 8 5  p r n A { 9 )  ;
A A TC C G G A C G C C G G C G G C G C C TG G G G C C G C G G C TTC G C G C A A C G C C A G C A
N P D A G G A W G R G F A Q R Q Q
AATCCGGACGCCGGCGGCGCCTGGGGCCGCGGCTTCGCGCAACGCCAGCA
AATCCGGACGCCGGCGGCGCCTGGGGCCGCGGCTTCGCGCAACGCCAGCA
AATCCGGACGCCGGCGGCGCCTGGGGCCGCGGCTTCGCGCAACGCCAGCA
2 0 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  : 
A F 4 5 6 3 5 6  p r n A ( 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 )  ;
G C TG G A C A A C C G C G C C G G G C G G C G C TTC G A C C A G A A G G TG G C C G G C TTC G
L D N R A G R R F D Q K V A G F
GCTGGACAACCGCGCCGGGCGGCGCTTCGACCAGAAGGTGGCCGGCTTCG
GCTGGACAACCGCGCCGGGCGGCGCTTCGACCAGAAGGTGGCCGGCTTCG
GCTGGACAACCGCGCCGGGCGGCGCTTCGACCAGAAGGTGGCCGGCTTCG
2 0 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 )  : 
A F 4 5 6 3 5 6  p r n A ( 9 ) ;  
A F 2 1 8 7 8 5  p r n A { 9 )  ;
A G C TG G G C G C CG AC C AC G C G G TG G CG G TG G C CG G C G G A C G C TG G CA C CTG
E L G A D H A V A V A G G R W H L
AGCTGGGCGCCGACCACGCGGTGGCGGTGGCCGGCGGACGCTGGCACCTG
AGCTGGGCGCCGACCACGCGGTGGCGGTGGCCGGCGGACGCTGGCACCTG
AGCTGGGCGCCGACCACGCGGTGGCGGTGGCCGGCGGACGCTGGCACCTG
2 1 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 ) \  
A F 4 5 6 3 5 6  p r n A ( 9 ) ;  
A F 2 1 8 7 8 5  p r n A ( 9 )  ;
G G CG G G C TG G C CG G C TA TA CG CG CG G C G A CC G C G G CTTC AC CG G C G A CG G
G G L A G Y T R G D R G F T G D G
GGCGGGCTGGCCGGCTATACGCGCGGCGACCGCGGCTTCACCGGCGACGG
GGCGGGCTGGCCGGCTATACGCGCGGCGACCGCGGCTTCACCGGCGACGG
GGCGGGCTGGCCGGCTATACGCGCGGCGACCGCGGCTTCACCGGCGACGG
2 1 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 ) :  
A F 4 5 6 3 5 6  p r n A ( 9 )  ; 
A F 2 1 8 7 8 5  p r n A { 9 )  ;
C G G C G G C C A C A C C G A C A G C G TG C A TG TC G G G G G C TA TG C C A C A TA TA TC G
G G H T D S V H V G G Y A T Y I
CGGCGGCCACACCGACAGCGTGCATGTCGGGGGCTATGCCACATATATCG
CGGCGGCCACACCGACAGCGTGCATGTCGGGGGCTATGCCACATATATCG
CGGCGGCCACACCGACAGCGTGCATGTCGGGGGCTATGCCACATATATCG
2 2 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 ) \  
A F 4 5 6 3 5 6  p r n A { 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 )  \
C C G A C A G C G G TTTC TA C C TG G A C G C G A C G C TG C G C G C C A G C C G C C TG G A G
A D S G F Y L D A T L R A S R L E
CCGACAGCGGTTTCTACCTGGACGCGACGCTGCGCGCCAGCCGCCTGGAG 
CCGACAGCGGTTTCl ACCTGGACGCGACGCTGCGCGCCAGCCGCCTGGAG 
CCGACAGCGGTTTCTACCTGGACGCGACGCTGCGCGCCAGCCGCCTGGAG
2 2 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 )  \ 
A F 4 5 6 3 5 6  p r n A { 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 )  ;
A ATG A C TTC A A G G TG G C G G G C A G C G A C G G G TA C G C G G TC A A G G G C A A G TA
N D F K V A G S D G Y A V K G K Y
a a t g a c t t c a a g g t g g c g g g c a g c g a c :g g g t a c g c g g t c a a g g g c a a g t a
AATGACTTCAAGGTGGCGGGCAGCGACGGGTACGCGGTCAAGGGCAAGTA
AATGACTTCAAGGTGGCGGGCAGCGACGGGTACGCGGTCAAGGGCAAGTA
2 3 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 )  ; 
A F 4 5 6 3 5 6  p r n A ( 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 )  :
C CG CA C CC A TG G G G TG G G C G C C TC G C TC G A G G C G G G C C G G C G C TTTA C C C
R T H G V G A S L E A G R R F T
CCGCACCCATGGGGTGGGCGCCTCGCTCGAGGCGGGCCGGCGCTTTACCC
CCGCACCCATGGGGTGGGCGCCTCGCTCGAGGCGGGCCGGCGCTTTACCC
CCGCACCCATGGGGTGGGCGCCTCGCTCGAGGCGGGCCGGCGCTTTACCC
2 3 5 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A ( 2 ) \  
A F 4 5 6 3 5 6  p r n A { 9 ) ; 
A F 2 1 8 7 8 5  p r n A { 9 ) ;
A TG C C G A C G G C TG G TTC C TC G A G C C G C A G G C C G A G C TG G C G G TA TT C C G G
H A D G W F L E P Q A E L A V F R
ATGCCGACGGCTGGTTCCTCGAGCCGCAGGCCGAGCTGGCGGTATTCCGG
ATGCCGACGGCTGGTTCCTCGAGCCGCAGGCCGAGCTGGCGGTATTCCGG
ATGCCGACGGCTGGTTCCTCGAGCCGCAGGCCGAGCTGGCGGTATTCCGG
2 4 0 6
CONSENSUS;
A J 0 1 1 0 9 2  p r n A { 2 ) \  
A F 4 5 6 3 5 6  p r n A ( 9 )  ; 
A F 2 1 8 7 8 5  p r n A ( 9 )  ;
G C C G G C G G CG G TG CG TA CC G C G C G G CC A AC G G CC TG CG G G TG C G C G A CG A
A G G G A Y R A A N G L R V R D E
GCCGGCGGCGGTGCGTACCGCGCGGCCAACGGCCTGCGGGTGCGCGACGA
GCCGGCGGCGGTGCGTACCGCGCGGCCAACGGCCTGCGGGTGCGCGACGA
GCCGGCGGCGGTGCGTACCGCGCGGCCAACGGCCTGCGGGTGCGCGACGA
2 4 5 6
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Figure 4.2. N u cle ic  acid alignm ent o f the Bordetella pertussis pertactin gene types,
pmA{2) and pm<4(9), continued
CONSENSUS ;
A J 0 1 1 0 9 2  p r n A ( 2 ) :  
A F 4 5 6 3 5 6  p r n A { 9 )  ;
AGGCGGCAGCTCGGTGCTGGGTCGCCTGGGCCTGGAGGTCGGCAAGCGCA
G G S S V L G R L G L E V G K R
AGGCGGCAGCTCGGTGCTGGGTCGCCTGGGCCTGGAGGTCGGCAAGCGCA
AGGCGGCAGCTCGGTGCTGGGTCGCCTGGGCCTGGAGGTCGGCAAGCGCA
A F 2 1 8 7 8 5  p r n A [ 9 ) : AGGCGGCAGCTCGGTGCTGGGTCGCCTGGGCCTGGAGGTCGGCAAGCGCA
CONSENSUS ;
A J 0 1 1 0 9 2  p r n A [ 2 ) : 
A F 4 5 6 3 5 6  p r n A { 9 ) ;
TCGAACTGGCAGGCGGCAGGCAGGTGCAGCCATACATCAAGGCCAGCGTG
l E L A G G R Q V Q P Y I K A S V
TCGAACTGGCAGGCGGCAGGCAGGTGCAGCCATACATCAAGGCCAGCGTG
TCGAACTGGCAGGCGGCAGGCAGGTGCAGCCATACATCAAGGCCAGCGTG
A F 2 1 8 7 8 5  p r n A ( 9 ) :  TCGAACTGGCAGGCGGCAGGCAGGTGCAGCCATACATCAAGGCCAGCGTG
2 5 0 6
2 5 5 6
CONSENSUS : CTGCAGGAGTTCGACGGCGCGGGTACGGTACACACCAACGGCATCGCGCA 
L Q E F D G A G T V H T N G I A H  
A J 0 1 1 0 9 2  p r n A ( 2 ) : CTGCAGGAGTTCGACGGCGCGGGTACGGTACACACCAACGGCATCGCGCA 
A F 4 5 6 3 5 6  p r n A ( 9 ) : CTGCAGGAGTTCGACGGCGCGGGTACGGTACACACCAACGGCATCGCGCA 
A F 2 1 8 7 8 5  p r n A ( 9 ) :  CTGCAGGAGTTCGACGGCGCGGGT-----------------------------------------------------------
2 6 0 6
CONSENSUS:
A J 0 1 1 0 9 2  p r n A { 2 ) : 
A F 4 5 6 3 5 6  p r n A { 9 )  : 
A F 2 1 8 7 8 5  p r n A ( 9 ) :
CCGCACCGAACTGCGCGGCACGCGCGCCGAACTGGGCCTGGGCATGGCCG
R T E L R G T R A E L G L G M A
CCGCACCGAACTGCGCGGCACGCGCGCCGAACTGGGCCTGGGCATGGCCG
CCGCACCGAACTGCGCGGCACGCGCGCCGAACTGGGCCTGGGCATGGCCG
2 6 5 6
CONSENSUS :
A J 0 1 1 0 9 2  p r n A ( 2 ) :  
A F 4 5 6 3 5 6  p r n A { 9 ) : 
A F 2 1 8 7 8 5  p r n A ( 9 ) :
CCGCGCTGGGCCGCGGCCACAGCCTGTATGCCTCGTACGAGTACTCCAAG
A A L G R G H S L Y A S T E Y S K
CCGCGCTGGGCCGCGGCCACAGCCTGTATGCCTCGTACGAGTACTCCAAG
CCGCGCTGGGCCGCGGCCACAGCCTGTATGCCTCGTACGAGTACTCCAAG
2 7 0 6
CONSENSUS : GGCCCGAAGCTGGCCATGCCGTGGACCTTCCACGCGGGCTACCGGTACAG 
G P K L A M P W T F H A G Y R Y S  
A JO 1 1 0 9 2  p r n A (2 )  : GGi:CCGAAGCTGGCCATGCCGTGGACCTTCCACGCGGGCTACCGGTACAG 
A F 4 5 6 3 5 6  p r n A { 9 )  : GGCCCGAAGCTGGCCATGCCG'IGGACCTTCCACGCGGGCTACCGGTACAG 
A F 2 1 8 7 8 5  p r n A ( 9 ) :  ------------------------------------------------------------------------------------------------------------------
2 7 5 6
CONSENSUS : CTGGTAAAGCGAGGAGGGTCTATCCCCCGCGGAGGAQGTTTTCCTGGAGC
w *
A J 0 1 1 0 9 2  p r n A ( 2 ) :  CTGGTAAAGCGAGGAGGGTCTATCCCCCGCGGAGGAGGTTTTCCTGGAGC
A F 4 5 6 3 5 6  p r n A ( 9 )  : CTGGTAAAGCGAGGAGGG ;'CTA :’CCCCCGCGGAGGAGGTTTTC---------------
A F 2 1 8 7 8 5  p r n A { 9 ) : ------------------------------------------------------------------------------------------------------------------
2 7 6 3
CONSENSUS: TT 
A J 0 1 1 0 9 2  p r n A { 2 ) : TT 
A F 4 5 6 3 5 6  p r n A { 9 ) : —  
A F 2 1 8 7 8 5  p r n A ( 9 )  : —
T h e  G e n B a n k  s e q u e n c e ,  A J 0 1 1 0 9 2 ,  a  pm AÇi) s t r a i n ,  w a s  u s e d  t o  a l i g n  t h e  s e q u e n c e s  g e n e r a t e d  
f r o m  M O - 1 2 1  ( A F 4 5 6 3 5 6 )  a n d  M O - 9 0 8  ( A F 2 1 8 7 8 5 ) .  T h e  a m i n o  a c i d s  a r e  c o d e d  a s  t h e  u n i v e r s a l  
s i n g l e  l e t t e r  d e s i g n a t i o n s  ( A p p e n d i x  1 ) ,  a n d  a r e  s h o w n  i n  b l a c k  u n d e r n e a t h  t h e  n u c l e o t i d e  c o d i n g  
s e q u e n c e .  T h e  b l a c k  h o r i z o n t a l  l i n e  a n d  b l a c k  a s t e r i x  ( * )  i n d i c a t e  t h e  s t a r t  a n d  s t o p  c o d o n s  o f  
p e r t a c t i n ,  r e s p e c t i v e l y .  D a s h e d  l i n e s  i n d i c a t e  t h a t  t h e  s e q u e n c e  i s  n o t  f o u n d .  T h e  b o x e d  a r e a  
e n c o m p a s s e s  r e g i o n  1 o f  t h e  p e r t a c t i n  g e n e ,  w h e r e  b o t h  pm A i^) s e q u e n c e s  p o s s e s s  a n  e x t r a  r e p e a t .
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SbiptxA  types have been described to à^tç^yptxA{\),ptxA(i^yptxA(ip) andptxA(A) (Mooi et 
al., 2000), andptxA(b) andptxA{G) (Poynten et al, 2004) (Figure 1.4, page 48), but only two 
types, ^ /Kr4(l) andptxA(l2) were found in the Missouri B. pertmsis isolates (Table 4.1, page 
167). TheptxA{V) variant doirdnated the population, occurring at a frequency of
80% (12/15) in 1984-1989 and 95% (18/19) in 1996-2001 (Fisher’s exact test, P=0.299, not 
significantly different). AH “Kansas City” isolates wereptxA (l).
The 44 isolates generated four prnA  types and two p txA  types and these were combined to 
give a definitive prnA lp txA  allele. Out of eight possible prnA jp txA  combinations, only five 
were found;prnA(\)!ptxA{\),prnAiX)!ptxA(l2),prnA(l^ fptxA(\),prnA{())/ptxA(2), and 
prnA(p>)fptxA(\), (Table 4.2, page 167). All five of these combinations were found from 
1984 to 1989, and typeprnA(V)!p txA il)  was present in seven of the 15 strains, (47%). Type 
prnAil^!ptxA(V) kas been seen almost exclusively from 1996 to 2001, and found in 18/19 
(95%) of the isolates, with the remaining isolate designated as prnA(\)lptxA(l^. This shift 
towardsprnA(l2)!ptxA{V) isolates is very significant (Fisher’s exact test, P<0.001). The ten 
isolates from Kansas City in 1999 were aUprnA (^lp txA (\).
4.3.3 IST^(?.2-Resttiction Fragment Length Polymorphism analysis
A total of 11 different IS/002-RFLP types were generated from the 44 isolates after 
normalisation using BioNumerics (Applied Maths) (Figure 4.3, page 175). The number of 
bands per RFLP type varied between three and seven, and most RFLP types (7/11) 
contained five. When grouped temporally, 15 isolates generated ten different RFLP types 
from 1984-1989 and 19 isolates from 1996-2001 produced four RFLP types (Table 4.3, 
page 176). The most frequent RFLP type, RFLP-1, was found in 29 (66%) of the total 
isolates tested, and was seen in six of die 15 isolates (40%) from 1984-1989, and 13 of 19 
(68%) from 1996-2001 (Table 4.3, page 176). The second most frequendy seen type, 
RFLP-2 occurred at a much lower frequency of 5/44 (11%) for the total number of isolates 
tested. When divided into the two subsets, RFLP-2 is present in one isolate of the 15 (7%) 
from 1984-1989 and four of the 19 (21%) isolates from 1996-2001. O f the 11 RFLP types 
seen, eight comprised one isolate each, where seven of the eight types were present in the 
years 1984-1989. All ten “Kansas City” isolates were of die same RFLP type, RFLP-1.
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Figure 4.3. IS7^?â2-RFLP types of Bordetella pertu ss is  isolates from
Missouri; USA
RFLP types: I 2 II  21 25 26 27 28 31 32 33
3 0 . 0 -
2 5 .0 -
20.0 -
3.6
3.4
3.2
3.0
2.8
2.6
2.4
2 .2 -
2.0 -  
1 . 9 -  
1. 8 -
T h e  t h i n  r e d  l i n e s  i n d i c a t e  b a n d s  i n c l u d e d  i n  t h e  a n a l y s i s ,  a s  n o r m a l i s e d  u s i n g  B i o N u m e r i c s  
( A p p l i e d  M a t h s ) .
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Table 4.3. Temporal distribution of IS./<?fl2-RFLP types in Bordetella
isolates from Missouri, USA
ISJ(?A3.RFLP
type
“Early”,
1984-1989
“Recent”,
1996-2001
“K ansas City” , 
1999
1 6 13 10
2 1 4
11 1
21 1
25 1
26 1
27 1 1
28 1
31 1
32 1
33 1
Total isolates 15 19 10
Table 4.4. Temporal distribution o f PFGE types, produced with Xba\y 
in Bordetella  isolates from M issouri, USA
PFGE type “Early”,
1984-1989
“Recent”,
1996-2001
“Kansas City”, 
1999
1 5
2 10 5
3 4 5
4 1
6 1
9 2
10 1 1
14 2
15 2
17 1
21 1
24 1
27 1
31 1
Total isolates 15 19 10
Numbers of isolates are shown. The “Kansas City” data are in grey, as the isolates were not 
included in the temporal analysis.
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4.3.4 Pulsed-Field Gel Electrophoresis analysis
The 44 isolates from Missouri, USA, produced 14 different PFG E profiles using Xbal 
(Table 4.4 and Figure 4.4, pages 176 and 178). There were nine different PFGE profiles 
from the 1984-1989 isolates and six profiles from the 1996-2001 isolates, but only one 
profile, PFG E-10, was seen in both time periods. Profile PFGE-2 was the dominant type, 
occurring in 15/44 o f the total isolates (34%), and was also present in 5/10 (50%) of the 
“Kansas City” isolates. Interestingly, serotyping, gene sequencing and IS/0(?2-RFLP 
analysis, grouped aU the “Kansas City” isolates as serotype \,'h ,prnA (^lp txA (\)  and RFLP- 
1, whereas PFG E divided this subset into two profiles, PFGE-2 (n=5) and PFGE-3 (n=5). 
These two profiles are closely related to each other and are clustered with another profile 
PFGE-15, to produce a clade with a simharit}; of 91.6% (Figure 4.5, page 179). The main 
difference between PFGE-2 and PFGE-3 is the presence of a 41,696 bp band in PFGE-3, 
and a 27,576 bp band in PFGE-2. Similar to IS / 002-RFLP, seven of the 14 PFGE profiles 
were unique, and five o f those were present only in the 1984-1989 isolates.
4.3.5 Discriminatory indices and associations of the various typing methods
In order to calculate the indices of discrimination (D) (section 2.8.3, page 99), nine of the 
“Kansas City” isolates were removed, as these were presumed to be epidemiologicaUy- 
related. Therefore, 35 isolates were evaluated.
The highest index of discrimination value was calculated for PFG E (79=0.88), and the 
lowest was D=0.21 for the pertussis toxin SI gene typing (Table 4.5, page 180). The otlier 
D  values for the other typing methods varied between 0.54 and 0.68 for pertactin gene 
typing and serotyping, respectively. These values however, are based on only 35 isolates, 
within a limited time period between 1984 and 2001. Chapter 5 describes a more detailed 
assessment of the discrimination of these typing mediods.
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Figure 4.4. PFGE types, with Xbal^ of Bordeteüa pertu ssis  isolates from
Missouri, USA
PFGE type: I 2 3 4 6 9 10 14 15 17 21 24 27 31
Kb
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T h e  t h i n  r e d  l i n e s  i n d i c a t e  b a n d s  i n c l u d e d  i n  t h e  a n a l y s i s  a s  n o r m a l i s e d  u s i n g  B i o N u m e r i c s  ( A p p l i e d  
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Table 4.5. Indices of discrimination o f the typing m ethods performed 
on the 43 B ordetellapertussis isolsLtcs from M issouri, USA
Typing  m ethod N um ber of Index of
types discrim ination (X>)
Sei'otyping 4 0.68
Pettactin gene typing 4 0.54
Pertussis toxin SI gene typing 2 0.21
prnA-lptxA combination 5 0.58
IS/O^/^-RFLP analysis 11 0.66
PFGE using ICbal 14 0.88
180
The Missouri isolates were predominantly serotype 1,3, (39/44), with 28/31 pn iA (^  
isolates, 25/29 RFLP-l isolates and 35/40ptxA {\) isolates associated with tliis serotype. 
Associations between RFLP types and pertactin and pertussis toxin SI gene variants were 
also investigated. All 29 RFLP-1 isolates were typeptxAiX)^ and 25 of these werepniAÇ). 
The remaining four RFLP-1 isolates were either pertactin variants prnAiV) or pniAi^')^ and 
present in the more diverse period of 1984-1989. Thirteen of the 19 isolates from 1996 to 
2001 were RFLP-1 2SxàprnA(p!)lptxA(pC)^ and in addition, all the "Kansas City” isolates 
(n=10) were also RFLP-1, j&/7?Al(2)//)/xM(l) and serotype 1,3. Associations between PFGE 
type and pertactin and pertussis toxin SI gene variants were also examined. All PFGE 
profiles with more than one isolate expressed the same prnK type, but PFGE-1 isolates 
exhibited eitherptxA i))  o rp tx A (^ .  The two predominant PFGE profiles, PFGE-2 (n—15) 
and PFGE-3 (n=9), were prnA.{^lptxA(\), and aU the isolates within these two PFGE 
types were recovered between 1996 and 2001.
Associations of the isolates between IS/002-RFLP and PFGE types were also examined. 
Four PFGE types with more than one isolate had unique genotypes; PFGE-3, RFLP-1, 
prnA{2)/ptxA{\) (n=9); PFGE-9, KPLV-l,pnv4(2)/p^xA{l) (n=2); PFGE-14, RFLP-1, 
prnA(9)/pi(xA{V) (n=2); and PFGE-15, 'RFLV-2,prnA(2)/p(xA{V) (n=2). There were tliree 
PFGE types that contained isolates with more than one RFLP type, and similarly, 3 RFLP 
types consisting of more than one PFGE type, indicating no conformity between tliese two 
typing methods.
4.4 D iscussion
A re-emergence of pertussis in the USA prompted colleagues from the Missouri State 
Laboratory to send isolates to RSIL for genotyping. In particular, a cluster of B. pertussis 
strains isolated within a six-week period m the summer of 1999 from Kansas City were 
received by Missouri State Laboratory. The question arose as to whether tliese isolates 
were; i) part of a specific outbreak; h) represented an upsurge of a particular strain, or Mi) 
were part o f a general increase in pertussis, caused by a variety of strains due to an 
unidentified event in pertussis epidemiology. To assess their relatedness, and whether any 
differences in the h . p o p u l a t i o n  had occurred, isolates from 1984 to 1989 and 1999 
to 2001 were compared with the isolates from Kansas City.
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4.4.1.1 Genotypic diversity of Botdetella pertussis isolates from Missouri, USA
A large-scale study of 152 B. pertussis strains from at least 12 states in the USA determined 
the pertactin and pertussis toxin SI gene type, and PFGE profile (Cassiday et al, 2000). 
Included in their study was at least one isolate from Missouri, but it is unclear from the 
paper which prnA lp txA  type were designated {prnA{\)lptxA(\), p rnA {\)!p txA i^  or 
prnAQL)lptxA(\)). Although the study had a wider spectrum of strains ranging from 1935 
to 1999 tliat originated from the entire country, it did not show a high diversity of strains 
compared to this study from a single state. Cassiday et al. (2000) reported tliree different 
prnA /p txA  alleles compared to five prnA /ptxA  types from this study of Missouri isolates in 
the same time span of 1989-1999. They also labelled certainprnA lp txA  alleles as either 
“old”, “new”, or “transitional” (section 3.4.3, page 146). This labelling could have been 
applied to these isolates from Missouri, but it does not explain how other alleles, such as 
prnA{6)lptxA(^, could be placed in this scheme.
During the course of this thesis, a new pertactin type, designatedprnAip), was discovered 
in two isolates, one from 1988, the other in 1989. These differed from prnAÇ) by an extra 
GGFGP repeat. It cannot be ascertained whether prnAtpi) is a “transitional” type or a 
“new” and recent variant, but a very recent study from Canada also describes this pertactin 
type, and suggests thsitprnA(p>)/ptxA (\) is a “new” strain (Peppier et al, 2003). However, 
prnAtp)) is, at the time of writing, not as successful as its close counterpart pruA(7), which is 
the present dominant pertactin type in Missouri.
The 44 isolates produced 11 different RFLP types, with a predominance of two types, 
RFLP-1 and RFLP-2. When divided into the three subsets, the 1984-1989 isolates showed 
a higher diversity in RFLP types (10/11 types) compared to isolates from 1996-2001 (3/11) 
and the “Kansas City” isolates (1 / I I ,  aU RFLP-1). When analysed using PFGE with Xbal, 
a higher diversity was also seen in the 1984-1989 isolates (10/14 PFG E profiles) compared 
to 6/14 in 1996-2001 and 2/14 in the “Kansas City” isolates. This higher diversity in earHer 
isolates compared to later ones was also reflected in tlie serotype, pertactin gene type and 
the comhmed p m A /p txA  type. The drop in diversity did not coincide with a change of 
vaccination schedule, a switch from whole-ceU vaccine (WCV) to aceUular vaccine (ACV), 
first licensed for infants in the USA in 1996, or a difference in reporting or improved 
laboratory diagnostic metliods. Flowever, it did coincide with the rise of pertussis incidence 
in Missouri (from 0.46 per 100,000 in 1984 to 1.91 per 100,000 in 2001) (Missouri 
Department of Health and Senior Services, 2002).
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These data from Missouri, USA, do not support the hypothesis of vaccine-driven evolution 
of B. pertussis for a number of reasons. The pertussis vaccines used in the United States 
since introduction in 1947 have been varied and widely distributed. Evaluation of the USA 
vaccine strains was confounded when Cassiday etal. (2000) investigated, although they 
reported that the whole-ceU. vaccines derived from the Tohama-I strain, and aU aceUular 
vaccines currently in use, aU exhibit type prnA{V)!p tx A (^ . This genotype indeed differs 
from those of isolates circulating between 1996-2001 in Missouri, which were 
predominantly prnA (^  jptxA^i), but the number of isolates was limited, and genotypes 
before 1984 cannot be ascertained. Also, the introduction of the ACV in 1996 in Missouri 
did not coincide with any significant change in pertussis incidence, although tire isolates 
tested between 1996-2001 were ahnost exclusively serotype \^'5^prnA.(l2)lptxA{\), RFLP-1 
and eitiier PFGE-2 or PFGE-3.
4.4.2 Geographical distribution of Bordetella pertussis  types
Pertactin gene typespnAiy),prnA(T)yprnA(€) andpruA(p>) were found in the isolates from 
Missouri, USA. The first two types have been seen globaUy, bu tprnA{6) has been seen only 
in circulating strains in this study andpm A ^')  was reported recently in Canada in 41 isolates 
from 1985 to 1994 (Peppier et al., 2003). This Canadian study also reported that 
approximately 5% of the 3334 isolates were prnA{b) (Peppier et aly 2003). It was previously 
thought tiiatprnAip) isolates were absent from North America after a large study involving 
152 B. pertussis hohx&s coUected between 1935 and 1999 from various states of tiie USA 
(Cassiday et al., 2000). Results reported here also showed thatp rn A i^  isolates were absent 
in Missouri state, bu tpruAipi) and prnA(p) isolates were present, suggesting some 
geographical constraint of B, pertussis.
Due to the lack of inter-laboratory standardisation of the IS/OtiARFLP method, the only 
comparisons that could be performed were with the other data presented in this tiiesis 
from the UK, and with the presence of the predominant RFLP type, RFLP-1 in other 
countries. The temporal distribution of the Missouri RFLP types differed from those in the 
UK. When comparing the data-sets 1984-1989 and 1996-2001 from Missouri (n=34, Table 
4.3, page 176) with the 1980s and 1990s data-sets from the UK (n=72. Figure 3.7, page 
118), tiiey both show a faU in diversity in recent years and the expansion of RFLP-1 
isolates. A drop in genotypic diversity of B. pertussis has also been seen in The Netherlands 
(van Loo et al.y 1999). The successful type RFLP-1, which is found in tiie UK (Chapter 3), 
The Netherlands (known as dt-29) (van Loo et al.y 1999), Italy (Mastrantonio et al., 1999),
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Germany, Canada (known as C2) (van der Zee et ai, 1996b) and Australia (Poynten et al., 
2004) can be seen as a prolific lineage which accounts for a large percentage of the global 
jB. pertussis population.
Similarly to IS/002-RFLP, data from pulsed-field gel electrophoresis cannot be compared 
directly with data from other countries because of differing running conditions and type 
designations. However, PFGE results from the evaluation panel used in Chapter 5 (Table 
5.2, page 193), which were predominantly UK isolates, can be compared with these results 
from tlie Missouri isolates. The PFGE types found in botli the Missouri and the UK were; 
PFGE-1, PFGE-3, PFGE-4, PFGE-6, PFGE-9 and PFGE-17 (Figure 4.4, page 178), 
although tlie latter type was from the type strain of B.pertussis (NCTC 10739^) present in 
the panel and originally from the USA, The Missouri and the UK isolates botli showed a 
large diversity of PFGE types, but the distributions of PFGE types differed, and although 
PFGE-2 was present in ten of the recent Missouri isolates, this type was markedly absent in 
the UK isolates. These PFGE data thus reveal the different geographical distribution of B. 
peHussis isolates.
Interestingly, where there was geographical variation in tlie pertactin gene, IS/902-RFLP 
and PFGE type distributions, there was no apparent constraint in the serotype or pertussis 
toxin type. Serotype distribution flucmates periodically, and serotypes 1,2,1,3 and 1,2,3 
have been seen in the UK and The Netherlands (Miller et al, 1992; Mooi, 1994). Thep txA  
types ptxAiV) andptxAPP) are found in most countries that have reported polymorphisms 
for tliis gene: The Netherlands (Mooi et al, 1998), Finland (Mooi et al, 1999), tlie USA 
(Cassiday et al, 2000), Japan (Guiso et al, 2001a), France (Weber et al, 2001), Poland (Gzyl 
et al, 2002), Canada (Peppier et al, 2003), Russia (Kourova et al, 2003) and the UK 
(Chapter 3). The geographical constraint of pertactin, IS/002-RFLP and PFGE types, 
compared to the comparative universal distribution of serotypes and pertussis toxin SI 
types, raises the question o f how the individual B. pertussis genomes and the bacterial 
population are regulated. In addition, IS/002-RFLP analysis and PFGE investigate whole 
genome changes, serotyping is dependent on tlie expression of agglutinogens 1, 2 and 3, 
and pertactin and pertussis toxin SI types focuses on differences in the chosen genes. 
Furtlier work is needed regarding the regulatory differences between conservative and 
variable areas of the genome.
The discriminatory indices of the tj'pmg methods from both the Missouri isolates (Table 
4.5, page 180) and the UK evaluation panel (Table 5.7, page 211) were compared. Overall,
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although the UK  evaluation panel was chosen for its diversity, and the Missouri isolates 
were hmited from one state in the USA and taken from 1984 to 2001, the discriminatory 
indices were very similar for most typing methods. The exceptions were theptxA  gene 
typing (D=0.37 cf. D -0.21, UK versus Missouri, respectively), and tlie RFLP typing 
(D-0.85 cf. 19=0.66, UK versus Missouri, respectively), where the lower discriminatory 
indices from Missouri were probably due to the limited time period (i.e., no isolates were 
recovered before 1984).
To ascertain whether the same B. pertussis lineages were circulating in the UK and Missouri, 
associations of method types were compared using data from Chapters 3 and 5. In 
Missouri, most RFLP-1 isolates were serotype \p>,prnAÇ) andp txA (l), and this successful 
lineage has also appeared in the UK as combined type P (Table 3.14, page 131). This B. 
pertussis lineage is therefore comparatively clonal, and has expanded and spread to distant 
geograpliical locations. However, this lineage (combined type P) can be divided into many 
different PFGE types. Other common B. pertussis included: PFGE-3, RFLP-1,
prnA(p)!ptxA{V) and serotype 1,3 isolates (n=2 in the UK and n=7 in Missouri); and 
W GBj-\,prnA(V)/ptxA{y) isolates (n=15 in the UK and n=4 from Missouri). Most of the 
other PFGE or RFLP types were not shared between tlie UK and Missouri, and B. pertussis 
has therefore diversified in various geographical niches.
4.4.3 Bordetella pertussis  isolates from Kansas City, Missouri, USA
All of the ten temporally-clustered isolates from Kansas City were serotype 1,3, 
prnAÇ)!ptxApŸ) and RFLP-1, wliich was also seen in 13 of the 19 isolates from 1996-2001 
that were epidemiologically distinct. Therefore it could not be ascertained as to whether the 
Kansas City isolates were part of an epidemiologicaUy-Hnked outbreak. However, the 
Kansas City isolates were split evenly into two groups using PFG E (PFGE-2 and PFGE- 
3), although the PFGE types cluster at 91.6% similarity, indicating a recent and close 
evolution of these two lineages. Furthermore, these PFGE types differ by two bands, 
indicating only one genetic difference between them, and thus being closely related 
according to Tenover et al. (1995). de Moissac et al (1994) studied the epidemiology using 
PFGE in a three-year epidemic period and found that more than one PFGE type was 
circulating, but that study was long-term, compared to tliis study of just two months. 
Hence, these isolates from Kansas City may not have been from the same clone, but had 
very similar genotypes. However, bodi of tliese PFGE types were also found in the
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geographically distinct 1996-2001 isolates, so that the Kansas City isolates are stiU 
indistinguishable from contemporary isolates.
The ten Kansas City isolates from 1999 were not derived from one clone or lineage of B, 
pertussis, and the majority of strains around this time were mostly o f the same type (serotype 
\,?),prnA(7)lptxA{\), RFLP-1 and PFGE-2 or PFGE-3). An unlmown event might have 
occurred between 1990-1995 (no isolates available), which led to a sustained rise ki 
perms sis incidence in Missouri. This event may also have seen the emergence and 
expansion of a few successful genotypes of B. pertussis. It appears tliat more than one strain 
was circulating concurrently and causing disease.
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5 Evaluation of typing methods for Bordetella
pertussis
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The UK and Missouri, USA B. pertussis studies in this thesis showed varying discrimination 
for the typing methods performed (Chapters 3 and 4, respectively). In particular, tlie ten 
Kansas City (Missouri, USA) isolates from 1999 clustered witliin the same IS/002-RFLP 
type, but were divided into two PFGE types (4.4.3, page 185). For epidemiological 
purposes, this result makes it hard to distinguish whether the isolates and the associated 
pertussis cases are closely related or not. This chapter, therefore, attempts to evaluate the 
various typing methods used for B. pertussis, and recommends a method, according to the 
criteria described below.
5.1 Strategy
At the time of writing, tliere has not been a published and comprehensive evaluation of 
typing metiiods on a well-defined panel o f B. pertttssis isolates. Therefore B, pertussis isolates 
were chosen to calculate the typability, reproducibMity, index of discrimination and 
epidemiological concordance of the following typing methods; serotyping, BS>1002 
restriction fragment length polymorphism (RFLP) analysis and pulsed-field gel 
electrophoresis (PFGE) using Xbal. Pertactin (pmA) and pertussis toxin SI {ptxA) gene 
sequencing were not included for this evaluation as this information was available and used 
to select the isolates. Linkage between different types of these various typing methods were 
also investigated, although not for statistical significance, as the number of strains were too 
low. The availability of the unpublished annotated B, peHussis genome sequence allowed the 
comparison of fragments derived experimentally from the Tohama-I strain with diose 
predicted by in silico analysis of its genome for both the IS/002-RFLP and the PFGE 
techniques.
5.1.1 Criteria used to select the representative Bordetella pertu ssis  panel
The objective was to choose 40 to 50 B, pertussis from die entire collection
described in Appendix 3, such that the maximum discrimination o f each mediod could be 
estimated. This was carried out after the majority ofprnA  andp txA  gene typing was 
completed and, hence, diese characteristics were used to select the greatest variation for 
diis sub-set; i.e., representatives of all three U K prnA  types, jü)r/zM(l-3) and the twop txA  
types, j!)/x>4(1) andptxAlpt). It was decided to select clinical B. pertussis o f UK origin
only, and to pick at least one isolate from every year available to maximise temporal spread. 
Therefore, there were 24 isolates selected between 1920 and 1985 for the panel (Table 5.1, 
page 190). These included two isolates from 1983, one previously investigated by
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determining 95% of the pertactin gene, and the other was the first known prnAip) isolate in 
the UK.
Isolates submitted to Manchester University in 1998 to 1999, also had epidemiological 
information available, such as name (not shown), date of birth, vaccination status and 
severity of disease (see Appendix 3, part B). Fourteen isolates from this data-set were 
selected for the panel, and the reasons for inclusion are listed in Table 5.1, page 190. This 
included two pairs of epidemiologicaUy-linked isolates. A further two epidemiologically- 
Hnked pairs were added to tlie panel which were submitted to RSIL in 2002 (n=4) (Table 
5.1, page 190). Two isolates from 1998 to 1999 were serotype 1,2 andprnAÇ), wliich were 
exceptions from the two common relationships of serotype 1,2 andprnAiX), or serotype
1,3 andprnApT) (3.3.6.5, page 139). An isolate from 1999 that was submitted for tlie 
Paediatric Intensive Care Unit (PICU) study to RSIL, PFILS CPHL, London (Crowcroft et 
al, 2003), was also selected.
The B. pertussis type strain (18323^=NCTC 10739^), isolated originally in the USA, was also 
included in the panel as a well-characterised reference strain. Other reference strains 
included were all the available UK vaccine strains (n=4). In order to calculate the 
reproducibility of the typing methods, repHcates of six isolates were assigned, malting a 
total of 54 B. pertussis isolates. To avoid observer bias, all o f tlie selected strains were 
randomly allocated a study control number, from UK 1 to U K 54“^.
5.2 M ethods
The isolates were assessed using the following methods, as described in Chapter 2; 
serotyping, IS/002-RFLP analysis and PFG E with Xbdi. Formulae for evaluating the above 
methods are expressed in section 2.8.3 (page 99).
5.2.1 The in  silico  digest of the Tohama-I genome
The B. pertussis genome was downloaded from tlie Sanger Institute web-site 
(http://www.sanger.ac.uk/Projects/B_pertussis/) after permission from Julian ParkhiU, 
and then imported into Kodon software.
•After tlie allocation o f study code numbers, and during the generation o f  laboratory data, it was discovered 
that one isolate (UK 38) was contaminated with B. parapertussis. Tliis isolate was thus removed from the 
analysis, so that die panel contained 53 isolates.
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To compare the observed and expected results of a IS/002-RFLP profile generated with 
the Tohama-I strain, a two-step procedure was required. An initial in silico digest, was 
performed using the recognition sequence of Smdi (CGC JGGG) in Kodon, The fragments 
were then sized and listed according to their position in the genome. The positions of the 
IS /002 element within the Tohama-I genome were then located and then matched with the 
appropriate fragments digested by S?ndi as containing an IS/002 element. These “virtual” 
fragment sizes were then compared witli the calculated band sizes from the acmal IS/002- 
RFLP pattern of the Tohama-I strain, following normalisation in BioNumerics.
To compare the observed PFGE profile of the Tohama-I genome with die expected one, a 
virtual digest using the recognition sequence of XhcH (TJCTAGA) was performed. The 
Kodon software generated a virtual picture of the migration of bands produced after 
restriction. The band sizes were recorded and compared (for standard deviation values) 
with the band sizes calculated after normalisation (in BioNumerics) o f a PFGE experiment.
5.3 Results
5.3.1 Typability of typing methods
Table 5.2 (page 193) shows the results of the three typing methods (n=53). AU four 
serotypes were found using the panel (1 only; 1,2; 1,3; and 1,2,3). There were 19 different 
RFLP types determined using the panel and over a third of isolates (20/53) were RFLP-1, 
The PFGE data produced more types than tlie RFLP data (23 PFG E types), and also 
revealed a dominant profile, PFGE-1, found in 16/54 isolates.
To evaluate typability, one isolate from each replicate pair (used to calculate the 
reproducibility values), was omitted (n=47), and the typabUity value (T), was calculated 
using the formula in section 2.8.3 (page 99), (Table 5.2, page 193). One isolate underwent 
two separate attempts for serotyping, as it auto-agglutinated, but typing was successful on a 
further third attempt. The typabUity value was T=0.98 before re-testing the auto- 
agglutinating isolate and, when successful, the typability value became T=1.00. This 
however, lowers the confidence in the typability value when re-testing is performed, and 
should tiius be expressed with caution. The typabUity values for both RFLP and PFGE 
were also T=1.00.
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Table 5.2. Results of the typing methods derived from the Bordetella
pertu ssis  typing panel
Typing m ethod Types observed N um ber of isolates Typability value
Serotyping Serotype 1.00*
1 6
1,2 20
1,3 19
1,2,3 9
ISJt?f?Z-RFLP analysis lS1002-RFhV  type 1.00
RFLP-1 20
RFLP-2 6
RFLP-3 6
RFLP-6 1
RFLP-7 3
RFLP-11 1
RFLP-12 1
RFLP-13 1
RFLP-21
RFLP-22 1
RFLP-24 1
RFLP-25
RFLP-29 1
RFLP-35 1
RFLP-36 1
RFLP-38 1
RFLP-39 1
RFLP-40 1
RFLP-47 1
PFG E analysis PFG E type (with X bal) 1.00
PFGE-1 16
PFGE-3 3
PFGE-4 4
PFGE-5 4
PFGE-6 2
PFGE-7 3
PFGE-8 3
PFGE-9 1
PFGE-11 2
PFGE-12 2
PFGE-13 2
PFGE-16 1
PFGE-17 1
PFGE-20 1
PFGE-22 1
PFGE-23 1
PFGE-25 1
PFGE-26 1
PFGE-28 1 ■
PFGE-29 1 ■
PFGE-32 1
PFGE-33 1 '
PFGE-34 1
*The typability value was previously 0.98 for serotyping, as one isolate was untypable. After three 
attempts, the isolate gave a serotype result, thus achieving the typability value of 1.00 (5.3,1, page 
192).
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5.3.2 Reproducibility of typing methods
In total there were six replicates in the panel, although a review of the results revealed an 
obvious discrepancy between the replicates of CN5476 (UK 44 and UK 49). These 
replicates differed from each other in all three typing methods evaluated here. Given tlie 
reported stability of serotyping and the marked differences in IS / 092-RFLP and PFGE 
profiles, this is unlikely to have arisen from experimental variation, therefore this pair was 
excluded from the analyses^ Therefore, the typing results from the remaining five 
replicates were used to calculate the reproducibility value as described in section 2.8.3 (page
99).
Serotyping, PFGE and IS/002-RFLP analysis generated the same Rvalue of 1.00 (Table 
5.3, Figure 5.1 and Figure 5.2, pages 195 to 197).
5.3.3 Discrimination indices of typing methods
Indices of discrimination (D) were calculated as described in 2.8.3 (page 99) using the 
unrelated isolates (n=44), which are in black in Table 5.1, page 190.
The phenotypic method serotyping generated a value of 19=0.70 and is low, as only four 
possible serotypes can be generated for B. peHussis (Preston, 1963). The DNA 
fingerprinting techniques IS/Q02-RFLP analysis and PFG E gave die highest indices of 
discrimination (D=0.85 and 0.89, respectively). However, these values still do not meet the 
requirements of an ideal typing system (I9>0.95) (Struelens et al., 1996), but they do 
approach die desired value described by Hunter and Gaston (D>0.90) (1988).
^Subsequent to the prepai'ation o f tliis thesis, the isolate CN5476, and its coded replicates U K  44 and U K  49, 
were re-examined by serotyping. Furdier isolates CN3099 and Tohama-I, and tlieir respective coded 
replicates were also repeated as controls, and U K  10 and the original strain CN3108 were tested because they 
possessed die same genotype as tiiat o f the rephcate U K  49. These serotyping results were consistent with 
diose found in the coded trial; i.e., CN5476 and U K  44 were serotype 1,3; CN3G99 and Tohama-I were 
serotype 1,2; and CN3108, U K  10 and U K  49 were serotype 1.
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Table 5.3. Type designations of replicate isolates from the panel, with
reproducibility values for each Bordetella pertu ssis  typing method
Strain Coded Serotype PFGE type ISFdflZ-RFLP Other details
CN3099 UK 43 1,2 1 1 UK WCV strain
UK 48 1,2 1 1 prnA.{\) IpixAil)
CN2992B UK 42 1,2,3 5 2 UK WCV strain
UK 47 1,2,3 5 2 prnA(\) jptxA{7)
Tohama-I UK 45 1,2 7 21 ACV strain
UK 50 1,2 7 21 prnA{V)/ptxA{2)
NCTC10739''’ UK 33 1 16 25 Type strain
UK 41 1 16 25 prnA{6) fptxA{4)
99K010 UK 31 1,2 8 3 Clinical isolate
UK 46 1,2 8 3 prnA(l) /  ptxA{V)
Reproducibility values: 100 100 100
The pertactin and pertussis toxin SI subunit gene types were not included in the evaluation and are 
shown for information only.
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5.3.4 Epidemiological concordance of typing methods
Originally, there were four pairs of isolates included in tlie panel that were 
epidemiologicaUy-Hnked through family contact (Table 5.4 page 199). However, one pair of 
isolates from a brotlier and sister, 99K062 and 99K063, when tested after coding, were not 
identical by serotyping, PFGE typing or IS/002-RFLP analysis. The serotyping results for 
isolate 99K063 were also inconsistent. This strain was previously serotyped at Manchester 
University as serotype 1,3 but, when performed here as UK 38, it was serotype 1,2,3. Also, 
the profiles generated by PFG E with Xbal and IS/002-RFLP analysis for this isolate 
differed from the rest o f the profiles from the epidemiological isolates, with 48.4% and 
13.2% similarities respectively, when clustered by Dice and UPGMA (Figures 5.3 and 5.4, 
pages 200 and 201). The ÏS/092-RFLP profile of 99K063 closely resembled B. parapertussis 
profiles obtained by van der Zee et al, (1996a), and this isolate was thus revealed, by shde- 
agglutination witli specific B. parapertussis antisera, to be mixed with B. parapertussis.
The only pair of isolates that gave die same types witii all three typing methods was the 
father/daughter isolates 98K322 and 98K323, bearing serotype 1,2, PFGE-1 and RFLP-1. 
The second epidemiologicaUy-related pair (brodier and sister), BP706 and BP707, differed 
in only the RFLP type, generating RFLP-47 and RFLP-2, respectively (Figure 5.3, page 
200). These two RFLP types differ only by a single band of approximately 7.09 Kb in 
RFLP-47 and are 90,9% similar when clustered. The other epidemiologicaUy-related pair of 
isolates, BP710 and BP711, also differed by one typing method, PFGE, and produced 
types PFGE-4 and PFGE-3, respectively. These too are 90.9% similar, notably widi die 
loss of an approximately 334 Kb band and gain of two lower bands in BP711 (Figure 5.4, 
page 201).
When calculating the epidemiological concordance (JB), 99K062 and 99K063 were 
excluded, as 99K063 was contaminated and not recoverable. Serotyping showed the 
liighest epidemiological concordance (E=1.00). Due to die mismatch of two of the three 
pairs o f isolates by PFG E or IS/002-RFLP analysis, diese methods gave low values, both at 
E=0.67.
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5.3.5 Linkage between typing methods
Linkage between one patticulat type by one typing method with another type of a different 
typing method, was investigated within this panel of B. pertussis isolates. This was assessed 
after the code was broken, and one isolate from each known replicate or epidemiologically- 
linked pair was removed to avoid any false associations. Thus, nine related isolates were 
removed, leaving 45 isolates for analysis, and types with three or more isolates were 
investigated. The pertactin and pertussis toxin SI subunit gene typing data were included in 
tliis analysis. AU 12 pru A i^  isolates were ptxA{l), and the nine p tx A i^  isolates were aU 
prnA(l). The predominant RFLP and PFGE types also had strong associations with 
pertussis toxin SI gene types; RFLP-1 isolates were aUptxA (l)  (n=16); and aU but one 
PFGE-1 isolates wereptxA (l)  (n= 13/14). The same 13 PFGE-1 isolates were mostly 
prnA(V) (n~12/13). RFLP-3 isolates werep txA (\)  (n=5) and RFLP-7 isolates wereprnA{\) 
(n=3). Other linkage was related to PFG E types, but was based on groups with only three 
isolates; three PFGE-4 isolates were serotype l,3,/imA[(2) andptxA(V)-, and tliree PFGE-5 
isolates were serotype \,2,?),prnA{\.) andptxAÇ ).
There was no apparent continuity between the association of predominant types by one 
typing method and another type by another method, except for those stated above. For 
example, RFLP-1 isolates (n=20) were associated witli eight different PFGE types and 
conversely PFGE-1 isolates (n=16) are associated with seven RFLP types.
5.3.6 Comparison of ISi<?^.2-RFLP analysis and PFGE profiles by in  silico  
and observed analysis of the Tohama-I strain
The IS / 002-RFLP band sizes estimated from the experimental analysis of the Tohama-I 
strain, after cleavage with Smal enzyme and hybridisation of the IS/0(?2 element, were 
exported from BioNumerics. The sequenced Tohama-I genome was cleaved in silico using 
the Smal recognition site in tlie software program Kodon, to locate the six predicted copies 
of the 1S1002 element. The restriction endonuclease Smal is a frequent cutter in the GC- 
rich (68% G+C mol) B. pertussis gosiome,, and the in silica digest generated 1564 fragments 
ranging from 6 to 27,563 bp from the 4 Mb genome. This does not however reveal where 
the six copies o f the 1^1002 element are located. A second in silico step was thus required, 
searching the annotated genome for the 1S>1002 elements, recording their positions and 
matching corresponding positions from the L/Wal-digested fragments. Table 5.5 (page 204) 
shows the comparison of the actual fragment sizes witli the in silico IS/(902-containing Smal 
fragments.
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Only five majoi* bands were produced experimentally by IS/OO^-RFLP analysis with tlie 
Tohama-I strain, but there was a lower, fainter band of 4070 bp (Figure 5.5, page 205). 
When this sixth, smaller fragment was included into the comparison analysis, the 
differences in fragment sizes between the observed and expected IS/002-RFLP profiles 
were small, ranging from 39 to 1968 bp (0.8-15.5% difference).
The in silico digest usitig the rare cutter recognition site of iKbal, to simulate the PFGE 
results with the Tohama-I strain, was more straightforward than the IS/002-RFLP analysis. 
The observed band sizes of the experimental PFGE analysis were exported from 
BioNumerics. Twenty-six fragments were generated ranging from 1236 to 789,751 bp. 
Kodon can also generate an image of the fragments as predicted if electrophoresed on an 
agarose gel. Figure 5.6 (page 207) shows the virtual gel analysis of the expected %^al-digest 
and of the observed profile of the Tohama-I genome and strain, respectively. The fragment 
range was limited to show those between 48,500 and 1,018,500 bp, as this was the range of 
the fragments visualised from the lambda ladder used in the PFG E experiments. The two 
profiles were very similar and this was supported by the band size comparison (Table 5.6, 
page 206). Although there were only 19 fragments from the observed Tohama-I PFGE 
profile, tlie two extra fragments generated from tlie in silico digest (134,788 and 107,399 bp) 
were relatively close to two other in silico fragments (135,100 and 102,981 bp, respectively) 
and have probably co-migrated (Figure 5.6, page 207). The difference in band size ranges 
from 21 to 13,641 bp (0.1-14.1% difference).
5.4 D iscussion
Various typing methods have been recommended for B. pertussis m  either; comparing the 
tliree typing methods PFGE, RAPD and ERIC-PCR (Moissenet et al, 1996); studying 
population genetics using IS/002-RFLP analysis (Musser et aL, 1986; van der Zee et at,
1997); or investigating outbreak situations witli PFGE (de Moissac et al^ 1994; Beall et al^ 
1995; Mooi et al, 2000). These recommendations are, however, subjective and the method 
is chosen usually to support the initial aims and objectives of the authors. Therefore, in this 
project, various typing methods were evaluated with a carefully selected panel of coded 
isolates, which included epidemiologically-linked and replicate isolates.
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Table 5.5. A comparison of observed and predicted band sizes of
fragments containing the IS elements of the Bordetella pertu ssis
Tohama-I strain
Observed/estimated 
RFLP band sizes (bp)
Expected/in silico 
band sizes (bp)
Difference in bp between observed 
and expected (% difference)
13700 11732 1968 (15.48)
11900 10671 1229 (10.89)
10400 9867 533 (5.26)
7670 6819 851 (11.75)
4880 4919 39 (0.80)
4070* 4169 99 (2.40)
*Tliis band was omitted for analysis of the coded typing panel. It is highlighted for the purposes of 
the comparison with the in silico results only.
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Figure 5.5. The observed ISi(?ft2-RFLP profile o f the B ordetella  
perfii55/s Tohama-I strain
Base pairs
13700
11900
10400
7670
4880
4070*
* T h i s  b a n d  w a s  o m i t t e d  f o r  a n a l y s i s  o f  t h e  c o d e d  t y p i n g  p a n e l .  I t  i s  h i g h l i g h t e d  f o r  t h e  p u r p o s e s  o f  
t h e  c o m p a r i s o n  w i t h  t h e  in silico r e s u l t s  o n l y .
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Table 5.6. A comparison of observed and expected band sizes of the
PFGE fragments of Bordetella  permss/s Tohama-I with X ba\
Observed/estimated 
band sizes (bp)
Expected/ in  silico 
band sizes (bp)
Difference in bp between observed 
and expected (% difference)
776110 789751 13641 (1.73)
370040 369791 249 (0.07)
335970 336766 796 (0.24)
314920 313494 1426 (0.45)
291920 295784 3864 (1.31)
204570 206090 1520 (0.74)
198110 200073 1963 (0.98)
174070 175438 1368 (0.78)
167620 169544 1924 (1.13)
152670 155290 2620 (1.69)
135000* 135100 100 (0.07)134788 212 (0.16)
104780* 107399 2619 (2.44)102981 1799 (1.75)
99630 99609 21 (0.02)
96240 97452 1212 (1.24)
85300 90412 5112 (5.65)
71680 78541 6861 (8.74)
56000 64970 8970 (13.81)
50720 59045 8325 (14.10)
39830 41187 1357 (3.29)
^Fragments visualised as one band on the observed PFGE profile, probably due to co-migration of 
the corresponding expected bands.
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Figure 5.6. A comparison of observed and expected band sizes of the
PFGE fragments of Bordetella pertu ssis Toham^iA with X bal
Expected 
size, (bp) 
789751 .
Observed 
size, (bp)
#— 776110
369791336766313494295784
370040
335970314920
291920
206090 & 200073
175438 & 169544
155290
135100 & 134788
107399, 102981, 
99609 & 97452
9041278541
6497059045
41187
204570 & 198110
174070 & 167620
152670
13500*
104780*, 99630 
& 96240
85300
71680
56000
50720
39830
* T h e  o b s e r v e d  f r a g m e n t s  c o r r e s p o n d  w i t h  t w o  e x p e c t e d  b a n d s  o n  t h e  a d j a c e n t  p r o f i l e .
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5.4.1 The suitability of the Bordetella pertu ssis typing panel
The panel of isolates comprised only 53 coded strains, and was used to calculate typability, 
reproducibility, index of discrimination and epidemiological concordance values to allow 
accurate comparisons of the different typing methods. However, there were a number of 
shortfalls of the panel. The availability of well-characterised, epidemiologically-linked 
isolates was limited, therefore only pairs of isolates originating from related family 
members were included in die panel. Unfortunately, one pair was eliminated from the 
analysis as one of the isolates was mixed with K  parapertussis. Hence, a future panel for 
further studies should contain more related isolates to calculate the epidemiological 
concordance value with more confidence, which would enable die panel to adhere to 
recommended guidelines to include five or more outbreak-related sets (Struelens et a/., 
1996).
The panel only included six replicates, including four UK vaccine strains, the B. pertussis 
type strain (NCTC 10739^) and one clinical isolate from 1999. Thus the reproducibility 
value may not be representative of the whole B. pertussis population.
One o f the replicates, UK 49, did not appear to be the same as the original strain CN5476. 
This strain differed from its pair in serotype, IS/ddi'-RFLP and PFG E type. Serotyping of 
UK 49 was repeated but the results remained the same (serotype 1). The only possible 
explanation for this discrepancy was incorrect labelling during the coding of the panel. It is 
noteworthy that the panel contained an isolate UK 10 (CN 3108), which had the same 
profile: serotype 1, PFGE-13 and RFLP-1, as that of UK 49. For these reasons, results 
from UK 49 and its replicate UK 44 were excluded from the analyses. As for tlie 
epidemiological concordance, again, the calculated reproducibility value would be more 
ideal if a larger number of replicates were used.
The pertactin and pertussis toxin SI gene types were completed before the isolates were 
selected for the panel, and are presented in Chapter 3. This gene typing data were also used 
to select some of the strains and were therefore excluded from tliis evaluation. ITowever, 
this information is used in the discussion so that comparisons with other typing methods 
could be made. These B. pertussis isolates have now become a well-characterised panel, used 
for investigation of sequence polymorphism in other gene markers (Packard et aL, 2004).
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5.4.2 Evaluation of the typing methods
The typing methods sero typing, PFGE typing (using XbaV) and IS/002-RFLP analysis were 
assessed using tlie B. pertussis panel. Typability, reproducibility, index of discrimination and 
epidemiological concordance values were calculated according to the Consensus Guidelines 
for Microbial Epidemiologic Typing Systems (Struelens et aL., 1996). Convenience criteria 
such as ease of use and interpretation, analysis time and cost of methods were also 
evaluated. These are summarised in Table 5.7 (page 211), which includes the pertactin and 
pertussis toxin SI subunit gene typing values not generated when the isolates were coded, 
but are nevertlieless shown to compare the various methods. The observed and the 
expected results of the methods IS/002-RFLP analysis and PFGE typing using an in silico 
digest o f the B. pertussis Tohama.-] strain and genome is also compared and described. The 
stability of each typing metliod was not assessed using the panel of isolates. According to 
Struelens and co-authors (1996), at least 10 strains should be studied after every fifth 
passage in an experiment of 50 serial passages and thus yielding 100 tests to be performed 
for each typing method.
There is some linkage between types of one mediod and types of other methods. These 
include: 15/16 PFGE-1 isolates prnA.(\) andptxA (\)\ aUp7'nA(T) isolates areptxA{\)\ 
aUptxAÇl) isolates areprnAip). These groups are not mutually exclusive with other method 
types, but can be described as clonal. Other, smaller clonal lineages are based on PFGE 
types, but these also show divergence in another typing method. For example, PFGE-3 
isolates are serotype l,3,^/7Z/4(2) andptxA(V), but generate two different RFLP types. So, 
although these linkages are not statistically vaHd, they can be viewed as true relationships, 
as the B. pertussis panel was originally chosen to comprise a large diversity.
When evaluating die various typing methods, there are several factors to consider:
1) The typability of a method is dependent on the user's skill and whether the definition of 
a type has a distinct end-point. Repeating a test is not reflected in the typability value, T, 
and diere are no guidelines in the literature as to how many attempts should be made on an 
untypcable isolate (Maslow et al, 1993; Struelens et aL, 1996; van Belkum et aL, 2001). Tins 
is therefore at the user’s discretion, and for data shown in this study, the author attempted 
serotyping on some isolates from the coded panel at three separate events (5.3.1, page 192). 
Also, it is rare for a DNA fingerprinting technique to fail, as bands can generally be 
visualised even, for example, if the restriction endonuclease step is not completed. An
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isolate would therefore produce a fingerpriiit profile and, whether it is valid or not, it will 
be assigned a type, and thus the typability value of these methods would be T=1.00.
2) Struelens and colleagues (1996) advise the use of a typing scheme that gives an index 
discrimination of D>0.95, although Hunter and Gaston (1988) recommend a more realistic 
value of over 0.90 as deskable. If  this cannot be achieved by one method, then it is possible 
to combine methods to reach a higher value. This may produce a system tliat has too much 
resolving power than is actually required, and die initial purpose of the system may be 
over-looked (i.e., to show epidemiologically-linked isolates related by a typing mediod, and 
not to separate them by using a more discriminatory one) (Maslow and MuUigan, 1996).
3) Different typing methods may monitor different genetic events that an organism can 
undergo. In the case of B. pertussis, serotyping relies on expression o f the fimbrial genes, 
ftm2 and fim3. There can be many genetic events altering the expression of these genes, but 
in B. pertussis, fimbrial variation is thought to be due to the sHpped-strand mis-pairing 
phenomenon (Wülems et al., 1990). DNA sequencing elucidates any variation in the genes 
encoding the virulence factors pertactin and pertussis toxin SI, which may be under 
environmental constraint due to the introduction of pertussis vaccines (Mooi et al., 1998). 
Point mutations and recombination are seen in these two virulence genes, which may be 
due to this environmental constraint (van Belkum et al., 2001). Sequencing and serotyping 
investigate specific genes, whereas PFGE and IS/662-RFLP analysis are dependent on 
restriction endonuclease sites and/or insertion elements situated dirougliout the entire 
genome. Both methods can monitor the same genetic events such as point mutations, 
recombination, inversions and the acquisition of transposons (van BeHmm el al, 2001), but 
1S/062-RFLP analysis limits tliis visualisation, as the transposable element 1^1002 is 
hybridised to only a few fragments. It is tlierefore not clear whether a mutation at the Smal 
restriction site is influencing the differences between lS/f?62-RFLP profiles (observed as 
differences in position of labelled fragments), or if it is the acquisition of the insertion 
element into a different part of the B. pertussis genome. Hence, there are many genetic 
events that can be monitored by these various typing metliods, and the choice of a 
particular method can greatly affect how the results are interpreted for epidemiological or 
genetic diversity studies.
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Serotyping was the only phenotypic method assessed, and has been widely used to type J3. 
pertussis isolates to investigate population trends in terms of vaccine efficacy and epidemic 
investigations (Preston and Carter, 1992; Khattak et al.^  1992). This method is easy to use, 
inexpensive and the end-point (by slide-agglutination) is easy to determine (Table 5.7, page 
211). Seven isolates from the panel of 53 expressed only agglutinogen 1, which is reported 
to be rare in isolates from humans (Preston, 1988; Roberts and Parton, 2001). The index of 
discrimination was also perhaps over-estimated, as circulating B. pertussis strains express 
three of the four different serotypes. Thus the index of discrimination would be much 
lower if the serotype 1 isolates were to be removed from the calculation (D—0.65 cf. 0.71). 
Recent recommendations for serotyping B. pertussis suggest tlie use of monoclonal 
antibodies against Fim2 and Fim3, over the use of polyclonal antisera to agglutinogens 1, 2 
and 3 (Mooi et al, 2000). If these recommendations had been followed, serotype 1 -only 
isolates would not have been typed, and both the index of discrimination and the typability 
value would have decreased.
The DNA fingerprinting methods, PFGE (using XbaT) and IS/002-RFLP analysis gave 
similar scores for botli the calculated value and the convenience criteria. Pulsed-field gel 
electrophoresis and IS/ti02-RFLP analysis are botli technically difficult, labour intensive, 
and require at least five days to generate a type. Interpretation can also be quite 
problematic; sophisticated software aids this process but it still relies to some extent on the 
user’s definition of a type. The exclusion and inclusion of bands can greatly affect tlie 
profile and the subsequent index of discrimination of the method. Interestingly, PFGE 
profiles contained approximately 20 bands, and IS / 002-RFLP generated between only 
three to nine bands, but they score similar indices of discrimination (D=0.89 cf. 0.83, 
respectively). This low number o f bands does not fit the recommended criteria of Struelens 
et al (1996) of about 30, but the resulting index of discrimination is high for both PFGE 
and IS/002-RFLP analysis. The method of designating types also affects tlie discrimination; 
either by building an identification library to screen unknown types: or by clustering known 
types with unknown ones, and using a defined similarity cut-off to group and assign types. 
The latter method was used for both PFGE and IS/002-RFLP analysis, although this step 
also relies on user-defined subjectivity. If time had allowed, the author would have 
preferred to set up an identification library for both PFGE and IS / 002-RFLP analysis.
The epidemiological concordance value was E —0.67 for both PFG E and IS / 092-RFLP 
analysis. This was dependent on three paits of epidemioloigically-related isolates, and both 
typing methods generated contradictory profiles witli two different paies. The
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brother/sister pair, UK 51 and UK 53, produced RFLP types that differed by the gain/loss 
of one band, and the father/son paie, UK 52 and UK 54, differed in three bands o f their 
corresponding PFGE fingerprints. According to Tenover et al. (1995), the pair that differed 
with PFGE are closely related as the three band difference corresponds to one genetic 
event, namely a gain of a restriction site in UK 54, or vice versa (Figure 5.4, page 201). It was 
unexpected and unusual that two epidemiologicaUy-related pairs were different by two 
separate methods, and this questions either the relatedness of the isolate pairs or of the 
typing method used. However, PFG E has, on numerous occasions, been shown to cluster 
epidemiologicaUy-related strains (de Moissac et ai^ 1994; Beall et al., 1995; Bisgard et al, 
2001; Brennan et al, 2000), whereas IS/002-RFLP analysis has not been used for this 
purpose.
The two gene targets, pertactin and pertussis toxin SI subunit, were not included for 
evaluation, but the values are shown in Table 5.7 (page 211) to discuss. The two metliods 
generated very similar values and convenience criteria scorings, because the same technique 
was used; PCR amplification, purification and subsequent direct sequencing of the targets. 
Only the discriminatory power differed (D=0.51 cf. 0.37) with prnA. typing scoring liigher 
than p txA  typing. This difference is due to the number o f types seen, and the isolates 
chosen for the panel contained fourpm A  types and threep tx A  types. By combining the 
prnA  and p txA  types, the index of discrimination increases to 79=0.70, but tliis still does 
not comply with the recommendations of Struelens et al (1996) or Hunter and Gaston 
(1988) of an ideal value of D>0.95 or 0.90, respectively. The typability, reproducibility and 
epidemiological concordance values forpruA  andp txA  are excellent at 1.00 (Table 5.7, 
page 211), but the types were determined before coding the panel. However, the author has 
confidence that these values reflect the methods witli equal merit, as they have been 
undertaken extensively throughout the thesis. Furthermore, when the determination of 
over 95% of the pertactin gene was performed upon six UK cHnical isolates, six USA 
clinical isolates and three vaccine strains (Chapters 3 and 4), all sequencing was double­
stranded and there were numerous occasions where three or four strands would overlap, 
including the polymorpliic region, region 1, and were completely concordant. However, 
disadvantages include the number of steps involved in the methods, the high cost of the 
sequencing equipment and reagents and, without automated systems, it is labour intensive 
and takes three days to achieve a type allocation.
The availability of the annotated Tohama-I genome enabled a direct comparison
between the observed results, generated using IS/d(?2-RFLP analysis and PFGE, and the
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predicted results of in silico digests using Smdi and Xbal recognition sites, respectively. 
Observed sizes of the IS / 002-contarning Smal-ôxgeste.d fragments appeared larger tlian the 
predicted sizes for most of the bands (Table 5.5, page 204). This is possibly due to the 
difference between the commmerciaUy available DIG-labelled DNA molecular weight 
marker II (Roche), which has a photodigoxigenin introduced at approximately every 200^’’ 
to 300* base in the DNA fragments, and the unlabeUed DNA digest investigated, resulting 
in a potential electrophoretic difference in the migration of fragments. Furthermore, it had 
been reported previously that the Tohama-I genome only had five copies of the YS1002 
element (Figures 5.1 and 5.5, pages 196 and 205, respectively) (van der Zee et al, 1997). 
However, a sixth smaller 4070 bp weakly-hybridised band is present and is also found in 
the annotated Tohama-I genome (Table 1.4, page 41) (ParkhiU et al, 2003).
The predicted and observed PFGE results were also similar when comparing the various 
fragment sizes. However, the in silico digest of tlie Tohama-I genome revealed two extra 
bands which, in the observed profile, could have been masked by co-migration events, and 
that there is, in general, a greater effect o f error at the top of the gel where high mass bands 
migrate, compared to the bottom of the gel where low mass bands migrate. Tliis difference 
between tlie observed and expected band sizes may also be due to the algorithm used for 
both the reference systems for IS/002-RFLP analysis and PFG E in BioNumerics, which is 
a logarithmic-dependent cubic spline fit. Other algorithms were tried, such as a first degree 
fit or a pole fit, but the chosen algorithm gave less variation and created a Une of best fit 
through the band sizes of the marker used for tlie reference system. This genome analysis 
illustrates how an entire nucleotide sequence of an organism can aid the scientist in botli 
experimental design and in optimisation of current methodologies.
5.4.3 Recommendation of a typing system for Bordetella pertu ssis
Pulsed-field gel electrophoresis has been reported as an effective tool for the 
epidemiological study oiB . petiussis (Kliattak et al, 1992; de Moissac et al, 1994; BeaU et al, 
1995). This metliod was later compared with RAPD and ERIC-PCR, using 15 clinical 
isolates recovered within a two-year period and in tlie same geographical area (Moissenet et 
al, 1996). The authors concluded that PFG E was indeed the better discrirninatory tool out 
of the three methods, but no repHcates were added to test for reproducibUity, and no 
isolates from different geographical areas were included to verify whether the 
discrimination was at a practical level to apply to larger epidemiological investigations 
(Moissenet et al, 1996). A few years later, in May 1999, a meeting to standardise methods
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for the epidemiological typing of B. pertussis took place, where serotyping, PFGE and 
pertactin and pertussis toxin SI gene typing were agreed as the recommended methods 
(Mooi et al, 2000). However, this was largely based on what was currently employed, and 
no further standardisation has been implemented within this European group. There has 
been a recent study in the USA, investigating the reproducibility of PFGE in five 
laboratories, using three strains that had been tested weekly for three weeks (Hardwick et 
al, 2002). They assessed the variability of die molecular sizes of each DNA fragment, and 
found the reproducibility within a gel was very high, there were some inter-lab oratory 
variation, but the profiles generated were identified witli the correct designation.
Recommendation of a typing method based on work in this thesis is difficult. There are 
advantages and disadvantages for each method. The DNA fingerprinting methods PFGE 
and IS/002-RFLP analysis, although obtaining high indices of discrirnination (Table 5.7, 
page 211), have low epidemiological concordance values and are difficult and laborious to 
use. However, the other methods have liigher epidemiological concordance values, but 
theit D  values are low. Serotyping is rapid and inexpensive, but pr/iA and p txA  gene typing 
are expensive and can take up to three days for a result. Struelens et al. (1996) advise that if 
the index of discrnnination power is not high enough, it may be easier to combine methods 
than to refine a difficult one. Although the prnA  andp txA  gene typing was not performed 
as part of the evaluation, I could have proposed tlie use of these metliods in conjunction 
with serotyping, as the index of discrimination increases to 0.89 (according to the panel 
results), wliich equals that o f PFGE. This D  value is also very close to 0.90, considered as 
desirable by Hunter and Gaston (1988). The option of semi-automated sequencing systems 
increases the ease of use of this system. The disadvantage of using these three methods 
together is that only defined genes are tested for variability or expression, as opposed to 
PFGE, which analyses the whole genome. Furthermore, there is a strong association of 
serotype and pertactin gene type, where recent UK islolates have been predominantly 
serotype 1,3 andprnA(2), and all recent isolates areptxA{l), thus restricting the 
discrimination and epidemiological concordance value. Therefore, if more time was 
allocated to optimise and evaluate PFGE, this would have been the recommended method. 
Regrettably, at the time of writing, the author cannot recommend a method to 
epidemiologicaUy type B. pertussis.
A multi-locus sequence typing (MUST) scheme has been devised recently by van Loo et al. 
(2002). This targets three surface protein genes, pertussis toxin SI, pertussis toxin S3 (ptxC) 
and tracheal colonisation factor {tcf) but, surprisingly, not pertactin. These additional
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targets (pertussis toxin S3 and tracheal colonisation factor) have also been shown to have 
polymorphism in UK isolates, where two ptxC  and five tcf alleles have been found between 
1920 and 2002 (Packard et aL, 2004). These additional targets could be used in conjunction 
with serotyping and prnA  andp txA  gene typing, although tlris scheme may not be adequate 
to discrirninate for outbreak settings.
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6 Novel Bordetella pertussis gene targets for 
epidemiological typing’*'
 ^Note: During the course of this thesis, Van Loo et al. (2002) reported an MLST scheme based on surface 
protein genes, mbich may have affected the approach of this work.
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6.1 Strategy
The use of pertactin and pertussis toxin SI gene sequencing for the epidemiological typing 
for B. pertussis have been used in this thesis (Chapters 3 and 4) and various countries 
(Mastrantonio et al., 1999; Mooi et al., 1998 and 1999). However, the discrimination of this 
typing scheme could be improved by adding otlier variable gene targets to the sequencing 
scheme. This multi-locus sequence approach has been successful for many bacteria and, 
although originally based on house-keeping genes (Enright and Spratt, 1998; Maiden et al.,
1998), other genes such as virulence factors can be targeted for inclusion of such a typing 
scheme (Gaia et al., 2003). Two strategies were used to identify suitable polymorpliic genes 
o f J3. pertussis.
The first strategy examined the MLEE technique used previously for Bordetella species, to 
identify any differences in electrophoretic mobilities in the enzymes tested (Musser et al, 
1986; van der Zee et al., 1997). Only four of tlie 15 enzymes used in the Bordetella scheme 
showed such variation for B. pertussis", phosphoglucomutase, adenylate kinase, leucine 
aminopeptidase and glutamic oxaloacetic transaminase. The genes encoding tliese enzymes 
should therefore contain sequence polymorphisms that could be useful for typing B. 
pertussis. However, at the time of tliis project, sequence data were available only for 
adenylate Idnase {adli), a tryptophan-containing enzyme that phosphoiylates adenosine 
monophosphate (AMP) (GenBank accession number Z29715).
The second strategy focused on tlie study of virulence-associated genes for any possible 
polymorpliisms. One virulence gene, tliat encoding filamentous haemagglutinin (JhaB), was 
screened for such variation. Filamentous haemagglutinin was chosen for its similarity to 
pertactin, as they are both adhesins, possess repeat domains and are included as important 
immunogens in WCVs and AC Vs (1.2.3.1, page 12). Filamentous haemagglutinin could 
therefore contain polymorphisms similar to pertactin in either the repeat unit number or 
tlie composition of the repeats. The JhaB sequence, X53405, deposited in the GenBank 
database by Dehsse-Gathoye and colleagues (1990), is derived from the Tohama-I strain.
6.2 M ethods
The descriptions of PCR preparation, purification of PCR products and the sequencing 
method are detailed in sections 2.5.2, 2.5.5 and 2.5.6 (pages 63, 76 and 77), respectively. 
The primers designed for both targets are listed in Table 2.3 (page 66). Amplification and 
optimisation parameters specific to tlie adk and JhaB gene targets are described below. For
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all targets identified and assessed, two temporaUy-different B. pertussis strains were used to 
test for polymorphism: the well-characterised type strain (NCTC 10739^, deposited before 
1947) and a clinical isolate (PICU 475) from 1999.
6.2.1 Adenylate kinase gene
The open reading frame of this gene (GenBank accession number Z29715) is 657 
nucleotides and oligonucleotides (primers) were designed to amplify a larger region 
encompassing this (702 bp).
Amplification of adk was tested using the following reaction mixtures with or without 10% 
v /v  DMSO: 2.5 mM MgCl^, 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP, 10 
pmol each of adkF and adkR primers, 2.5 U Baq DNA polymerase, and 10 or 100 ng 
template DNA. The cycling conditions involved an initial dénaturation at 95°C for 5 
minutes, then 30 cycles of 95°C for 30 or 45 seconds, annealing at 40-70°C for 30 or 45 
seconds, and extension of 72°C for 1 minute. Tliis was completed with a final extension of 
7 minutes at 72°C, and a 4”C hold. An ampHcon size of 702 bp was predicted.
6.2.2 Filamentous haemagglutinin gene
The JhaB sequence, X53405, was used to design the fourteen primers (Table 2.3, page 66) 
to amplify and sequence the fkst 3.5 Kb of the JhaB gene in various overlapping ampHcons.
To successfully amplify the 5'-end of the JhaB gene, two or three separate reactions 
targeting overlapping regions were attempted. The following five primer paits were 
evaluated; fha-224F and flia-1889R, fha-1705F and fha-3482R, fha-224F and fha-1366R, 
flia-1219F and fha-2361R and fha-2223F and fha-3482R, producing amplimers of 1682, 
1796, 1159, 1159, and 1277 bp, respectively (Figure 6.1, page 221). AU primer pairs were 
optimised in the foUowing reaction mixtures with or without 10% v /v  DMSO; 1.5-5.5 mM 
MgCfy 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP, 10 pmol each of forward 
and reverse primers, 2.5 U Taq DNA polymerase, and 10 or 100 ng template DNA.
AU reactions were run with optimisation parameters of initial dénaturation at 95“C for 5 
minutes, foUowed by 30 cycles of 95°C for 30 or 45 seconds, annealing between 40-70"C 
for 30 or 45 seconds, and extension of 72°C for 1 minute, with a final extension at 72°C for 
7 minutes, and a 4°C hold.
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The amplification o f the JhaB gene was not completely optimised, and details ate given in 
section 6.3.2 (page 226).
6.3 Results
6.3.1 Adenylate kinase gene
Figure 6.2 (page 222) illustrates the optimised ampHfication using 10 ng of DNA template, 
10% DMSO, and varying the annealing temperature from 40”C to 64°C. No products were 
visualised when no DMSO was added and 100 ng of DNA was used. Flence, amplification 
o f the adenylate kinase gene was successfully optimised when tlie reaction mixtures 
contained 10% DMSO, 2.5 mM MgCfy 10 mM Tris-FICl (pFI 8.3), 2.5 mM KCl, 200 pM 
dNTP, 10 pmol of each primer, 2.5 U Taq DNA polymerase and 10 ng of template DNA. 
The optimum cycHng conditions had an initial dénaturation at 95°C for 5 minutes, then 30 
cycles consisting of dénaturation at 95°C for 45 seconds, annealing at 50°C for 45 seconds, 
and extension at 72°C for 1 minute, followed by a final extension of 7 minutes at 72°C, 
with a final 4°C hold.
Both NCTC 10739^ and PICU 475 generated discrete bands of approximately 700 bp 
(Figure 6.2, page 222), and the two adk amplicons were purified and sequenced. The 
subsequent sequence data were of sufficient quality to investigate for polymorphisms. An 
alignment of these two adk sequences with that deposited in GenBank (accession number 
Z29715) (derived from the type strain oiB.pertussis 18323fy revealed a single nucleotide 
difference (A—»G) in the generated sequence from strain NCTC 10739^ (Figure 6.3, page 
223). This confers as a predicted amino acid difference; a glutamic acid (E) in the deposited 
sequence and a glycine (G) in the NCTC 10739^ strain sequenced. The NCTC 10739^ 
sequence started at position 12 and finished at position 634, according to the start codon 
position ATG of the deposited sequence, and was 622 nucleotides long. The deposited 
sequence Z29715 showed no differences with the 645 nucleotides generated from PICU 
475 (start at —8, stop at 637). Therefore, there was one nucleotide difference between the 
adk sequences generated from NCTC 10739^ and PICU 475 at position 364 (Figure 6,3, 
page 223).
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Figure 6.3. Nucleic acid alignment of the B ordetella p ertu ssis  adenylate
kinase gene
C o n s e n s u s  : GCCGCCGGCGTGGACACGCCAGCCGACCTGGAACGTGCCCGGGCCGCATA
Z 2 9 7 1 5  : GCCGCCGGCGTGGACACGCCAGCCGACCTGGAACGTGCCCGGGCCGCATA
NCTC 1 0 7 3 9  : 
PICU 4 7 5 :
C o n s e n s u s  
Z 2 9 7 1 5  
NCTC 1 0 7 3 9 ^  
PICU 4 7 5
C o n s e n s u s  : 
Z 2 9 7 1 5 :  
NCTC 10739"^ : 
PICU 4 7 5 :
CACGAATCGGTTATAAGGGTTATTTCCCATGGCGCGGCCCCACATCCGGT
CACGAATCGGTTATAAGGGTTATTTCCCATGGCGCGGCCCCACATCCGGT
B p - a d k F
GCTGCATTGCGGCATAATCGCCCCGATCACAAAAAACAAACCCATCAGGA
GCTGCATTGCGGCATAATCGCCCCGATCACAAAAAACAAACCCATCAGGA
■GA
C o n s e n s u s  : GCCCCCATGCGTCTCATTCTGCTCGGACCGCCCGGAGCCGGCAAAGGCAC 
W  R L I L L G P P G A G K G T  
Z 2 9 7 1 5  : GCCCCCATGCGTCTCATTCTGCTCGGACCGCCCGGAGCCGGCAAAGGCAC
NCTC 1 0 7 3 9 ^ :  --------------------------------------- CTGCTCGGACCGCCCGGAGCCGGCAAAGGCAC
PICU 4 7 5 :  GCCCCCATGCGTCTCATTCTGCTCGGACCGCCCGGAGCCGGCAAAGGCAC
44
C o n s e n s u s  : CCAAGCCGCCTTTCTCACCCAACACTACGGCATCCCGCAGATATCCACCG 
Q A A F L T Q H Y G I P Q I S T  
Z 2 9 7 1 5 : CCAAGCCGCCTTTCTCACCCAACACTACGGCATCCCGCAGATATCCACCG 
NCTC 1 0 7 3 9 ^ :  CCAAGCCGCCTTTCTCACCCAACACTACGGCATCCCGCAGATATCCACCG 
PICU 4 7 5 :  CCAAGCCGCCTTTCTCACCCAACACTACGGCATCCCGCAGATATCCACCG
94
C o n s e n s u s  : GTGACATGCTGCGCGCCGCCGTCAAGGCCGGCACGCCGCTGGGCCTGGAA 
G D M L R A A V K A G T P L G L E
GTGACATGCTGCGCGCCGCCGTCAAGGCCGGCACGCCGCTGGGCCTGGAA 
GTGACATGCTGCGCGCCGCCGTCAAGGCCGGCACGCCGCTGGGCCTGGAA
Z 2 9 7 1 5TNCTC 1 0 7 3 9
PICU 4 7 5 :  GTGACATGCTGCGCGCCGCCGTCAAGGCCGGCACGCCGCTGGGCCTGGAA
144
C o n s e n s u s  : GCCAAGAAGGTCATGGACGCGGGCGGCCTGGTCTCGGACGACCTGATCAT 
A K K V M D A G G L V S D D L I I  
Z 2 9 7 1 5  : GCCAAGAAGGTCATGGACGCGGGCGGCCTGGTCTCGGACGACCTGATCAT 
NCTC 1 0 7  3 9 ’*' : GCCAAGAAGGTCATGGACGCGGGCGGCCTGGTCTCGGACGACCTGATCAT 
PICU 4 7 5 :  GCCAAGAAGGTCATGGACGCGGGCGGCCTGGTCTCGGACGACCTGATCAT
19 4
C o n s e n s u s
Z 2 9 7 1 5  
NCTC 10739* ' 
PICU 4 7 5
CGGCCTGGTGCGCGATCGCCTGACCCAGCCCGATTGCGCCAACGGCTACC
G L V R D R L T Q P D C A N G Y
CGGCCTGGTGCGCGATCGCCTGACCCAGCCCGATTGCGCCAACGGCTACC
CGGCCTGGTGCGCGATCGCCTGACCCAGCCCGATTGCGCCAACGGCTACC
CGGCCTGGTGCGCGATCGCCTGACCCAGCCCGATTGCGCCAACGGCTACC
2 4 4
C o n s e n s u s
Z 2 9 7 1 5  
NCTC 1 0 7 3 9 ^  
PICU 4 7 5
TGTTCGACGGTTTCCCGCGCACCATCCCGCAGGCCGACGCGCTCAAGAGC
L F D G F P R T I P Q A D A L K S
TGTTCGACGGTTTCCCGCGCACCATCCCGCAGGCCGACGCGCTCAAGAGC
TGTTCGACGGTTTCCCGCGCACCATCCCGCAGGCCGACGCGCTCAAGAGC
TGTTCGACGGTTTCCCGCGCACCATCCCGCAGGCCGACGCGCTCAAGAGC
2 9 4
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Figure 6.3. N u cle ic  acid alignm ent o f the Bordetella pertussis adenylate kinase
gene, continued
C o n s e n s u s
Z 2 9 7 1 5  
NCTC 1 0 7 3 9 '  
PICU 4 7 5
B p - a d k M
:gga^ cGCCGGCATCGCGCTGGATTACGTGGTCGAGATCGAAGTGCCGGAAAGCGA
A G I A L D Y V V E I E V P E S D
GCCGGCATCGCGCTGGAn’ACGTGGTCGAGATCGAAGTGCCGGAAAGCGA
GCCGGCATCGCGCTGGATTACGTGGTCGAGATCGAAGTGCCGGAAAGCGA
GCCGGCATCGCGCTGGATTACGTGGTCGAGATCGAAGTGCCGGAAAGCGA
3 4 4
C o n s e n s u s  : CATCATCGAACGCATGAGCGRACGCCGCGTGCACCCGGCCAGCGGCCGCA 
I I E R M S - R R V H P A S G R  
Z 2 9 7 1 5  : CATCATCGAACGCATGAGCGAA' GCCGCGTGCACCCGGCCAGCGGCCGCA
E
:TC 1 0 7 3 9 *  : CATCATCGAACGCATGAGCGGACGCCGCGTGCACCCGGCCAGCGGCCGCA
G
PICU 4 7 5 :  CATCATCGAACGCATGAGCGAACGCCGCGTGCACCCGGCCAGCGGCCGCA
E
3 9 4
C o n s e n s u s
Z 2 9 7 1 5  
NCTC 10739'*'
g c t a c c a c g t a c g c t t c a a t c c g c c c a a g g c c g a a g g c g t g g a c g a c g t c
S Y H V R F N P P K A E G V D D V
GCTACCACGTACGCTTCAATCCGCCCAAGGCCGAAGGCGTGGACGACGTC 
GCTACCACGTACGCTTCAATCCGCCCAAGGCCGAAGGCGTGGACGACGTC 
PICU 4 7 5 :  GCTACCACGTACGCTTCAATCCGCCCAAGGCCGAAGGCGTGGACGACGTC
4 4 4
C o n s e n s u s  : ACGGGCGAACCGCTGGTGCAGCGCGACGACGACCGCGAGGAAACCGTGCG 
T G E P L V Q R D D D R E E T V R  
Z 2 9 7 1 5  : ACGGGCGAACCGCTGGTGCAGCGCGACGACGACCGCGAGGAAACCGTGCG 
NCTC 10739*^ : ACGGGCGAACCGCTGGTGCAGCGCGACGACGACCGCGAGGAAACCGTGCG 
PICU 4 7 5 :  ACGGGCGAACCGCTGGTGCAGCGCGACGACGACCGCGAGGAAACCGTGCG
4 9 4
C o n s e n s u s  : CCATCGTCTCAACGTCTACCAGAACCAGACCCGCCCGCTGGTCGACTACT 
H R L N V Y Q N Q T R P L V D Y
CCATCGTCTCAACGTCTACCAGAACCAGACCCGCCCGCTGGTCGACTACT 
CCATCGTCTCAACGTCTACCAGAACCAGACCCGCCCGCTGGTCGACTACT
Z 2 9 7 1 5TNCTC 1 0 7 3 9
PICU 4 7 5 :  CCATCGTCTCAACGTCTACCAGAACCAGACCCGCCCGCTGGTCGACTACT
54 4
C o n s e n s u s  : ACTCGTCCTGGGCCCAGTCCGATGCCGCCGCGGCGCCCAAGTACCGCAAG 
Y S S W A Q S D A A A A P K Y R K  
Z 2 9 7 1 5 : ACTCGTCCTGGGCCCAGTCCGATGCCGCCGCGGCGCCCAAGTACCGCAAG 
NCTC 1 0 7 3 9 ^  : ACTCGTCCTGGGCCCAGTCCGATGCCGCCGCGGCGCCCAAGTACCGCAAG 
PICU 4 7 5 :  ACTCGTCCTGGGCCCAGTCCGATGCCGCCGCGGCGCCCAAGTACCGCAAG
5 9 4
C o n s e n s u s
Z 2 9 7 1 5  
NCTC 10739* ' 
PICU 4 7 5
C o n s e n s u s
Z 2 9 7 1 5  
NCTC 1 0 7  39*' 
PICU 4 7 5
ATCTCCGGCGTCGGCTCGGTCGACGAAATCAAGAGCCGCCTGTCGCAGGC
I S G V G S V D E I K S R L S Q A
ATCTCCGGCGTCGGCTCGGTCGACGAAATCAAGAGCCGCCTGTCGCAGGC
ATCTCCGGCGTCGGCTCGC'CGACGAAATCAAGAGCCGCC---------------------
ATCTCCGGCGTCGGCTCGGTCGACGAAATCAAGAGCCGCCTGT---------------
B p - a d k R
6 4 4
6 5 7
TCTGCAGAGCTAAACCGCGCCGCGAGGCCGCCGCGCCGCCCGCGCAGGGG 
L Q S *
TC'iGCAGAGCTAAACCGCGCCGCGAGGCCGCCGCGCCGCCCGCGCAGGGG
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Figure 6.3. N u cle ic  acid alignm ent o f the Bordetella pertussis adenylate kinase
gene, continued
C o n s e n s u s  : TGCGCGGCCGCGCGCGCCCTGCCCGCCTTCAT
Z 2 9 7 1 5  : TGCGCGGCCGCGCGCGCCCTGCCCGCCTTCAT
NCTC 1 0 7  3 9 ’*': ----------------------------------------------------------------------
PICU 4 7 5 :  ----------------------------------------------------------------------
T h e  G e n B a n k  se q u e n c e , Z 2 9 7 1 5 , w a s u se d  to  align  th e  se q u e n c e s  g e n e ra te d  fr o m  N C T C  1 0 7 3 9  * 
an d  P IC U  4 7 5 . T h e  a m in o  ac id s are c o d e d  as th e  u n iv ersa l s in g le  le tter  d e s ig n a tio n s  (A p p e n d ix  1), 
a n d  are sh o w n  in  b lack  u n d ern ea th  th e  n u c le o tid e  c o d in g  se q u en ce ; th e  b la ck  h o r izo n ta l lin e  an d  
b lack  asterix  (*) in d ica te  th e  start and  s to p  c o d o n s  o f  aden y la te  k in a se , resp ectiv e ly . T h e  
o lig o n u c le o t id e  p o s it io n s  are illu stra ted  as b lu e  arrow s, w ith  th e  d ir ec tio n  a n d  n a m e  o f  prim er  
sh o w n .
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6.3,2 Filamentous haemagglutinin gene
Valions optimisation expeiiments weie peiformed. An initial attempt to amplify the 3514 
base pail legion using two oveilapping fiagments was laigely unsuccessful. The 5 -fiagment 
could not be amplified with piimeis fha-224F and fha-1889R. Piimeis fha-1705F and fha- 
3482R, although yielding a product of the predicted size of 1796 bp (Figure 6.4, page 227), 
other lower-sized fragments were also produced, which impeded tdie subsequent 
purification and sequencing of tlie targeted amplicon. Amplification of three smaller 
overlapping fragments was thus attempted and, during optimisation experhuents, single 
amplicons were produced of tlie predicted sizes. Figures 6.5 and 6.6 (pages 228 and 229) 
show the optimisation witli primers fha-224F and fha-1366R, and primers flia-1219F and 
fha-2361R respectively, by adjusting the MgCl^ concentration and the annealing 
temperature. The optimisation experiment using primers fha-2223F and fha-3482R is 
shown in Figure 6.7 (page 230).
Appropriate single amphcons were purified, sequenced and assembled into larger contigs 
using tlie GenBank sequence X53405 as a reference sequence for alignment.
Poor quality sequence data arose from both the two B. pertussis isolates, NCTC 10739 and 
PICU 475, but three and five contigs were produced, respectively, by aligning tlie data. No 
sequence data were available before position 1706 for NCTC 10739 and position 1753 for 
PICU 475 (position according to GenBank sequence X53405). Figure 6.8 (page 231) shows 
the pictorial representation of tlie arrangement and position of the various contigs for both 
of the B. pertussis strains. Altliough the sequences generated were not of good quality, there 
were four and three definite single nucleotide polymorphisms (SNPs) in NCTC 10739 and 
PICU 475, respectively, when compared witli the deposited sequence X53405 from the 
Tohama-I strain. The other differences shown in Figure 6.8 (page 231) were not judged to 
be true polymorphisms. The true SNPs were at the following codons for NCTC 10739 , 
with their respective amino acid changes: position 1799, G T G -^G A G  = valine->glutamic 
acid; 2745, CAA-^CAC = glutamine—^ -histidine; 3363, GTG—>GTA = valine; and 3445, 
GCC-^ACC = alanine—>threonine. Although PICU 475 generated single-stranded data 
only, SNPs were present at; position 1799, G TG —>GAG = valine-^glutamic acid; 2345, 
qq^Q—^ TCC = phenylalanine-^serine; and 3500, GGC—>GAC = glycine—^ aspartic acid. 
According to findings of DeUsse-Gathoye et al. (1990), the polymorphisms found in both 
strains at position 1799 correspond to tlie first region encoding a repetitive amino acid 
sequence. Another mutation at position 2745 lies within the second repetitive region.
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6.4 D iscu ssion
When investigating variability in genes for epidemiological typing, the clonaHty of the 
organism, the function of tlie gene and the motive of the researcher have to be considered. 
Bordetellapertussis is seen to be clonal when MLEE has been applied. Thus, variation in 
house-keeping genes is rare, but has been found in this study in the adenylate kinase gene. 
As the open reading frame of this gene is 657 bp, double-stranded consensus sequences 
can be produced for most of this gene using only two sequence reactions. However, 
variation was seen at only one nucleotide position and, although this translated to an amino 
acid difference, this was between tlie GenBank sequence Z29715 of 18323% and the 
sequence generated from this study of NCTC 10739^. Theoretically, there should not be 
any differences as they are from the same strain of B. pertussis and, interestingly, the 
sequence from PICU 475 did match the deposited sequence in GenBank. The data held at 
GenBank may not necessarily be correct, as there are no independent checks when 
sequence data is submitted. Furthermore the B. peiiussis adk deposited sequence could be 
wrong due to the relatively early production of the sequence (circa 1993) and the method 
used to generate the data (plasmid cloning and possibly a manual sequencing technique) 
(GiUes et al.^  1993). To check this discrepancy, further sequencing would be required, 
although the sequences generated for this study were from double-standed contigs. 
Sequencing of other isolates of B. pertussis  ^ ideally using the panel described in Chapter 5, 
would help determine whether adenylate Idnase could be used as an epidemiological 
marker.
As most of the house-keeping genes do not show variation (as seen in MLEE), and B. 
pertussis is shown to be mostly clonal, virulence genes could potentially be more 
polymorphic and thus would be good epidemiological markers. Indeed, pertactin and the 
81 subunit of pertussis toxin exhibit polymorphisms (Mooi et ai., 1998), but two recent 
papers from van Loo et al. (2002) and van Loo and Mooi (2002), report variation in other 
virulence genes, including tlie S3 subunit of pertussis toxin, fimbriae for serotype 2, a porin 
protein, tracheal colonisation factor, virulence-activated gene-8, Bvg-intermediated phase 
protein and filamentous haemagglutinin. Six polymorphisms from the two strains were 
identified from a region in the jhaB gene between positions 1799 and 3500. The two strains, 
the type strain NCTC 10739^, and the clinical strain PICU 475, were isolated over twenty 
years apart, where the type strain has been shown to be genetically distinct from otlier B. 
petiussis strains, and it was therefore expected to see differences between these two strains 
(Musser et aL, 1986; Gerlach et aL, 2001). The two SNPs that He within regions encoding
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amino acid repeat sequences translate to different amino acids. This is similar to the 
findings widi pertactin, although the PRN protein possesses direct repeat regions (Mooi et 
aL, 1998).
The one difference found in flaB  by van Loo et aL (2002) is at the same location (position 
2488) as one of the differences found in this study (position 2745, numbering notation of 
this study). Van Loo et aL (2002) initially based their data on 13 strains (origin not stated) 
and then confined the region investigated between positions 2250 and 2750 (their 
numbering commences on the first nucleotide of the coding region, which corresponds to 
2507-3007 for this study) in 22 strains. The additional polymorphisms identified in this 
study, which code for differences in the amino acid sequence of filamentous 
haemagglutinin, may also have virulence and vaccine impHcations, and further study may be 
useful. Indeed, the MLST scheme of van Loo et aL (2002) could also be enhanced with the 
extended JljaB sequence and fur tirer optimisation may increase the quality and reliability of 
tire data. The extent of polymorphism in JbaB could also be determined, as suggested for 
adenylate kinase, with the panel of B. pertussis isohx&s described in Chapter 5.
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7 Assessment of single-enzyme Amplified Fragment 
Length Polymorphism analysis of Bordetella
pertussis
234
7.1 Strategy
Single-enzyme AFLP analysis has been applied to several bacteria, including Legione/ia 
pneumophila, and tliis method has been chosen by the European Working Group on 
Legionella Infections (EWGLI) to standardise for use as an epidemiological typing scheme 
across 11 European countries (Fry et aL, 2000). As tliis method has been demonstrated 
previously to be flexible, simple, quick and relatively inexpensive, AFLP was attempted for 
this project on a selection of B. perttissis from Missouri, USA. The methodology and
assessment of this technique is described in this chapter only (and not in Chapter 2), as it 
has not been validated thoroughly to justify its use for epidemiological or population 
studies of B. pertussis.
7.2 M ethod
The B. pertussis isolates from Missouri, USA, wliich were previously investigated in Chapter 
4, were selected to attempt AFLP because they had been sorted into three sub-sets. Nine 
were chosen, where three were ' ‘Early” isolates, three were “Kansas City” isolates and three 
were “Recent” isolates. Theoretically, the “Early” isolates would show different profiles to 
tlie “Recent” isolates, and the “Kansas City” isolates, being geographically and temporally 
clustered witliin seven weeks between June and July 1999, could be of the same AFLP 
profile. In addition, typing data from Chapter 4 prnA ,ptxA , IS/OtiP-RFLP and
PFGE) were compared with the AFLP data for any associations between types.
The basic method was adapted from Valsangiacomo et al. (1995) and the standard EWGLI 
AFLP protocol as detailed on the EWGLI Legionella pneumophila Typing Database, 
http://www.hpa.org.uk/srmd/bioinfbrmatics/ewgh/ewgHmetli.htm (Fry et aL, 1999). 
Briefly, genomic DNA is digested witli a restriction enzyme and concurrently incubated 
with T4-DNA hgase and short adapters designed to Hnk to die newly restricted DNA 
fragments (Figure 7.1, page 236). These restricted fragments are then amplified with 
primers that match both the adapter sequence and part of the recognition sequence of the 
restriction enzyme. The numbers o f amplified fragments produced can be reduced by 
adding one or two extra bases on the primer. The amplified fragments are finally separated 
using conventional gel electrophoresis (Figure 7.1, page 236).
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Six enzymes and adapters were evaluated for band patterns produced witli the nine isolates. 
Two enzymes were frequent cutters containing a four base recognition sequence (Msel and 
Taql) and the other four were rare cutters, with a six base recognition sequence (/ipal, 
EcoKl, H indni and PstT) (Table 7.1, page 238). The adapters and non-selective primers for 
the above enzymes were taken from previous studies (Valsangiacomo et al, 1995; Janssen et 
al., 1996). Primers were used that select one in four or one in eight o f the digested and 
tagged fragments, by adding one or two nucleotides to the non-selective core primer 
sequence, respectively (Table 7.1, page 238).
7.2.1 Single step restriction-ligation of genomic DN A
Reactions were prepared in round-bottomed 1.5 ml Sarstedt tubes and consisted of 1.5 pg 
of genomic DNA (extracted by the method described in 2.4.1, page 60), 0.2 pg of each 
adapter-oligonucleotide (Table 7.1, page 238), 20 U of restriction endonuclease, 1 U of T4- 
DNA Hgase (Roche) and 1 x Hgation buffer (66 mM Tris-HCl, 5 mM MgClj, 1 mM 
dithioerythritol, 1 mM ATP, pH 7.5) (provided with T4-DNA Hgase). Nuclease-free water 
was added to a final volume of 20 pi and reactions were incubated at 37“C for 3 hours.
The tagged DNA fragments were then precipitated by die addition of ammonium acetate 
to a final concentration of 2.5 M in 100 pi (33 pi of 7.5 M ammonium acetate, 47 pi water, 
and 20 pi Hgation mix). One hundred microHtres of ice-cold 100% ethanol were also added, 
mixed gently, and the DNA allowed to precipitate for 5 minutes at room temperature. 
Tubes were then centrifuged at 4°C for 10 mhiutes at 12,000 x .^ After the supernate was 
removed, 100 pi of 70% ethanol were added to wash tlie peUet. The tubes were centrifuged 
as before. The ethanol was removed from the tubes and the peUets left to air-dry on the 
bench for approximately 15 to 30 minutes. The DNA was re-suspended in 100 pi of 1 x 
TE buffer and either used immediately for the PGR ampHfication (7.2.2, see below) or 
stored at —30“C until required.
7.2.2 PCR amplification of tagged D N A  fragments
Selective prhners were used to ampHfy a sub-set of the tagged DNA fragments produced, 
depending on the adapter sequence and the bases of the restricted DNA fragment directly 
adjacent to the adapter. These are Hsted m Table 7.1 (page 238).
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Table 7.1. Restriction endonucleases, adapters and primers used for
AFLP on Bordetella. p ertu ssis
E n z y m e / A d a p t e r /  
P r im e r  n a m e
R e c o g n i t io n  s e q u e n c e S u p p l i e r /  R eference
‘\pii\ G G G C C  i  C In teg ra  B io sc ie n c e s
A p a - 1 T C G T A G A C T G C G T A C A G G C C Janssen et aL (1996)
.A p a -2 C A T C T G A C G C A T G T Janssen et aL (1996)
A p a -A G A C T G C G T A C A G G C C A Janssen et aL (1996)
A p a -C G A C T G C G T A C A G G C C C T h is  th esis*
A p a -G G A C T G C G T A C A G G C C G Janssen et ai (1996)
A p a -T G A C T G C G T A C A G G C C T T h is  th esis*
A p a -A  r G A C T G C G T A C A G G C C A T T h is  th esis*
A p a -C G G A C T G C G T A C A G G C C C G T h is  th esis*
A p a -G C G A C T G C G T A C A G G C C G C T h is  th esis*
A p a -T A G A C T G C G T A C A G G C C T A T h is  th esis*
EcoK\ G f A A T T C R o c h e
1 \ C (  )- 1 C T C G T A G A C T G C G T A C C Janssen et aL (1996)
E c o -2 A A T T G G T A C G C A G T C Janssen et ai (1996)
E c o -C G A C T G C G T A C C A A T T C C Janssen et al. (1996)
E c o -G G A C T G C G T A C C A A T T C G T h is  th esis*
E c o -T G A C T G C G T A C C A A T T C T Vosetal. (1995)
HincaW A J A G C T T R o c h e
I iincl-1 C T C G T A G A C T G C G T A C C Janssen et al. (1996)
1 iinci-2 A G C T G G T A C G C A G T C Janssen et aL (1996)
I fin d -A G A C T G C G T A C C A G C T T A Janssen et al. (1996)
Mse\ T j T A A N e w  E n g la n d  B io L a b s
M s c - 1 G A C G A T G A G T C C T G A G Janssen et al. (1996)
M se -2 T A C T C A G G A C T C A T C Janssen et al. (1996)
M se-A G A T G A G T C C T G A G T A A A Janssen et a l (1996)
M se-C G A T G A G T C C T G A G T A A C Janssen et al. (1996)
M se-G G A T G A G T C C T G A G T A A G Vos et al. (1995)
M s e - r G A T G A G T C C T G A G T A A T Janssen et al. (1996)
M se-A  1 G A T G A G T C C T G A G T A A A T Vosetal. (1995)
IM C T G C A J G R o c h e
Pst-Ej^l C T C G T A G A C T G C G T A C A T G C A Valsanjifocomo et aL (1995)
P st-E g 2 T G T A C G C A G T C T A C Valsangiacomo et aL (1995)
P st G A C T G C G T A C A T G C A G Valsangiacomo et a i (1995)
P st-A G A C T G C G T A C A T G C A G A Valsangiacomo et al (1995)
Psr-C G A C T G C G T A C A T G C A G C Carter et al. (1998)
P st-G G A C T G C G T A C A T G C A G G Valsangiacomo et al (1995)
P st-T G A C T G C G T A C A T G C A G T Carter et al (1998)
Taq\ T f C G A R o c h e
l a q - l G A C G A T G A G T C C T G A G Janssen et al. (1996)
T a q -2 C G G T C A G G A C T C A T Janssen et al. (1996)
l a q - A C G A T G A G T C C T G A C C G A A Janssen et al. (1996)
E n z y m e s  are lis ted  in  red  w ith  their  r e c o g n it io n  s e q u e n c e  an d  th e  su p p lier  u sed . T h e  adap ters  
n a m e d  in  o ra n g e  h a v e  a n u m erica l su ff ix , w h ils t  th e  a m p lifica tio n  p r im ers, lis te d  in  g reen , h a v e  th e  
se le c te d  b a se(s) a d d ed  in  b o ld . R e fe r e n c e s  are ita lic ised .
* S e lec tiv e  p r im ers w ere  d e s ig n e d  w ith  th e  k n o w le d g e  o f  th e  c o r e  se q u e n c e  fr o m  J a n sse n  et al. 
(1 9 9 6 ) , a n d  th e  s e le c t iv e  b a ses  w e r e  c h o s e n  fo r  th is w ork .
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Ready-To-Go PCR beads (Amersham) were used. The reaction mixtures consisted of 20 
mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgC%, 200 pM each dNTP, 75 ng primer, 1- 
1.5 U Taq DNA polymerase, and approximately 1 ng of template DNA (5 pi of a 1 in 100 
dilution of product from 7.2.1). The final volume (25 pi) was overlaid with mineral oil 
(Sigma) before transferring the tubes to a thermal cycler. Cycling conditions were as 
follows: an initial dénaturation at 94°C for 4 minutes, then 33 cycles of dénaturation of 
94°C for 1 minute, annealing of 60°C for 1 minute, and extension o f 72"C for 2.5 minutes, 
with a final 4°C hold. The ampHfied products were then separated by standard horizontal 
gel electrophoresis on a 1.5% agarose gel in 1 x TBE buffer for 4 hours at 3.45 V/cm . Five 
microHtres o f each reaction mix were loaded in each lane, with 0.75 pg/lane of 
GeneRuler'*'^ DNA Ladder Mix (MBI Fermentas) as the molecular size marker loaded m 
the fkst and last lanes. Gels were stained in 1 pg/m l of ethidium bromide, and a 
photograph was taken under UV Hght (305 nm).
7.2.3 Amplified Fragment Length Polymorphism analysis
Banding patterns were analysed visuaUy. Distinct patterns were recorded, dependent on the 
number and position o f bands present in each profile.
7.3 Results
Six different enzymes and 23 primers were used to produce AFLP profiles of nine isolates 
(Tables 7.1 and 7.2, pages 238 and 240), resolved by standard gel electrophoresis. Eighteen 
of the 23 prhners generated profiles, although some were faint and others revealed similar 
profiles for aU tlie nine isolates tested.
The restriction endonuclease y4pal digest was successful, and six of the eight primers 
(Table 7.1, page 238) resulted in AFLP profiles. The primers Apa-T and Apa-TA did not 
generate any profiles, and Apa-A and Apa-AT produced only faint profiles. The other four 
primers (Apa-C, Apa-G, Apa-CG and Apa-GC) each gave varying intensities between the 
isolates, but generated tlie same profile for aU the isolates tested. Figure 7.2 (page 241) 
shows the profiles produced from Apa-C and Apa-GC. Therefore there was no diversity in 
the profiles using a number of selective primers for y^H-restricted digests.
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O f the three jEfoRI selective primers attempted, only one, Eco-T, did not produce any 
AFLP profiles. The primers Eco-C and Bco-G (Figure 7.3, page 243) gave varying 
intensities for the isolates tested, and In the most intense profiles, Eco-C produced eight 
bands for isolate MO-1503 (lane 1) and Eco-G generated 18 bands for MO-234 (lane 3). 
The profiles appear different from isolate to isolate, and differences in DNA concentration 
may be the cause. So when analysing in more detail it is apparent tliat all isolates for both 
primers Eco-C and Eco-G generate the same AFLP profile.
Only one primer was attempted for the enzyme HincUll (primer Hind-A), and either the 
restriction digest or the amplification with the selective primer was unsuccessful in 
generating any AFLP profiles.
AU five selective primers for MM-restricted profUes contained between two and 15 bands. 
Primers Mse-C, Mse-T, and Mse-AT, whilst exhibiting between only two and seven bands 
in a typical AFLP profile, generated at least two different AFLP profiles. This is seen 
clearly when comparing two earlier Missouri isolates, MO-20 (lane 7) and MO-814 (lane 8) 
using Mse-AT (Figure 7.4.b, page 244). The most promising enzyme-primer combination 
Mse-A, amplifies up to 16 bands in an isolate, but generates only two different types of 
AFLP profiles (Figure 7.4.a, page 244). This difference in profiles is due to an additional 
band of approximately 1100 bp, visible in isolates MO-1482 (lane 5) and MO-908 (lane 9).
Four selective primers for the enzyme Pst\ were tested. The primers Pst-A (Figure 7.5.a, 
page 245) and Pst-T generated only a few bands, whilst primer Pst-G produced a large 
number of bands. Only one AFLP profile was generated with Pst-T and Pst-G for aU tlie 
isolates tested. The best candidate for further investigation for epidemiological typing of B. 
pertussis the primer Pst-C (Figure 7.5.b, page 245). This produced many bands, and 
there are at least four different AFLP profiles generated. Altliough the differences between 
the profiles were due to the presence or absence of bands, the intensities of the remaining 
bands were equal to those in profiles with a greater number of bands. This can be seen 
when comparing isolates MO-20, MO-814 and MO-908 (lanes 7, 8 and 9, Figure 7.5.b, 
page 245),
The only primer tested for Taql, Taq-A, gave smeared, undefined profiles (Figure 7.6, page 
246). The procedure was repeated a number of times, including an adjustment of the 
restriction endonuclease temperature from 37°C to 65°C, but results were not improved on 
the gel illustrated in Figure 7.6 (page 246).
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The pioffles from Mse-A, Mse-AT, Pst-A and Pst-C weie investigated fot associations with 
othet typing data {pmA,ptxA, IS/002-RFLP and PFGE), as these enzyme-ptimer 
combinations generated different AFLP profUes (Table 7.2, page 240). Serotyping data 
:e omitted from this investigation, as eight of the nine isolates were serotype 1,3.were
The AFLP profiles o f tlie two isolates MO-1482 and MO-908 shared the same AFLP type 
when Mse-A was used (Figure 7.4.a, page 244). They were also both;^/xM(l) and RFLP-1, 
but differed m prnA  and PFG E type and were from different time periods. Similarly, the 
Pst-A profile shared by MO-234 and MO-908 (Figure 7.5.a, page 245) was associated with 
ptxA(V) and RFLP-1, but differed in prnA  and PFGE type and these two strains were from 
different time periods. Neither of tlie two Mse-AT profiles that divided the nine isolates 
(Figure 7.4.b, page 244), were associated with one particular y i m M , I S / 0 0 2 - R F L P  or
PFG E type.
The most discriminatory enzyme-primer combination, Psll and Pst-C, divided the isolates 
into four groups; I, MO-1503 and MO-814; II, MO-83, MO-73 and MO-908; III, MO-234, 
MO-1440 and MO-1482 and; IV, MO-20 (Figure 7.5.b, page 245). Isolates from type I 
were both7?r/iîM(l), type II isolates were aUp^xA{l) and RFLP-1, type III isolates were aU 
prnA{2),ptxA{l) and RFLP-1, and the type IV isolate wasprnA{6). AU tlie isolates from 
types II and III were isolated in 1999.
7.4 D iscussion
A novel typing method to K  pertussis, AFLP, was attempted on selected isolates from 
Missouri, USA. Tliis was thought to be a potentiaUy convenient and rapid approach, using 
restriction endonucleases and specific primers, for strain discrimination. Although tliis 
technique has proved useful for typing a wide range of bacteria, such as U  pneumophila, 
Chlamydiapsittaci and Clostridium decile (Fry et al, 2000; Boumedine and Rodolakis, 1998; 
McLauchlin et al, 2000), tlie results with six different restriction endonucleases and B. 
pertussis weïQ largely unsatisfactory. The enzymes Apal, Pstl and Taql have G+C-rich 
recognition sequences, making them ideaUy suited as frequent cutters in the G+C-rich B. 
pertussis genome (67.7 mol %) (ParkhiU et al, 2003). Although the other enzymes were more 
suited to cleave A+T-rich organisms, frequent cutters such as Apal and Pstl can produce 
too many bands, and may not give sufficient resolution for typing purposes. However, die 
selective primers either failed to amplify any restricted fragments (for example Apa-T, Eco- 
T and Hind-A), or produced identical AFLP profiles for the nine isolates tested (Apa-G,
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Eco-C and Pst-G). Only a few combinations generated different AFLP profiles with a 
sufficient number of bands in the profile to be of any value. These included Mse-T, Mse-A 
and Pst-C, where the latter gave the best discrimination, producing four AFLP types in the 
nine isolates tested (Figure 7.5.b, page 245).
Although three of the four enzyme-primer combinations, Msel and Mse-A or Mse-AT, and 
Pstl and Pst-A, generated different profiles, Mse-AT profiles were not associated with any 
other typing methods. Furthermore, the Mse-A and Pst-A profiles that were shared by only 
two isolates, were associated with ptxAip) and RFLP-1, which were the two predominant 
types present in the nine isolates examined. Two of the four profiles produced by Pst-C 
were associated withprnA  (group I andpm A{\), group IV andpntAip)), and the three type 
III isolates were alsop rn A (^ ,p txA (\)  and RFLP-1. The latter Pst-C type, type III, shares 
these predominant types with combined type P (section 4.4.2, page 183), highlighting the 
success of this B. pertussis lineage. Altliough these associations are based on a small number 
of isolates, further work using Pst-C on a wider selection of isolates may identify more 
significant associations.
An in silico digest was performed for tlie techniques IS / 002-RFLP analysis and PFGE using 
X/’fîI, using the recently annotated Tohama-I genome (5.3.6, page 202). This could have 
been performed for the single-enzyme digest and subsequent PCR amplification of each 
AFLP analysis, but the many enzymes and primers would have made this task arduous. 
Also, the Toliama-I strain was not used in the AFLP experiments in tliis work, so a direct 
comparison could not be made. However, with the appropriate in silico AFLP software, the 
Tohama-I genome could be screened for promising enzyme and primer combiaations for 
further investigation o f this technique.
Optimisation of the AFLP PCR conditions was not performed, and this may have affected 
the results quite significantly. The magnesium chloride concentration (2.5 mM) and the 
annealing temperature of 60°C were not altered. This temperature is relatively low for a B. 
pe?tussis-speci£ic PCR assay due to the high G+C-rich genome. Also, most of the primers 
tested wliich had pyrimidine bases added such as Apa-AT and Pst-T gave faint profiles, and 
this also could be due to the lack of optimisation and the G+C-rich genome of B. pertussis. 
Other enzyme and primer combinations could have been investigated. In conclusion, 
single-enzyme AFLP, although flexible and simple, did not generate a substantial 
discrirnitiation for B. pertussis, and further optimisation would be needed in order to apply 
this technique confidently to epidemiological investigations.
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8 Epidemiological typing direct from UK clinical
samples
249
8.1 Strategy
Although isolation of B. pertussis is considered to be the “gold standard” for laboratory 
diagnosis of pertussis, it is relatively insensitive and can take up to a week for visible 
colonies to appear. The detection of pertussis infection has been successful using other 
methods such as serology and PCR, but for epidemiological analyses, techniques such as 
PFG E and IS/002-RFLP require pure cultures of the organism to get satisfactory results. 
Another recent epidemiological typing method, based on pertactin and pertussis toxin SI 
subunit gene variation by direct sequencing, has been described but used genomic DNA 
extracted from pure B. pertussis cxAtme.s (Mooi et al., 1998; this diesis). Direct t)^ping of these 
genes was therefore attempted on nasopharyngeal aspirates (NPAs) and pernasal swabs 
(PNSs), received by RSIL as part o f the PICU study (Crowcroft et al., 2003), that were 
known to be eitlier culture- and/or PCR-positive for B. pertussis. Samples were detected as 
PCR-positive in the earlier PICU study, using two targets: tlie pertussis toxin promoter 
(with an internal positive control) and the 1S481 element (Fry et al, 2004). To increase tlie 
sensitivity of detection of the prnA  and p txA  genes, some optimisation and modifications 
to the published method (Mooi et al, 1998) were necessary. If successful, tliis direct typing 
approach could yield new epidemiological data that was not possible with previous 
methods.
8.2 Methods
Extraction of DNA from aU the clinical samples (NPAs and PNSs) was performed with the 
Qiagen Blood & Cell Culture DNA Mini Kit (Qiagen) (2.4.3, page 62). The descriptions of 
general methodology of PCR, purification of PCR products and the sequencing method are 
detailed in sections 2.5.2, 2.5.5 and 2.5.6 (pages 63, 76 and 77), respectively. DNA from the 
B. pertussis type strain (NCTC 10739^) was used as the positive control and, for 
optimisation experiments for amplification of both the pertactin and pertussis toxin SI 
genes, at 10 ng DNA per reaction, as quantified using tlie GeneQuant spectrophotometer 
(2.4.2, page 61).
8.2.1 Amplification of the pertactin gene
The amplification of the two polymorphic regions (Figure 1.2, page 16), usmg primers AF 
and BR (Table 2.3 and Figure 2.1, pages 66 and 69), was attempted (predicted ampHcon 
size approximately 1428 bp) on: (i) four culture-positive, PCR-positive clinical samples and
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(ii) 16 culture-negative, PCR-positive clinical samples, using 20 pi of clinical extract. The 
method is described in 2,5.4.1, page 68.
A smaller region, encompassing the major polymorphic region 1 was targeted, with primers 
AF and AR, to generate a product of approximately 585 bp. This was attempted on one 
culture-positive, PCR-positive clinical sample and 15 culmre-negative, PCR-positive clinical 
samples. Reaction mixtures (50 pi) contained 10% v /v  DMSO, 2.5 mM MgClg, 10 mM 
Tris-HCl (pFI 8.3), 2.5 mM KCl, 200 pM dNTP, 10 pmol each of AF and AR primers, 2.5 
U Taq DNA polymerase, and 20 pi of clinical extract. Optimisation of the cycling 
conditions were as follows, initial dénaturation at 95°C for 5 minutes, then 40 cycles 
consisting of dénaturation at 95°C for 15 seconds, anneaHng at 48-68°C for 15 seconds, and 
extension at 72°C for 45 seconds, followed by a final extension o f 7 minutes at 72°C, with a 
final 4'^C hold.
Optimised conditions with primers AF and AR
Successful amplification (Figure 8.1, page 253) was achieved with the above reaction 
mixtures and the following cycling conditions; initial dénaturation at 95°C for 5 minutes, 
then 40 cycles consisting of dénaturation at 95°C for 15 seconds, annealing at 60°C for 15 
seconds, and extension at 72°C for 45 seconds, followed by a final extension of 7 minutes 
at 72°C, with a final 4°C hold.
8.2.2 Amplification of the pertussis toxin SI gene
The primers SF and SR were used to generate a product of approximately 876 bp (Table 
2.3, page 66), using the method described in 2.5.4.2, page 73, The amplification of tliis 
p txA  fragment was attempted on one culture-positive, PCR-positive clinical sample and 16 
culture-negative, PCR-positive clinical samples, using 20 pi of clinical extract.
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A smaller region encompassing known polymorphic regions of the pertussis toxin SI gene 
was also targeted with primers SIFM and SR (Table 2.3, page 66), to generate a smaller 
ampHcon of approximately 404 bp (Figure 2.5, page 75). Reaction mixtures of 50 pi 
contained 1.5 mM MgCl^, 10 mM Tris-HCl (pH 8.3), 2.5 mM KCl, 200 pM dNTP, 10 
pmol each of SIFM and SR primers, 2.5 U Taq DNA polymerase, and 20 pi of clinical 
extract. Amplification parameters for optimisation consisted of initial dénaturation at 95“C 
for 5 minutes, then 40 cycles of 95°C for 15 seconds, annealing at 48-68°C for 15 seconds, 
and 72°C for 45 seconds, with a final extension of 72“C for 7 minutes, and a final 4°C hold. 
Amplification of this smallerp fxA  region was attempted on one culture-positive, PCR- 
positive clinical sample and 15 culture-negative, PCR-positive clinical samples.
Optimised conditions with primers SIFM and SR
The optimised cycling conditions consisted of an initial dénaturation at 95°C for 5 minutes, 
then 40 cycles of dénaturation at 95°C for 15 seconds, annealing at 67°C for 15 seconds, 
and extension at 72°C for 15 seconds, followed by a final extension of 7 minutes at 72”C, 
with a final 4°C hold (Figure 8.2, page 255).
8.3 Results
8.3.1 Detection of the pertactin gene, with primers AJF and BR, in clinical 
samples from the UK
An initial attempt to detect the pertactin gene was investigated with a selected group (n=5) 
of clinical specimens: PICU 519, PICU 521, PICU 522, PICU 523 and PICU 524 (Table 
8.1, page 256). All specimens were previously shown to be culture-positive and PCR- 
positive for Pi. pertussis, except PICU 521, which was culture-negative and PCR-positive. 
The visualisation of the amplicons generated are shown in Figure 8.3 (page 257). Three of 
the five specimens tested were positive for pertactin (PICU 519, PICU 523 and PICU 524). 
Unfortunately, the PCR products from clinical samples were unavailable for further 
investigation to determine the nucleotide sequence, although sequences were determined 
previously using DNA extracts from pure culture isolates from the same patient.
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As amplification of the pertactin gene was shown to be worthwhile, a second round was 
attempted on clinical specimens that were previously culture-negative, but PCR-positive 
(n=15) (Table 8.2 and Figure 8.4, pages 259 and 260). Only two of the 15 specimens were 
positive (PICU 705 and PICU 708) with primers AF and BR, and nucleotide sequences 
were determined as described in 2.5.6.2 (page 79).
8.3.2 Detection of the pertussis toxin SI gene, using primers SF and SR, in 
UK clinical samples
The detection of p txA  was performed with tlie same clinical specimens as above (n=15) 
(Table 8.2 and Figure 8.5, pages 259 and 261). Amplification o fp txA  was marginally more 
successful thanprnA^ i.e., six of the 15 samples were positive, which included the two 
clinical extracts that were also positive for prnA  (PICU 705 and PICU 708). Nucleotide 
sequences were determined for these six products as described in 2.5.6.2 (page 79).
8.3.3 Detection of the pertactin and pertussis toxin SI genes, with primers 
AF and AR, and SIFM and SR, respectively, in UK clinical samples
To try to increase tlie sensitivity of the two targets pertactin and pertussis toxin SI, smaller 
regions were attempted and optimised, as described earlier (8.2, page 251). The 
amplification of pertactin witli primers AF and AR, was applied to previously culture- 
negative and PCR-positive clinical specimens (n==15), and one culture- and PCR-positive 
clinical specimen (Table 8.3, page 262). Figure 8.6 (page 263) shows the successfulpm A  
amplification of the positive control and six of tlie 16 clinical extracts tested. Amplification 
of the pertactin gene from specimens PICU 643, PICU 644 and PICU 666 witli primers 
AF and BR was previously unsuccessful. Nucleotide sequences were determined as 
described in 2.5.6.2 (page 79).
The optimisation o fp tx A  using primers SIFM and SR was successful, but the PCR failed 
when it was applied on the same 16 clinical specimens used for the AF ARprnA  
amplification (Table 8.3, page 262). A further identical optimisation experiment was 
successful and identified the same optimum annealing temperature, but when the clinical 
specimens were tested a second time, PCR ampHfication was unsuccessful. Investigations 
using the same clinical extracts could not be attempted a third time, due to insufficient 
material.
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Table 8.2. Bordetella pertussis clinical specimens investigated for PCR 
amplification of the pertactin and pertussis toxin SI genes, as visualised
in Figure 8.4 and 8.5
R e s u l t s  fr o m  P I C U  stu d y^ R e s u l t s  f r o m  t h i s  s t u d y
L a n e
n u m b e r
C l in ic a l
s p e c i m e n
P e r t u s s i s  t o x in  
p r o m o t e r  P C R
I S 4 ^ i P C R P e r t a c t in  P C R  
( A F - B R )
P e r t u s s i s  t o x in  
S I  P C R  ( S F -S R )
1 PICU 617 Positive Positive Negative Negative
2 PICU 642 Positive Positive Negative Negative
3 PICU 643 Positive Positive Negative Positive
4 PICU 644 Positive Positive Negative Positive
5 PICU 649 Positive Positive Negative Negative
6 PICU 650 Positive Positive Negative Negative
7 PICU 654 Negative Positive Negative Negative
8 PICU 655 Negative Positive Negative Negative
9 PICU 656 Positive Positive Negative Negative
10 PICU 666 Positive Positive Negative Positive
11 PICU 667 Positive Positive Negative Positive
12 PICU 705 Positive Positive Positive Positive
13 PICU 706 Positive Positive Negative Negative
14 PICU 707 Positive Positive Negative Negative
15 PICU 708 Positive Positive Positive Positive
^Results obtained from Fry et al (2004). Isolates were previously culture negative.
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Table 8.3. Bordetelîa pertussis clinical DNA extracts investigated for 
detection of the pertactin gene, as visualised in Figure 8.6
Results from PICU study^ Results from this project
Lane
number
Clinical
specimen
Pertussis toxin 
promoter PCR
\%48t
PCR
Pertactin PCR (AF-AR)
1 PICU 519% Positive Positive Positive
2 PICU 617 Positive Positive Negative
3 PICU 642 Positive Positive Negative
4 PICU 643 Positive Positive Positive
5 PICU 644 Positive Positive Positive
6 PICU 649 Positive Positive Negative
7 PICU 650 Positive Positive Negative
8 PICU 654 Negative Positive Negative
9 PICU 655 Negative Positive Negative
10 PICU 656 Positive Positive Negative
11 PICU 666 Positive Positive Positive
12 PICU 667 Positive Positive Negative
13 PICU 705 Positive Positive Positive
14 PICU 706 Positive Positive Negative
15 PICU 707 Positive Positive Negative
16 PICU 708 Positive Positive Positive
^Results obtained from Fry et al. (2004).
^Isolate PICU 519 was also previously culture-positive.
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8.3.4 Pertactin and pertussis SI gene types generated from PCR-positive 
clinical specimens
All available PCR products generated were investigated further to determine their 
nucleotide sequence. The pertactin and pertussis toxin SI gene types are recorded in Table
8.4 (page 265). The two clinical specimens, PICU 705 and PICU 707, generated amplicons 
using both AF and BR, and AF and AR, and produced tlie same pertactin gene type, 
p rn A i^  when sequenced. The remaining three AF-ARpniA  amplicons from clinical 
specimens PICU 643, PICU 644 and PICU 666, were alsop rn A i^ , and these specimens, as 
well as PICU 705 and PICU 707, aU generated the same pertussis toxin 81 type,/?£>c/4(l). 
These five clinical specimens, previously non-culturable, generatedpruA  andp txA  results, 
which were then used for the UK B. pertussis population dynamics study, detailed in 
Chapter 3.
The pertactin gene type had been determined previously for the three clinical specimens, 
PICU 519, PICU 523 and PICU 524, using DNA extracted from pure cultures. 
Unfortunately, when investigated directly from the clinical specimen with primers AF and 
BR, the pertactin gene type was not identified and therefore could not be compared. The 
pertactin gene ty^&,prnA(2), was however, generated from the clinical extract of PICU 519 
using the primer pair AF and AR, and this matched the prnA  type as identified using AF 
and BR on the DNA extract from culture.
Although the clinical specimen PICU 667 was faindy positive for pertussis toxin 81 
amplification (Figure 8.5, page 261), the purified amplicon faded to give a nucleotide 
sequence when analysed on the CEQ™  2000 (Beckman Coulter). This negative result was 
probably due to the insufficient concentration of amplicon, as visualised in Figure 8.5 (page 
261, lane 11).
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8.4 Discussion
Simultaneous detection and epidemiological typing has proved valuable for bacteria, such 
as N . meningitidis (Moiling etal, 2002), and other organisms, such as HIV and hepatitis C 
virus (HCV) (Re et al, 2001; Gargiulo et al, 2003) that are difficult to isolate. To date, this 
direct typing approach has not been performed for B. peHussis. Previous epidemiological 
methods applied to B. pertussis, such as serotyping and PFGE, require bacterial cells and 
large amounts of DNA, respectively. However, determining the genotypic variation of 
virulence factors, such as the pertactin and pertussis toxin 81 subunit by PCR detection and 
DNA sequencing, should be possible, as this utilises the PCR technique, which amplifies 
tlie target gene required to determine the nucleotide sequence.
Work presented in this thesis demonstrates that direct typing of B. pertussis in clinical 
specimens is possible and worthwhile. Three of the four culture-positive specimens were 
typed directly from the clinical extract. Furthermore, two of the 15 culture-negative clinical 
specimens gave prnA  types and five generatedp txA  types, producing B. pertussis genotypes 
that would normally not be deduced due to the lack of isolate material. To increase the 
sensitivity, smaller fagments which still encompassed the polymorphic region of interest, 
were targeted for both p rtA  and ptxA . A further three prnA  types were generated from 
culture-negative clinical extracts (n= 5/15 clinical extracts) but, unfortunately, the 
respective amplicon failed to generate any gene type for the clinical extracts tested.
These two methods could be improved furtlier to increase the sensitivity when using 
clinical extracts directly. For example, by using nested PCR, this would involve a first 
round amplification for bo thpm A  -mAptxA  genes then, using internal primers, a second 
amplification that encompasses the polymorphic regions would be done. Amplification 
problems may occur due to the rich GC content of the B. pertussis genome, which could 
affect the annealing temperature. Hence, tlie second amplification may require a liigher 
annealing temperature than the first round PCR, to prevent any first round primers from 
annealing, and this higher temperature could initiate the extension of DNA. Therefore, 
various optimisation and titration experiments would have to be performed. Another 
approach would be real-time PCR technology with specific hybridisation probes for each 
prnA  andp txA  type. This has been developed for botlip n A  andp tx A  by Makinen et al 
(2001 and 2002), although hybridisation probes have not been designed for each known 
prnA  and p txA  type, and is rehant on a negative result as representing certain types, 
includingy>£w4(l). This would not be adequate when testing clinical extracts that may have
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insufficient DNA to amplify; if they are negative, they would be reported as ptxAiV) 
isolates, although they could also harbour a novelp txA  type, or that there are no B. pertussis 
cells in the clinical specimen to detect. Therefore, the suggested amendments of these two 
methods of nested PCR or real-time PCR with hybridisation probes, could potentially 
identify prnA  and p tx A  gene variation from previously non-culturable B. pertussis.
Boi'detellapertussis is a slow-growing, fastidious organism, and isolation rates are as low as 20- 
40% (Heininger, 2001). Recent sensitive techniques such as PCR and serology are only 
detecting the presence of the organism or past infection, respectively. More information 
can be gained by combining PCR and subsequent sequencing and/or differential probe 
hybridisation, and these direct typing approaches should be actively pursued to broaden the 
Imowledge of B. pertussis popubAoti dynamics. Tliis kind o f direct typing has also been 
successful using MLST in N. meningitidis (Diggle et aL, 2003), and additional targets could be 
added to prnA  and p tx A  to form a similar direct typing scheme. However, the need to 
attempt B. pertussis i%o\?Aon from tliese clinical specimens should still be encouraged, as 
serotyping and PFG E have become established epidemiological typing techniques, and 
these rely on isolates. Furthermore, the lack of isolation could lead to the loss of 
information, despite future typing methods promising detailed data using unculturable 
organisms.
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There has been a resurgence of pertussis in several countries despite liigh vaccination 
coverage. The use of various regimens of different pertussis vaccines available (WCV and 
ACV) has made it difficult to compare these countries, and each one should be investigated 
individually, as pertussis resurgence may be due to a combination of factors. The 
resurgence of pertussis has, in part, coincided with the introduction o f more sensitive 
diagnostic techniques, such as serology and PCR detection. Thus, pertussis cases are now 
ascertained in babies, adolescents and adults in larger numbers than before, so that many 
countries including the USA and Australia (Guris et al., 1999b; Andrews et al., 1997) are 
finding an increase in pertussis notification rates. In the UK, P>. pertussis 'll detected routinely 
in our national laboratories only by culture isolation. However, since April 2002, PCR (for 
infants under six montlis of age with suspected pertussis) and ELISA serology (for adults 
with a cough persisting for over 21 days and clfildren with a cough persisting for over 14 
days), have been available through RSIL, CPHL, London (Anon, 2002). Therefore, the true 
extent of pertussis incidence in the UK has yet to be established, altliough at the time of 
writing, 35 laboratory confirmations of pertussis infection were seen between January 2003 
and March 2003, compared to 74 within the same quarter period in 2002 (Health 
Protection Agency, 2003a and 2003b). This reduction in laboratory-confirmed pertussis 
cases could be due to the effect of the ACV booster, introduced in November 2001, or as 
part of the three-yearly cycle seen in the notification of pertussis cases.
Although there is no apparent resurgence in tlie UK, studies from The Netherlands,
Finland and Italy have stimulated the investigation of tlie genotypic diversity of the B. 
pertussis popsA^ùon in the UK (Mastrantonio et al., 1999; Mooi et al., 1998 and 1999).
Various well-established typing methods were used for this, and to directly compare with 
other countries. Results indicated tliat, between 1940 and 1999, B. pertussis changed in its 
diversity of prnA ,p txA  and IS/002-RFLP types. The prnA  andp tx A  data showed a sliift 
from predominantlyprnA(\) andptxA {\) o rptxAÇ ) isolates, to mostly prnA{2) and 
ptxA {\)  isolates. This shift was probably not due to vaccine-driven evolution, as suggested 
for The Netherlands (Mooi et al., 1998), because the earlier UK WCV, manufactured by 
Wellcome, contains ptxA (\)  strains, and also there has not been a resurgence of pertussis in 
tlie UK. The IS/titi2-RFLP data also support this view, as tlie UK Wellcome WCV strains 
are RFLP-1, RFLP-2 and RFLP-3, and match the current predominant RFLP types in UK 
B. pertimis isd[sLt&^ . The low number of IS/titi2-RFLP types seen in the 1990s, is also 
reflected in the low genotypic diversity value. A resurgence of pertussis would likely be 
seen as either a rise in genotypic diversity, due to an increase of different B. pertussis strains, 
or a drop in genotypic diversity, as successful lineages of B. pertussis expand. Therefore,
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studying the genotypic diversity alone does not give a realistic depiction of B. pertussis 
population dynamics, and information on pertussis incidence, how pertussis cases are 
ascertained, and the schedule and type of pertussis vaccine used, can greatly enhance the 
data interpreted.
Combining laboratory, clinical and epidemiological data provides a rich data-set, and is 
invaluable to the epidemiologist in tracking serious disease traits in outbreaks and 
epidemics. Work in this thesis has emphasised that the under two month age group is most 
at risk of pertussis infection, and that cases admitted to hospital are more liltely to be 
infected with a serotype \,2/prnA{\) strain. The detection of tliese significant associations 
has been unexpected, as they are based on just 90 isolates from a six month period in the 
UK. With the introduction of tlie ACV pre-school booster in the UK, furtlier analyses 
could reveal whether these risks have decreased, and if any other associations are evident. 
This could prove difficult however, as the UK is experiencing a historically low reported 
incidence of pertussis. Nevertheless, this type of study would be o f benefit in identifying 
new severe markers or predicting the outcome of pertussis disease.
The characterisation of a small selection of isolates from Missouri, USA has strengthened 
many of the conclusions reached on tlie UK  data. These include tlie suggestion that RFLP- 
1 and RFLP-2 are successful lineages of B. pertussis, and that the diversity of B. pertussis has 
dropped from the 1980s to tlie 1990s. Pertussis resurgence has occurred in Missouri, USA, 
but this study indicated no apparent reason for tliis. Although there has been a shift in 
isolates towards prnAC^!ptxA{\) types, no conclusion can also be made regarding shifts to 
non-vaccine types, as the earliest isolate tested is from 1984, and vaccination was 
introduced in the USA in the 1950s. This small sub-set of B. pertussis isolates also generated 
a novel pertactin gene type,yj?vzAl(9), found in two of tlie 43 isolates obtained, and 
subsequently found in Canada (Peppier et al, 2003). Whetlier this prnA  type, Vk^prnAip), 
has geographical limitations, has yet to be seen. The Canadian study also found prnAQ) in 
circulation, and this type was originally thought to occur only in Europe. The ten isolates 
from Kansas City were also studied to elucidate whether tliey could be linked by 
epidemiological typing methods. These isolates did indeed share the same serotype, p n A  
^xA ptxA  type, and IS/002-RFLP type, but were divided into two groups when investigated 
by PFGE. This highlights tlie difficulty in deciding on the level of strain discrimination, 
which is deemed necessary for epidemiological investigations.
269
Thus, when comparing epidemiological studies of B. pertussis from other countries, the use 
of the same typing method is ideal. In addition, the ability to standardise a typing scheme 
between laboratories is essential, and standardised methods for serotyping, pertactin and 
pertussis toxin SI gene typing and PFG E for B. pertussis B'xvq been recommended (Mooi et 
al, 2000). Pertactin and pertussis toxin 81 gene typing have become ubiquitous methods, as 
die results are easily portable, and direct comparisions can be performed. Various studies 
g e n e r a t i n g a n d p tx A  data from countries bodi with and without pertussis resurgence 
have been exhaustively compared. Overall, there has been the expansion o f new prnA  types 
such as prnA(2) andprnAÇi), and die reduction o fp txA  types to predominandy ptxA{\). 
Whedier diis is due to vaccine-driven evolution is unclear, but this has not halted die 
acceptance of this hypodiesis. In order to clarify this hypothesis, the prnA  and p txA  
diversity is required in areas or countries where there is a very low or negligible pertussis 
vaccine coverage, so that a set of “control” data can be compared with those countries with 
high vaccination coverage.
Although pertactin and pertussis toxin SI gene typing have become popular, other 
methods used to type B. pertussis include serotyping and PFGE for epidemiological 
investigations (Beall et al, 1995; Preston, 1988) and IS/002-RFEP analysis for population 
genetic studies (van Loo et al, 1999). These methods, except for pertactin and pertussis 
toxin SI gene typing, were evaluated in this thesis, according to the guidelines of Struelens 
et al (1996). This study revealed that, aldiough PFGE had die greatest index of 
discrimination, a combination of serotyping and prnA  and p tx A  gene typing could equal 
this discrimination. In addition, diese latter methods are more available, easier to perfom 
and the interpretation of results is less subjective. However, the recommendation of a 
metiiod could not be given, as the pertactin and pertussis toxin SI gene typing data was not 
generated from the blinded panel of isolates, and further work is required to optimise the 
PFGE technique.
Other approaches to type B. pertussis were also attempted, namely single-enzyme AFLP and 
adenylate kinase and filamentous haemagglutiniii gene typing. Unfortunately, the AFLP 
technique did not generate sufficiendy good results to warrant further investigation, and 
would require the optimisation of each primer for amplification. Amplified fragment length 
polymorphism is also dependent on the availability of a large amount of DNA from the B. 
pertussis isolate, and the subjectivity of gel profile analysis. The variations found in both adk 
and ffjaB does, however, merit further investigation, and diese two targets could be 
included in a DNA sequence-based scheme widiprnA  andptxA . This type of scheme.
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focusing on virulence factors, was first devised for B. pertussis by van Loo et al. (2002). The 
additional gene targets, the S3 subunit of pertussis toxin, tlie fttnbrial gene for serotype 2, 
and tlie tracheal colonisation factor, have also been evaluated by Packard et al (2004), using 
U K isolates collected for tliis thesis. When coded into the multi-locus sequence types 
(MLSTs), all but one o f UK clinical isolates from 2000 to 2002 were identified as MLST-5, 
which differed from the three Wellcome WCV strains (MLST-2 or MLST-3), and the ACV 
strain Tohama-I (MLST-2).
All of the typing methods described above rely on the isolation of the organism B. pertussis. 
Therefore, any past pertussis infection detected only by PCR and serology, would not be 
subjected to further characterisation, as the organism wdl not be available. I therefore 
investigated the possibility of typing prnA  and p txA  direcdy from a clinical extract. The 
results were promising but further work is required to confidendy obtain the prnA  and 
p txA  types from cases where no isolate was obtained and is thus untypeable; e.g., from 
babies or adults presenting atypical symptoms. This sub-group could be harbouring 
different genotypes to those found in culture-positive cases.
Thanks to D r J Parkhill, the annotated B. pertussis Toh.2im A  genome was available for this 
thesis, and was invaluable for comparing the observed and expected results of both 
IS/0d2-RFLP analysis and PFG E with Xbal. The genome could also have been used for 
predicting single-enzyme AFLP profiles (Chapter 7) and to ascertain odier potential genes 
targets for epidemiological typing (Chapter 6). Indeed, several workers have used the 
genome to screen for virulence factors and other putatitive BvgAS-regulated genes 
(Antoine et al, 2000; Passerini de Rossi et al, 2003). The availability and publication of the 
annotated B. pertussis genome will therefore become an important tool for diagnostic and 
pathogenic research (ParldaiH et al, 2003).
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10 FUTURE WORK
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10.1 Pertactin and pertussis toxin gene sequencing of UK isolates
The analysis of prnA 2itiàptxA  sequences o f current and future UK isolates will verify 
whether (2) and prnAipi) types are increasing in the circulating population. Such strains
could cause epidemics, as in The Netherlands (Mooi et al, 1998). Also, the introduction of 
the ACV in November 1999, which is formulated from purified products of one strain 
(compared to three strains in the WCV), may have an effect on prnA  type distribution. By 
combining this data with the epidemiological data available from CD SC, a larger data-set 
can be generated to measure any significant severe markers of pertussis disease, using 
multiple logistic regression analysis.
10.2 Pertactin and pertussis toxin gene sequencing in other countries
There have been many studies looking at the temporal distribution of prnA  and p txA  types 
in vaccinated countries. Several studies have reported a sliift in types and it has been 
hypothesised that the B. pertussis circulating population is undergoing antigenic shift due to 
vaccine pressure. In order to evaluate this hypothesis without bias, a countr)^ with no 
vaccination programme, or little vaccine coverage (e.g., Sweden, or a developing country) 
could be tested for their prnA  and p txA  variants.
10.3 Pulsed-Field Gel Electrophoresis
Epidemiological typing of B. pertussis has been studied using PFGE in a number of 
countries. This method, after evalution in Chapter 5, was found to be sub-optimal. 
Consequently, further work is required to improve this estabhshed method and to re­
examine the reproducibility, as PFGE can produce good discrimination, and could possibly 
be invaluable in an outbreak setting.
10.4 Amplified Fragment Length Polymorphism typing
Following a small-scale study investigating the potential of AFLP in typing B, pertussis, this 
could be adapted into a fluorescent-AFLP protocol. The use o f Pstl in a single digest or 
EfoRI and Msel in a double digest, could be evaluated with the well-characterised strains 
described in Chapter 7. With tlie availability of the B. pertussis T o h a m A  genome, AFLP 
profiles could be predicted for other enzyme and primer combinations.
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10.5 Epidemiological typing of Bordetelîa pertussis direct from clinical 
samples
Pertactin and pertussis toxin SI subunit gene typing may be optimised using either nested 
PCR or real-time PCR techniques, as already mentioned in 8.4, page 266. An attempt to 
amplify other genes such as pertussis toxin S3 subunit, tracheal colonisation factor, etc, 
directly from clinical samples could be advantageous, as these have been shown to exhibit 
polymorphisms (Packard et al., 2004; van Loo et al., 2002). Therefore, these clinical samples 
could be used to determine the type characteristics pertactin, pertussis toxin, and tracheal 
colonisation factor of the B. pertussis organism present. Real-time PCR technology could 
also be used on clinical samples to target pertactin and otlier genes, and evaluate whether 
the resulting products could be sequenced.
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12.1 Appendix 1. Amino acid abbreviations
N A M E 3 L etter A bbreviation I L
Alanine Ala A
Cysteine Cys C
Aspartic Acid Asp D
Glutamic Acid Glu E
Phenylalanine Phe F
Glycine Gly G
Histidine His H
Isoleucine He I
Lysine Lys K
Leucine Leu L
Methionine Met M
Asparagine Asn N
Proline Pro P
Glutamine Gin Q
Arginine Arg R
Serine Ser S
Threonine Thr T
Valine Val V
Tryptophan Trp W
Tyrosine Tyr Y
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12.2 Appendix 2. Address list of suppliers
Applied Biosystems, Lingley House, 120 Birchwood Boulevard, Warrington, Cheshire, WA3 7QH. 
Applied Maths BVBA, Keistraat 120, 9830 Sint-Martens-Latem, Belguim.
Amersham Biosciences UK Ltd, Amersham Place, Little Chalfont, Bucldnghamsliire, HP7 9NA. 
Aventis Pasteur MSD Ltd, Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 IQP. 
hioMérieux UK Limited, Grafton Way, Basingstoke, Hampsliire, RG22 6HY.
Bio Whittaker Molecular Applications (BMA), 1 Ashville Way, Wokingham, Berksliire, RG41 2PL. 
BDH Laboratory Supplies, Poole, Dorset, BH15 ITD.
Beckman Coulter UK Ltd, Oakley Court, Kingsmead Business Park, High Wycombe, 
Buckinghamsliire, H Pll lJU.
Bio-Rad Laboratories Ltd, Bio-Rad House, Maylands Avenue, Hemel Hempstead, Hertfordshire, HP2 
7TD.
Camlab Ltd, Nuffield Road, Cambridge, Cambridgeslrire, CB4 ITH.
Centre for Applied Microbiology and Research (CAMR), Porton Down, Salisbury, Wiltsliire, SP4 OJG.
Creative Beadcraft Ltd, Denmark Works, Beamond End, Nr Amersham, Bucldnghamshire, HP7 ORX.
Cruachem Ltd, Todd Campus, West of Scotland Science Park, Acre Road, Glasgow, G20 QUA.
Eppendorf UK Ltd, 10 Signet Court, Swanns Road, Cambridge, Cambridgesldre, CB5 8LA.
Genetic Research Instrumentation Limited (GRI), Gene House, Queensborough Lane, Rayne, 
Braintree, Essex, CM7 8TF.
Grant Instruments (Cambridge) Ltd, Shepreth, Cambridgesldre, SG8 6 GB.
Hewlett Packard, CC Centre, Cain Road, Bracknell, Berkshire, RG12 IHU.
Hybaid Limited, Action Court, Ashford Road, Ashford, Middlesex, TW15 IXB.
Institut Pasteur, 25-28, rue du Dr Roux, 75015 Paris, France.
Integra Bio sciences, Northumbria Biologicals Ltd, Nelson Industrial Estate, Cramlington, 
Northumberland, NE23 9BL.
Invitrogen Ltd"^ , Incldnnan Business Park, 3 Fountain Drive, Paisley, PA4 9RF.
MBI Fermentas, Fermentas UAB, V. Graiciuno 8, Vilnius 2028, Lithuania.
‘’Life Technologies has now merged with Invitrogen
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Media Services, Public Health Laboratory Service (PHLS), 61 CoHndale Avenue, London, NW9 5HT.
Missouri State Public Health Lab, MO DOH, 307 W. McCarty Street, Jefferson City, MO 65102.
MWG-BIOTECH (UI<) Ltd, Mill Court, Feathers tone Road, Wolverton Mill South, Milton Keynes, 
Bedfordshire, MK12 5RD.
National Center for Biotechnology Information (NCBI), National Library of Medicine, Budding 38A, 
Bethesda, MD 20894.
National Collection of Type Cultures (NCTC), Health Protection Agency (HPA), 61 Colindale Avenue, 
London, NW9 5HT.
National Institute for Biological Standards and Control (NIBSC), Blanche Lane, Soutlr Mimms, Potters 
Bar, Hertfordshire, EN6 3QG.
National Institute of Public Health and the Environment in The Netherlands (RIVM), Antonie van 
Leeuwenhoeldaan 9, 3721 MA Bilthoven, The Netherlands.
New England BioLabs (UK) Ltd, 73 Knowl Piece, Wilbury Way, Hitchin, Hertfordsliire, SG4 OTY.
Numerical Algorithms Group Ltd, Wilkinson House, Jordan HiU Road, Oxford, 0X2 8DR.
Pertussis Reference Laboratory (PRL), University of Manchester, Central Manchester Healthcare NHS 
Trust, Oxford Road, Manchester, Ml3 9WL.
Promega UK Ltd, Delta House, Cliilwordi Research Centre, Soutliampton, SO 16 7NS.
Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RHIO 9AX.
Roche Diagnostics Ltd, Bed Lane, Lewes, East Sussex, BN7 ILG.
The Sanger Institute, Wedcome Trust Genome Campus, Hinxton, Cambridge, CBIO ISA.
Sigma-Aldrich Company Ltd, Fancy Road, Poole, Dorset, BH12 4QH.
Stata Corporation, 4905 Lakeway Drive, Codege Station, Texas, 77845, USA.
Thermo Life Sciences, Unit 5, The Ringway Centre, Edison Road, Basingstoke, Hampsliire, RG21 
6YH.
Unicam Limited, PO Box 209, York Street, Cambridge, Cambridgesldre, CBl 2SX.
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112.4 Appendix 4. Enhanced surveillance forms used by the Communicable
Disease Surveillance Centre
' i.î'V'M'-ïv'feG   ■PHLST^ SURVEILLANCE DF LABORATORY CONFIRMED PERTUSSIS INFECTION IN ENGLAND AND WALES
STRICTLY CONFIDENTIAL Form 1 (CDR) -  last revision d o te  Dec 1996
RESPONSIBLE CENTRES FOR LABORATORY CONFIRMED PERTUSSIS INFECTION IN 
ENGLAND AND WALES:
PHLS Com m unicable Disease Surveillance C entre , immunisation Division 
University of M anchester, Pertussis R eference Laboratory
OBJECTIVES:
• To obtain epidem iological a n d  m icrobloiogicai information. Including serotyping, 
on oil coses of laboratory confirm ed pertussis in E&W
• To monitor the Impact*of pertussis vaccination  in E&W, using laboratory, 
notification a n d  v acc in e  c o v e ra g e  d a ta
For CDSC/R*f. Lab. us* only. 
Study no.
Reporting Laboratory
Date of CDR report 
_____ /_____ /19_
Dote specimen taken 
/ /19
Serotype
Please complete as far as possible, ticking appropriate boxes
Was th e Isolate sen t for serotyping? Yes Q  No Q  
PERSONAL DETAILS
N am e of patient: S urnam e_____________________________
D ate of birth________/________ /___
N am e of G P _____________________
A d d ress_________________________
First nam e Sex: M Q  F Q
A g e If GP not known: n a m e  of clin ician  In c h a r g e  of c a s e
A ddress
Postcode , Postcode
CLINICAL HISTORY OF CASE
Did th e  patient h a v e  c lin ically  ty p ica l pertussis? Yes CU No CD Not known CD 
P lea se  a d d  an y  relevant inform ation (e .g . severity, trea tm en t, co m p lica tio n s)_________
VACCINATION HISTORY OF CASE
At the tim e of d iagn osis, w a s  fh e  p a tien t v a c c in a te d  aga inst pertussis? Yes CD No CD Not known CD 
if yes, num ber of doses ______________
C om pleted by (please print) 
Position h e ld ____________ .S ignature, . D a te  !______/_
P U B L I C  H E A L T H  L A B O R A T O R Y  S E R V I C E
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/ . M r- V /^ 4 — • ■' -  ■ •-•V t^ÿ.V‘'n^ '  - '  V/ ,^ .^.....- - 'PHLS-SURVEILLANCrOF LABORATORl^ CONFIRMEDi P^ERTUSSIS INFECTION IN ENGLAND AND WALES
(Ref lab) -  làsf revision d o te  Dec 1996
RESPONSIBLE CENTRES FOR LABORATORY CONFIRMED PERTUSSIS INFECTION IN 
ENGLAND AND WALES:
PHLS C om m unicable Disease Surveillance C entre , immunisation Division 
University of M anchester, Pertussis R eference Laboratory
OBJECTIVES:
• To ob tain  epidem ioiogicai a n d  microbloiogicai information, including serotyping, 
on oil cases of iaboratç»ry confirm ed pertussis in E&W
• To monitor the  im pact of pertussis vaccination  in E&W, using laboratory, 
notification an d  v acc in e  co v e ra g e  d a ta
For CDSC/Rel. Lab. uw only.
study no.
Reporting Laboratory
Date of CDR report 
_____ /______/19_
Date specimen taken 
/ /19
Serotype
Please complete as far as possible, ticidng appropriate boxes
Was th e  Isolate reported to  th e  CDR? Yes CD No CD 
•' PERSONAL DETAILS ,
N a m e of patient: Surnam e_____________________________
D ate of birth ' j ________ /___
N a m e of G P _____________________
A d d re ss_________________________
First nam e Sex: M □  F CD
A g e If GP not known: n a m e  of c lin ician  In c h a r g e  of c a s e
A ddress
Postcode . Postcode
CLINICAL HISTORY OF CASE
Did th e  patient h a v e  clin ically  typ ica l pertussis? Yes CD No CD Not known CD 
P lease  a d d  any  relevant Information (e.g . severity, trea tm en t, com piico tions)_________
VACCINATION HISTORY OF CASE
At th e  tim e of d iagn osis , w as th e  patien t v a c c in a te d  aga in st pertussis? Yes CD No CD Not known CD 
if yes, num ber of doses ______________
C om pleted by (please print) 
Position h e ld ____________ .Signature . D a te  /_____ /_
P U B L I C  H E A L T H  L A B O R A T O R Y  S E R V I C E
P! R OVTÇ Et !C',Tl lb'Ni ;T. H;,E;i : F , R O M r l- N Er C T I
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RESPONSIBLE CENTRES FOR LABORATORY CONFIRMED PERTUSSIS INFECTION IN ENGLAND AND WALES:
PHLS Communicable Disease Surveilance Centre, Immunisation Division 
University of Manchester, Pertussis Reference Laboratory
OBJECTIVES:
• To obtain epidemioiogicai and mIcrobloloQicai information, including serotyping, on all cases of laboratory 
confirmed pertussis in E&W
• To monitor the impact of pertussis vacdrxjtlon In E&W, using laboratory, notification and vaccine coverage d ata
Please complete as farkis passible, ticking appropriate boxes 
PERSONAL DETAILS
For CDSC u se  only.
Study no.
Dote B. pertussis isolated 
_____ I_____ /I9___
N am e of patient: Surname __
D ate of birth /  L
First nam e Sex: M □  F □
A g e
CLINICAL HISTORY OF CASE
Did th e patient h a v e  clin ically  typ ica l pertussis? Yes CD No CD
If no  d escrib e  clinical p re se n ta tio n :_______ :_______________________
P lease  Indicate If there w ere  an y  o f th e following co m p lica tio n s
None CD Pneumonia CD Convulsions CD Conjunctival tiaem orrhage [0 Apnoetc attacks CD 
Ottier (describe)_____________________________________________________________________________________________
Did th e patien t r ec e iv e  erythrom ycin? Yes CD No CD
If yes, w as this: for prevention CD Duration of cou rse :_________
for treatm ent Q  Duration of course: .
Was th e  patien t adm itted  to  Hospital? Yes CD No CD
VACCINATION HISTORY OF CASE
Has th e  patien t b e e n  v a c c in a te d  a ga in st pertussis? Yes CD No CD
If yes, how  m any  doses w ere  given PRIOR to  on se t o f pertussis? ________
days
days
D ate s ta rte d . 
D ate s ta rte d .
Dates of vaccination (it available) 1 st d o s e . J. 2nd d o s e . 3rd d o se .
PLEASE QIVE N A |i f  e .fl, PgNTAVAC OR INFANRIX OR BATCH NUMBER OF ANY DOSE GIVEN AFTER 1*t N «v  IM S
SOURCE OF INFECTION
In th e m onth b efore o n set, did this c a s e  h a v e  c o n ta c t  with a  known or s u sp e c te d  c a s e  of pertussis?
Not knoyyn CD if yes, p lease specify where an d  a g e  of c o n ta c t__________________________________
Yes CD No CD
P lease  a d d  a n y  add itional co m m en ts  on  th e  reverse o f th e  form
C om pleted by (please print)_________________________________________
Position h e ld ______________________________________ Signature___ .D a te .
PLE ASF Rf M.iRrj f ORT/ lO
B m y c y h lf& u h io a b le  E
.,.*D.r.'Eli.’nO';:i Mil,--: i l';
Die D ise a se  Survet ! r Cenfr^h éW 'Coiimdale- A v en u e , London ' NW9 5EQ
 refccrrair-: 03 aaa - Fax:-orar 200 /Mg' Tr" ?'
P U B L I C  H E A L T H  L A B O R A T O R Y  S E R V I C E
P R O^  t  E' C I  I N G T H E  i h f - O  P U L À I  I O N F R O M  ^ j . N F E C  Til  O ,N
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